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Background: Familial hypercholesterolemia (FH) is an autosomal dominant genetic 
condition causing a high risk of coronary heart disease. The prevalence of this disease is 
about 1 in 500 in the UK, affecting about 120,000 people across the whole of the UK. 
Current guidelines recommend DNA testing, however, these guidelines are poorly 
implemented, therefore 102,000 or 85% of this group remain undiagnosed.
Objectives: To assess the diagnostic accuracy, effect on patient outcomes and cost-
effectiveness of Elucigene FH20 and LIPOchip for the diagnosis of FH.
Data sources: Electronic databases including MEDLINE, MEDLINE In-Process & Other 
Non-Indexed Citations, EMBASE, BIOSIS, Science Citation Index, Conference Proceedings 
Citation Index – Science and Cochrane Controlled Trials Register were searched until 
January 2011.
Review methods: A systematic review of the literature on diagnostic accuracy was carried 
out according to standard methods. An economic model was constructed to assess the 
cost-effectiveness of alternative diagnostic strategies for the confirmation of clinically 
diagnosed FH in index cases and for the identification and subsequent testing of first-, 
second- and possibly third-degree biological relatives of the index case. Twelve strategies 
were evaluated linking diagnostic accuracy to treatment outcomes and hence quality-
adjusted life-years (QALYs). Deterministic and probabilistic sensitivity analyses were 
undertaken to investigate model and parameter uncertainty.
Results: Fifteen studies were included for diagnostic accuracy; three reported Elucigene 
FH20, five reported LIPOchip, four reported low-density lipoprotein cholesterol (LDL-C) 
tests and three reported an age- and gender-specific LDL-C test against a reference 
standard of comprehensive genetic analysis (CGA). Sensitivity ranged from 44% to 52% for 
Elucigene FH20 and from 33.3% to 94.5% for various versions of LIPOchip in detecting 
FH-causing mutations in patients with a clinical diagnosis of FH. For LIPOchip version 10 
(designed to detect 189 UK specific mutations), sensitivity would be 78.5% (based on 
single-centre data – Progenika, personal communication). For all other Elucigene FH20 or 
LIPOchip studies (apart from one LIPOchip study), specificity could not be calculated as no 
false-positive results could be derived from the given data. The LDL-C test was generally iv Abstract
reported to be highly sensitive but with low specificity. For age- and gender-specific LDL-C 
cut-offs for cascade testing, sensitivity ranged from 68% to 96%. One UK-based study 
reported sensitivity of 91% and specificity of 93%. For the cost-effectiveness review, only 
one study reporting cost-effectiveness of any one of the comparators for this assessment 
was identified. Pre-screen strategies such as Elucigene FH20 followed by CGA were not 
cost-effective and were dominated by the single more comprehensive tests (e.g. CGA). Of 
the non-dominated strategies, Elucigene FH20, LIPOchip platform (Spain) and CGA were 
all cost-effective with associated incremental cost-effectiveness ratios (ICERs) relative to 
LDL-C of dominance (test is less costly and more effective), £871 and £1030 per QALY 
gained respectively. CGA generates the greatest QALY gain and, although other tests have 
lower ICERs relative to LDL-C, this is at the expense of QALY loss compared with the CGA 
test. Probabilistic sensitivity analysis shows that CGA is associated with an almost 100% 
probability of cost-effectiveness at the conventional value of willingness to pay of £20,000 
per QALY gain.
Limitations: There was much uncertainty regarding the diagnostic accuracy of the included 
tests, with wide variation in sensitivity across reported studies. A lack of published 
information for the most recent version of LIPOchip created additional uncertainty, 
especially in relation to the chip’s ability to detect copy number changes. For the economic 
modelling, we aimed to choose the best studies for the base-case sensitivity of the tests; 
however, a number of informed choices based on clinical expert opinion had to be made in 
the absence of published studies for a number of other parameters in the modelling. This 
adds some uncertainty to our results, although it is unlikely that these would be sufficient in 
magnitude to alter our main results and conclusions.
Conclusions: As targeted tests designed to detect a limited number of genetic mutations, 
Elucigene FH20 and LIPOchip cannot detect all cases of FH, in contrast with CGA. CGA is 
therefore the most effective test in terms of sensitivity and QALY gain, and is also highly 
cost-effective with an associated ICER of £1030 per QALY gain relative to current practice 
(LDL-C). Other tests such as Elucigene FH20 and LIPOchip are also cost-effective; 
however, because of inferior sensitivity compared with CGA, these tests offer cost savings 
but at the expense of large QALY losses compared with CGA. Further prospective 
multicentred studies are required to evaluate the diagnostic accuracy of new and emerging 
tests for FH with the LDL-C test in patients with a clinical diagnosis based on the Simon 
Broome criteria. Such studies should verify both test-positive and -negative results against 
a reference standard of CGA and should include a full economic evaluation.
Funding: The National Institute for Health Research Health Technology 
Assessment programme.© Queen’s Printer and Controller of HMSO 2012. This work was produced by Sharma et al. under the terms of a commissioning contract issued by the 
Secretary of State for Health.
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Glossary
T
echnical terms and abbreviations are used throughout this report. The meaning is usually 
clear from the context, but a glossary is provided for the non-specialist reader.
Autosomal dominant pattern of inheritance  An affected individual has one copy of a mutant 
gene and one normal gene on a pair of autosomal (i.e. non-sex) chromosomes. Therefore, one 
copy of the mutant gene is sufficient to express the phenotype. Individuals with autosomal 
dominant diseases have a 50 : 50 chance of passing the mutant gene, and therefore the disorder, 
on to each of their children.
Cascade testing  A mechanism for identifying people at risk of a genetic condition by a process 
of family tracing. Relatives of the individual diagnosed with familial hypercholesterolaemia are 
tested for the condition, as are their relatives; ideally, cascade testing should be undertaken in 
first-, second- and third-degree relatives. For familial hypercholesterolaemia the test employed is 
measurement of (low-density lipoprotein) cholesterol in the blood and/or a DNA test if a disease-
causing mutation has been identified in the proband/index.
Coronary heart disease  An abnormal condition characterised by narrowing of the small blood 
vessels that supply blood and oxygen to the heart (coronary heart disease is synonymous with 
coronary artery disease).
First-degree relatives  A person’s biological parents, brothers and sisters and children.
Heterozygous familial hypercholesterolaemia  High low-density lipoprotein cholesterol 
concentration in the blood caused by an inherited mutation from one parent only. 
Homozygous familial hypercholesterolaemia  Very high low-density lipoprotein cholesterol 
level in the blood caused by an inherited mutation from both parents. When a person inherits 
exactly the same affected gene from both parents this is called truly ‘homozygous’ familial 
hypercholesterolaemia. When the mutations in the low-density lipoprotein receptor gene (or 
equivalent) are different, this state is called ‘compound heterozygous’.
Mutation  An identified change in the DNA sequence of a gene that is predicted to damage the 
normal function of the gene and so cause disease.
p-value  The probability that an observed difference could have occurred by chance if the null 
hypothesis is true. A p-value of < 0.05 is conventionally considered to be statistically significant.
Proband  The affected (index) individual through whom a family with a genetic disorder 
is ascertained. The terms ‘index case’, ‘index individual’, ‘index patient’ and ‘proband’ are 
synonymous with one another in this report.
Second-degree relatives  A person’s biological grandparent, uncle, aunt, niece, nephew, half-
sister or half-brother.viii Glossary
Tendon xanthoma/xanthomata  A clinically detectable nodularity and/or thickening of the 
tendons caused by infiltration with lipid-laden histiocytes (macrophages in connective tissue). 
A distinctive feature of familial hypercholesterolaemia that most frequently affects the Achilles 
tendons but can also involve tendons on the back of the hands, elbows and knees.
Third-degree relatives  A person’s biological great-grandparent, great-grandchild, great-aunt, 
great-uncle, first cousin, grand-nephew or grand-niece.© Queen’s Printer and Controller of HMSO 2012. This work was produced by Sharma et al. under the terms of a commissioning contract issued by the 
Secretary of State for Health.
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List of abbreviations
APOB  apolipoprotein B
ARMS  amplification refractory mutation system
BNF   British National Formulary
CEAC  cost-effectiveness acceptability curve
CG71  clinical guideline number 71
CGA  comprehensive genetic analysis
CHD  coronary heart disease
CI  confidence interval
CMGS  Clinical Molecular Genetics Society
DFH  definite familial hypercholesterolaemia
DGGE  denaturing gradient gel electrophoresis
dHPLC  denaturing high-performance liquid chromatography
Ext Dom  Extendedly dominated
FH  familial hypercholesterolaemia
ICER  incremental cost-effectiveness ratio
iPLEX  multiple MassARRAY spectrometry 
LDL-C  low-density lipoprotein cholesterol
LDLR  low-density lipoprotein receptor
MedPed  make early diagnosis, prevent early death
MI  myocardial infarction
MLPA  multiplex ligation-dependent probe amplification
MOLU  MOLecular Unit
N/A  not applicable
NA  not available
NC  not calculable
NICE  National Institute for Health and Clinical Excellence
NR  not reported
PAD  peripheral arterial disease
PBR  Payment by Results
PCR  polymerase chain reaction
PCSK  protein convertase subtilisin/kexin
PCVD  premature cardiovascular disease
PFH  possible familial hypercholesterolaemia
PSSRU  Personal Social Services Research Unit
QALY  quality-adjusted life-year
QMFSP  quantitative multiplex PCR methodology
RCT  randomised controlled trial
SROC  summary receiver operating characteristic 
SSCP  single-strand conformation polymorphism
TC  total cholesterol
UFH  unclassified familial hypercholesterolaemia
UKGTN  United Kingdom Genetic Testing Network
All abbreviations that have been used in this report are listed here unless the abbreviation is well 
known (e.g. NHS), or it has been used only once, or it is a non-standard abbreviation used only 
in figures/tables/appendices, in which case the abbreviation is defined in the figure legend or in 
the notes at the end of the table.© Queen’s Printer and Controller of HMSO 2012. This work was produced by Sharma et al. under the terms of a commissioning contract issued by the 
Secretary of State for Health.
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Executive summary
Background
Familial hypercholesterolaemia (FH) is an autosomal dominant genetic condition causing a 
risk of premature coronary heart disease (CHD). In the UK, prevalence is estimated at 1 in 500, 
affecting around 100,000 people in England, around 6000 in Wales and approximately 10,000 
in Scotland. At least 85% (around 102,000) of people with FH in the UK remain undiagnosed. 
Current guidelines recommend DNA testing using comprehensive genetic analysis (CGA) by 
mutation screening of the low-density lipoprotein receptor (LDLR) gene, using sequencing and 
dosage analysis by multiplex ligation-dependent probe amplification (MLPA), and targeted 
testing for specific mutations in apolipoprotein B (APOB) and protein convertase subtilisin/kexin 
(PCSK9). It has been suggested that use of assay systems targeted to detect the most common 
FH mutations in a population might either replace CGA or be usefully used as a pre-screen to 
reduce the number of samples requiring the apparently more expensive CGA. Elucigene FH20 
(Gen-Probe Life Sciences, UK) and LIPOchip (Progenika Biopharma, Spain) are commercially 
available genetic tests designed to detect mutations that are most frequent in a European 
Caucasian population.
Objectives
The aim of this assessment is to assess the diagnostic accuracy, effect on patient outcomes and 
cost-effectiveness of Elucigene FH20 and LIPOchip for the diagnosis of FH.
Methods
Studies were identified by searching electronic databases and relevant websites, contact with 
experts in the field and the scrutiny of bibliographies of retrieved papers. The date of the last 
search was January 2011. Types of studies considered were randomised controlled trials, direct 
comparative diagnostic studies, diagnostic cross-sectional studies and case–control studies. The 
populations considered were adults and children with a clinical diagnosis of FH (index cases) 
based on the Simon Broome, Dutch or MedPed (make early diagnosis, prevent early death) 
criteria and, for cascade testing, the first-, second- and third-degree biological relatives of the 
index cases. The intervention (index) tests considered were Elucigene FH20 and LIPOchip and 
the comparators considered were low-density lipoprotein cholesterol (LDL-C) concentration 
measurement as part of the Simon Broome, Dutch or MedPed criteria in the diagnosis of index 
cases and, for relatives, targeted gene sequencing (the genetic test for sequencing a specific part 
of the gene where the family mutation is found) and gender- and age-specific LDL-C criteria 
as recommended in the National Institute for Health and Clinical Excellence (NICE) clinical 
guideline CG71. The reference standard considered was CGA in combination with Simon 
Broome, Dutch or MedPed criteria. These criteria primarily include a combination of high 
cholesterol, presence of tendon xanthomata in the patient or first-degree relative or a family 
history of premature CHD or high cholesterol.
Two reviewers screened the titles, abstracts and full-text papers of all articles identified by 
the search strategy. Data extracted by one reviewer were checked by a second reviewer. Two 
reviewers independently assessed the quality of the diagnostic studies using a modified xii Executive summary
version of the QUADAS instrument. For each study, where there was sufficient information, 
sensitivity, specificity and positive and negative likelihood ratios and their confidence intervals 
were calculated. Because of the heterogeneous nature of the studies, no formal meta-analysis 
was undertaken although sensitivity results were presented graphically as forest plots without 
pooled estimates.
An economic model was constructed in Microsoft Excel to assess the cost-effectiveness of 
alternative diagnostic strategies for the confirmation of clinically diagnosed FH in index cases 
and for the identification and subsequent testing of first-, second- and possibly third-degree 
biological relatives of the index case. The model described care pathways from clinical diagnosis 
through treatment over a lifetime horizon using predominantly statin-based therapies. The main 
tests considered were LDL-C (current practice), CGA (recommended indirectly by NICE CG71), 
Elucigene FH20 and LIPOchip. Test strategies in which MLPA was used as an add-on test to 
either Elucigene FH20 or LIPOchip were also considered. These tests were combined into a total 
of 12 different diagnostic testing strategies, all of which represented potential testing strategies 
in clinical practice. The main analysis refers to the comparison of each strategy with current 
practice (LDL-C); however, a comparison against CGA is also considered. The main analysis 
also refers to the combined process of confirming a clinical diagnosis in index cases and cascade 
testing of relatives; however, additional analysis also considered the identification of index cases 
only. Data from the diagnostic accuracy review were used in the development of the model. 
Costs associated with each diagnostic test were based on the MOLecular Units (MOLU) system, 
which assigns genetic tests to predetermined bands based on the test complexity. Total MOLUs 
were calculated and multiplied by a cost of £30 per MOLU to cost each strategy. Additional costs 
associated with cardiovascular events, treatments and NHS staff time were sourced from standard 
NHS reference cost sources (Payment by Results, British National Formulary and Personal 
Social Services Research Unit). Quality-adjusted life-years (QALYs) were estimated based on 
treatment effect and reduced cardiovascular events and therefore a cost–utility analysis was 
carried out, with incremental cost-effectiveness ratios (ICERs) presented for the base case and a 
range of deterministic sensitivity analyses undertaken to assess uncertainties in the estimates and 
assumptions. Probabilistic sensitivity analysis was also carried out using the net benefit approach 
with the results presented as cost-effectiveness acceptability curves.
Results
Diagnostic performance
Fifteen studies (seventeen articles) reported the performance of Elucigene FH20 (three studies), 
LIPOchip (five studies), LDL-C tests (four studies) and age- and gender-specific LDL-C (three 
studies) against a reference standard of CGA in which participants received a clinical diagnosis of 
FH using the Simon Broome, MedPed or Dutch criteria. Three of these studies reported targeted 
gene sequencing. Only studies published as full-text articles were quality assessed (one reporting 
Elucigene FH20, two reporting LIPOchip and six reporting LDL-C). The included studies on 
Elucigene FH20 and LIPOchip reported a sequential genotyping test in which (1) the participants 
received a clinical diagnosis of FH followed by the index test (as a pre-screen) and then (2) those 
who tested negative received further genetic investigations such as gene sequencing and MLPA. 
Overall, the participants were representative of those who would receive the test in practice 
(all received a clinical diagnosis of FH using Simon Broome, Dutch or MedPed criteria). The 
Elucigene FH20 and LIPOchip studies suffered from partial and differential verification bias (not 
all patients received a reference standard test and patients did not receive the same reference 
standard test regardless of the index test result respectively), whereas all but one of the LDL-C 
studies avoided these biases. Only one study reporting Elucigene FH20, one reporting LIPOchip 
and three (50%) of the LDL-C studies used CGA as defined in the assessment.© Queen’s Printer and Controller of HMSO 2012. This work was produced by Sharma et al. under the terms of a commissioning contract issued by the 
Secretary of State for Health.
xiii   Health Technology Assessment 2012; Vol. 16: No. 17 DOI: 10.3310/hta16170
Sensitivity ranged from 44% to 52% for Elucigene FH20 and was 78.5% for LIPOchip version 10 
(designed to detect 189 UK-specific mutations, based on data received from the manufacturer) 
in detecting FH-causing mutations in patients with a clinical diagnosis of FH based on the Simon 
Broome criteria. The LIPOchip designed to detect 251 mutations that were not specific to the UK 
showed 33.3–56.9% sensitivity. Specificity of 93.8% (one false-positive) was reported for LIPOchip 
version 8 against CGA. The Elucigene FH20 kit had higher sensitivity in those with a clinical 
diagnosis of definite FH (49%) than in those with a clinical diagnosis of possible FH (40%).
The LDL-C test was generally reported to be highly sensitive against a reference standard of CGA. 
In two studies, the LDL-C test as part of the Simon Broome criteria had high sensitivity (90% and 
93%) but low specificity (28% and 29%) in detecting FH. One study reported higher sensitivity 
of LDL-C cut-offs as part of the MedPed criteria in children (81%) than in adults (66%). For 
age- and gender-specific LDL-C cut-offs for cascade testing, sensitivity ranged from 68% to 96%. 
One study reported sensitivity of 91% and specificity of 93% for cascade testing in a cohort from 
the UK. Sensitivities of 68%, 79%, and 84% and specificities of 85%, 85% and 84% in cohorts of 
first-degree relatives from the Netherlands, Denmark and Norway, respectively, were reported.
Cost-effectiveness
We identified one study that evaluated LIPOchip as a cascade testing strategy for identification 
of index cases and the testing of first-degree relatives of the index case. The comparator for the 
assessment was no cascade testing. The ICER was estimated as €3243 per life-year gained and 
there was a 94% probability of cost-effectiveness at a willingness to pay of €7400 per life-year 
gained. We did not identify any additional studies or models evaluating the candidate tests.
In relation to confirming the clinical diagnosis and identifying patients for cascade testing, single 
test strategies such as CGA dominate combination test strategies of CGA testing for those who 
initially test-negative on Elucigene FH20 or LIPOchip [e.g. CGA is less costly and generates 
greater QALY gain than Elucigene FH20/LIPOchip followed by CGA for negatives (on the 
initial test)]. The base-case analysis shows that, for a cohort of 1000 index cases tested, CGA is 
£4.6M more costly but also generates an additional 4487 QALYs compared with current practice 
(LDL-C). The associated ICER is £1030 per QALY gained. In addition to the cost-effectiveness 
of CGA, a number of other strategies may be potentially considered cost-effective with ICERs 
falling below that reported for CGA. Elucigene FH20 as a stand-alone testing strategy is less 
costly, more effective and thus dominant compared with LDL-C. LIPOchip platform (Spain) had 
an ICER of £871 per QALY gained. The difficulty, however, is that the cost-effectiveness of these 
tests is driven by cost savings relative to CGA, but also QALY losses. In fact, compared with CGA, 
all other testing strategies generate inferior sensitivity to CGA and are thus associated with fewer 
QALY gains. The sequences of the presented ICERs do not change for age subgroup analysis or 
for a range of plausible deterministic sensitivity analyses undertaken. Probabilistic sensitivity 
analysis suggests that, for willingness to pay for QALY gain values ≥ £3500, there is a > 90% 
probability of CGA being the most cost-effective strategy relative to LDL-C. Some slight variation 
is evident depending on age subgroup and prevalence for low ceiling ratios of willingness to pay 
for a QALY gain; however, the message that CGA is the most likely cost-effective strategy remains 
for all ceiling ratios > £5000 regardless of age or prevalence rate. The probability of CGA being 
the most cost-effective testing strategy increases to almost 100% at the conventional value of 
willingness to pay of £20,000 per QALY gained.
Discussion
The results reported here are based on a small number of studies. There was no published 
evidence on LIPOchip version 10; data for LIPOchip version 10 were available from the xiv Executive summary
manufacturer. The evidence on LIPOchip version 10 and Elucigene FH20 suggests that 
approximately 20–50% of FH-causing mutations will be missed using these targeted tests alone 
among those who have a clinical diagnosis of FH based on Simon Broome criteria. Further 
genetic testing with sequencing and MLPA would potentially detect the FH cases missed by 
Elucigene FH20 or LIPOchip. The LDL-C tests compared with a reference standard of CGA were 
generally observed to be highly sensitive in both index cases and cascade testing of relatives. 
However, two of the LDL-C studies used CGA that did not include the analysis of the APOB and 
PCSK9 genes, which would not necessarily detect all cases of FH, and in addition there may be 
other genes as yet unrecognised that may give rise to the FH phenotype. It was not possible to 
calculate specificity for Elucigene FH20 and LIPOchip version 10 as none of the test-positives 
went on to receive CGA; therefore, it was not known whether or not there were any false-positive 
results. One false-positive diagnosis with LIPOchip version 8 (does not contain five mutations 
that are present in the Elucigene FH20 kit) was reported in a study with a small sample size 
(n = 22). LDL-C test performance in both index cases and cascade testing of relatives (except 
for LDL-C as a part of MedPed criteria) reported lower specificity with a high number of false-
positive diagnoses in terms of people with a clinical diagnosis of FH having no FH-causing 
mutation detected.
Comprehensive genetic analysis is the most sensitive test and hence generates the greatest QALY 
gain of all tests and is therefore highly cost-effective. Other less sensitive non-dominated tests 
such as Elucigene FH20 and LIPOchip (Spain) are slightly more cost-effective but generate 
lower QALY gains than CGA. In addition, CGA detects all known FH-causing mutations, 
thereby eliminating any ethical or equity issues involved with the process. Additionally, it was 
not possible to link the utility of diagnostic information to treatment outcome and QALY gains; 
however, it is highly unlikely that this would be meaningful in the context of the quality of life 
gained from lifelong treatment for FH. The economic modelling was associated with a number of 
assumptions that add uncertainty to the results. First, there is much variation in test sensitivity, 
especially surrounding the LIPOchip estimates. Assumptions have also been made around the 
number of relatives who do not have a mutation but who may have high cholesterol. A further 
limitation of the analysis refers to the accuracy of test sensitivity and specificity differentials 
between those relatives of genetically negative index cases and those relatives of genetically 
confirmed index cases. Finally, there is much uncertainty among clinicians in how best to treat 
FH and non-FH patients with high cholesterol. Many may start with a low-intensity treatment 
and increase treatment intensity if a satisfactory response is not achieved. Others believe that, as 
statin therapy generates very few adverse events, it would be appropriate to treat everyone with 
a high-intensity statin (e.g. atorvastatin). We have tested all assumptions made in deterministic 
and probabilistic sensitivity analysis and find that the model outcomes are robust to assumptions 
surrounding treatment choice. Although some variations exist in the ICERs reported, all remain 
< £20,000 per QALY gained and the results of the probabilistic sensitivity analysis broadly 
confirm the deterministic analyses.
Generalisability of the findings
The frequency of FH-causing mutations can vary by country of origin and within countries 
by ethnicity. As Elucigene FH20 and LIPOchip kits are designed to detect a limited number of 
mutations, the sensitivities of both of the kits are largely dependent upon the prevalence of these 
specific FH-causing mutations in the population. Therefore, the sensitivities observed here may 
not be generalisable to other populations or ethnic groups. Even within the UK, some variation 
in the detection rate of FH-causing mutations by Elucigene FH20 across six centres was observed. 
Given this variation in the prevalence of FH-causing mutations that are detectable by Elucigene 
FH20 and LIPOchip, CGA gives the most accurate test results available and would appear to be 
generalisable to the whole of the UK population.© Queen’s Printer and Controller of HMSO 2012. This work was produced by Sharma et al. under the terms of a commissioning contract issued by the 
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Conclusions
Implications for service provision
Based on evidence that was limited in quantity and of variable quality, Elucigene FH20 and 
LIPOchip version 10 (designed to detect 189 UK-specific mutations) have been shown to detect 
44–52% and 78.5%, respectively, of FH-causing mutations that are also detected by CGA amongst 
people with a clinical diagnosis of FH based on the Simon Broome criteria. As targeted tests 
designed to detect a limited number of genetic mutations, Elucigene FH20 and LIPOchip cannot 
detect all cases of FH; therefore, further genetic screening using MLPA and sequencing is still 
required to give an unequivocal diagnosis of FH. Using the LDL-C test (high sensitivity and low 
specificity) as part of the Simon Broome criteria means that a large number of people will receive 
a clinical diagnosis of FH who will not have a detectable FH-causing mutation.
Comprehensive genetic analysis appears to provide a favourable cost-effective method of 
diagnosis, with an associated ICER of £1030 per QALY gain. Elucigene FH20 and LIPOchip 
(Spain) are even more cost-effective in terms of deterministic analysis because of their lower 
costs; however, they generate substantially lower QALYs than CGA (which is also highly cost-
effective). Cost-effectiveness (for Elucigene FH20 in particular) is driven primarily by the cost 
savings associated with the test. There may be practical and resource issues associated with full-
scale implementation in the recommending of CGA for everyone with a clinical diagnosis of FH. 
If so, then a judgement is required whether or not it is ethical to implement cascade testing based 
on an index test result that is less sensitive than CGA (e.g. Elucigene FH20/LIPOchip). Doing 
so would mean that potentially FH-positive relatives will be missed. These patients may not get 
potentially life-saving treatment if index patients are managed only on the basis of their clinical 
diagnosis as opposed to their genetic test.
As there are an estimated 100,000 undiagnosed people with FH in the UK, the testing and 
treatment of all will place a substantial resource burden on already tight NHS budgets. On the 
other hand, costs associated with genetic testing are reducing and will continue to do so with the 
emergence of next-generation sequencing techniques. ‘Next generation’ refers to the emergence 
in recent years of new (non-Sanger-based) DNA sequencing techniques. This allows higher 
throughput in genetics laboratories to test for more mutations, more quickly, and hence reduce 
costs. Early estimates suggest that the emergence of next-generation sequencing may reduce the 
sequencing costs in the testing of FH by approximately 40%. Costs of treatment are also likely to 
reduce in the near future as atorvastatin is due to come off patent in 2011 with an expected retail 
cost similar to that of generic simvastatin.
Suggested research priorities
  ■ A prospective multicentre study comparing the performance of Elucigene FH20 and 
LIPOchip with the LDL-C test in patients with a clinical diagnosis of FH based on the 
Simon Broome criteria, in which both test-positives and test-negatives are verified against a 
reference standard of CGA, would be informative. Such a study should also include subgroup 
analysis of the performance of the tests in different ethnic groups, if possible have a period 
of follow-up to allow provision of relevant longer-term clinical effectiveness outcomes and 
incorporate an economic evaluation. An economic evaluation should consider the effect of 
utility of diagnostic information (false-negative results or false-positive results) on survival 
and quality of life in FH patients. Such information could be used to inform the estimation of 
QALYs in future modelling exercises.
  ■ There is little evidence linking efficacy of statins in children to the onset of CHD. There is a 
need to assess the relative risks of onset of disease in this group of patients.xvi Executive summary
  ■ There is a need for a systematic review of all of the FH-causing mutations currently 
detectable in the UK population as a whole and in specific ethnic groups and their associated 
impact on risk of CHD.
  ■ There is a need for ongoing clinical research to continue to update the list of genes 
and mutations which are linked to FH. As a result, the positive detection rate for CGA 
(i.e. mutation prevalence) needs to be updated to reflect such new discoveries on a 
regular basis.
  ■ It was outwith the scope of this review to assess tests such as multiple MassARRAY 
spectrometry (iPLEX) that may also be used for detecting FH but are not as yet CE marked 
for this purpose. Therefore, further research into the diagnostic accuracy and cost-
effectiveness of this test would be informative.
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Chapter 1 
Background and definition of the 
decision problem
Description of health problem
Introduction
Familial hypercholesterolaemia (FH) is a genetic condition in which people inherit an abnormal 
(mutant) gene that affects the rate at which cholesterol is cleared from the blood, giving rise to a 
high level of cholesterol in the bloodstream. An individual can inherit a mutant gene either from 
one parent (a condition known as heterozygous FH) or from both parents (a condition termed 
as homozygous FH or compound heterozygous FH). Homozygous FH occurs if a person inherits 
two copies of exactly the same gene alteration from each parent. Compound heterozygous FH 
occurs when a person inherits two different types of gene alterations, one from each parent. A 
person with homozygous FH or compound heterozygous FH usually has a much more severe 
form of the disease than someone with heterozygous FH. Almost all people with FH have 
heterozygous FH.
Affected individuals have raised cholesterol concentrations from birth, and this leads to early 
development of atherosclerosis and coronary heart disease (CHD), and high risk of premature 
death. FH is generally characterised by the presence of physical symptoms such as tendon 
xanthomata (cholesterol deposits) and arcus cornealis (cholesterol deposits in eyes) and clinical 
symptoms (high cholesterol levels).
However, treatment from late childhood with statin therapy, combined with lifestyle changes such 
as stopping smoking, healthy eating and exercising, can restore normal life expectancy. A recent 
National Institute for Health and Clinical Excellence (NICE) guideline on the identification 
and management of FH reviewed strategies for case ascertainment and effective treatment.1 
A key element was the recommendation that cascade testing of first-, second- and if possible 
third-degree relatives of affected individuals should be offered. Such cascade testing should be 
carried out either by offering DNA-based testing to consenting individuals or by biochemical 
measurement of cholesterol levels.1
Aetiology, pathology and prognosis
The major aetiological determinant of FH is the presence of a highly penetrant mutation 
(penetrance refers to the proportion of individuals with the mutation who exhibit clinical 
symptoms) in a gene important in cholesterol metabolism. FH is mainly caused by a mutation 
in the low-density lipoprotein receptor (LDLR) gene, which is found on the short form of 
chromosome 19 and is responsible for primary hepatic low-density lipoprotein cholesterol 
(LDL-C) uptake, processing up to 70% of circulating LDL-C. LDL-C is bound to the receptor (a 
structural protein molecule on the cell surface that binds to a specific factor, such as a drug or 
other molecules) and then transported into the cell, where it is metabolised. High-affinity LDLRs 
are found in the endothelium, smooth muscle cells and liver. In FH, there are four groups of 
mutations leading to a high level of total cholesterol (TC) and LDL-C:
  ■ those resulting in impaired receptor synthesis2 Background and definition of the decision problem
  ■ those resulting in impaired transport of receptors to the cell surface
  ■ those resulting in failure of LDL-C to bind the LDLR properly
  ■ those resulting in failure to transport bound LDL-C into the cell.
Mutations associated with FH have also been found in the apolipoprotein B (APOB) and protein 
convertase subtilisin/kexin 9 (PCSK9) genes but with fewer variants than in the LDLR gene. 
The APOB gene makes a protein that helps hold cholesterol-carrying lipoproteins together in 
the blood. If there is an alteration in this gene, the LDL does not bind well to the LDLRs on the 
surface of the liver and it is removed only slowly from the blood. If there is an alteration to the 
PCSK9 gene, more LDLRs are broken down in the liver, resulting in fewer to remove LDL from 
the blood. The result in both cases is that the level of LDL-C in the blood remains high. The 
overall effect of these gene alterations is that the liver is less able to take up excess cholesterol 
from the blood, meaning that less is excreted into the intestines, from where it can be removed 
from the body.2
As the gene is inherited in an autosomal dominant manner, the probability of inheriting the 
condition is 50% in first-degree biological relatives (parents, siblings, children), 25% in second-
degree relatives (aunts, uncles, grandparents, nieces, nephews) and 12.5% in third-degree 
relatives (first cousins and siblings of grandparents).3
High cholesterol levels in the blood have complex causes, with genetic and environmental causes 
operating simultaneously4. As with all genetic conditions, there are several other genes and 
metabolic and environmental factors contributing to the clinical course of the condition:4
  ■ examples of genetic causes: specific mutations leading to the FH phenotype, genetic factors 
that influence lipoprotein metabolism, genetic factors that influence CHD
  ■ examples of metabolic causes: hormonal, diet/body weight, lipoproteins and enzymes and 
apolipoproteins modulating their metabolism, factors involved in inflammation, clotting 
and thrombosis
  ■ examples of environmental causes: prevalence of CHD in the community, drugs affecting 
lipoprotein metabolism used without identifying FH.
There is strong evidence that smoking greatly increases the risk of CHD in FH and modest 
evidence that diet is an important contributory factor.
Familial hypercholesterolaemia is latent (presymptomatic period) from birth to the second 
decade of life and if diagnosed by then can be successfully treated. FH is usually evident (by 
blood cholesterol levels) in the first year of life and physical signs such as xanthomata are seen in 
the second decade of life. Tendon xanthomata are frequent but not always present. Symptomatic 
CHD usually appears by the fourth decade of life. People with heterozygous FH usually have 
LDL-C levels that are double the normal level (with TC often between 7.5 and 10 mmol/l), and 
receptor activity that is about half the normal level.5 People with homozygous FH typically 
present with very severe hypercholesterolaemia, with LDL-C levels six times the normal level (i.e. 
LDL-C levels 15–20 mmol/l) and early onset of disease in childhood.5
If untreated, approximately 50% of men and 30% of women with FH will develop CHD by age 
60 years6 and around 50% of men will die before the age of 60 years.7 People with homozygous 
FH have a significantly poorer prognosis than those with heterozygous FH and most will die 
before the age of 30 years. However, the risk of CHD can be greatly reduced if FH is diagnosed 
before the onset of the condition, by treatment with lipid-modifying drug therapy (statins) in 
combination with lifestyle changes.1 Statins have been shown to be effective in lowering the risk 
of mortality from CHD in patients with clinical FH (see Figures 1 and 2).8,9 © Queen’s Printer and Controller of HMSO 2012. This work was produced by Sharma et al. under the terms of a commissioning contract issued by the 
Secretary of State for Health.
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Epidemiology, incidence and prevalence
It has been estimated that worldwide around 10 million people have FH, of whom around 
200,000 die each year from CHD.11 The prevalence of heterozygous FH varies in different 
populations. In the UK, prevalence is estimated at 1 in 500, affecting around 100,000 people in 
England, around 6000 in Wales and approximately 10,000 in Scotland. Homozygous FH and 
compound heterozygous FH are much rarer, with a prevalence of 1 in 1 million.12 The frequency 
of FH-causing mutations can vary by country and within countries by ethnicity. The Centre for 
Cardiovascular Genetics (University College London)13 keeps an up-to-date database of genetic 
mutations associated with FH.
The LDLR, APOB and PCSK9 genes are most frequently implicated, but other genes remain to 
be discovered. Therefore, it is possible that in some people other, yet undiscovered, mutations 
will not be detected using current genetic strategies. Approximately 1400 unique mutations 
have been identified worldwide so far, of which over 200 have been reported in the UK 
population.14 Approximately 93% of genetic mutations associated with FH occur in the LDLR 
gene, whereas mutations in the APOB and PCSK9 genes account for approximately 5% and 2% of 
cases respectively.15
Impact of the health problem
People with FH have consistently been shown to be at high risk of cardiovascular-associated 
morbidity and mortality.9,16 Adults with FH aged 20–39 years have a 100-fold increased risk of 
dying from CHD.17 FH is an underdiagnosed condition. It has been estimated that > 85% (around 
102,000) of the 120,000 people in the UK thought to be affected with FH are undiagnosed,18 
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FIGURE 1  Kaplan–Meier curve showing the cumulative event-free survival in patients with and without statin treatment. 
Source: Versmissen et al.8
FIGURE 2  Pre- and post-statin death rates in FH patients (20–59 years). Source: Department of Health Familial 
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putting them at increased risk of CHD. Often a diagnosis is made too late for an individual to 
benefit from treatment.1 A definitive diagnosis through DNA screening of suspected FH patients 
and then testing of their relatives has been identified as the best possible approach to improve 
diagnosis of FH.19
Measurement of disease
Clinical diagnosis
Different sets of clinical criteria have been developed for the diagnosis of FH. These criteria 
primarily include a combination of high cholesterol, presence of tendon xanthomata in the 
patient or first-degree relative and a family history of premature CHD or high cholesterol.
The most widely utilised and validated sets of clinical criteria are:
1.  the UK Simon Broome Register criteria
2.  the US MedPed (make early diagnosis, prevent early death) criteria
3.  the Dutch Lipid Clinic Screening Network criteria.
Simon Broome criteria
The Simon Broome criteria include a combination of family history of CHD, physical signs 
such as tendon xanthomata, cholesterol concentration and DNA testing for the diagnosis of 
FH (Table 1).5,20 This approach categorises FH as ‘definite’ or ‘possible’. The major distinction 
between definite and possible FH is the presence of tendon xanthomata in the definite FH 
cases. DNA-based evidence was subsequently introduced into the criteria for provision of an 
unequivocal diagnosis of FH. However, around 10% of people with FH do not meet the Simon 
Broome criteria.
The Simon Broome Register was set up, utilising an endowment donated by his wife Katherine, 
after his premature death from cardiovascular disease, when he was found to have FH.21
MedPed criteria
The US MedPed criteria take account of the prior probability of a LDLR mutation, which is 
different for first-, second- and third-degree relatives and the general population. For each 
of these groups and for four age groups, different cholesterol level cut off points were then 
designated (Table 2).5 FH is diagnosed if TC levels exceed the cut off point.
Dutch Lipid Clinic Screening Network criteria
The Dutch criteria5 are similar to the Simon Broome criteria except that a scoring system is used 
to distinguish between definite, possible or probable FH (Table 3). A diagnosis of FH is definite if 
the score is > 8 points, probable if the score is 6–8 points and possible if the score is 3–5 points. A 
score of < 3 points is considered non-FH. The only difference between the Dutch criteria and the 
Simon Broome criteria is the requirement of tendon xanthomata in the Simon Broome criteria 
for a diagnosis of definite FH (if a mutation has not been identified).
However, identification of patients by elevated cholesterol levels is not fully reliable. An overlap 
in blood cholesterol levels between people with FH and those with non-genetic polygenic 
hypercholesterolaemia has been reported.22,23 In some FH cases, LDL-C levels are not elevated, 
resulting in a false-negative diagnosis.20,24
Genetic diagnosis
DNA-based mutation screening methods provide a definitive diagnosis of FH by identifying a 
causative mutation and confirming the clinical diagnosis.25 DNA testing adds clinical certainty 
to a diagnosis among relatives. Mutations associated with FH have been mostly found in the © Queen’s Printer and Controller of HMSO 2012. This work was produced by Sharma et al. under the terms of a commissioning contract issued by the 
Secretary of State for Health.
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TABLE 1  Simon Broome diagnostic criteria5,20
Criteria required for clinical diagnosis of FH  Definite FH Possible FH
Cholesterol concentration
Child/young person: TC > 6.7 mmol/l, LDL-C > 4 mmol/l; adult: TC > 7.5 mmol/l, LDL-C 
> 4.9 mmol/l
Yes Yes
Clinical symptoms
Tendon xanthomata or evidence of these signs in first- or second-degree relative
Yes No
Family history of
MI in second-degree relative aged < 50 years or in first-degree relative aged < 60 years or
Raised TC (> 7.5 mmol/l in adult first- or second-degree relative or > 6.7 mmol/l in child or 
sibling < 16 years)
No  Yes (at least one of these 
criteria)
MI, myocardial infarction
Or DNA-based evidence of mutation in LDLR, APOB or PCSK9 gene gives an unequivocal diagnosis of FH.
TABLE 2  MedPed diagnostic criteria5
Age (years)
LDL-C (mmol/l)
First-degree relatives 
with FH
Second-degree relatives 
with FH
Third-degree relatives 
with FH) General population
< 18 5.7 5.9 6.2 7.0
20 6.2 6.5 6.7 7.5
30 7.0 7.2 7.5 8.8
40 7.5 7.8 8.0 9.3
TABLE 3  Dutch Lipid Clinic Screening Network criteria5
Criteria  Point
Family history
First-degree relative with known premature (< 55 years men, < 60 years women) coronary and vascular disease or
First-degree relative with known LDL-C > 95th percentile and/or
First-degree relative with tendon xanthomata and/or arcus cornealis or
1
Children < 18 years with LDL-C > 95th percentile 2
Clinical history
Patient has premature (< 55 years men, <60 years women) coronary artery disease 2
Patient has premature (< 55 years men, <60 years women) cerebral or peripheral vascular disease 1
Physical examination
Tendon xanthomata 6
Arcus cornealis < 45 years  4
Cholesterol (mmol/l)
LDL-C ≥ 8.5 8
LDL-C ≥ 6.5–8.4 5
LDL-C ≥ 5.0–6.4 3
LDL-C ≥ 4.0–4.9 1
DNA analysis
Functional mutation in the LDLR present 86 Background and definition of the decision problem
LDLR gene and rarely in the APOB and PCSK9 genes.26 The LDLR gene is divided into 18 exons 
(coding regions in a gene) and 17 introns (non-coding regions in a gene).27 There are different 
types of mutations. Large rearrangements or deletions in the LDLR gene have been reported in 
5% of FH patients in the UK.5 Different genetic screening systems are used to screen the entire 
coding region for the LDLR gene, such as single-strand conformation polymorphism (SSCP) 
analysis, denaturing gradient gel electrophoresis (DGGE), DNA sequencing and RNA analysis.27 
None of these techniques has been reported to be 100% accurate, with detection rates of 75–85%. 
Techniques such as Southern blot analysis27 or multiplex ligation-dependent probe amplification 
(MLPA) are used to identify larger rearrangements and deletions. MLPA analysis, being a simple 
and rapid method for detecting large rearrangements, has been recommended to be included in 
the comprehensive genetic analysis (CGA) testing strategy for FH.28
Current service provision
Diagnosis and management
The NICE clinical guideline1 on the identification and management of FH recommends that 
diagnosis should be based upon the Simon Broome criteria. Health-care professionals should 
inform people with a diagnosis of FH based on the Simon Broome criteria that they have 
a clinical diagnosis of FH. To confirm a diagnosis of FH, health-care professionals should 
undertake two measurements of LDL-C concentration because biological and analytical 
variability occurs.
The NICE guideline1 recommends that health-care professionals should inform all people who 
have an identified mutation diagnostic of FH that they have an unequivocal diagnosis of FH even 
if their LDL-C concentration does not meet the diagnostic criteria. Health-care professionals 
should offer all people with FH a referral to a specialist with expertise in FH for confirmation of 
diagnosis and initiation of cascade testing in relatives.
Cascade testing using a combination of DNA testing and LDL-C concentration measurement is 
recommended to identify affected relatives of those index cases with a clinical diagnosis of FH. 
This should include at least the first- and second- and, when possible, third-degree biological 
relatives. In families in which a mutation has been identified, the mutation and not LDL-C 
concentration should be used to identify affected relatives. In the absence of a DNA diagnosis, 
cascade testing using LDL-C concentration measurements should be undertaken to identify 
people with FH. To diagnose FH in relatives of an index case, age- and gender-specific criteria for 
LDL-C concentration should be used, as using the Simon Broome LDL-C criteria for index cases 
would result in underdiagnosis. The age- and gender-specific LDL-C levels are split into three 
zones: green (relatives unlikely to have FH), red (relatives are likely to have a clinical diagnosis of 
FH) and grey (uncertain)1 (see Appendices 1 and 2).
For the management of adults, the NICE guideline1 recommends that a high-intensity statin 
should be prescribed to achieve a recommended reduction in LDL-C concentration of > 50% 
from baseline. Health-care professionals should offer all children and young people diagnosed 
with, or being investigated for, FH a referral to a specialist with expertise in FH in children 
and young people. This should be in an appropriate child/young person-focused setting that 
meets the standards within the National Service Framework for Children, Young People and 
Maternity Services.29
Current service cost
Currently, the majority of cascade testing is conducted using LDL-C. This is relatively inexpensive 
compared with DNA testing; however, it is associated with test inaccuracies. Costs are estimated © Queen’s Printer and Controller of HMSO 2012. This work was produced by Sharma et al. under the terms of a commissioning contract issued by the 
Secretary of State for Health.
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to occur over a 5- to 10-year period, after which time the number of cascade tests would be 
expected to fall. The estimated cost implications for implementing the current NICE guidance in 
the NHS are shown in Table 4.
Cost implications associated with cascade testing will probably be most relevant to secondary 
care. Savings from reductions in coronary events are likely to apply to both primary and 
secondary care. It is estimated that the cascade testing process will take approximately 5–10 years. 
Therefore, costs in year 3 would be expected to be extrapolated in a similar pattern out to 
10 years, after which overall cost implications would start to fall as fewer people would require 
testing and savings from coronary events avoided would continue to increase. The costing 
report referenced in Table 4 did not extrapolate over a 10-year time horizon and these numbers 
are based on strong assumptions about how these costs might change over time. For example, 
treatment costs are likely to be less than shown owing to the reduction in prices associated with 
next-generation gene sequencing and the forthcoming reduction in the cost of atorvastatin as it 
comes off patent. ‘Next generation’ refers to the emergence in recent years of new (non-Sanger-
based) DNA sequencing techniques. This allows higher throughput in genetics laboratories 
to test for more mutations, more quickly, and hence reduce costs. Early estimates suggest that 
the emergence of next-generation sequencing may reduce the sequencing costs in the testing 
of FH by approximately 40%. Therefore, the results presented are a guideline only and should 
be interpreted with caution. They are not an estimate of the resource use implications from 
implementing the recommendations of this report. Further details of how the above were derived 
are available from the NICE website.1
Variation in services and/or uncertainty about best practice
A 2004 census of clinics providing specialist lipid services in the UK30 reported that, of the 
165 clinics on Heart UK’s database, 144 provided specialist lipid services; however, the service 
provision was reported to be patchy, with < 10% of the estimated FH patients in the UK recorded 
on the computerised system. In such a scenario, the implementation of fully effective national 
cascade testing would be impeded.30 Furthermore, it was reported that 64% of these clinics 
employed only one doctor and > 20% did not employ a nurse, with only 22% providing two or 
more sessions per week (see also Current usage in the NHS).
Relevant national guidelines and related documents
These include:
  ■ Identification and Management of Familial Hypercholesterolaemia, NICE clinical 
guideline 71, 20081
  ■ The National Audit of the Management of Familial Hypercholesterolaemia 2010, Royal College 
of Physicians18
  ■ Primary Care Service Framework: Familial Hypercholesterolaemia, Primary 
Care Commissioning, 201031
  ■ Model of Care: Familial Hypercholesterolaemia, Western Australia Program Committee, 20086
  ■ Familial Hypercholesterolemia: Screening, Diagnosis and Management of Paediatric and Adult 
Patients, National Lipid Association Expert Panel on Familial Hypercholesterolemia, 200832
  ■ Screening for Lipid Disorders in Children, US Preventive Services Task Force, 2007.33
Description of technologies under assessment
Elucigene FH20 (Gen-Probe Life Sciences, UK) and LIPOchip (Progenika Biopharma, Spain) 
have been designed to reduce the need for CGA for the detection of genetic mutations associated 
with FH. These kits detect fewer genetic mutations than CGA.8 Background and definition of the decision problem
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Summary of Elucigene FH20
The Elucigene FH20 kit detects 20 genetic mutations associated with FH commonly found in the 
UK population. These mutations, with a frequency ranging from 1.3% to 11.4%, were identified 
from a cohort study in the UK involving 400 patients with FH.26 Of these 20 mutations, 18 are 
found in the LDLR gene and one each in the APOB and PCSK9 genes (Table 5).
The kit uses ARMS (AstraZenera, UK) allele-specific amplification technology, which detects 
point mutations, insertions or deletions in the LDLR, APOB and PCSK9 genes in human whole 
blood. The principle of ARMS technology is that oligonucleotides with a 3′ mismatched residue 
will not function as polymerase chain reaction (PCR) primers under specified conditions. 
Selection of appropriate oligonucleotides allows specific mutant or normal DNA sequences to 
be amplified and detected by fluorescent analysis using capillary electrophoresis (a technique 
for separating substances from a fluid substrate). Elucigene FH20 can also be processed using 
gel-based analysis. The gel-based version is currently the only version available in the UK.
Mutations detected in the Elucigene FH20 assay are believed to be pathogenic; in other words, if 
the individual tests positive on the Elucigene FH20 kit, they have a confirmed diagnosis of FH.
A limitation of the kit is that it tests for only 20 genetic mutations associated with FH commonly 
found in the UK population. Hence, less frequently occurring FH-causing mutations will not be 
detected. Worldwide, approximately 1400 FH-causing mutations have been identified,14 of which 
over 200 have been reported in the UK population. Therefore, in terms of the number of different 
FH-causing mutations found in the UK population, Elucigene FH20 would detect only around 
10% of them.
Summary of LIPOchip
LIPOchip is a genetic test that uses DNA array technology as part of a tiered system (LIPOchip 
platform). The current version (version 10) of the chip tests for 189 mutations in the three 
principal genes causing FH, i.e. LDLR, APOB and PCSK9, known to occur in the UK population. 
The chip is designed to detect both point mutations and copy number changes of the LDLR gene 
that are associated with FH. The LIPOchip platform involves the following steps:
1.  Samples are analysed using the DNA array system, which is designed to detect targeted 
mutations in the LDLR, APOB and PCSK9 genes as well as copy number variations.
2.  If these mutations are not detected the samples are fully sequenced for the mutations in the 
LDLR gene.
To process the chip, a thermal cycler, hybridisation station 4800 (Tecan, Switzerland) and a 
glass-slide scanner are required. The data are analysed by the LIPOchip software, which generates 
a report containing information on the pathogenicity of detected mutations based on either 
scientific publications or bioinformatics analysis.
The manufacturer of LIPOchip also offers a sample testing service in its laboratory in Spain. 
The laboratory has achieved ISO 9001:2008 certification. Two processing options are available. 
TABLE 5  Familial hypercholesterolaemia genetic mutations detected by Elucigene FH20
Gene Mutation
LDLR P664L, L458P, R329X, E207X, D200G, E80K, IVS3+1G>A, D461H, ∆G197, fs206, Q363X, W66G, V408M, D206E, C656R, 
K290RfsX20, C163Y, D461N
APOB R3500Q
PCSK9 D374Y10 Background and definition of the decision problem
The first is to run the LIPOchip test only (as described in step 1 above). The second runs the 
LIPOchip test and, in addition, for samples that are negative for a mutation after the LIPOchip 
test, carries out automated sequencing of the 18 exons of the LDLR gene (as described in steps 1 
and 2 above). If step 2 fails to detect any mutations then the sample is confirmed as FH negative 
by the manufacturer.
Comparators
Low-density lipoprotein cholesterol concentration measurement 
(Simon Broome criteria)
Low-density lipoprotein cholesterol is most commonly assessed using an estimated figure 
calculated from the TC and high-density lipoprotein (HDL) cholesterol values and the 
triglyceride level, the combination commonly being referred to as ‘lipids’. Because triglyceride 
measurements vary with fasting status, assessments are usually performed after an overnight 
fast. LDL-C by itself is neither fully sensitive nor specific for the diagnosis of FH, with 
considerable overlap between FH and non-FH individuals. LDL-C assessment would be 
recommended whether or not a genetic test is being undertaken, as other hyperlipidaemias (and 
the small proportion, perhaps around 5%, of patients with gene-negative FH) would have to be 
managed on the basis of lipid analysis, and the response to treatment would also be gauged by 
measuring lipids.
Comprehensive genetic analysis
Comprehensive genetic analysis is defined as the most complete genetic analysis generally 
available for FH within a diagnostic setting and is expected to detect almost all known 
FH-causing mutations. This analysis includes DNA sequence analysis of the promoter, all exons 
and the exon/intron boundaries and into the 3′ untranslated region of the LDLR gene, which 
will detect the majority (around 88%) of detectable FH mutations, MLPA for each exon and the 
promoter region of the LDLR gene to detect deletions and duplications (around 5% of detectable 
FH mutations) plus analysis for the common APOB p.Arg3527Gln gene mutation (around 5% of 
FH mutations) and the PCSK9 p.Asp374Tyr gene mutation (around 2% of FH mutations).
Targeted gene sequencing
Targeted gene sequencing is used to describe the genetic test for sequencing a specific part of 
the gene where the family mutation is found. Targeted gene sequencing may be used for cascade 
testing to identify FH in the biological relatives of index cases.
Identification of important subgroups
There are few data on mutation frequencies in different ethnic groupings across the UK. 
Extrapolation from genetic studies of a range of other diseases would suggest that it is likely that 
mutation frequencies could vary markedly between different ethnic groups.
Current usage in the NHS
At present, because of current NHS commissioning arrangements for genetic tests and in 
common with much specialist genetic testing across the UK, only a small number of laboratories 
offer genetic testing for FH. As a result, the main test currently used to diagnose FH is 
measurement of LDL-C concentration. Those laboratories that do offer genetic testing for FH 
include hospitals in Aberdeen, Belfast, Birmingham, Bristol, Cardiff, Great Ormond Street and 
Salisbury. Most laboratories proceed straight to CGA rather than using a pre-screen, and most 
perform MLPA in addition to DNA sequencing.
UK national audit of the management of familial hypercholesterolaemia
Following the publication of the NICE guideline for FH in 2008,1 a national clinical audit 
investigating the care received by individual patients with FH was undertaken by the Royal © Queen’s Printer and Controller of HMSO 2012. This work was produced by Sharma et al. under the terms of a commissioning contract issued by the 
Secretary of State for Health.
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College of Physicians, with the results published in 2010.18 A 2008 survey had shown that around 
15,000 adults and 500 children were being managed in UK lipid clinics and the audit examined 
around 15% (n = 2324) of the adults and 30% (n = 147) of the children.34
The results, key findings and recommendations of the audit in relation to cascade and DNA 
testing are detailed below.
Results
  ■ A total of 42% of sites reported having no database for FH patients.
  ■ Only 12% of sites had a commissioned cascade testing service.
  ■ Only 15% of sites received NHS funding for DNA testing.
  ■ In individuals in whom DNA testing was carried out, a mutation was detected in 62% of 
adults and 65% of children.
  ■ When the family mutation was known the child had been offered a DNA test in 94% of cases.
Key findings
  ■ Current resources were inadequate to cope with the identification of the predicted FH 
relatives of affected cases UK-wide. This included access to trained staff (86% of sites had no 
lipid specialist nurses), IT provision and pedigree drawing.
  ■ There was a major lack of family ‘cascade’ testing, whether carried out on the basis of lipid 
levels or, more effectively, of a DNA diagnosis.
  ■ Although there was good access to DNA diagnosis and funding for DNA testing in Scotland, 
Northern Ireland and Wales, access in England was poor.
Key recommendations
  ■ Additional resources would be needed to cope with the care of new FH patients identified by 
cascade testing. Training to address the shortage of staff with key skills would be required.
  ■ Systems needed to be developed and implemented to carry out comprehensive ‘cascade’ 
testing. This would require trained health professionals with the appropriate skills to follow 
up the families of index patients, improved IT resources, including a FH patient database, 
and pedigree drawing.
  ■ Resources were needed for DNA diagnosis and clinical genetics input.
  ■ Based on published data, cascade testing alone would find < 50% of the predicted 100,000 
unidentified FH patients in the UK, and other methods for finding FH index cases would 
need to be explored.
  ■ Given that FH families were geographically dispersed, cascade testing might be facilitated by 
a specifically funded UK FH Register to which all FH cases would be notified.
Anticipated costs associated with the intervention(s)
Diagnostic technologies
With regards to genetic tests, two novel screening techniques have emerged (Elucigene FH20 and 
LIPOchip). Some reports suggest that DNA testing for FH costs approximately £400, whereas 
other work estimates that the process could cost between £500 and £1000 per test. The main 
reasons for the large variation in reported costs are (1) the definition of DNA testing has varied 
in previous reports with differences in the genes sequenced and whether or not genes were 
screened for deletions or duplications and (2) the cost of DNA sequencing has reduced over time 
as laboratories build up economies of scale and improve equipment allowing for faster processing 
and reporting times; as a result, previous cost estimates for testing for FH have varied greatly 
across reports and studies.
The Elucigene FH20 kit is available at a cost of £15 per test and LIPOchip is available at a cost 
of €250 or approximately £198. However, these costs do not account for staff time to process 12 Background and definition of the decision problem
samples, consumables or overheads. Therefore, the costs of Elucigene FH20 and LIPOchip will be 
much greater in practice than just their unit test cost.
A standard NHS tariff does not exist per se for genetic tests; however, a recently developed 
system is now increasingly used by genetics laboratories across the UK to apportion costs to 
genetic testing services. This ‘MOLU’ (MOLecular Units) pricing system is the most commonly 
used costing mechanism for genetic testing of FH in laboratories across the UK. Genetic testing 
strategies vary in complexity depending on the type and volume of analysis required for different 
reports (genetic tests). The PCR amplicon or equivalent was chosen as a measure of complexity, 
which is transparent and easily counted. Reports are grouped into a total of six ‘bands’ (A–F). 
Bands are assigned and given a weighting according to the number of amplicons analysed to 
produce a report in that band. The number of reports multiplied by the appropriate band weight 
produces a final number of MOLUs. The total number of MOLUs derived from the exercise can 
be divided into the total laboratory budget to give an approximate monetary value to MOLUs. 
This in turn produces an indicative cost for the various testing strategies. Laboratories that can 
keep their budget constant or can reduce it but increase the number of MOLUs produced will 
have lower unit costs. It is estimated that the average cost per MOLU is between £30 and £35. 
Costs of all genetic tests including targeted gene sequencing for relatives can be estimated in 
this way.
Although the MOLU costing approach has been decided upon as the most appropriate and 
generally accepted method to cost these test strategies, it is far from ideal. The approach does 
not necessarily account for full economic costing or indeed opportunity costs of resources. 
The MOLU approach is basically a price banding agreed upon in collaboration between the 
laboratories from a UK Genetic Testing Network (UKGTN) group and the Clinical Molecular 
Genetics Society (CMGS). This has limitations in terms of the accuracy of the costs produced; 
however, in the absence of any more robust costing methods for these genetic tests, the MOLU 
classification system has been deemed the most appropriate method with which to compare these 
testing strategies.
Costs of LDL-C measurement will need to take into account the costs of resource use to 
retrieve samples and the costs of testing the samples by a laboratory. LDL-C testing is relatively 
inexpensive compared with genetic testing. These assays are performed routinely in most 
laboratories using current fully automated equipment (e.g. the laboratory in Aberdeen Royal 
Infirmary performs > 100,000 per annum) and the reagent cost is minimal (pence), so the overall 
cost of the procedure consists almost entirely of the general costs associated with processing any 
sample (around £3–10).
Ancillary costs
The genetic equipment required to process the tests is assumed to be readily available in UK 
laboratories. However, should this not be the case as standard, the costs of one-off purchases of 
this equipment will be included in the laboratory budget and thus indirectly accounted for using 
the MOLU system identified above.
Treatments
As per recommendations from NICE clinical guideline CG71,1 the recommended treatment 
for patients with FH is high-intensity statin therapy (usually atorvastatin 80 mg). For patients at 
risk of CHD based on high lipid levels but who do not have FH, the recommended treatment is 
low-intensity statin therapy (e.g. simvastatin 40 mg). The cost of atorvastatin is due to decrease 
during the course of this assessment and is likely to be equivalent to that of generic simvastatin. 
The implications of this are explored in the cost-effectiveness analysis. Costs of a number of other 
statin-based therapies such as rosuvastatin, pravastatin, etc. are considered. Other treatments 
include ezetimibe (evidence of efficacy uncertain) and bile acid sequestrants (costly).© Queen’s Printer and Controller of HMSO 2012. This work was produced by Sharma et al. under the terms of a commissioning contract issued by the 
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Other costs
Other cost considerations include the cost of health-care professionals to identify family pedigree 
and the costs of initiating contact with relatives for cascade testing. Costs of annual follow-ups for 
patients diagnosed with FH are also considered in the analysis.
Care pathways
The care pathway for this evaluation is determined by NICE clinical guideline CG711 on the 
identification and management of FH. The key elements from the care pathway are as follows:
  ■ A diagnosis of FH should be made on the basis of a combination of the Simon Broome 
criteria for a clinical diagnosis and a DNA test to confirm this diagnosis unequivocally. This 
confirmation should include two measures of LDL-C because of biological and analytical 
variability of the tests.
  ■ The children of adults identified with FH should be offered a DNA test if the family mutation 
is known; alternatively, if the mutation is unknown, LDL-C testing should be carried out and 
repeated after puberty.
  ■ Cascade testing of at-risk relatives is recommended using a combination of DNA testing and 
LDL-C concentration measurement in first-, second- and possibly third-degree biological 
relatives. If the family mutation is known then DNA testing and not LDL-C should be used 
to identify relatives.
  ■ Prescription of a high-intensity statin should be considered to achieve a recommended 
reduction in LDL-C concentration of > 50% for patients with FH. Lipid-modifying treatment 
in children with FH should be considered by age 10 years and initial treatment should be 
statin therapy.
It is important to note that, in practice, the guideline is not very well implemented across the UK 
because of a lack of funding for the genetic testing of patients with FH and cascade genetic testing 
of identified relatives. In many cases, LDL-C is the most commonly administered test to identify 
FH but is subject to poor accuracy and reliability.
Definition of the decision problem
Purpose of the decision to be made
The purpose of this assessment is to address the following questions:
1.  What are the most effective and cost-effective strategies for confirming a diagnosis of FH in 
index cases and for cascade testing of relatives?
2.  In cascade testing of relatives for mutations identified in index cases by Elucigene FH20 
or LIPOchip, would it be more cost-effective to use those tests rather than targeted 
gene sequencing?
Definition of the intervention
The interventions are described in Description of technologies under assessment.
Populations and relevant subgroups
Populations and relevant subgroups are described in Chapter 2, Inclusion and exclusion criteria.14 Background and definition of the decision problem
Place of the interventions in the treatment pathway(s)
The care pathway for this assessment is based on NICE clinical guideline CG711 on the 
identification and management of FH.
Index cases
The assessment investigates the use of diagnostic strategies including Elucigene FH20 and/or 
LIPOchip for providing an unequivocal diagnosis of FH for those with a clinical diagnosis based 
on the Simon Broome criteria.
Cascade testing of relatives
The assessment investigates the use of diagnostic strategies including Elucigene FH20 and 
LIPOchip for cascade testing to identify FH in the relatives of index cases. The use of Elucigene 
FH20 or LIPOchip for cascade testing depends on the mutation detected in the index case 
and the cost of targeted gene sequencing. (In index cases with an identified genetic mutation, 
targeted gene sequencing is also considered for cascade testing of relatives. In index cases 
without an identified genetic mutation, cascade testing using LDL-C concentration measurement 
is considered.)
A scenario encompassing a single test strategy (Elucigene FH20 or LIPOchip) that does not 
end in CGA for test-negatives may not detect all cases of FH. In such a scenario there may be 
implications for test-negative patients in terms of how their condition is managed.
Relevant comparators
Relevant comparators are described in Description of technologies under assessment.
Overall aim and objectives of the assessment
The overall aim of the assessment is to assess the diagnostic accuracy, effect on patient outcomes 
and cost-effectiveness of Elucigene FH20, LIPOchip and comparators for the diagnosis of FH.
The objectives of the assessment are to:
  ■ systematically review the evidence on the test performance and clinical effectiveness of 
Elucigene FH20, LIPOchip and comparators in confirming a diagnosis of FH in patients with 
a clinical diagnosis of FH
  ■ systematically review the evidence on the test performance and clinical effectiveness of 
Elucigene FH20, LIPOchip and comparators in cascade testing of relatives of index cases 
with a confirmed diagnosis of FH
  ■ review the evidence on the cost-effectiveness of Elucigene FH20 and LIPOchip for the 
identification of index cases and cascade testing of relatives
  ■ estimate the costs of different diagnostic strategies for detecting FH in index cases and for 
cascade testing of relatives of index cases with a diagnosis of FH
  ■ develop a comprehensive health economic model to link test accuracy of various diagnostic 
testing strategies to lifelong cost and treatment outcomes using a linked evidence approach to 
the modelling process
  ■ determine the most cost-effective testing strategy relative to current practice (LDL-C) 
and also to investigate which strategies may be cost-effective compared with current 
NICE guideline recommendations (i.e. DNA testing), akin to CGA in the context of 
this assessment.© Queen’s Printer and Controller of HMSO 2012. This work was produced by Sharma et al. under the terms of a commissioning contract issued by the 
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Chapter 2 
Assessment design and results: 
test performance
Methods for reviewing test performance
Identification of studies
Studies were identified by searching electronic databases and relevant websites, contact with 
experts in the field and the scrutiny of bibliographies of retrieved papers. Highly sensitive 
electronic searches were conducted to identify reports of published and ongoing studies on the 
diagnostic accuracy and clinical effectiveness of tests for FH in index cases and for cascade testing 
of relatives. The search strategy excluded studies published before 2000.
The databases searched were MEDLINE (1948 to Week 1 2011), MEDLINE In-Process & Other 
Non-Indexed Citations (10 January 2011), EMBASE (1980 to 2011 Week 1), BIOSIS (1956 to 
10 January 2011), Science Citation Index (1970 to 10 January 2011), Conference Proceedings 
Citation Index – Science (1990 to 10 January 2011) and Cochrane Controlled Trials Register (The 
Cochrane Library, Issue 1, 2011), as well as current research registers: Current Controlled Trials 
(January 2011), Clinical Trials (January 2011) and the World Health Organization International 
Clinical Trials Registry (January 2011). Additional databases searched for systematic reviews 
and other background information included the Cochrane Database of Systematic Reviews (The 
Cochrane Library, Issue 1, 2011), Database of Abstracts of Reviews of Effects (January 2011) and 
Health Technology Assessment database (January 2011). Recent conference proceedings were 
also searched. Full details of the search strategies used and websites consulted are documented in 
Appendix 3. In addition, reference lists of all included studies were scanned to identify additional 
potentially relevant studies.
Inclusion and exclusion criteria
Population
The population considered was adults and children with a clinical diagnosis of FH (the index 
cases/probands) based on the Simon Broome, Dutch or MedPed criteria and, for cascade testing, 
the first-, second- and third-degree biological relatives of the index case. (In the protocol for 
the review we stated that we would consider those with a clinical diagnosis based on the Simon 
Broome criteria as recommended for clinical diagnosis of FH in the UK. However, we also 
identified a few studies based on the Dutch and MedPed criteria and in consultation with our 
clinical advisers we relaxed our inclusion criteria to also include studies in which participants had 
received a clinical diagnosis of FH based on these criteria, as clinical advice suggested that these 
criteria were sufficiently similar to the Simon Broome criteria and if consistently applied would 
also provide potentially useful evidence.)
Given sufficient evidence, subgroup analysis was to be undertaken on the performance of 
Elucigene FH20 and LIPOchip in ethnic populations.
Setting
The settings considered were secondary or tertiary care.16 Assessment design and results: test performance
Interventions and comparators
The interventions considered were Elucigene FH20 and LIPOchip for index cases and cascade 
testing of relatives. The comparators considered for testing in index cases were (1) CGA and 
(2) LDL-C concentration measurement (Simon Broome, Dutch or MedPed criteria). The 
comparators considered for cascade testing of relatives were (1) targeted gene sequencing and (2) 
LDL-C concentration measurement (age- and gender-specific criteria as recommended in NICE 
clinical guideline CG711).
Reference standard
The reference standard was CGA in combination with the Simon Broome, Dutch or MedPed 
criteria. CGA was defined as the ‘most complete genetic analysis’ generally available for FH 
within a diagnostic setting and is expected to detect almost all known FH-causing mutations. 
This analysis includes DNA sequence analysis of the promoter, all exons and the exon/intron 
boundaries and into the 3′ untranslated region of the LDLR gene, which will detect the majority 
(~88%) of detectable FH mutations, MLPA for each exon and the promoter region of the 
LDLR gene to detect deletions and duplications (~5% detectable FH mutations) plus analysis 
for the common APOB p.Arg3527Gln gene mutation (~5% of FH mutations) and the PCSK9 
p.Asp374Tyr gene mutation (~2% of FH mutations).
During the screening process it was ascertained that some studies reporting genetic analysis did 
not fulfil all of the above criteria for CGA, for example:
  ■ LDLR, APOB and PCSK9 gene analysis but testing for deletion/duplication was carried out 
using a process other than MLPA such as Southern blot analysis or quantitative multiplex 
PCR methodology (QMFSP)
  ■ LDLR and APOB gene analysis, but no PCSK9 analysis.
Therefore, we took a pragmatic decision to still include studies reporting such an ‘incomplete 
CGA’ and to assess the quality of such a reference standard in terms of comprehensiveness and 
variations in test accuracy.
Studies reporting the following single genetic analyses were excluded:
  ■ APOB gene analysis only
  ■ PCSK9 gene analysis only
  ■ test for deletion/duplication only.
In the event of a sequential mutational detection strategy used for the diagnosis of FH, for 
example Elucigene FH20 followed by gene sequencing for those negative on Elucigene FH20 and 
then followed by MLPA tests for those negative on gene sequencing, the combination of these 
sequences could be considered to be CGA.
Low-density lipoprotein cholesterol measurement as part of the clinical diagnosis was one of 
the comparators. Estimates of the accuracy of LDL-C using the reference standard of CGA 
plus a clinical diagnosis that includes LDL-C measurement are likely to be inflated compared 
with the estimates of accuracy of other index tests being evaluated. Therefore, for inclusion of 
studies reporting the diagnostic accuracy of LDL-C (which is a part of the clinical diagnosis), we 
considered the estimates of accuracy of LDL-C against a reference standard of CGA (either most 
complete or incomplete) only.© Queen’s Printer and Controller of HMSO 2012. This work was produced by Sharma et al. under the terms of a commissioning contract issued by the 
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Outcomes
The following outcomes were considered:
  ■ test accuracy: sensitivity, specificity, positive likelihood ratio and negative likelihood ratio.
In any studies reporting the above outcomes the following outcomes were also considered:
  ■ proportion of cases with an unequivocal diagnosis identified by Elucigene FH20 
and LIPOchip
  ■ proportion requiring CGA after Elucigene FH20 and LIPOchip
  ■ proportion of FH identified from cascade testing
  ■ acceptability of the tests
  ■ interpretability of the tests.
Test accuracy data on the absolute numbers of true-positives, false-positives, false-negatives and 
true-negatives were extracted or calculated from the information provided in the studies. We 
also considered studies in which derivation of a complete 2 × 2 diagnostic table was not possible 
but which reported data to allow derivation of one of the test accuracy measures, for example 
sensitivity but not specificity.
Study design
The following types of studies were considered:
  ■ direct (head-to-head) studies in which the index test, comparator test and reference standard 
test were carried out independently in the same group of people
  ■ randomised controlled trials (RCTs) in which people were randomised to the index and 
comparator test(s) and all received the reference standard test.
In case of insufficient evidence from direct and randomised studies, indirect (between-study) 
comparisons in the following types of study were also considered:
  ■ diagnostic cross-sectional studies comparing the index test or comparator test against a 
reference standard test
  ■ case–control studies in which two groups were created, one known to have the target disease 
and one known not to have the target disease, in which it was reasonable for all included to 
go through the tests.
Exclusion criteria
The following types of reports were excluded:
  ■ preclinical and biological studies
  ■ reviews, editorials and opinions
  ■ case reports
  ■ reports investigating technical aspects of a test.
Non-English-language reports were excluded.
Data extraction strategy
Two reviewers (PS and GM) independently screened the titles and abstracts of all reports 
identified by the search strategy. Full-text copies of all studies deemed to be potentially relevant 
were obtained and two reviewers (PS and GM) independently assessed them for inclusion. 
Disagreements were resolved by consensus or arbitration by a third party (ZM and WS).18 Assessment design and results: test performance
A data extraction form was developed and piloted (see Appendix 4). One reviewer (PS) extracted 
the details of study design, participants, index, comparator, reference standard tests and outcome 
data. A second reviewer (GM) checked the data extraction. Any disagreements were resolved by 
consensus or arbitration by a third party (ZM and WS). Any study data requested and received 
from the manufacturers that met the inclusion criteria were to be extracted and quality assessed 
in accordance with the procedures outlined in the protocol for the assessment.
Quality assessment strategy
The methodological quality of the included diagnostic studies was assessed using QUADAS,35 a 
quality assessment tool developed for use in systematic reviews of diagnostic studies. QUADAS 
was developed through a formal consensus method and was based on empirical evidence. The 
checklist was adapted for the purposes of this review (it is designed to be adapted to make it 
more applicable to a specific review topic) (see Appendix 5 for the modified QUADAS checklist). 
The original QUADAS checklist contained 14 questions. Questions 1, 3, 5–7 and 10–14 of the 
original QUADAS tool were retained (questions 1–10 in the modified version). Three questions 
in the original QUADAS tool that related to the quality of reporting rather than methodological 
quality were omitted from the modified version (questions 2, 8 and 9). These questions related 
to the description of (1) the selection criteria, (2) the execution of the index test and (3) the 
execution of the reference standard test. A fourth question relating to whether or not the time 
period between the reference standard and index test was short enough to be reasonably sure that 
the target condition did not change between the two tests was also omitted. This question was not 
considered to be relevant as a person will either have or not have FH.
Three questions were added to the modified checklist on (1) whether or not cut-off values were 
established before the study was started, (2) whether or not the technology of the index test 
was unchanged since the study was carried out and (3) whether or not the study provided a 
clear definition of what was considered to be a ‘positive’ result. Three questions in the modified 
checklist were considered to be relevant to studies reporting LDL-C but not applicable to studies 
reporting Elucigene FH20 or LIPOchip owing to the nature of these tests: question 8, ‘Were 
the same clinical data available when test results were interpreted as would be available when 
the test is used in practice?’; question 11, ‘Were cut-off values established before the study was 
started?’; and question 13, ‘Did the study provide a clear definition of what was considered to be a 
“positive” result?’.
Two reviewers independently assessed the quality of all included full-text diagnostic studies 
using the modified version of QUADAS. Each question was checked as ‘yes’, ‘no’ or ‘unclear’, 
or, for questions 8, 11 and 13, ‘not applicable’ for reports of Elucigene FH20 or LIPOchip. Any 
disagreements were resolved by consensus or arbitration by a third party. Studies were not 
included or excluded on the basis of their methodological quality. Conference abstracts were not 
quality assessed on the basis that they were not considered to contain sufficient information to 
allow for an adequate assessment of their methodological quality.
Data analysis
Analysis focused on the ability of Elucigene FH20, LIPOchip and its comparators to confirm FH 
in index cases of FH diagnosed clinically. Two-by-two tables were extracted from each of the 
included studies in which information was provided on the numbers of true- and false-positives 
and -negatives for the index and/or comparator test compared with the reference standard for 
detecting those mutations that the index and/or comparator test are designed to identify. For 
each study, where there was sufficient information, sensitivity, specificity, positive and negative 
likelihood ratios and their confidence intervals (CIs) were calculated.© Queen’s Printer and Controller of HMSO 2012. This work was produced by Sharma et al. under the terms of a commissioning contract issued by the 
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Where appropriate and given sufficient information, we had planned to use summary receiver 
operating characteristic (SROC) curves for the meta-analysis of data from studies reporting 
estimates of true- and false-positives and -negatives. Where appropriate, it was planned to fit 
models using the hierarchical summary receiver operating characteristic (HSROC) framework, 
which takes proper account of the diseased and non-diseased sample sizes in each study, and 
allows estimation of random effects for the threshold and accuracy effects, and testing of the 
impact of potential sources of heterogeneity. However, there was insufficient information to 
enable pooling of results or to provide SROC curves as planned and so forest plots of sensitivity 
and specificity were used to visualise the heterogeneity amongst the included studies. No formal 
meta-analysis was therefore carried out.
Diagnostic accuracy metrics
For the purpose of this assessment, we define test-positive and test-negative as follows:
  ■ Elucigene FH20/LIPOchip tests: those with a FH-causing mutation detected by Elucigene 
FH20 or LIPOchip were defined as ‘test-positive’ and those with no mutations detected were 
defined as ‘test-negative’.
  ■ LDL-C tests (as a part of the Simon Broome criteria): we assumed that people with positive 
clinical criteria would have positive cut-offs of LDL-C as suggested in the definition of the 
criteria. A minimum LDL-C level of 4 mmol/l is required to diagnose index cases.
  ■ Age- and gender-specific LDL-C test (as recommended in NICE guideline): those with 
LDL-C levels greater than the cut-offs were defined as ‘test-positive’ and those with LDL-C 
levels lower than the cut-offs were defined as ‘test-negative’.
  ■ True-positives: people with clinical FH who are positive on tests (Elucigene FH20 or 
LIPOchip or LDL-C as part of the Simon Broome criteria or age- and gender-specific 
LDL-C) and positive on CGA.
  ■ False-negatives: people with clinical FH who are negative on tests, but positive on CGA.
  ■ False-positives: people with clinical FH who are positive on tests, but negative on CGA.
  ■ True-negatives: people with clinical FH who are negative on tests and negative on CGA.
  ■ Sensitivity = true-positive/(true-positive + false-negative) × 100.
  ■ Specificity = true-negative/(true-negative + false-positive) × 100.
Results of test performance
Quantity of research available
Quantity of studies identified
The searches identified 1529 records for the review of test performance. Following screening 
of titles and abstracts, 1296 articles were excluded and full-text reports of the remaining 233 
articles were obtained for further assessment. Figure 3 shows a flow diagram outlining the 
screening process.
Appendix 6 lists the 15 studies (17 reports) that were included in the review of test performance 
(Table 6 lists the studies, tests evaluated, publication status and other linked reports). Of 
the 15 studies, three (four reports) reported Elucigene FH20,36–38 five (six reports) evaluated 
LIPOchip,39–43 four reported LDL-C compared with genetic analysis44–47 and three reported age- 
and gender-specific LDL-C for cascade testing of relatives.48–50 We did not identify any studies 
reporting a combination of the index tests, that is Elucigene FH20 and LIPOchip.
Number and type of studies excluded
A list of the 221 potentially relevant studies identified by the search strategy for which full-text 
papers were obtained but which subsequently failed to meet the inclusion criteria is given in 
Appendix 7.20 Assessment design and results: test performance
1529 titles and abstracts identified from
primary searches
1296 excluded
233 selected for full-text assessment
plus 5 full texts received from experts
221articles excluded:
Not FH, n = 2
Reviews or guidelines, n = 7
Letters or editorials, n = 6
Background papers, n = 47
Case reports, n = 1
Non-English language, n = 1
Unavailable papers, n = 11
 
15 studies (17 reports) included
FIGURE 3  Flow diagram outlining the screening process.
TABLE 6  Summary of included studies
Main studya Test(s) evaluated  Publication status
Other reports linked to the 
study (not included in the 
review)
Alonso 200939  LIPOchip  Full text
Callaway 201040 LIPOchip Presentation plus information from 
author
Civeira 200844 LDL-C Full text plus information from 
author
Damgaard 200545 LDL-C, targeted sequencing Full text
Hooper 200936 Elucigene FH20  Abstract
Lee 201048 LDL-C age and gender specific 
(NICE criteria)
Abstract and information from 
author
Mabuchi 200546 LDL-C Full text Yu 200251
Palacios 201041 [Stef 201052] LIPOchip  Abstract and poster plus 
manufacturer data 
Starr 2008,49 Damgaard 200545 LDL-C age and gender specific 
(NICE criteria), targeted 
sequencing
Full text Leren 2004,53 Umans-
Eckenhausen 200119
Stef 200942 LIPOchip Abstract
Taylor 201037 [Taylor 200754] Elucigene FH20, targeted 
sequencing
Full text plus information from 
author
Taylor 2009,28 Tabrah 200555
Tejedor 200543 LIPOchip Full text Tejedor 2006,56 Oliva 200957
Widhalm 200747 LDL-C Full text
Wiegman 200350 LDL-C age specific, targeted 
sequencing 
Full text Fouchier 200158
Yarram 201038 Elucigene FH20, cascade test Presentation
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Characteristics of the included studies
Appendix 8 shows the characteristics of the individual included studies.
Study design
All of the studies were diagnostic cross-sectional studies evaluating the performance of Elucigene 
FH20,36–38 LIPOchip39–43 or LDL-C44–50 against a reference standard of genetic analysis (either 
incomplete or complete in terms of the definition of CGA as stated in Inclusion and exclusion 
criteria) in which all participants received a clinical diagnosis using Simon Broome, Dutch or 
MedPed criteria. No RCTs were identified that randomised participants to any of the tests of 
interest with all receiving a reference standard test.
Country and setting
Of the eight studies evaluating Elucigene FH20 or LIPOchip, four were conducted in the 
UK37,38,40,41 (two37,38 reporting Elucigene FH20 and two40,41 reporting LIPOchip) and one was 
conducted in Australia36 (evaluating Elucigene FH20), with the remaining three taking place in 
Spain39,42,43 (all of which reported LIPOchip). Of the seven studies reporting the performance of 
LDL-C (in index cases or for cascade testing of relatives), one each was conducted in the UK,48 
Spain,44 Denmark,45 Austria,47 Japan46 and the Netherlands.50 The study by Starr and colleagues49 
included participants from the Netherlands, Denmark and Norway. When reported (seven 
studies), the clinical diagnosis was performed in lipid clinics.
Clinical diagnosis
The clinical diagnostic criteria used tended to differ according to the country where the study 
was carried out. The studies by Palacios and colleagues,41 Callaway and colleagues,40 Taylor and 
colleagues,37 Yarram38 and Lee and colleagues48 were conducted in the UK and their participants 
had a clinical diagnosis based on the Simon Broome criteria. Of three studies set in Spain, those 
by Stef and colleagues42 and Alonso and colleagues39 used the Dutch criteria, whereas the study 
by Tejedor and colleagues43 employed the MedPed criteria. The study by Hooper and colleagues,36 
set in Australia, used the Dutch criteria whereas the study by Widhalm and colleagues,47 set in 
Austria, used the MedPed criteria.
In the studies by Civeira and colleagues44 and Damgaard and colleagues45 patients were given 
a clinical diagnosis followed by a genetic diagnosis and were then retrospectively classified 
by the Simon Broome, Dutch and MedPed criteria. Civeira and colleagues44 used an initial 
clinical diagnosis based on the MedPed criteria, whereas Damgaard and colleagues45 included 
participants who fulfilled two of the following three criteria: (1) LDL-C > 6 mmol/l, TC 
> 8 mmol/l and triglycerides < 2.5 mmol/l; (2) tendon xanthomata; and (3) a history of coronary 
artery disease before the age of 60 years in the patient and/or in a first-degree relative and/or 
hypercholesterolaemia in a first-degree relative.
In the studies by Starr and colleagues49 and Mabuchi and colleagues46 a genetically tested cohort 
of relatives was recruited to study the test performance of age- and gender-specific LDL-C 
cut-offs and a cut-off of 4 mmol/l, which is the minimum cut-off required by Simon Broome 
criteria respectively. In the study by Starr and colleagues, clinically diagnosed index cases based 
on the Dutch criteria (the Netherlands) and a combination of lipid levels, clinical characteristics 
and family history (Norway and Denmark) were included, whereas the study by Mabuchi 
and colleagues46 included clinically diagnosed index cases based on TC (≥ 5.9 mmol/l and 
< 12.9 mmol/l) with tendon xanthomata or primary hypercholesterolaemia with/without tendon 
xanthomata in a family with FH patients among first-degree relatives. The study by Wiegman and 
colleagues50 recruited relatives of index cases with a clinical diagnosis of FH based on the MedPed 
criteria or from a genetic diagnosis.22 Assessment design and results: test performance
Participants
In the studies by Taylor and colleagues,37 Damgaard and colleagues,45 Mabuchi and colleagues,46 
and Tejedor and colleagues43 the participants were all adults. In the study by Wiegman and 
colleagues50 the participants were children. In the studies by Starr and colleagues49 and Widhalm 
and colleagues47 the participants were a mixture of adults, adolescents and children, whereas 
in the study by Civeira and colleagues44 they were adults and adolescents. The remaining seven 
studies36,38–42,48 (six abstracts and one full text) did not specify whether the participants (index 
patients or relatives) were adults, children or adolescents.
Eight studies reported diagnostic accuracy in index cases only,36,39–44,46 whereas four37,38,45,47 
reported this information both for index cases and for cascade testing of relatives, with the 
remaining three studies48–50 reporting test performance for cascade testing of relatives only. In 
studies reporting cascade testing of relatives these were all first-degree relatives apart from the 
two studies by Damgaard and colleagues45 and Lee and colleagues,48 in which this information 
was not specified.
For studies evaluating the test performance of Elucigene FH20 and LIPOchip, the sample size 
ranged from 22 patients40 to 2462 patients.42 In studies reporting test performance of LDL-C, 
the sample size ranged from 26347 to 3294.49 In studies reporting cascade tests through targeted 
sequencing the sample size of relatives ranged from 27 relatives (from 104 index cases)38 to 1034 
relatives (from 591 index cases).50
In the study by Lee and colleagues48 all included relatives were heterozygous FH (coming from 
homozygous FH index cases), whereas in the study by Mabuchi and colleagues46 none was 
homozygous. The rest of the studies did not report on the status of FH patients. Three studies43–45 
reported the number of participants at baseline with coronary artery disease, which ranged from 
15% to 20%, and xanthomata, which ranged from 16% to 56%. The mean LDL-C concentration 
of participants as reported in two studies ranged from 4.3 mmol/l to 5.7 mmol/l.47,49
Only one study reported the proportion of participants by ethnic group.37 In this study most of 
the patients were white British (85.4%), 5.8% were of European origin and very few were from 
ethnic minorities, including 1.7% of Middle Eastern origin, 4.5% of Indian-Asian origin, 1.3% of 
African or Afro-Caribbean origin and 0.8% from the Far East.
Characteristics of the tests reported by the included studies
Table 7 summarises the characteristics of the studies reporting Elucigene FH20 or LIPOchip, 
whereas Table 8 summarises the characteristics of the studies reporting LDL-C.
Elucigene FH20
Three studies, by Taylor and colleagues,37 Hooper and colleagues36 and Yarram,38 reported 
Elucigene FH20 (Gen-Probe, UK) as a pre-screen genetic tool for the diagnosis of FH. In all three 
studies, the genetic screening of clinically diagnosed patients took place in three stages of tests: 
(1) Elucigene FH20 to screen for 20 common genetic mutations found in the UK (18 LDLR, one 
PCSK9, one APOB); (2) MLPA to screen for deletions and duplications in the LDLR gene for 
those negative on Elucigene FH20; and (3) sequencing of the entire LDLR gene for those negative 
on MLPA. In the study by Taylor and colleagues37 sequencing was performed using SSCP, 
denaturing high-performance liquid chromatography (dHPLC) and direct sequencing (promoter, 
all exons, the exon intron boundaries, 3′ untranslated region). Hooper and colleagues36 reported 
exon-by-exon sequencing of the LDLR gene, whereas Yarram38 reported sequencing of all 18 
LDLR exons and the promoter region.© Queen’s Printer and Controller of HMSO 2012. This work was produced by Sharma et al. under the terms of a commissioning contract issued by the 
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.24 Assessment design and results: test performance
Taylor and colleagues37 and Yarram38 included unrelated patients who were clinically diagnosed 
as having definite FH or possible FH based on the Simon Broome criteria. These studies also 
reported on clinical cases who could not be classified as having definite or possible FH because 
of insufficient information provided from the lipid clinics (usually because of missing untreated 
cholesterol data), grouped as unclassified FH. Additionally, Yarram38 included 18% (19/104) of 
patients who did not met Simon Broome criteria in the analysis. Hooper and colleagues,36 on the 
other hand, included patients with a diagnosis of definite FH based on the Dutch criteria who 
were enrolled in the FH Western Australia (FHWA) pilot programme.
A paper54 relating to the study by Taylor and colleagues (for which Taylor and colleagues37 is 
considered the primary reference) reported results on an earlier version of the Elucigene FH20 
kit (Elucigene FH013 B1), which screened for 13 common genetic mutations found in the 
UK population (11 LDLR, one PCSK9 and one APOB). Detection rate data from this test were 
included with those from Elucigene FH20 in the results reported by Taylor and colleagues37 
but were treated as if all samples had been tested with Elucigene FH20. Results from the 
Taylor and colleagues 2007 report54 were included because all study participants received both 
Elucigene FH20 and also a reference standard of sequencing of the LDLR gene, unlike the 
Taylor and colleagues 2010 report,37 in which only test-negatives on Elucigene FH20 went on to 
receive CGA.
Both of the studies by Taylor and colleagues37 and Hooper and colleagues36 reported, for index 
cases with a clinical diagnosis of FH, the detection rate using Elucigene FH20 as a pre-screening 
test alone and when used in combination with sequencing and MLPA. Yarram38 reported 
the sensitivity of Elucigene FH20 against CGA. Taylor and colleagues37 additionally reported 
detection rates for FH by ethnicity. The studies by Taylor and colleagues37 and Yarram38 also 
reported results for cascade testing of relatives, in which the index cases had been identified 
using Elucigene FH20 initially followed by genetic screening in the form of sequencing and 
then MLPA.
LIPOchip
Five studies evaluated various versions of the LIPOchip platform (Progenika Biopharma, 
Spain).39–43 In two studies, by Palacios and colleagues41 and Stef and colleagues,42 the LIPOchip 
platform comprised detection of point mutations in the LDLR, APOB and PCSK9 genes by the 
LIPOchip DNA array and copy number changes in the LDLR gene followed by sequencing 
of the LDLR gene for test-negatives on the chip. In the study by Alonso and colleagues,39 
LIPOchip detected mutations in the LDLR and APOB genes and also large rearrangements, 
followed by sequencing of the LDLR gene for test-negatives. Callaway and colleagues40 reported 
the performance of LIPOchip against dHPLC/sequencing and MLPA in one of the genetic 
laboratories in the UK, in which all samples (negative on Elucigene FH20) received LIPOchip 
and also sequencing and MLPA, analysing all three genes. The study by Tejedor and colleagues43 
reported only the performance of the DNA array in detecting point mutations in the LDLR and 
APOB genes.
The studies by Palacios and colleagues41 and Callaway and colleagues40 reported detection of 
FH mutations in a UK population using version 8 of LIPOchip, which included 251 of the most 
prevalent mutations in Spain, the Netherlands, Italy and the UK. Information on version 10 of 
LIPOchip, which was developed by analysing 1000 patients from several cohorts, was obtained 
from the manufacturer based on the former study.41 This version of the chip detects 189 of the 
most frequent FH mutations known to occur in the UK population and can also detect copy 
number changes in the LDLR gene. Palacios and colleagues41 analysed samples from Newcastle 
and from Wales using version 8, and version 8 or version 9 of LIPOchip, respectively; however, 
the Welsh samples did not have information on clinical diagnosis (response by manufacturer to 
queries) and therefore did not meet the review’s inclusion criteria.© Queen’s Printer and Controller of HMSO 2012. This work was produced by Sharma et al. under the terms of a commissioning contract issued by the 
Secretary of State for Health.
25   Health Technology Assessment 2012; Vol. 16: No. 17 DOI: 10.3310/hta16170
Stef and colleagues42 reported on a Spanish version of LIPOchip containing 247 of the most 
frequent Spanish FH mutations (238 LDLR, three APOB and six PCSK9) designed to detect point 
mutations in the LDLR, APOB and PCSK9 genes and copy number changes in the LDLR gene. 
Alonso and colleagues39 also evaluated the performance of a Spanish version of the LIPOchip 
platform containing a DNA array designed to detect 191 different point mutations in the LDLR 
gene and four different mutations in the APOB genes and adapted QMFSP for the analysis of 
large deletions or insertions in the LDLR gene. Tejedor and colleagues43 reported the earliest 
version of LIPOchip comprising a DNA array including 118 mutations (117 LDLR and one 
APOB) as identified from SSCP/sequencing/restriction polymorphism analysis, with more than 
half of these mutations having been reported in Holland, France, Germany, Italy, Greece, the UK 
and the USA.
In all of these studies (except in the study by Callaway and colleagues40), the analysis was 
performed in the manufacturer’s laboratory in Spain.
The study by Palacios and colleagues41 was the only study that used DNA samples from patients 
with a clinical diagnosis based on the Simon Broome criteria. All of the samples had previously 
undergone genetic testing comprising Elucigene FH20 followed by, for test-negatives, SSCP/
dHPLC/direct sequencing of all exons and finally MLPA for test-negatives on the previous 
test. In the study by Callaway and colleagues40 selection criteria included one or more of the 
following: clinical diagnosis of Simon Broome ‘definite FH’ or high cholesterol (> 8 mmol/l) with 
family history of high cholesterol or cardiovascular disease. Alonso and colleagues39 included 
unrelated cases with a clinical diagnosis of definite or probable FH based on the Dutch criteria 
(all participants had a score of ≥ 6 points). The studies by Stef and colleagues42 and Tejedor and 
colleagues43 included participants with a clinical diagnosis based on Dutch–MedPed criteria. 
Tejedor and colleagues43 included patients with definite FH (score ≥ 8 points) and probable or 
possible FH (score 4–8 points).
Four studies reported the detection rate of FH by LIPOchip but only three39,41,42 provided true-
positive test data for each stage of testing and overall, to allow calculation of the sensitivity of 
LIPOchip in the diagnosis of FH against CGA. One study reported true-positive, true-negative, 
false-positive and false-negative data along with sensitivity and specificity.40 The studies 
by Alonso and colleagues39 and Tejedor and colleagues43 reported the diagnostic accuracy 
(sensitivity and specificity) of the LIPOchip DNA array at the mutational level. The sensitivity 
of the array was determined by the number of mutations detected by sequencing LDLR in the 
samples in which the DNA array failed to detect mutations, whereas specificity was determined 
by random verification of DNA array-positive samples by automatic sequencing.
The studies by Palacios and colleagues41 and Alonso and colleagues39 provided information on the 
time taken to obtain LIPOchip platform results.
None of the LIPOchip studies reported results for cascade testing of relatives.
Low-density lipoprotein cholesterol as part of the Simon Broome criteria
The studies by Civeira and colleagues,44 Damgaard and colleagues,45 Mabuchi and colleagues46 
and Widhalm and colleagues47 reported the diagnostic accuracy of LDL-C using the Simon 
Broome criteria cut-offs against a reference standard of genetic analysis. However, only the 
study by Civeira and colleagues44 reported the analysis of all three genes (LDLR, APOB, PCSK9), 
using the LIPOchip platform designed to detect 203 mutations. Two studies analysed LDLR 
and APOB genes by using screening of three common mutations in a Danish population/SSCP/
sequencing/APOB analysis/MLPA45 or PCR/DGGE/sequencing,47 whereas the study by Mabuchi 
and colleagues46 reported an analysis of the LDLR gene only, by using PCR/DGGE/direct 
sequencing/Southern blot analysis.26 Assessment design and results: test performance
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The study by Damgaard and colleagues45 also reported cascade testing by targeted sequencing 
of relatives.
Age-and gender-specific low-density lipoprotein cholesterol cut-offs 
according to the NICE clinical guideline
The studies by Lee and colleagues,48 Starr and colleagues49 and Wiegman and colleagues50 
reported the test performance of age- and gender-specific LDL-C cut-offs according to the NICE 
clinical guideline CG711 against a reference standard of CGA, in cascade testing of relatives for 
the diagnosis of FH.
Lee and colleagues48 evaluated the validity of these cut-offs in a Welsh population and 
compared them with genetic testing. This study included index cases with a definite diagnosis 
of homozygous FH based on the Simon Broome criteria and genetic testing from an ongoing 
national cascade testing project in Wales, and genetically tested relatives of genotyped FH index 
cases. Genetic tests were performed in three different laboratories (two in the UK and one in 
Spain), which included screening the LDLR, APOB and PCSK9 genes using Elucigene FH20/
dHPLC/MLPA or LIPOchip/sequencing or multiple MassARRAY spectrometry (iPLEX) (50 
mutations)/sequencing/MLPA.
In the study by Starr and colleagues,49 age- and gender-specific LDL-C cut-offs were derived from 
a genetically tested large Dutch cohort of relatives with known mutational status and validated 
against genetically tested cohorts from Denmark and Norway in which the participants were 
first-degree relatives of index cases with a definite genotyped diagnosis of FH, and also compared 
with the MedPed age-specific LDL-C cut-offs. Genetic testing of cohorts was performed in three 
different countries (the Netherlands, Norway and Denmark) and included analysis of the LDLR 
and APOB genes using (1) screening for three common mutations in the Danish cohort using 
SSCP/sequencing/MLPA or (2) sequencing of all exons/MLPA in the Norwegian cohort or (3) 
PCR/DGGE/direct sequencing in the Dutch cohort.
In the study by Wiegman and colleagues,50 age-specific LDL-C cut-offs ≥ 3.50 mmol/l were 
derived from children who had been genetically tested (PCR/DGGE/sequencing/Southern blot 
of the LDLR and APOB genes) and who came from families with a definite diagnosis of FH based 
on either (1) a documented LDL mutation or (2) plasma LDL-C levels above the 95th percentile 
for age and gender in a family with a history of premature cardiovascular disease (PCVD) along 
with (3) tendon xanthomata. The LDL-C cut-offs used in this study represented the red zone of 
the age- and gender-specific criteria as recommended by the NICE guideline, in which children 
are likely to have a clinical diagnosis of FH.
Quality of the included studies
Figures 4, 5 and 6 summarise the results of the quality assessment of the full-text studies 
reporting Elucigene FH20 (one study), LIPOchip (two studies) and LDL-C (six studies) 
respectively. Quality assessment results for the individual studies (nine full text) are summarised 
in Appendix 9. For the purposes of the quality assessment, Elucigene FH20, LIPOchip and 
LDL-C were considered to be index tests and CGA the reference standard. Three questions were 
considered to be not applicable to studies reporting Elucigene FH20 or LIPOchip:
  ■ Q8: ‘Were the same clinical data available when test results were interpreted as would be 
available when the test is used in practice?’ This question was considered not applicable 
because this information would have no effect on the results of the tests.
  ■ Q11: ‘Were cut-off values established before the study was started?’ This question was 
considered not applicable as there is no range of cut-off values applied, but rather a mutation 
is either detected or not.© Queen’s Printer and Controller of HMSO 2012. This work was produced by Sharma et al. under the terms of a commissioning contract issued by the 
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  ■ Q13: ‘Did the study provide a clear definition of what was considered to be a “positive” 
result?’ This question was considered to be not applicable as, similar to above, a mutation is 
either detected or not.
In the study by Taylor and colleagues37 reporting Elucigene FH20, both studies reporting 
LIPOchip and 83% (n = 5) of the studies reporting LDL-C, the spectrum of patients was 
considered to be representative of those who would receive the test in practice. For this question 
patients were considered to be representative if they had received a clinical diagnosis of FH 
(index cases) or were relatives of index cases with confirmed FH. In the Elucigene FH20 study, 
one of the two LIPOchip studies and 50% (n = 3) of the LDL-C studies the reference standard 
used was considered likely to correctly classify FH. Given that the FH-causing PCSK9 gene 
is rare and was discovered only fairly recently, for this question those studies that included 
DNA sequence analysis of the promoter, all exons, the exon/intron boundaries and into the 
3′ untranslated region of the LDLR gene; MLPA for each exon and the promoter region of 
the LDLR gene to detect deletions and duplications; and APOB p.Arg3527Gln gene mutation 
analysis but without assessing the PCSK9 p.Asp374Tyr gene mutation were still considered to 
be comprehensive and were considered to correctly classify FH in this assessment. The studies 
that were considered not to classify FH correctly either were missing a test for deletions and 
duplications in the LDLR gene (one LIPOchip study,43 one LDL-C study47) or did not undertake 
APOB p.Arg3527Gln gene mutation analysis (two LDL-C studies46,50).
Partial verification bias was avoided in all LDL-C studies in that all patients who underwent 
LDL-C also received a reference standard, which was not the case with Elucigene FH20 or 
LIPOchip, for which only test-negatives went on to receive further genetic tests. In practical 
terms this meant that it was not possible to calculate the specificity of these studies, other 
than making an assumption of no false-positives and therefore 100% specificity. Differential 
verification bias was avoided (patients received the same reference standard test regardless of 
the index test results) in 83% (n = 5) of the LDL-C studies but none of the Elucigene FH20 or 
LIPOchip studies. In all nine studies incorporation bias was avoided in that the index test was 
considered to be independent of the reference standard test, even though, for Elucigene FH20 
and LIPOchip, these tests formed part of a sequence of tests.
Test review bias was avoided (the results of the index test were interpreted without knowledge 
of the results of the reference standard) in the study reporting Elucigene FH20, one of the two 
studies reporting LIPOchip but only 33% (n = 2) of the LDL-C studies. It was unclear in the 
Elucigene FH20 study, both LIPOchip studies and 83% (n = 5) of the LDL-C studies whether 
or not diagnostic review bias had been avoided (the results of the reference standard being 
interpreted without knowledge of the results of the index test).
Clinical review bias was avoided (the same clinical data were available when the index test result 
were interpreted as would be available when the test was used in practice) in all of the LDL-C 
studies. In the Elucigene FH20 study, both LIPOchip studies and 83% (n = 5) of the LDL-C 
studies either un-interpretable test results were not reported or there were none, whereas in all 
nine studies either an explanation was not given for any withdrawals from the study or there were 
none. In three LDL-C studies (50%) cut-off values were established before the start of the study. 
The technology of the index test remained unchanged for Elucigene FH20 as this study reported 
the FH20 kit; however, the two LIPOchip studies reported earlier versions of this technology. 
Finally, in 50% (n = 3) of the LDL-C studies a clear definition of a positive result was given.30 Assessment design and results: test performance
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FIGURE 4  Summary of quality assessment of Elucigene FH20 studies (n = 1).
FIGURE 5  Summary of quality assessment of LIPOchip studies (n = 2).
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Assessment of test performance
Overview
This section reports the performance of the index tests Elucigene FH20 and LIPOchip and 
comparator test LDL-C against a reference standard in the diagnosis of FH in index cases and for 
cascade testing of relatives. Elucigene FH20 and LIPOchip are designed to detect mutations that 
are most frequent in the European Caucasian population and which have already been identified 
using sequencing techniques, a ‘gold standard’ of genetic tests, in this population. Therefore, 
the mutational analysis of these techniques against the gold standard is most likely to give 100% 
sensitivity and 100% specificity in this population. Therefore, the results focus mainly on patient-
level analysis at trial level. Studies evaluating Elucigene FH20 or LIPOchip comprised a sequence 
of genetic tests in which the participants received the index test as a pre-screen and test-negatives 
would then receive further genetic tests such as gene sequencing and MLPA. None of the studies 
directly compared Elucigene FH20 or LIPOchip with LDL-C, and none reported the acceptability 
or interpretability of the test or the clinical effectiveness outcomes resulting from use of the test. 
The results for each of the different tests are reported under the broad headings of Diagnosis of 
index cases and Cascade testing of relatives. This is followed by sections on other outcomes and 
subgroup analysis, including by ethnicity, region and type of gene, followed by a brief summary 
of the chapter. Individual study results are given in Appendix 10.
Diagnosis of index cases
Elucigene FH20
Table 9 shows the test performance results for the three studies that reported Elucigene FH20, 
by Taylor and colleagues,37 Hooper and colleagues36 and Yarram,38 involving 802 participants. 
Taylor and colleagues37 and Yarram38 reported the performance of Elucigene FH20 in detecting 
FH-causing mutations in patients with a clinical diagnosis of definite FH and possible FH and 
overall for both (Simon Broome criteria) against CGA, whereas Hooper and colleagues36 reported 
the performance of Elucigene FH20 for those with a clinical diagnosis of definite FH (Dutch 
criteria) against CGA. Sensitivity of Elucigene FH20 in detecting FH-causing mutations in overall 
clinical diagnosis ranged from 44.0% in the study by Taylor and colleagues37 to 52.0% in the study 
by Yarram.38 Data were not pooled because there was no information on true- and false-positives 
and negatives in the study by Yarram38 to compute a CI.
Taylor and colleagues37 reported sensitivities of 48.6% and 40.2% of Elucigene FH20 in detecting 
FH in patients with a clinical diagnosis of ‘definite’ and ‘possible’ FH respectively. Hooper and 
colleagues36 reported a lower sensitivity of Elucigene FH20 of 28.6% in detecting FH in those 
with a clinical diagnosis of definite FH. The difference may be explained at least in part by the 
fact that the two studies used different clinical diagnostic criteria and that the Elucigene FH20 kit 
was used in two different populations (UK and Australia), given that the kit is designed to screen 
for the most common mutations in the UK population. For the same reason, a pooled estimate 
was not calculated but the estimated sensitivities of Elucigene FH20 in confirming FH-causing 
mutations of definite FH are represented graphically to visualise the heterogeneity (Figure 7). The 
specificity of Elucigene FH20 in these studies could not be calculated as test-positives did not go 
on to receive a reference standard test.
A previous report54 to Taylor and colleagues37 provided information on an earlier version of 
Elucigene (FH13). In this report the FH13 kit was validated against a reference standard of 
sequencing the LDLR gene in a patient population in which all patients were clinically diagnosed 
with definite or possible FH based on the Simon Broome criteria and all received testing with the 
kit and sequencing of the LDLR gene. The sensitivity of the kit was found to be 30% for patients 
with a clinical diagnosis of possible FH, 52% for patients with definite FH and 38% for those with 
a clinical diagnosis of definite or possible FH (Table 10).32 Assessment design and results: test performance
TABLE 9  Sensitivity: individual study results for Elucigene FH20
Study, country Diagnosis Criteria n Sensitivity (%)
Hooper 200936
Australia
DFH Dutch  63 28.6
Taylor 201037a
England
DFH Simon Broome 190 48.6
Taylor 201037a
England
PFH Simon Broome 394 40.2
Taylor 201037a
England
UFH Simon Broome 51 38.5
Taylor 201037a
England
DFH/PFH/UFH Simon Broome 635 44.0
Yarram 201038
England
DFH/PFH/UFH Simon Broome 104 52.0
DFH, definite FH; PFH, possible FH; UFH, unclassified FH.
a  In Taylor 2010 initial testing was carried out with the FH13 kit and then later the FH20 kit was used, but detection rate data were reported as if 
all samples were tested using FH20.
Reference standard: Elucigene FH20 + MLPA for test-negative with Elucigene + sequencing for test-negative with MLPA (included LDLR, PCSK9, 
APOB genes).
Sensitivity (95% CI)
Hooper 2009
36 29 (17 to 43)
Taylor 2010
37 49 (39 to 58)
Sensitivity (95% CI)
01 02 03 04 05 06 07 08 09 01 00
FIGURE 7  Forest plot of Elucigene FH20 sensitivity for patients with a clinical diagnosis of definite FH.
TABLE 10  Sensitivity: individual study results for Elucigene FH13
Study Diagnosis Test(s) evaluated n Sensitivity (%)
Taylor 200754 (linked to Taylor 201037) DFH Elucigene FH13  400 52
PFH Elucigene FH13  400 30
DFH/PFH Elucigene FH13  400 38
DFH/PFH SSCP/dHPLC (LDLR 
only)
400 62
DFH, definite FH; PFH, possible FH.
Reference standard: Elucigene FH13 + SSCP/dHPLC (included LDLR, PCSK9, APOB genes but no MLPA).
Mutation-level analysis  The previous report54 to the study by Taylor and colleagues37 reported 
that there were no false-positive and no false-negative results from the Elucigene FH13 kit for 
detection of FH-causing mutations in patients.
In the study by Taylor and colleagues,37 99 mutations plus eight different deletions and 
duplications were identified in total. Of the 20 mutations present in the Elucigene FH20 kit, three 
were not identified in any of the participants. Taylor and colleagues37 also reported the prevalence © Queen’s Printer and Controller of HMSO 2012. This work was produced by Sharma et al. under the terms of a commissioning contract issued by the 
Secretary of State for Health.
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of each mutation that was present in the Elucigene FH20 kit and was identified in the study. The 
most frequently identified mutations were the mutation in the APOB gene, with a prevalence of 
12%, and the three LDLR mutations, p.Gly218del, the intron 3 splice variant c.313+1G>A and the 
p.Pro685Leu exon 14 variant, with a prevalence of 5% of the total mutations detected.
LIPOchip
Table 11 shows the test performance results for the four studies that reported LIPOchip, by 
Alonso and colleagues,39 Callaway and colleagues,40 Palacios and colleagues41 and Stef and 
colleagues,42 and involving 3418 participants. The studies used different versions of LIPOchip. 
Palacios and colleagues41 and Callaway and colleagues40 reported results for LIPOchip version 
8 (Spanish version but study conducted in the UK). Based on the sample reported in Palacios 
and colleagues,41 the manufacturer of LIPOchip provided further information on version 10, 
which contains mutations specific to the UK population. Alonso and colleagues39 and Stef and 
colleagues42 used Spanish versions but did not provide information on the version number. 
Although the Spanish versions are not specific to the UK, they cover the mutations that are more 
frequent in Western Europe including the UK.
The sensitivity reported by the studies ranged from 33.3%40 (LIPOchip version 8, Simon Broome 
criteria) to 94.5%42 (Spanish version designed to detect 247 mutations, Dutch–MedPed criteria). 
Palacios and colleagues41 reported sensitivity of 56.9% for LIPOchip version 8, which was 
based on 126 samples (120 analysed). Based on the above sample, the sensitivity of LIPOchip 
UK version 10 would be 78.5% (51/65) (Progenika, 2011, personal communication) There was 
heterogeneity across the studies, particularly in relation to Palacios 201041 (version 8 LIPOchip) 
and Stef 2009,42 and therefore a pooled estimate was not calculated. The estimated sensitivities 
(with 95% CIs) of LIPOchip in confirming FH-causing mutations are graphically represented to 
visualise the heterogeneity (Figure 8). The heterogeneity may be explained at least in part by the 
fact that different versions of LIPOchip and different clinical diagnostic criteria were used. In 
addition, the difference may also be explained by the fact that the LIPOchip kit was used in two 
different populations (UK and Spain), given that the prevalence of the FH-causing mutations 
varies according to the country of origin. The specificity of FH detection by LIPOchip in three 
studies could not be calculated as test-positives did not go on to receive a reference standard 
test.39,41,42 In the study by Callaway and colleagues40 the specificity of LIPOchip version 8 was 
reported to be 93.8% with one false-positive diagnosis.
None of the included LIPOchip studies reported accuracy data according to definite or 
possible FH.
Mutation-level analysis  In a mutational-level analysis, the studies by Alonso and colleagues,39 
Palacios and colleagues41 and Tejedor and colleagues43 reported sensitivity and specificity of 
LIPOchip of around 100%. Results on validation with mutation-negative samples and LIPOchip-
positive samples by sequencing and QMFSP against MLPA were reported in these studies. See 
Appendix 10 for the tabulated results.
In the study by Tejedor and colleagues,43 59/118 mutations were detected using this earliest 
version of LIPOchip. Palacios and colleagues41 reported that in 37 patients 17/251 mutations 
were picked up by LIPOchip and in 28 patients 25/251 mutations were picked up by sequencing. 
Overall, the mutation detection rate (by the LIPOchip platform) was 42/251 mutations in 
65 patients.41
Low-density lipoprotein cholesterol
Table 12 shows the test performance results for the four studies that reported LDL-C, by Civeira 
and colleagues,44 Damgaard and colleagues,45 Mabuchi and colleagues,46 and Widhalm and 34 Assessment design and results: test performance
colleagues,47 involving 1777 participants. The sensitivity of LDL-C as part of the Simon Broome 
criteria for those with a clinical diagnosis of possible or definite FH was 90%45 and 93%,44 
although specificity was much lower at 29% and 28% respectively. The sensitivity of LDL-C as 
part of the Dutch criteria was 88%44 and 99%,45 although specificity again was also much lower at 
18% and 6% respectively. For LDL-C as part of the MedPed criteria the sensitivity reported was 
54%45 and 91%,44 although specificity was 83% and 53% respectively. Widhalm and colleagues47 
reported sensitivity of LDL-C as part of the MedPed criteria separately for adults and children 
(66% and 81% respectively), whereas Mabuchi and colleagues46 in a study from Japan reported 
sensitivity of 98% for LDL-C at a cut-off of > 4 mmol/l. We could not reproduce the specificity of 
98.5%, as was reported in this study, from the given values.
Cascade testing of relatives
Age- and gender-specific low-density lipoprotein cholesterol cut-offs
Table 13 shows the results for the three studies that used LDL-C age- and gender-specific cut-
offs as recommended in NICE clinical guideline CG711 for cascade testing of relatives of index 
cases with FH.
TABLE 11  Sensitivity: individual study results for LIPOchip
Study, country
LIPOchip 
version Diagnosis Criteria  n
Sensitivity 
(%)
Specificity 
(%)
Palacios 201041 and data received 
from the manufacturer
UK
Version 10, UK 
mutations 
NR Simon Broome 126 78.5 NC
Callaway 201040
UK
Version 8 (251 
mutations)
DFH or 
possible FH
Simon Broome 22 33.3 93.8
Palacios 201041
UK 
Version 8 (251 
mutations)
NR  Simon Broome  120 56.9 NC
Stef 200942
Spain
247 mutations NR Dutch–MedPed  2462 94.5 NC
Alonso 200939
Spain
195 mutations DFH or 
probable FH
Dutch criteria  808 78.0 NC
DFH, definite FH; NC, not calculable (test-positives on LIPOchip did not receive a reference standard test); NR, not reported.
Reference standard: (1) LIPOchip platform (DNA array + QMFSP for test-negative + sequencing for test-negative) (LDLR, APOB) (Alonso 200939); 
(2) LIPOchip platform (LIPOchip including copy number changes in the LDLR gene + sequencing of the LDLR gene for test-negatives on the chip) 
(LDLR, PCSK9, APOB) (Palacios 2010,41 Stef 200952); (3) Elucigene FH20 + dHPLC/sequencing + MLPA (LDLR, PCSK9, APOB) (Callaway 201040). 
Elucigene FH20 + SSCP/dHPLC/direct sequencing + MLPA against reference standard 2, sensitivity = 95% (n = 126).
Sensitivity (95% CI)
Palacios LIPOchip version 841 (UK) 57 (44 to 69)
Palacios LIPOchip version 1041 (UK) 78 (67 to 88)
Stef LIPOchip Spanish version42 95 (93 to 96)
Alonso LIPOchip Spanish version39 78 (74 to 81)
Callaway 2010 version 840 33 (4 to 78)
Sensitivity (95% CI)
0 10 20 30 40 50 60 70 80 90 100
FIGURE 8  Forest plot of LIPOchip sensitivity for patients with a clinical diagnosis of FH.© Queen’s Printer and Controller of HMSO 2012. This work was produced by Sharma et al. under the terms of a commissioning contract issued by the 
Secretary of State for Health.
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Lee and colleagues48 reported sensitivity and specificity of 91.5% and 93%, respectively, in the 
UK cohort.
Wiegman and colleagues50 reported 96% sensitivity for those with LDL-C cut-offs ≥ 3.50 mmol/l 
(age adjusted), which represents the LDL-C cut-off value in children as stated in NICE clinical 
guideline CG71.1 Because of the lack of information on false-positive diagnosis, specificity 
could not be calculated for this LDL-C cut off. All of the parents of these children had a definite 
diagnosis of FH. Wiegman and colleagues50 further reported that, out of 228 children of 
genetically or clinically diagnosed FH parents, 131 (57%) had LDLC ≥ 3.50 mmol/l.
Starr and colleagues,49 for the first-degree relatives, reported sensitivity of 68.0% (the 
Netherlands), 79.4% (Denmark) and 83.7% (Norway), with specificity of around 85% for all 
three groups. Starr and colleagues49 also reported test performance by age band including 
0–14 years, 15–24 years, 35–44 years, 45–54 years and ≥ 55 years (Table 14). In the Netherlands 
(n = 3294) and Norway (n = 1116) cohorts, the test performance of LDL-C decreased as the age 
increased, with a sensitivity ranging from 84.7% (specificity 93.4%) in the < 15 years group to 
38.2% (specificity 85.6%) in the 55+ years group (the Netherlands cohort) and sensitivity of 
92.5% (specificity 93.5%) in the < 15 years group to 66.7% (specificity 79%) in the 55+ years 
group (Norway cohort). In the Danish cohort (n = 321) the sensitivity increased as age increased 
with 95.5% sensitivity in the older group (55+ years) and 76.2% sensitivity in the younger group 
(15–24 years). Test specificity in this cohort varied across groups, at 72.4% in the 45–54 years 
group to 94.4% in the 25–34 years group. Starr and colleagues also reported the performance 
of MedPed LDL-C cut-offs in these cohorts, reporting low sensitivity but consistently higher 
specificity compared with the age- and gender-specific LDL-C cut-offs.
Targeted gene sequencing for a mutation found in a family member
Table 15 shows the results of the four studies that investigated cascade testing of relatives. Three 
studies reported cascade testing of relatives using targeted gene sequencing for a mutation 
in a family member.37,45,50 One study published as a presentation did not specify whether or 
not cascade testing was carried out by targeted sequencing.38 Three of these studies reported 
that 53–56% of relatives were positive for FH,37,38,45 which was more or less consistent with the 
expected 50% probability of diagnosis in relatives.
TABLE 13  Sensitivity and specificity: age- and gender-specific LDL-C cut-offs for cascade testing 
Study Country  Participants n
Sensitivity 
(%)
Specificity 
(%) Reference standard: CGA
Lee 201048 UK  Relatives  90 91.5 93.0 Elucigene/dHPLC/MLPA or LIPOchip/
sequencing or iPLEX/sequencing/
MLPA (LDLR, APOB, PCSK9)
45–54 years 80.0 70.0
Starr 200849 The 
Netherlands
First-degree relatives 3294 68.0 85.2 DGGE/sequencing/PCR (LDLR, APOB)
Denmark First-degree relatives 321 79.4 85.1 Screening of three common 
mutations in Danish population/
SSCP/sequencing/MLPA (LDLR, 
APOB)
Norway First-degree relatives 1116 83.7 83.8 Sequencing/MLPA (LDLR)
Wiegman 
200350
The 
Netherlands
Children of definite FH 
parents
611 96.0 NC PCR/DGGE/sequencing/Southern blot 
(LDLR)
NC, not calculable.© Queen’s Printer and Controller of HMSO 2012. This work was produced by Sharma et al. under the terms of a commissioning contract issued by the 
Secretary of State for Health.
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TABLE 14  Sensitivity and specificity: age-and gender-specific LDL-C cut-offs in first-degree relatives by age group
n 
+ve/–ve 
mutation
Sensitivity  
(95% CI) (%)
Specificity  
(95% CI) (%)
False-negative  
(95% CI) (%)
False-positive  
(95% CI) (%)
The Netherlands
0–14 years 183/243 84.7 (78.7 to 89.6) 93.4 (89.5 to 96.2) 15.3 (10.4 to 21.3) 6.6 (3.8 to 10.5)
15–24 years 187/276 71.1 (64.1 to 77.5) 85.1 (80.4 to 89.1) 28.9 (22.5 to 35.9) 14.9 (10.9 to 19.6)
25–34 years 138/293 64.5 (55.9 to 72.4) 82.6 (77.8 to 86.8) 35.5 (27.6 to 44.1) 17.4 (13.2 to 22.2)
35–44 years 136/471 71.3 (62.9 to 78.7) 83.4 (79.8 to 86.7) 28.7 (21.3 to 37.1) 16.6 (13.3 to 20.2)
45–54 years 92/449 57.6 (46.9 to 67.9) 83.7 (80.0 to 87.0) 42.4 (32.1 to 53.1) 16.3 (13.0 to 20.0)
55+ years 89/737 38.2 (28.1 to 49.1) 85.6 (82.9 to 88.1) 61.8 (50.9 to 71.9) 14.4 (11.9 to 17.1)
Overall  3294 825/2469 68.0 (64.7 to 71.2) 85.2 (83.8 to 86.6) 32 (28.3 to 35.3) 14.8 (13.4 to 16.2)
Denmarka
15–24 years 42/23 76.2 (60.5 to 87.9) 91.3 (72.0 to 98.9) 23.8 (12.1 to 39.5) 8.7 (1.1 to 28)
25–34 years 34/36 58.8 (40.7 to 75.4) 94.4 (81.3 to 99.3) 41.2 (24.6 to 59.3) 5.6 (0.7 to 18.7)
35–44 years 39/27 89.7 (75.8 to 97.1) 81.5 (61.9 to 93.7) 10.3 (2.9 to 24.2) 18.5 (6.3 to 38.1)
45–54 years 18/29 88.9 (65.3 to 98.6) 72.4 (52.8 to 87.3) 11.1 (1.4 to 34.7) 27.6 (12.7 to 47.2)
55+ years 22/40 95.5 (77.2 to 99.9) 90.0 (76.3 to 97.2) 4.6 (0.1 to 22.8) 10.0 (2.8 to 23.7)
Overall  321 160 /161 79.4 (72.3 to 85.4) 85.1 (78.6 to 90.2) 20.6 (14.6 to 27.7) 14.9 (9.8 to 21.4)
Norway
0–14 years 106/107 92.5 (85.7 to 96.7) 93.5 (87.0 to 97.3) 7.6 (3.3 to 14.3) 6.5 (2.7 to 13.0)
15–24 years 82/103 86.6 (77.3 to 93.1) 91.3 (84.1 to 95.9) 13.4 (6.9 to 22.7) 8.7 (4.1 to 15.9)
25–34 years 69/124 87.0 (76.7 to 93.9) 85.5 (78.0 to 91.2) 13.0 (6.1 to 23.3) 14.5 (8.8 to 22.0)
35–44 years 51/145 78.4 (64.7 to 88.7) 82.8 (75.6 to 88.5) 21.6 (11.3 to 35.3) 17.2 (11.5 to 24.4)
45–54 years 39/120 66.7 (49.8 to 80.9) 74.2 (65.4 to 81.7) 33.3 (19.1 to 50.2) 25.8 (18.3 to 34.6)
55+ years 27/143 66.7 (46.0 to 83.5) 79.0 (71.4 to 85.4) 33.3 (16.5 to 54.0) 21.0 (14.6 to 28.6)
Overall  1116 374/742 83.7 (79.5 to 87.3) 83.8 (81.0 to 86.4) 16.3 (12.7 to 20.5) 16.2 (13.6 to 19.0)
MedPed age-specific LDL-C cut-offs 
The 
Netherlandsb
3294 42.3 97.8  57.7 2.2
Denmark 321 68.8 89.4 31.3 10.6
Norwayb 1116 74.9 92.7 25.1 7.3
a  Please note that all the figures presented in this table were sourced from Starr and colleagues,49 where an error was observed in the total 
number reported for Denmark group (the age subgroups do not add to the total reported). Authors were unable to get the correct values from 
the original source.
b  Significant compared with age- and gender-specific LDL-C cut-offs of this study.
Source of data: Starr and colleagues.49
Taylor and colleagues37 reported results of cascade testing of relatives of index cases with a 
documented mutation who had received an initial clinical diagnosis based on the Simon Broome 
criteria. This study used a sequence of tests for detecting mutations in index cases that included 
Elucigene FH20 as a pre-screen test and then sequencing for test-negatives on Elucigene FH20, 
which in turn was followed by MLPA for test-negatives on sequencing. Relatives of the index 
cases received targeted gene sequencing for the specific mutation found in the family member. 
A total of 296 first-degree relatives from 100 families were recruited and a FH-causing mutation 
was identified in 56%. The detection rate was similar (around 55%) in relatives from families 
with an initial diagnosis of definite FH or an initial diagnosis of possible FH. Yarram38 used a 
similar approach as in the study by Taylor and colleagues37 to diagnose index cases and reported 38 Assessment design and results: test performance
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that 27 relatives from 104 index cases were identified through cascade testing and 56% had a 
FH-causing mutation.
The fourth study, by Wiegman and colleagues,50 used conventional sequencing of the LDLR gene 
in children of heterozygous (a documented LDLR mutation) or clinically diagnosed (plasma 
LDL-C levels above the 95th percentile for age and gender in a family with a history of PCVD in 
conjunction with tendon xanthomata) parents (n = 591) and reported 77% to have a FH-causing 
mutation. The authors suggested that the high proportion diagnosed might be due to the fact 
that siblings with very low levels of LDL-C were not referred to the paediatric clinic. Moreover, 
the paediatric hyperlipidaemic are less likely to have polygenic cases of hyperlipidaemia and are 
therefore more likely to have a higher mutation detection rate.
There were no studies using LIPOchip in relatives.
Other outcomes
Proportion with unequivocal diagnosis by Elucigene FH20 and LIPOchip  Table 16 gives the 
proportions with an unequivocal diagnosis by Elucigene FH20 and LIPOchip and the 
proportions that would subsequently require sequencing as reported in six studies.36,37,39,41–43 
Elucigene FH20 identified a mutation in only 16% of cases in a cohort of 635 clinically diagnosed 
FH cases, with > 80% still requiring sequencing for confirmation of diseases.37 In Spanish 
studies, 46%42,43 to 52%39 were confirmed to have a mutation using LIPOchip. LIPOchip version 
8 confirmed 29% of cases in a UK setting but in the same population 40% would be identified 
with a FH-causing mutation by LIPOchip version 10, with 60% still requiring sequencing.41 
Elucigene FH20 or LIPOchip detected, almost twice as many people with FH-causing mutations 
who were definite FH than those classed as possible FH (27% vs 11% in the study by Taylor and 
colleagues;37 51% vs 37% in the study by Tejedor and colleagues43).
Time taken to obtain test result  Two studies on LIPOchip reported the time taken to obtain 
test results.39,41 The time taken to obtain positive test results with LIPOchip (including data 
extraction and analysis) ranged from 10 days41 to an average of 15 days.39 Additionally, the time 
taken to detect rearrangements was 7 days and then 3041–4539 days for sequencing. Palacios and 
TABLE 16  Proportion with unequivocal diagnosis by Elucigene FH20 and LIPOchip
Study  Country Test FH diagnosis Total tested
Number with unequivocal 
diagnosis (%)
Number requiring 
sequencing (%)
Hooper 200936 Australia Elucigene FH20 DFH 63 14 (22) 49 (78)
Taylor 201037 UK Elucigene FH20 DFH 190 52 (27) 138 (73)
PFH 394 45 (11) 349 (89)
UFH 51 5 (10) 46 (90)
Total  635 102 (16) 533 (84)
Alonso 200939 Spain LIPOchip (195 Spanish 
mutations)
DFH or 
probable FH
808 419 (52) 389 (48)
Palacios 
201041
UK LIPOchip version 8 NR 126 37 (29) 89 (71)
LIPOchip version 10 NR 126 51 (40) 75 (60)
Stef 200942 Spain LIPOchip (247 mutations) NR 2462 1140 (46) 1322 (54)
Tejedor 200543 Spain DNA array (118 mutations) DFH 252 129 (51) 123 (49)
Possible/
probable FH
155 58 (37) 97 (63)
Total 407 187 (46)  220 (54)
DFH, definite FH; NR, not reported; PFH, possible FH; UFH, unclassified FH.40 Assessment design and results: test performance
colleagues41 reported that 2 months was required to obtain results by sequencing in conjunction 
with MLPA. An average of 68 days (range 10–93 days) was reported for obtaining complete 
results with the LIPOchip platform, with the majority of mutations being detected within 
15–22 days after the start of the analysis.39
Subgroup analysis
Subgroup analysis by ethnicity  The mutation detection rate may vary in ethnic groups as 
FH-causing mutations may be more frequent in one group of people than in another. The 
Elucigene FH20 and LIPOchip genetic tests are designed to detect mutations that are more 
frequent in European Caucasian populations.
Only the study reporting Elucigene FH20 by Taylor and colleagues37 reported the detection rate 
of FH for ethnic groups. By using a sequence of tests in which Elucigene FH20 was used as a 
pre-screen followed by sequencing for test-negatives on Elucigene FH20 and then MLPA for 
test-negatives on sequencing, the mutation detection rate in a population of Indian Asian origin 
was 32.3% (n = 31) and in a population of African origin was 25% (n = 8). The study suggested 
that detection rates were lower for these groups than for white British groups, but the difference 
was not statistically significant (p = 0.63). The study population also comprised those of Middle 
East, Far East and non-British European origin, although detection rates for these groups were 
not reported.
In total, 10 out of 20 FH-causing mutations were identified in 31 patients of Indian Asian origin 
and only 1 out of 20 FH-causing mutations was identified in four patients of African origin. Only 
3 out of the 10 mutations detected in the Indian Asian group were detected by Elucigene FH20.
Subgroup analysis by regions  Taylor and colleagues37 also reported the overall detection rate 
by CGA across six different centres in the UK. The detection of FH ranged from 8.3% to 73.6% 
among definite FH (p = 0.001) and from 21.7% to 39.5% for those with possible FH (p = 0.13). The 
authors further reported that when a centre with the smallest sample size was removed from the 
analysis the difference was no longer significant for the definite FH category (p = 0.07).
Familial hypercholesterolaemia detection according to type of gene  Five studies reported 
FH detection according to the type of gene (Table 17). In patients with a genetic diagnosis 
of FH, most mutations detected by Elucigene FH20 or LIPOchip were in the LDLR gene 
(range 69–97%), followed by the APOB gene (range 3–27%) and the PCSK9 gene [4% and 6% 
(two studies)].
Summary
In total, 15 studies (17 reports) were included. Three studies (four reports) evaluated Elucigene 
FH20, five studies (six reports) evaluated various versions of LIPOchip, four studies reported 
data on the performance of LDL-C as part of the Simon Broome criteria or LDL-C cut-offs of 
> 4 mmol/l and three studies reported age-and gender-specific LDL-C cut-offs for cascade testing 
of relatives. Five studies conducted in the UK recruited participants who had received a clinical 
diagnosis of FH based on the Simon Broome criteria, reporting Elucigene FH20, LIPOchip and 
age- and gender-specific LDL-C cut-offs. Three studies reported targeted gene sequencing for a 
mutation found in a family member.
Only studies reported as full-text papers (n = 9) were quality assessed. In the studies reporting 
Elucigene FH20 (n = 1) and LIPOchip (n = 2) and five of the six studies reporting LDL-C, the 
participants were representative of those who would receive the tests in practice. As Elucigene © Queen’s Printer and Controller of HMSO 2012. This work was produced by Sharma et al. under the terms of a commissioning contract issued by the 
Secretary of State for Health.
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FH20 and LIPOchip were used as a pre-screen with only test-negatives going on to receive 
further genetic tests, these studies suffered from partial verification bias, whereas in all of 
the LDL-C studies all of the participants who received the index test (LDL-C) also received a 
reference standard test. Patients received the same reference standard regardless of the index test 
result in 83% (n = 5) of the LDL-C studies but none of the Elucigene FH20 or LIPOchip studies 
(differential verification bias).
For Elucigene FH20, two studies, one by Taylor and colleagues37 involving 635 participants and 
another by Yarram38 involving 104 participants, reported 44% and 52% sensitivity, respectively, in 
detecting FH-causing mutations in patients with a Simon Broome clinical diagnosis of possible or 
definite FH. The kit had higher sensitivity in those with a clinical diagnosis of definite FH (49%) 
than in those with possible FH (40%).37 Hooper and colleagues,36 in a study set in Australia, 
reported a lower sensitivity of 29% for Elucigene FH20 in detecting FH-causing mutations in 
patients with a clinical diagnosis of definite FH based on the Dutch criteria.
Four studies reported the sensitivity of different versions of LIPOchip. LIPOchip version 10, 
containing mutations frequent in the UK population, showed sensitivity of 78.5% (n = 126) (based 
on hypothetical data received from the manufacturer) in detecting FH-causing mutations in 
those with a Simon Broome clinical diagnosis, whereas the LIPOchip version designed to detect 
251 mutations that were not specific to the UK showed from 33.3% (n = 22) to 56.9% (n = 120) 
sensitivity. The sensitivity of two Spanish versions of LIPOchip containing 195 mutations and 
247 mutations was reported as 78% (n = 808) and 95% (n = 2462), respectively, with the clinical 
diagnosis being made according to Dutch criteria or Dutch–MedPed criteria respectively.
One study reporting the performance of LIPOchip version 8 against CGA reported one false-
positive, with specificity of 93.8%. In all other studies evaluating the performance of Elucigene 
FH20 and LIPOchip in detecting patients with FH-causing mutations, specificity was not 
calculable because none of the test-positives went on to receive CGA and therefore it was not 
known whether or not there were any false-positive results.
In two studies, the LDL-C test as part of the Simon Broome criteria had high sensitivity (90% and 
93%) in detecting FH compared with a reference standard of CGA; however, both studies also 
reported high rates of false-positives, resulting in low specificity (28% and 29%). In these studies, 
LDL-C as part of the Dutch clinical diagnostic criteria was also shown to be highly sensitive 
TABLE 17  Familial hypercholesterolaemia detection according to type of gene
Study Test
Total 
analysed
Total 
detected
Detected with 
LDLR gene, n (%)
Detected with 
APOB gene, n (%)
Detected with 
PCSK9 gene, n (%)
Taylor 201037 Elucigene FH20  635 102 70 (69) 28 (27) 4 (4)
Palacios 201041
Newcastle sample
LIPOchip version 
8 + sequencing
120 65 52 + 1 CNC 
(80 + 2)
8 (12) 4 (6)
Stef 200942 LIPOchip Spanish version 
(247 mutations)
2462 NR 94% + 6% CNC 0 0
Tejedor 200543 LIPOchip earlier version 
(118 mutations)
407 187 181 (97) 6 (3) NAn
Alonso 200939 LIPOchip Spanish version 
(191 mutations)
808 537 521 (97) 16 (3) NAn
DNA array 808 419 403 (96) 16 (4) NAn
CNC, copy number change; NAn, not analysed; NR, not reported.42 Assessment design and results: test performance
(88% and 99%) in detecting FH but with very low specificity (18% and 6%) compared with CGA. 
The reported sensitivity of LDL-C as part of the MedPed diagnostic criteria varied. Widhalm 
and colleagues47 reported that the sensitivity of LDL-C cut-offs as part of the MedPed criteria 
was higher in children (81%) than in adults (66%) in detecting FH. Mabuchi and colleagues46 
reported higher accuracy of LDL-C cut-offs of 4.1 mmol/l (sensitivity 98.5%, specificity 98.5%) 
among genetically diagnosed FH patients and unaffected relatives.
Three studies reported data for age- and gender-specific LDL-C cut-offs for cascade testing 
compared with a reference standard of CGA. Lee and colleagues48 reported sensitivity of 91% and 
specificity of 93% for cascade testing in a cohort from the UK. Starr and colleagues49 reported 
sensitivities of 68%, 79% and 84% and specificities of 85%, 85% and 84% in cohorts of first-degree 
relatives from the Netherlands, Denmark and Norway respectively. Wiegman and colleagues50 
reported high sensitivity of 96% in children. Using an approach of targeted gene sequencing for 
a mutation found in a family member, 53–77% of relatives with FH were identified in different 
study populations. There were no studies using LIPOchip in relatives.© Queen’s Printer and Controller of HMSO 2012. This work was produced by Sharma et al. under the terms of a commissioning contract issued by the 
Secretary of State for Health.
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Chapter 3 
Assessment design and results: 
cost-effectiveness
Review of cost-effectiveness studies
Search strategy
Two separate searches were conducted for studies considering the cost-effectiveness of any of the 
intervention tests (Elucigene FH20 or LIPOchip) for proband testing or for the cascade testing of 
relatives. Studies were sourced from searching a range of electronic databases and websites. This 
was supplemented with a quality-of-life search. Contact with experts in the field and the scrutiny 
of bibliographies of retrieved papers were also used to identify any additional studies. Highly 
sensitive electronic searches were conducted to identify reports of published studies on the cost-
effectiveness of tests for FH in index cases and for cascade testing of relatives. The search focused 
on identifying RCTs and comparative studies and the results were restricted to articles written in 
English. The search strategy included searches of all relevant journals since inception.
The databases searched were MEDLINE (1948 to Week 1 2011), MEDLINE In-Process & Other 
Non-Indexed Citations (10 January 2011), EMBASE (1980 to 2011 Week 1), BIOSIS (1956 to 
10 January 2011), Science Citation Index (1970 to 10 January 2011), Conference Proceedings 
Citation Index – Science (1990 to 10 January 2011), Centre for Reviews and Dissemination 
databases including Database of Abstracts of Reviews of Effects, NHS Economic Evaluation 
Database (NHS EED) and Health Technology Assessment database. Searches were also carried 
out of the Cost-Effectiveness Analysis Registry. A supplementary quality-of-life search was also 
undertaken, including MEDLINE (1948 to Week 1 2011), MEDLINE In-Process & Other Non-
Indexed Citations (10 January 2011), EMBASE (1980 to 2011 Week 1) and IDEAS Economics 
and Finance Research (February 2011). Full details of the search strategies used and websites 
consulted are documented in Appendix 3. In addition, reference lists of all included studies were 
scanned to identify additional potentially relevant studies
Methods (inclusion and exclusion criteria)
Studies were deemed to be relevant for the cost-effectiveness review if they included a measure 
of cost-effectiveness of the intervention tests (Elucigene FH20 – or alternative earlier versions 
or LIPOchip version 8–version 10) relative to any of the included clinical diagnostic criteria 
(Simon Broome, MedPed or Dutch criteria). The population and setting for the studies retrieved 
for further investigation were as described in Chapter 2. In terms of outcomes, the preferred 
type of analysis was cost-effectiveness measured as cost–utility analysis [cost per quality-
adjusted life-year (QALY) gained]. However, because of a lack of data, we also considered other 
measures of cost-effectiveness, including cost per case detected or cost per diagnostic accuracy 
measurement. Study type inclusion and exclusion criteria were limited as we did not want 
to exclude any potentially relevant studies at this stage, the principal requirement being that 
studies were for a population of index cases or relatives of index cases with a clinical diagnosis 
of FH. Titles and abstracts of all reports identified by the search strategy were screened. Full-text 
copies of all studies deemed to be potentially relevant were obtained and assessed for inclusion. 
Disagreements were resolved by consensus or arbitration by a local clinical advisor. A data 
extraction form was developed, with data extracted by one health economist. A second health 44 Assessment design and results: cost-effectiveness
economist checked the data extraction and any disagreements were resolved by consensus among 
the review team. Additional further studies that did not meet our specific inclusion criteria but 
were none the less informative for development and population of the economic model were 
also retained. As these additional included studies did not form a vital part of the assessment, 
they have not been systematically critically appraised in depth but are included and narratively 
described in the following sections.
Results of the cost-effectiveness searches
A total of 258 papers were initially identified through the database searches, with a further 11 
potentially relevant titles identified through the diagnostic accuracy search. However, on reading 
the titles and abstracts, only nine were judged potentially relevant to the cost-effectiveness 
review, with the remaining 260 not meeting the inclusion criteria of health economic analysis 
(cost-effectiveness or cost–utility) of a genetic test. We requested full-text articles of these nine 
papers that reported the cost-effectiveness of genetic testing and cascade testing techniques. 
These papers were further assessed by reading the full text of each retrieved paper and reapplying 
the inclusion and exclusion criteria. At this stage, only one study reported the cost-effectiveness 
of any of the comparators for this assessment. Of the remaining eight papers, three did not 
include any measure of cost-effectiveness and only briefly referred to cost implications, thus 
leaving a total of five relevant studies. Four of the five studies retrieved have been summarised 
in the previous systematic review undertaken as part of NICE clinical guidance CG71.1 Data 
are extracted and published in appendix D of the clinical guidance document. The remaining 
study, which was not previously summarised as part of CG71,1 is discussed below. In relation to 
additional searches for utility of diagnostic information, effect of mutation type on treatment 
choice and the efficacy of statins in children, potentially relevant full-text papers were retrieved 
and read in full, and have been considered in the economic modelling process and/or discussion 
where appropriate.
Discussion of included studies evaluating the cost-effectiveness of 
Elucigene FH20 and/or LIPOchip
One study57 was identified that met our inclusion criteria and evaluated the cost-effectiveness of 
one of the intervention tests. This study assessed the cost-effectiveness of LIPOchip in identifying 
and testing first-degree relatives of index cases identified with FH in a Spanish population. The 
analysis also included subsequent treatment with statins of test-positive individuals. Screening 
and treatment management was compared with a strategy of no screening and the perspective 
of the analysis was that of the national health system (payer). Cost-effectiveness outcome was 
measured as incremental cost per life-year gained. Clinical diagnosis of at-risk individuals was 
based on a uniform protocol for clinical diagnosis and genetic testing of index cases was carried 
out using the LIPOchip platform, which included the following diagnostic steps:
1.  LIPOchip DNA array
2.  multiplex quantitative PCR used to identify significant gene rearrangements (applied if DNA 
array was negative)
3.  complete sequencing of the LDLR gene (applied if the previous two steps were negative).
Among confirmed cases, the DNA array had a specificity and sensitivity of 99.7% and 99.9%, 
respectively, for all 118 mutations tested. Once index patients were identified, first-degree 
relatives were tested using steps 1 and 2 above only. Effectiveness among relatives was based on 
relative risks adjusted for age and sex59 and applied to national mortality rates. Once identified 
and treated, it was assumed that mortality risk reduced relative to untreated patients. The total 
cost of detecting a positive case was €1447 based on the assumption that, to detect one positive 
case, 3.4 relatives would need to be tested. This was combined with treatment costs based on 
simvastatin 40 mg and costs of acute myocardial infarctions (MIs) avoided based on risks © Queen’s Printer and Controller of HMSO 2012. This work was produced by Sharma et al. under the terms of a commissioning contract issued by the 
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calculated from Wonderling and colleagues.59 The cost-effectiveness was thus estimated based 
on cost per life-year gained as €3243 in the base-case analysis. Sensitivity analyses conducted 
varied the incremental cost-effectiveness ratio (ICER) from €1073 to €7235 per life-year gained. 
Probabilistic analyses indicated a 95% probability of cost-effectiveness at a societal willingness to 
pay for a life-year gained of > €7400 and a probability of 45% at a willingness to pay of €3450. The 
results suggest that genetic screening of first-degree relatives with LIPOchip in Spain is a cost-
effective use of resources. The main limitation to this study in terms of this assessment is that 
there is no active comparator – it is assumed that no screening would take place in routine care. 
However, the study is useful and informative regarding the potential of LIPOchip. No studies 
were available reporting on cost-effectiveness for any of the other intervention tests.
Discussion of supplementary cost-effectiveness evidence
The remaining supplementary papers detailing cost-effectiveness of cascade testing among 
relatives using targeted cascade testing and other methods are briefly summarised and discussed 
below. Full data extraction pertaining to these reports is available from the NICE website as 
appendix D to the NICE clinical guideline document CG71.1 None of these studies evaluated 
the cost-effectiveness of any of the tests specifically in index patients; however, all indicated 
cost-effectiveness of cascade testing for FH among relatives of known FH index patients. The five 
included studies are discussed briefly below.
Marang-van de Mheen and colleagues60 compared five screening options in the Dutch population 
compared with no screening: treating (1) all patients with cholesterol level > the 95th percentile 
for the general Dutch population; (2) individuals fulfilling treatment criteria based on Dutch 
Institute of Health Care Improvement guidelines on hypercholesterolaemia; (3) (1) above but 
only those untreated at screening; (4) (2) above but only those untreated at screening; and 
(5) all FH-positive patients. The Framingham equation61 was used to estimate risk, survival 
and costs and the economic outcome measure is cost per life-year gained. This is explicitly 
not recommended as part of CG711 for calculating risk in the Simon Broome population. 
The most cost-effective option is option (2) with an associated ICER of €24,376 per life-year 
gained. Discounting was not conducted and there are questions relating to generalisability to a 
NHS perspective.
Marks and colleagues62 completed a cost-effectiveness analysis of screening for FH patients aged 
16–24 years from the perspective of the NHS. Strategies evaluated were universal screening, 
opportunistic screening (unrelated reasons), opportunistic screening (patients with premature 
MI) and full screening of all first-degree relatives diagnosed with FH. The main comparison for 
the analysis was no screening. The primary outcome measure was cost per life-year gained and 
the study showed that tracing family members (first-degree relatives) systematically was the most 
cost-effective strategy with an ICER of £3097 per life-year gained.
Marks and colleagues63 conducted additional work over a 10-year period estimating the cost-
effectiveness of (1) family tracing of index cases and (2) systematically screening all 16-year-olds. 
Primary economic outcomes were cost per case detected and cost per death averted. The main 
comparison for the analysis was no screening and no incremental analyses were conducted 
between groups. Costs per case identified were £3505 (family tracing) and £13,141 (universal 
screening). Costs per death averted were £3187 and £1.6M for the family tracing and universal 
options respectively. Therefore, the authors conclude that a more targeted screening programme 
identifying relatives of index cases is more cost-effective.
Wonderling59 used data from the Dutch screening programme from year 2000 in a sample of 
18- to 60-year-olds to estimate the cost-effectiveness of screening compared with no screening. 
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26 MIs per 100 patients receiving statin therapy. Primary outcome measures for the economic 
analysis were cost per case detected and cost per life-year gained, which were $7500 and $8800 
respectively. Results were sensitive to the price of statins and a worst-case scenario estimated that 
the ICER could increase to $38,300 per life-year gained.
The additional included study was an older version of the currently included Marks study.64 
Therefore, the up-to-date data have been reported. Other studies, including those by Leren,65 
Humphries and colleagues66 and Hadfield and colleagues67 all suggest that genetic screening is a 
cost-effective use of NHS resources and should be implemented across the UK.
The main background for the economic modelling of these candidate tests comes from NICE 
clinical guideline CG71,1 in which an economic model was developed to compare DNA testing 
with LDL-C testing. The results showed that DNA testing was cost-effective with an associated 
ICER of £2676 per QALY gained. This model has been updated and integrated to account for the 
testing of Elucigene FH20 and LIPOchip and other plausible scenarios for the identification of 
FH and is described in more detail in the following sections.
We did not identify any other health economic models for the identification of FH that would be 
informative to the development of this assessment.
Summary
NICE clinical guidance (CG71)1 concluded that genetic testing of relatives of index cases with 
FH is cost-effective. There was, however, no available evidence detailing the cost-effectiveness of 
genetic testing of index patients specifically using any of the candidate tests in this review (i.e. 
Elucigene FH20 or LIPOchip). One study evaluated the cost-effectiveness of an intervention 
test for cascade testing of relatives.57 This is cascade testing based on LIPOchip; however, there 
are less costly methods of cascade testing of relatives (targeted sequencing) and so this analysis 
may be of limited use for informing the economic evaluation for this appraisal. A number of 
supplementary studies discussed provide strong evidence that cascade testing of relatives of index 
cases with FH is cost-effective. Based on this evidence together with the results of CG71,1 we have 
developed an economic model to assess the cost-effectiveness of Elucigene FH20, LIPOchip and 
comparators (including CGA and LDL-C) for the identification and treatment of index cases with 
FH and the identification of relatives by cascade testing.
Methods for economic analysis
The care pathway for this economic evaluation has been defined by NICE clinical guidance 
(CG71)1 and is as summarised in Chapter 1 (see Care pathways). In brief, the key points set out in 
this guideline that have implications for the economic evaluation recommend:
  ■ DNA testing to confirm clinical diagnosis of FH based on Simon Broome criteria in index 
(proband) patients suspected of having FH. A clinical diagnosis will include two LDL-C 
concentration measurements.
  ■ DNA testing for identified mutations in first-, second- and possibly third-degree 
family relatives.
  ■ Patients identified with FH should be offered a high-intensity statin therapy option.
A number of diagnostic pathways were specified as part of the NICE scope and review group 
protocol for analysis and are used to develop the economic modelling for this assessment; they 
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TABLE 18  Diagnostic strategies for identifying a genetic mutation (or LDL-C level) in index cases
Strategya  Stage 1  Stage 2  Stage 3 
1 Clinical diagnosis of FH (LDL-C test 
required)
Elucigene FH20 Treatment decision for index case and 
initiation of cascade testing for test-
positive first-, second- and possibly 
third-degree biological relatives of the 
index case
2 LIPOchip 
3 CGA
4 Elucigene FH20 then LIPOchip for 
negatives
5 Elucigene FH20 then CGA for negatives
6 LIPOchip then CGA for negatives
7 Elucigene FH20 then LIPOchip for 
negatives then CGA for negatives
8 Elucigene FH20 then MLPA for negatives
9 LIPOchip then MLPA for negatives
10 Elucigene FH20 then LIPOchip for 
negatives then MLPA for negatives
11 LDL-C test 
a  LIPOchip platform (processed in Spain).
Using these care pathways we developed an economic model to estimate the cost-effectiveness of 
several diagnostic strategies for the confirmation of clinical diagnosis of FH among index cases 
and the subsequent identification and treatment of FH-positive first-, second- and third-degree 
biological relatives of the index case.
Model structure
The model structure was developed based on clinical advice in line with the NICE scoping 
document and assessment group protocol. As diagnostic strategies in themselves do not lead 
to quality-of-life implications directly, the model follows a linked evidence approach in which 
intermediate outcomes (diagnostic accuracy) are linked to treatment outcomes and hence QALY 
gains. By a linked evidence approach we mean that, based on diagnostic test result, a patient 
will be either positive or negative. Positive-testing patients receive a high-intensity treatment 
and negative-testing index cases receive a low-intensity treatment as they will still be at risk of 
cardiovascular events based on high LDL-C levels. The treatment received by each group (true-
positive, true-negative, false-positive, false-negative) will determine their cardiovascular events 
avoided and hence their QALYs gained from that treatment decision. The outcomes on the index 
diagnostic test also determine whether or not the relatives will receive targeted sequencing in 
combination with LDL-C or LDL-C alone as the cascade test of choice. Therefore, we can say that 
the diagnostic test outcome of the index case is ‘linked’ to treatment choice and overall health 
outcomes over a lifetime horizon.
A decision tree model has been developed to identify the most cost-effective method of 
identification of index cases and subsequent testing and identification of at-risk relatives. 
Diagnostic accuracy outcomes are linked to treatment outcomes and hence QALY gains using a 
previously developed economic Markov model used for clinical guidance (NICE CG711).
One of the most important advantages of genetic testing is the identification of family members 
for cascade testing. The test used to cascade test relatives of index cases will depend on the test 
used to identify the index case. Three tests (targeted gene sequencing, LIPOchip and Elucigene 
FH20) are substantially cheaper than CGA and may be used for cascade testing. For the majority 
of genetically confirmed index cases, targeted sequencing for the culprit mutation is the most 
commonly applied genetic cascade testing method (Dr Zosia Miedzybrodzka, University of 
Aberdeen, 2011, personal communication). For relatives of index cases identified using the 48 Assessment design and results: cost-effectiveness
Elucigene FH20 or LIPOchip tests, the cheaper test designed to detect the identified mutation 
(LIPOchip, Elucigene FH20 or targeted sequencing) may be used to cascade test relatives. 
LIPOchip or Elucigene FH20 may also be used to cascade known mutations picked up on other 
tests that would also be detected by the candidate tests.68 This scenario would apply only if 
LIPOchip or Elucigene FH20 were cheaper than targeted sequencing. For index cases identified 
based on Simon Broome criteria and not a genetic test, then LDL-C concentration measurement 
is the most common method used to cascade test relatives. The model structure for relatives 
assumes that, once a patient has a confirmed diagnosis, his/her close relatives will be identified 
and cascade testing will begin, first testing all first-degree relatives. For the base-case analysis it is 
assumed that each index case will have on average five first-degree relatives and each first-degree 
relative will have on average a further two first-degree relatives (second-degree relatives of each 
index case) who will require testing. For the purposes of this assessment we assume that once a 
first-degree relative tests positive, the process moves on to second-degree relatives and similarly 
on to third-degree relatives if appropriate. If a first-degree relative tests negative for FH, then the 
cascade testing process stops irrespective of the test used for cascading.
A copy of the model decision tree is illustrated in Figure 9, detailing the identification strategies 
for index cases in the model. Each circle represents a chance node at which probabilities of 
positive and negative test results are assigned. Index cases receive cost and QALY payoffs at 
each terminal node (triangle), at which point relatives are identified for cascade testing as 
described above.
Identification of probabilities for the decision model
The probabilities used to populate this model were estimated using standard conventions of 
Bayes’ theorem. Basically, once we know the sensitivity and specificity of a test as well as the 
a priori probability of disease in the target population, we can calculate positive, negative, 
true-positive, true-negative and thus false-positive and false-negative values for the model. The 
formulae used for the calculation of each branch of the tree for single test strategies (e.g. CGA 
alone) are described in Table 19.
When tests are connected in series as add-ons to each other (i.e. the second test detects the 
same mutations as the first test plus additional FH-causing mutations), the theory is essentially 
the same but will be represented by the associated values of the second test. Taking Elucigene 
FH20 followed by CGA as an example, the positive rate will be [(proportion testing positive on 
Elucigene FH20 + proportion testing positive on CGA) – proportion testing positive on Elucigene 
FH20]. The proportions testing positive on Elucigene FH20 cancel each other out as they are 
incorporated in CGA and CGA detects all the mutations detected by Elucigene FH20 and more; 
therefore, the proportion testing positive on this example strategy is simply the value of the most 
comprehensive test in the strategy (i.e. CGA). A similar argument applies to Elucigene FH20 
followed by LIPOchip.
For strategies in which MLPA is used as an add-on test to Elucigene FH20 or LIPOchip, 
the calculations are slightly different. As MLPA detects additional cases not detected using 
Elucigene FH20 or LIPOchip (we assume here that the detection of deletions and duplications 
on LIPOchip is inadequate and MLPA will still be needed to give a more robust estimate), the 
effect of the two tests in series is not as before. Therefore, for the calculation of true-negatives 
on Elucigene FH20 followed by MLPA, the effect will be multiplicative and can be calculated as 
[(1 – prevalence) × (specificity of Elucigene FH20) × (specificity of MLPA)]. The MLPA test has not 
been considered separately from CGA because, by definition, CGA will already include MLPA as 
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FIGURE 9  Economic decision tree model for index cases. DFH, definite familial hypercholesterolaemia; PFH, possible 
familial hypercholesterolaemia.50 Assessment design and results: cost-effectiveness
Sensitivity and specificity values used in the calculations of the model are presented in Table 20 
for information. More detailed information on sensitivity and specificity for all included studies 
is presented in Chapter 2. Studies chosen to inform the economic modelling fulfilled two main 
criteria: (1) they were based on patients with a Simon Broome definite FH or possible FH 
clinical diagnosis of FH (preferably in a UK population) where possible and (2) when tests were 
conducted in a number of different countries (outwith the UK) in a study, we have chosen the 
cohort with the largest sample size (unless some explicit reason existed why this would not be 
appropriate). These were assumed to offer the most robust estimates in the absence of UK data. 
When studies did not report clinical diagnosis based on the Simon Broome criteria or when 
evidence was of poor quality and limited usability, we obtained parameter values from Dutch and 
MedPed criteria instead. For reasons discussed in the statistical analysis, it has not been possible 
to pool estimates of sensitivity and specificity for a combination of definite FH and possible 
FH diagnoses across studies in a robust way because of study heterogeneity (see Chapter 2, 
Assessment of test performance). Therefore, single studies have been chosen based on the best 
available evidence and the most recent version of each test analysed. The impact of these choices 
on our base-case conclusions will be explored through the use of lowest and highest estimates 
available from all of the included studies, based on all clinical criteria (MedPed and Dutch 
criteria included), in sensitivity analysis.
It is important to note that there is likely to be some correlation between those patients detected 
on MLPA and those detected using LIPOchip. Clinical expert opinion (Dr Zosia Miedzybrodzka, 
University of Aberdeen, personal communication) suggests that the LIPOchip test may be 
inadequate to detect deletions and duplications and in practice MLPA may be required to give a 
more accurate diagnosis.
LIPOchip can be used within the model in two separate ways. First, the strategy ‘LIPOchip’ 
refers to the test purchased by a laboratory in the UK from the manufacturer and processed at 
the UK laboratory. Additionally, the manufacturer offers a service whereby blood samples can be 
sent to the manufacturer’s plant in Spain for analysis using a two-stage process, first testing with 
LIPOchip and then sequencing of the LDLR gene for those testing negative. This is referred to 
as LIPOchip platform (Spain). Because of its second stage, at an additional cost of €100, this test 
has a higher sensitivity. It is, however, not CGA as the process does not include MLPA. Therefore, 
the sensitivity is less than that of CGA. Clinical expert opinion in the UK suggests that, to be 
able to fully detect all deletions and duplications of the gene, the MLPA test would be required as 
LIPOchip’s own method of detecting these cases may be inadequate. Additional data presented at 
the spring meeting of the CMGS70 suggest that (using data from Bristol’s NHS Hospital Genetics 
Laboratory) LIPOchip version 10 may be inadequate to detect copy number changes compared 
with MLPA, with only two cases out of a sample of seven correctly identified using LIPOchip.
In addition, there is much debate about the true prevalence of detectable FH-causing mutations 
among patients testing positive (definite FH or possible FH) based on the Simon Broome 
TABLE 19  Calculation of probabilities for decision tree
Test results for decision tree Calculation
Positive Sensitivity × prevalence + (1 – specificity) × (1 – prevalence)
Negative 1 – positive
False-positive 1 – PPV
False-negative 1 – NPV
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criteria. There is also great variation in this number between laboratories and this is likely to be 
because of issues of ethnicity as some tests will have different detection rates based on different 
ethnic groups (see Chapter 2, Assessment of test performance for additional information). For the 
purposes of our base-case analysis, we have assumed that 36.5% of clinically diagnosed patients 
(Simon Broome definite FH or possible FH) will have an identifiable mutation.37 Data from 
four regional Scottish genetics services (Aberdeen, Dundee, Edinburgh and Glasgow; Dr Zosia 
Miedzybrodzka, University of Aberdeen, 2010, personal communication) suggest that, between 
2007 and 2010, this value was approximately 35% for the whole of Scotland based on data 
classifiable as definite FH or possible FH. This has been confirmed in personal communication 
with Dr Zosia Miedzybrodzka, who estimates that, for every three patients tested in Aberdeen 
using CGA, on average only one will have a detectable FH-causing mutation. NICE CG711 
estimates, using data extracted from the UK FH Cascade Audit Project (FHCAP),70 that 80% of 
patients clinically diagnosed with definite FH will have a detectable FH-causing mutation and 
30% of those diagnosed as possible FH will have a detectable mutation. Given that the FH audit 
201018 identifies 36% as definite FH and 58% as possible FH (the remainder being homozygous 
or not stated), this would suggest that 46.2% of patients clinically diagnosed as definite FH 
or possible FH would have an identifiable genetic mutation using CGA. Other studies quote 
varying estimates of these values and so maximum and minimum values will be explored in the 
sensitivity analysis. It is estimated that 50% of first-degree relatives of an index case will have 
an inherited mutation. This evidence for first-degree relatives has been applied to second- and 
third-degree relatives in the model. The reason for this is that the process of cascade testing is an 
iterative approach. Second-degree relatives will not be tested using targeted sequencing unless a 
first-degree relative has an identified mutation. Therefore, it is assumed that the second-degree 
relative is in fact the first-degree relative of an individual with an identified FH-causing mutation 
and so will also have a 50% probability of having inherited that mutation.
TABLE 20  Sensitivity and specificity of tests used to populate the economic model
Test Sensitivitya Specificitya
Source used for economic 
modelling Justification for choice of source
Elucigene FH20 0.44 1 Taylor 201037 This is the most up-to-date test for Elucigene FH20
LIPOchip 0.79 1 Palacios 201041 Only available data based on UK version 10 of LIPOchip
CGA 1 1 Assumption Based on clinical expert opinion, this will correctly detect 
all known mutations causing FH; it is assumed, therefore, 
that if a patient tests negative he/she will not have FH
LDL-C (Index)b 0.90 0.29 Damgaard 200545 This was the best available data based on Simon Broome 
criteria
LDL-C (Relatives) 0.68 0.85 Starr 200849 the Netherlands 
group
The Netherlands group chosen as it represented the 
greatest number of patients being tested (sensitivity 
analysis explores high and low estimates of both 
sensitivity and specificity based on all studies)
MLPAc 0.12 1 Calculation Relates to a stand-alone detection rate of approximately 
5%, confirmed through clinical expert opinion (Dr Gail 
Norbury, Guy’s Hospital, London, 2011 and Dr Zosia 
Miedzybrodzka, University of Aberdeen, Aberdeen, 2010)
a  Comparator for calculation of sensitivity and specificity is CGA; values are rounded to two decimal places.
b  Note that the comparator for the Damgaard study was just complete genetic analysis of the LDLR and APOB genes and did not include the 
PCSK9 gene.
c  The sensitivity for MLPA is not used for MLPA as a stand-alone test in the model as this would not happen in clinical practice. The sensitivity 
reported here is used to calculate the sensitivity of test strategies such as Elucigene FH20 followed by MLPA for negatives, in which MLPA 
might be expected to add to the sensitivity of the main test.52 Assessment design and results: cost-effectiveness
Markov model
The Markov model for this assessment has been adapted from the model used for the estimation 
of treatment effect used to inform NICE CG71.1 The model was developed by the Royal College 
of Physicians Guideline Development Group and is updated in this assessment. This model 
calculated the lifelong treatment costs and outcomes of high-intensity statin therapy for the 
management of FH and low-intensity statin therapy for the management of others at risk of 
CHD because of elevated lipid levels. In addition to those who were classed as well, a total of 
eight further health states were modelled [unstable angina, MI, peripheral arterial disease (PAD), 
stroke, heart failure, revascularisation, cardiovascular death and other death]. Baseline risks were 
sourced from NICE technology appraisal 9471 and relative risks were sourced from the Simon 
Broome register. Utility weights were sourced from the literature and validated by the health 
economist working on this assessment. Utility of the general population was taken from the 
Health Survey for England 1996,72 which is the most up-to-date data source for the UK general 
population, and was adjusted for age and sex differentials. Beneficial health outcomes were used 
to estimate QALYs based on reduced risks of cardiovascular incidents. These treatment effects 
were sourced from a meta-analysis of two RCTs, the Incremental Decrease in Clinical Endpoints 
Through Aggressive Lipid Lowering (IDEAL) and the Treating to New Targets (TNT) trials 
conducted as part of the NICE CG71 assessment.1 Data from Versmissen and colleagues8 were 
checked against and found to be consistent with the assumptions and data used for CG71,1 in so 
far as they show the efficacy of statins in improving the clinical causes of cardiovascular disease 
and by extension the reduction in serious cardiovascular events such as MI. However, they do not 
describe the exact causal relationship between the improved clinical outcome and reduced events. 
The data from Versmissen and colleagues8 are consistent with those of the CG711 assessment 
in that they suggest efficacy of statins and by extension the reduction in serious cardiovascular 
events such as MI. Costs and outcome data have been updated to current values using the latest 
available literature in the field or inflated to current prices (2010/2011) if no updated literature 
was available. Further details of the model structure are available from the NICE website 
(appendix E to the clinical guideline document1). The perspective of this economic evaluation 
is that of the UK NHS and all costs and resource use are applied in accordance with NICE 
guidelines on the methods of technology appraisal. NICE recommends that, where possible, 
the desired economic outcome is cost per QALY gained. Treatment costs and QALYs gained are 
extrapolated to the patient’s lifetime horizon and discounted at a rate of 3.5% per annum in line 
with standard NICE methods. It was not deemed necessary to discount diagnostic costs for each 
individual as the time taken for diagnosis is < 1 year. Sensitivity analyses explore the impact of 
varying the discount rate for both costs and QALYs between 0% and 6%. All other follow-up 
clinical costs that are expected to occur annually once a diagnosis of FH has been made are 
discounted as described.
Relevant patient populations
The relevant patient population for the base-case analyses is adults with heterozygous FH, 
focusing on index patients with a clinical diagnosis of FH based on the Simon Broome criteria 
(either definite or possible FH). Sensitivity and specificity of the tests included for the economic 
modelling both implicitly account for patients with either definite or possible FH. Data showing 
separate sensitivity and specificity rates for definite FH and possible FH were not available 
for all tests under consideration, thus making accurate subgroup analysis difficult. The data 
that were available are detailed in Tables 9–14 (index cases) and Table 15 (testing of relatives). 
Children with a clinical diagnosis are considered as a separate age subgroup in line with current 
CG71 recommendations.1 Patients with an identified mutation causing FH are informed of 
their diagnosis and first-, second- and third-degree biological relatives are identified. Sensitivity 
analysis explores a situation in which only first- and second-degree biological relatives are 
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Treatment options to be evaluated
Treatment options to be evaluated are based on NICE CG71,1 which recommends that a patient 
with FH should be offered a high-intensity statin therapy for the aggressive lowering of lipid 
levels by a recommended 50%. Index cases who have elevated lipids on the basis of the Simon 
Broome criteria (i.e. the majority of patients) will benefit from statin therapy as they are at a 
≥ 20% 10-year risk of cardiovascular disease events.71 We assume that 10% of relatives testing 
negative on targeted sequencing will also require some cholesterol-lowering therapy. This is 
an author assumption based on clinical expert opinion and previous NICE guidance and is 
varied between 0% and 50% in the sensitivity analyses. This refers to the estimated percentage 
of relatives without an identified mutation who will require treatment on the basis of high 
cholesterol levels. Such cases receive a low-intensity treatment in the model. As relatives are not 
clinically diagnosed with FH based on the Simon Broome criteria, it would be inappropriate 
to treat all patients, as only a percentage will have elevated lipids. The impact of varying this 
assumption is explored in sensitivity analysis. There is, however, much debate among clinicians 
over how to treat FH and patients at an increased risk of cardiovascular disease as a result of 
elevated lipids, with some choosing a ‘start low’ treatment option (starting all patients on a low-
intensity statin such as simvastatin 40 mg) and others giving everyone a high-intensity statin (e.g. 
atorvastatin 80 mg or rosuvastatin). For the base-case analysis, we have assumed a multitreatment 
regimen for FH patients based on and adapted from the FH clinical audit 2010.18 Patients with 
a Simon Broome-positive diagnosis but who have no genetic confirmation of FH will receive 
low-intensity statin therapy to reduce their elevated lipid levels. Such cases (especially those 
relatives who are false-positive) may also respond adequately to exercise and diet therapy, the 
effects on quality of life of which are beyond the scope of this assessment. Cole and colleagues73 
have conducted a detailed systematic review of the literature to explore the evidence in relation 
to the effects of dietary and lifestyle interventions in chronic heart disease risk reduction. Also, 
NICE guidance on dietary interventions in CHD provides additional information in the UK. 
Personal communications from Dr Anthony Wierzbicki (2011, Guy’s and St Thomas’ Hospitals 
NHS Trust) and Dr William Simpson (2011, NHS Grampian) are used in sensitivity analyses to 
explore the sensitivity of the model to treatment choice in practice.
Resource use estimation
Clinical resource use
For the purposes of this evaluation, we have assumed that all index cases will have received a 
clinical diagnosis of FH based on the Simon Broome criteria. Resource use and costs associated 
with this diagnosis are common to all tests being evaluated and so are not included. This is 
standard economic evaluation practice to include only resource-use estimations which differ 
between tests under consideration. However, the resource use associated with tests after the 
initial diagnosis is important and has been considered in the analysis. It is assumed that, once 
the proband has a genetic test or LDL-C confirmation of FH, he or she will attend a lipid clinic 
to discuss treatment and lifestyle management of the condition. It is at this point that family 
pedigree will be identified and contact with relatives will be initiated. It is assumed that initially 
only first-degree relatives will be contacted as there would be no point in contacting second-
degree relatives until a diagnosis was confirmed in first-degree relatives using a genetic screen. 
Table 21 details resource use and cost estimation for this process based on clinical expert opinion 
and Hadfield and colleagues.70
Index cases or relatives diagnosed with FH are offered an annual follow-up appointment 
with a lipids specialist at an outpatient clinic. In the absence of a specific unit cost tariff for 
a lipids specialist, this service is assumed similar to a cardiologist appointment (Dr William 
Simpson, University of Aberdeen, 2011, personal communication) and is costed at £222 per 
outpatient consultation.54 Assessment design and results: cost-effectiveness
Diagnostic resource use
A new national activity unit has been developed for molecular genetics and cytogenetic tests 
in the UK. This is based on a weighted report and uses for molecular genetics an amplicon 
as the base unit. All molecular genetic tests are then assigned a relative number of units that 
slot into bands with some efficiency built in as the number of amplicons increases. This new 
methodology for measuring activity for molecular genetic tests was developed by collaboration 
between the CMGS and the UKGTN. The objective was to devise a transparent and consensus 
system for measuring molecular test activity that could be implemented by all laboratories. Tests 
are weighted by complexity so that, for example, simply booking in a sample has the lowest 
weight and sequencing a gene of over 100 exons, for example RYR2, the highest. All realisable 
costs of each laboratory are collated and a total cost of the service is then calculated including 
salaries, consumables, overheads, etc. Each laboratory can derive its own unit cost, based on 
dividing budget by activity, and thus in effect derive a cost per test. For example, a £1.2M service 
producing 30,000 MOLUs will have a unit cost of £40.00. This system of pricing has been 
modelled by most of the laboratories in the UK and has been accepted by the professional bodies 
and UKGTN as a suitable approach to establishing a national tariff for genetic tests. Details of the 
national MOLU bands are included in Appendix 11 for information. The MOLU system is not a 
perfect system of estimating costs, however, and the limitations are outlined in Chapters 1 and 5.
For the base-case analysis, transportation costs of samples (preferably blood samples) for DNA 
testing and blood samples for LDL-C testing are included. Based on clinical expert advice 
TABLE 21  Resource use of health-care professionals for both index and cascade testing of patients after diagnosis
Health-care professional
Unit cost/
hour (£)
Time (hours) 
index case
Cost index 
case (£)
Time (hours) 
relatives
Cost per 
relative 
positive (£)
Cost per 
relative 
negative (£)
Source for unit 
costs
Consultation with lipid 
specialist 
222.00 222.00 222.00 0 PBR, cardiologist, 
first attendance74
Clinical nurse specialist, 
grade 7, to confirm family 
pedigree and discuss
57.00 1.86 106.02 1.20 68.40 68.40 PSSRU 2010,75 cost 
per hour of client 
contact, Hadfield 
200870
Clerk time to initiate 
contact with relativesa
26.00 0.25 48.75 0.25 39.00 0 PSSRU 2010,75 
band 5 
administrator
Cost of consumables 
to initiate contact with 
relatives
0.78 5.85 4.68 0 Cost per letter, NICE 
CG711
Two lipid profile tests to 
confirm diagnosis
8.00 16.00 16.00 16.00 Personal 
communication, Dr 
William Simpson, 
2011, NHS 
Grampian
Cost of processing the 
lipid tests
1.60 3.20 3.20 3.20 PBR national 
tariff for clinical 
biochemistry74
Cost of GP consultation to 
take second cholesterol 
measure for confirmation
36.00 36.00 36.00 36.00 11.7 minutes, 
surgery consultation, 
PSSRU 201075
Total 438.00 389.00 124.00
PBR, Payment by Results; PSSRU, Personal Social Services Research Unit.
a  Calculations for cost of index case and relatives are based on an average of 1.5 letters sent for each relative of an index case. Assuming the 
average index case has five first-degree relatives, and the time taken per letter is 0.25 hours, then the cost is £26 × 0.25 × 1.5 × 5 = £48.75. 
Similarly for the cost per positive relative, again an average of 1.5 letters per first-degree relative and an average of four contacts for a positive 
case, the resultant cost is £26 × 0.25 × 1.5 × 4 = £39.00.© Queen’s Printer and Controller of HMSO 2012. This work was produced by Sharma et al. under the terms of a commissioning contract issued by the 
Secretary of State for Health.
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(Dr Gail Norbury, Guy’s Hospital, London, 2011, personal communication), an increasing 
number of genetics samples are tested by processing saliva samples. Saliva-based samples are less 
costly to transport as they are more stable and require only first-class postage; however, the kits to 
extract the DNA are substantially more expensive. These resource use differences, however, will 
be included in the MOLU consumables mentioned above based on 1 MOLU for DNA extraction. 
The majority of tests are carried out in the UK; however, LIPOchip may be processed by the 
manufacturer on site in Spain. The additional resource and transportation costs associated with 
sending a blood sample overseas via air are considered for the LIPOchip platform processed in 
Spain. This was assumed to take a cost of 1 MOLU, commonly applied in genetic testing to cost 
transferring samples to laboratories overseas. Therefore, a cost of £30 has been applied in the 
base case. Additionally, there may be extra costs associated with resampling an estimated 3% of 
samples (Progenika, 2011, personal communication). These costs are also incorporated.
Unit cost estimation
Clinical costs
Costs of clinician time for treating patients, identifying a family pedigree, counselling relatives 
on the importance of their condition and contacting relatives themselves are estimated using 
Payment by Results (PBR) national tariffs where available (e.g. for a first appointment with a 
lipid specialist). For all other resource use, including clinical nurse specialist (to identify pedigree 
and counsel patients), GP time to confirm second LDL-C test and administrator time to contact 
relatives, costs are estimated using Personal Social Services Research Unit (PSSRU) unit costs of 
health and social care.75 Costs are based on the median of the appropriate agenda for change pay 
scale and include overheads, training costs, insurance, annual leave, etc.
Diagnostic costs
Costs of genetic testing strategies vary greatly among laboratories, especially based on their 
area of expertise and also in relation to their size – the greater the laboratory size, the greater 
the throughput of samples tested and thus the lower the costs based on economies of scale 
through mass genetic testing. Laboratories that can keep their budget constant or can reduce it 
but increase the number of MOLUs produced will have lower unit costs. The incentive then is 
to reduce the total budget while maintaining or increasing output. This system is simplistic and 
transparent and is the method adopted by most laboratories in the UK in setting their genetic 
testing tariffs (Dr Zosia Miedzybrodzka, University of Aberdeen, and Dr Gail Norbury, Guy’s 
Hospital, London, 2011, personal communication). For the purposes of the base-case analysis, 
it is assumed that the MOLU cost is £30 per MOLU (Dr Kevin Kelly, University of Aberdeen, 
2011, personal communication). The cost of each MOLU will be varied in sensitivity analysis 
provided by Dr Gail Norbury (£33 per MOLU). Unit cost estimation is adjusted within the model 
for strategies that have more than one test in order to account for the cost differentials associated 
with earlier positive test identification. The cost of DNA extraction is also incorporated into the 
analysis and receives a unit of 1 MOLU. Details of MOLU units applied and the associated costs 
for each test strategy are presented in Table 22. The cost of testing a hypothetical cohort of 1000 
index cases with combination strategies is dependent on the numbers testing positive on the 
first test in that strategy. For example, in a strategy such as Elucigene FH20 followed by CGA for 
negatives, an index case who tests positive on Elucigene FH20 will not receive the second more 
comprehensive test.
In addition to the tests outlined above, the LIPOchip platform (Spain) as a genetic testing 
platform is a potential alternative to CGA. The test, which involves using the LIPOchip followed 
by sequencing of test-negative cases, is offered by the manufacturer (Progenika) at a cost of 
€250 for a LIPOchip test and €350 for the whole process. The associated costs are incorporated 
into the analysis using an exchange rate of €1 = £0.89. The LIPOchip platform processed in 
Spain is explained in Chapter 1. Briefly, this is a two-stage process whereby, if the sample is 
positive on LIPOchip, no further testing takes place. If the sample is negative on LIPOchip 56 Assessment design and results: cost-effectiveness
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then the sample is sequenced for an additional €100. Therefore, assuming that the sensitivity of 
LIPOchip is the same regardless of where it is processed and using similar methodology to that 
in Table 22, we estimate the total cost of the strategy (before transportation of samples costs) as 
(1000 × 250 × 0.89) + (713 × 100 × 0.89) = £285,957.
The cost of targeted sequencing may also be estimated using the MOLU system. Targeted 
sequencing (including DNA extraction) is allocated a MOLU of 3. At a cost of £30 per 
MOLU, this would amount to £90 per targeted sequencing test. Based on the MOLU system, 
targeted sequencing is cheaper than Elucigene FH20 and is therefore the strategy of choice for 
cascading relatives.
Low-density lipoprotein cholesterol concentration measurements will be taken for all members 
of the study, regardless of testing strategy. Additional measures will, however, be carried out 
to confirm the diagnosis. Therefore, an additional two LDL-C tests will be required (at least 
one of which will be a fasting blood sample) to confirm the Simon Broome diagnosis if this is 
the method of diagnosis being adopted. It is assumed that, in order to get an extra blood test 
taken for the additional LDL-C measurement, an additional visit to a GP will be required. It 
is not expected that transportation costs of samples sent to laboratories for analysis will differ 
significantly between LDL-C and genetic tests as both require the transportation of potentially 
hazardous blood specimens.
Treatment costs
As discussed in Treatment options to be evaluated and as recommended by CG71,1 treatment will 
be of either high or low intensity, predominantly with statins. Should a patient be intolerant to 
statins, treatment may be administered using ezetimibe as per the NICE CG711 guideline. There 
is, however, some debate as to the relative effectiveness of ezetimibe monotherapy; therefore, 
only a small proportion of patients are likely to receive this treatment in practice (Dr William 
Simpson, NHS Grampian, personal communication). Also based on personal communication 
(Dr Anthony Wierzbicki), ezetimibe as monotherapy is ineffective and patients who have an 
inadequate response to statins may need to be treated with ezetimibe plus bile acid sequestrants. 
A number of FH patients will receive polypharmacy incorporating treatment with statins and 
ezetimibe. Table 23 details the unit costs per year of treatment with all of the potential drugs 
included in the modelling process with costs sourced from the British National Formulary 
(BNF).76 To reflect differential treatment practice among clinicians, various combinations of 
these drugs (based on clinical expert opinions) are explored in the model. The most common 
combination therapies are included in Table 23.
For the base-case analysis, we used data from the FH audit 2010,18 the most up-to-date data 
source on FH treatment in practice. We also use data from clinical experts (Dr Anthony 
Wierzbicki, Guy’s and St Thomas’ Hospitals NHS Trust, 2011, personal communication, and 
Dr William Simpson, NHS Grampian, personal communication) to conduct sensitivity analysis 
surrounding the proportions of patients on each treatment as part of either a high- or a low-
intensity statin therapy. The cost impact of atorvastatin, which is due to come off patent during 
the course of this assessment, will have implications for treatment costs in the model. This will be 
explored in sensitivity analyses.
Costs of cardiovascular events avoided as a result of treatment
Table 24 details the costs of cardiovascular events avoided. For the base-case analysis, these 
costs have been calculated using weighted averages of all Health Resources Group (HRG) codes 
pertaining to each cardiovascular event avoided. Elective and non-elective tariffs from PBR data 
for 2010–1174 are used and weighted for the numbers of elective and non-elective cases sourced 
from the Hospital Episodes Statistics online database (www.hesonline.nhs.uk/Ease/servlet/Conte
ntServer?siteID=1937&categoryID=192).58 Assessment design and results: cost-effectiveness
Data sourced from current NICE guidelines1 such as for subsequent MI are not available as part 
of PBR nor do any national tariff prices exist for these events. Therefore, values have been sourced 
from CG711 and inflated to current price levels for use in the model. Costs of cardiovascular 
death or other deaths have been assumed to be equal to £0 as it is not envisaged that this would 
have cost implications for the NHS. However, such deaths avoided would have great impact on 
the results from a societal perspective.
List of assumptions
A number of assumptions have been made throughout the modelling exercise and for the 
base-case model; the impact of each will be explored in relevant sensitivity analyses. Table 25 
summarises the main assumptions made throughout the health economic modelling process.
TABLE 23  Unit costs of drug treatments used in the economic modelling
Treatment strategy Number of tablets per pack Cost per pack (£) Cost per year (£) Source
Atorvastatin monotherapy 40 mga 28 24.64 321.20 BNF 201176
Atorvastatin monotherapy 80 mga 28 28.21 367.74 BNF 201176
Rosuvastatin monotherapy 10 mg 28 18.03 235.03 BNF 201176
Rosuvastatin monotherapy 20 mg 28 26.02 339.19 BNF 201176
Rosuvastatin monotherapy 40 mg 28 29.69 387.03 BNF 201176
Simvastatin monotherapy 20 mg 28 1.01 13.17 BNF 201176
Simvastatin monotherapy 40 mg 28 1.32 17.21 BNF 201176
Simvastatin monotherapy 80 mg 28 2.29 29.85 BNF 201176
Ezetimibe monotherapy 28 26.31 342.97 BNF 201176
Rosuvastatin 20 mg + ezetimibe 28 52.33 682.16 BNF 201176
Simvastatin 40 mg + ezetimibe 28 27.63 360.18 BNF 201176
Atorvastatin 40 mg + ezetimibea 28 50.95 664.17 BNF 201176
Simvastatin 40 mg + ezetimibe 28 38.98 508.13 BNF 201176
a  Cost of atorvastatin based on current BNF pricing. Atorvastatin is likely to come off patent in 2011 and costs will mirror those of the 
simvastatin generic equivalent.
TABLE 24  Costs of cardiovascular events
Event Cost (£) Source
No event 74 NICE 20081 
MI (first year) 3780 Department of Health 201174
MI (subsequent) 500 NICE 20081 
Stroke (first year) 4335 Department of Health 201174 
Stroke (subsequent) 2336 Department of Health 201174 
PAD (first year) 2212 Department of Health 201174 
PAD (subsequent) 285 NICE 20081 
Heart failure 4379 Department of Health 201174 
Heart failure (subsequent) 500 Assumption 
Revascularisation 8610 Department of Health 201174 
Revascularisation (subsequent) 500 As MI (subsequent) 
Unstable angina (first year) 2074 Department of Health 201174 
Unstable angina (subsequent) 500 As MI subsequent 
Cardiovascular death 0 NICE 20081
Death, other 0 NICE 20081© Queen’s Printer and Controller of HMSO 2012. This work was produced by Sharma et al. under the terms of a commissioning contract issued by the 
Secretary of State for Health.
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Data analysis
Base-case analysis
For the base-case analysis, we analyse an index patient of age 50 years, with an assumed average 
first-degree relative age of 50 years. The decision model is run on the basis of a hypothetical 
cohort of 1000 patients with a clinical diagnosis of FH based on the Simon Broome criteria 
(including both definite FH and possible FH). Cost and QALY values are estimated as described 
in the preceding sections and applied to the number of people passing through each branch of 
the decision tree illustrated in Figure 9. On the basis of test accuracy, a proportion of all 1000 
index patients are positive (true-positive or false-positive) or negative (true-negative or false-
negative). These patients are assigned the relevant cost and QALY values as described and total 
costs and QALYs are generated for the full cohort.
Test strategies are ranked in ascending order of cost. Those strategies that are more costly 
and less effective are excluded on the basis of simple dominance. Additional tests that are 
dominated by a combination or two or more alternative strategies are excluded by extended 
dominance. ICERs are calculated as incremental costs divided by incremental QALYs between 
non-dominated strategies. This is the most common method of presenting ICERs and relates 
the options sequentially ranked by costs. For the purposes of this assessment, the most relevant 
comparators are:
1.  CGA, recommended indirectly by NICE guidance CG71.1
TABLE 25  List of major assumptions, justification and method for dealing with associated uncertainty
Assumption Justification for assumption Additional comments
Cascade testing is of first-, second- and third-
degree relatives of the index proband case
This is the widest spectrum of relatives 
recommended by NICE clinical guideline CG711 
and is recommended if possible
Sensitivity analysis will explore cascade testing 
of first- and second-degree relatives only
The percentage of probands providing family 
history and agreeing for the initiation of contact 
with relatives is 60% and the proportion of 
relatives agreeing to be tested is 65%
Assumption based on NICE clinical guideline 
CG711
Assumption will be adapted and varied in 
sensitivity analyses based on data from 
Hadfield and colleagues67
Cost of atorvastatin is based on BNF values BNF Cost of atorvastatin based on reduced pricing 
as a result of coming off patent will be 
explored in sensitivity analysis
10% of negative relatives receive low-intensity 
statin therapy
Relatives who are negative for FH are test-
negative and are unlikely to require treatment 
(author assumption)
In sensitivity analysis a proportion of negatives 
will receive lipid-lowering therapy based on 
low-intensity statins (this will not assume costs 
of annual follow-up in secondary care). A range 
of 0–50% will be explored
No QALY decrements for patients testing false-
positive for FH
Author assumption Patients who test false-positive may incur a 
QALY decrement due to stress and anxiety 
associated with having a condition; however, if 
they have high LDL-C levels it is likely that this 
will be offset by the knowledge that they are 
being treated for their high cholesterol and will 
be at reduced risk of cardiovascular disease
Prevalence, sensitivities and specificities for 
cascade testing using LDL-C are assumed to 
be the same for cascade testing from index 
test-negatives and index test-positives
Author assumption All index cases have a clinical diagnosis of 
FH regardless of whether or not they have a 
detectable mutation. Sensitivity analysis varies 
all estimates of test sensitivity and specificity 
in the model
All index cases will require treatment of some 
kind
As patients will be positive for FH, they will 
have elevated cholesterol levels by definition 
and will be at increased risk of cardiovascular 
events
Sensitivity analyses will assume a fraction of 
these patients are treated (i.e. only those with 
a genetically confirmed mutation)60 Assessment design and results: cost-effectiveness
2.  LDL-C concentration measurement only. The reason for this is that, in practice, LDL-C is the 
main method of identification presently adopted in the UK (although genetic testing is more 
common in Scotland, Wales and Northern Ireland than in England).
Therefore, ICERs are presented as cost per QALY compared with the two suggested reference 
standards for this evaluation (LDL-C and CGA).
This process is applied to two distinct research questions. First, we investigate the cost-
effectiveness of each of the 12 strategies for index cases alone. However, of greater importance 
and thus the primary focus of the analysis is to present cost-effectiveness estimates for the 
complete process of index case confirmation of clinical diagnosis but also for the identification 
and testing of relatives (i.e. the whole cascade testing process).
Subgroup and additional scenario analysis
The cost and QALY results for different age groups are explored in this section for the full 
cascading project only (i.e. index and relative cases). Results for index cases alone are presented 
in Appendix 12.
These subgroup analyses include a range of age profiles and also include the incorporation of any 
available evidence relating to the efficacy of statins in the treatment of children. To this end, we 
have completed a structured search of the literature, which has identified four systematic reviews 
of the efficacy of statins in children, the most recent of which is a Cochrane review of high quality 
that is used to inform the discussion and the model.77 The data suggest that statins are efficacious 
in children in reducing cholesterol and have non-significantly different adverse events to placebo. 
Therefore, statins are likely to be safe in children with FH although long-term follow-up of this 
patient group is required. As data relating directly to CHD are lacking, treatment effect relative to 
CHD is assumed to be similar to that of a young adult (equivalent to a 30-year old index case in 
the economic model).
A number of age-specific subgroups were considered (probands aged 15, 30, 50, 65, 75 and 
85 years). These age subgroups are similar to those used in previous economic modelling for 
FH1 and represent a good distribution of the ages of the population who may present for testing. 
Table 26 details the calculated number of relatives for each index case and their average age used 
in the model.
As discussed in Model structure, there may be alternative estimates of cost-effectiveness based 
on whether the index case is identified as definite FH or possible FH as their clinical diagnosis. 
It should be noted, however, that because of a lack of sensitivity data for each test separated into 
definite FH and possible FH subgroups, it was not possible to conduct robust analyses of FH 
cases split by clinical diagnosis subgroup. We have, however, conducted threshold analyses which 
TABLE 26  Details of index case age and associated number and age of relatives
Age of index case years
Number of first-degree 
relatives
Number of second-
degree relatives
Number of third-degree 
relatives
Average age of all 
relatives years
15 3 6 8 50
30 5 4 4 30
50 5 4 4 50
65 3 6 8 30
75 3 6 8 50
85 2 6 4 30© Queen’s Printer and Controller of HMSO 2012. This work was produced by Sharma et al. under the terms of a commissioning contract issued by the 
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show the combination of mutation prevalence and test sensitivity that would be required for the 
candidate test to be considered cost-effective as a pre-screen to CGA. The probabilistic sensitivity 
analysis accounts for the combined variation in all of the input parameters.
Sensitivity analyses
As many assumptions are made throughout the modelling process and selective data are chosen 
to inform the parameters, it is possible that the results generated will be sensitive to some of 
the judgement calls, assumptions and decisions made in the analysis. Therefore, we carry out a 
range of sensitivity analyses to determine the sensitivity of the base-case results to changes in 
our assumptions. A range of univariant deterministic analyses are presented in Appendix 14, the 
main results of which are reported and discussed in Analysis of uncertainty, including probabilistic 
sensitivity analysis. In addition, a probabilistic sensitivity analysis is also presented to explore 
uncertainty in the model.
Areas of uncertainty that are explored include:
1.  Prevalence rates of FH-causing mutations among clinically diagnosed index cases and 
at-risk relatives.
2.  Treatment differences for those with genetically confirmed FH and those without a 
genetic confirmation. The implication of forthcoming price reductions of atorvastatin is 
also explored.
3.  Uncertainty surrounding the proportion of probands and relatives with a given test result 
receiving treatment (e.g. the proportion of those with a false-negative or true-negative test 
result receiving statin therapy).
4.  The costs of diagnostic strategies, especially issues of uncertainty surrounding the MOLU 
pricing system and the likely cost of a 1-unit MOLU output.
5.  Key assumptions relating to the model structure, including cascade testing only of first- and 
second-degree relatives, discount rates applied to costs and effects, the impact of not cascade 
testing negative index cases and the proportion of index and relative cases agreeing to 
participate in the identification and testing process.
6.  Uncertainty associated with assumptions listed in Table 25 including structural assumptions 
regarding management of negative-testing index and relative cases.
Probabilistic sensitivity analysis
Deterministic one-way sensitivity analyses and point estimates of ICERs do not adequately 
provide information on the true impact of uncertainty surrounding the model parameters. 
Because of imperfect information on both the resource use and effectiveness of each treatment 
strategy, costs and QALYs are highly likely to be subject to at least some degree of uncertainty. 
Therefore, we conducted additional probabilistic sensitivity analysis using Monte Carlo 
simulation (5000 repetitions). Distributions were fitted to each of the parameters based on 
published studies (where available), CG71 data1 and a number of assumptions where no 
data were available. For example, where insufficient data existed in published sources to fit 
distributions to parameters, standard errors were assumed in order to calculate alpha and beta 
values. This may slightly under- or overestimate the variation in some of the parameters; however, 
it is not likely to impact greatly on resultant cost-effectiveness acceptability curves (CEACs). 
For sensitivity of test strategies (Elucigene FH20 and LIPOchip) the analysis was bounded by 
the highest and lowest reported mean values in all of the studies identified from the systematic 
review of the literature. Full details of probabilistic sensitivity analysis parameters are presented 
in Appendix 16.
The net benefit framework was used to estimate net monetary benefits for each simulation 
as described in Briggs.78 The defining characteristic of this approach is that all strategies add 62 Assessment design and results: cost-effectiveness
to a probability of cost-effectiveness equal to 1. This uncertainty is illustrated in the form of 
CEACs for each of the non-dominated strategies of testing. CEACs for the base-case analysis 
are presented in the text, with supplementary analyses following the same approach for each 
age subgroup in the model presented in Appendix 15 for completeness. The analysis is presented 
for non-dominated test strategies only. The comparison for the calculation of incremental costs 
and QALYs for this analysis is LDL-C as this is current practice in the NHS. As the remit of 
this report is primarily to assess the cost-effectiveness for index cases and relatives, we have 
not conducted probabilistic sensitivity analysis for index cases alone. In addition, CEACs are 
presented for 5%, 10%, 20% and 50% mutation prevalence rates in order to reflect the uncertainty 
surrounding mutation detection rates in various subgroups of the population, primarily varying 
based on ethnic background.
Results of economic analysis
Results presented for the base-case analysis are subject to the assumptions listed in Table 25.
Summary of test results for a hypothetical cohort of 1000 familial 
hypercholesterolaemia patients
Table 27 details the flow of a hypothetical cohort of 1000 patients through the model based 
on those testing false-positive, true-positive, false-negative and true-negative. The values for 
sensitivity and specificity are combined values for all definite FH or possible FH patients based 
TABLE 27  Test results for a hypothetical cohort of 1000 patients by testing strategy for index cases and cascading of 
both test-positive and test-negative relativesa
Diagnostic test
Index cases
Relatives of positive index cases 
(tested using targeted sequencing)b
Relatives of negative index cases 
(tested using LDL-C)b
TP FP TN FN Total TP FP TN FN Total TP FP TN FN Total
Elucigene FH20 161 0 635 205 1000 374 0 374 0 748 900 255 1307 662 3124
Elucigene  
FH20_LIPOchip
287 0 635 79 1000 667 0 667 0 1335 765 216 1111 563 2655
Elucigene FH20_CGA 365 0 635 0 1000 851 0 851 0 1701 680 193 989 501 2362
Elucigene  
FH20_LIPOchip_CGA
365 0 635 0 1000 851 0 851 0 1701 680 193 989 501 2362
Elucigene FH20_MLPA 205 0 635 160 1000 478 0 478 0 956 852 241 1238 627 2958
Elucigene  
FH20_LIPOchip_MLPA
331 0 635 34 1000 772 0 772 0 1543 717 203 1042 528 2489
LIPOchip 287 0 635 79 1000 667 0 667 0 1335 765 216 1111 563 2655
LIPOchip platform 
(Spain)
321 0 635 45 1000 747 0 747 0 1493 728 206 1058 536 2529
LIPOchip_CGA 365 0 635 0 1000 851 0 851 0 1701 680 193 989 501 2362
LIPOchip_MLPA 331 0 635 34 1000 772 0 772 0 1543 717 203 1042 528 2489
CGA 365 0 635 0 1000 851 0 851 0 1701 680 193 989 501 2362
LDL-C 329 451 184 37 1000 835 236 1214 615 2901 236 67 344 174 821
FN, false-negative; FP, false-positive; TN, true-negative; TP, true-positive.
a  Numbers are rounded to the nearest whole person.
b  Cascaded numbers include assumptions in relation to number of first-degree relatives, number of subrelatives, percentage of indexes 
providing family pedigree information, and percentage of relatives responding to contact and agreeing to cascade testing as well as 
prevalence rates among tested relatives.© Queen’s Printer and Controller of HMSO 2012. This work was produced by Sharma et al. under the terms of a commissioning contract issued by the 
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on the Simon Broome criteria. We have used estimates of sensitivity and specificity derived 
from the clinical effectiveness review and applied these to the model as discussed in Methods for 
economic analysis.
Assumptions relating to the incidence of FH among the tested population are discussed in Model 
structure; however, for the base-case model we assume a mutation detection rate of 36.5%37 
among people who are either possible or definite FH using the Simon Broome clinical diagnosis 
(i.e. approximately one in three reporting for testing will test positive based on CGA). Sensitivity 
analysis explores the variation in this estimate.
As we have assumed that each genetic test is associated with specificity equal to 1, there are no 
false-positives for the base-case analysis. However, data suggest that LDL-C among index cases 
has a specificity of 0.29,44 indicating that a substantial number of positive test results will in fact 
be false-positives.
Mean cost and mean treatment effects associated with each diagnostic strategy
Index (proband) familial hypercholesterolaemia patients
Table 28 presents total costs and total QALYs for each treatment strategy for index cases alone 
ranked according to cost with dominance or otherwise indicated. Patients without FH will have 
a slightly longer survival prognosis and will thus receive slightly greater QALY gains than those 
with FH. Such patients are clinically diagnosed as having FH, have high lipid levels and are at an 
increased risk of CHD and so will have a positive response to cholesterol-lowering therapy.
The Elucigene FH20 diagnostic strategy alone generates the lowest costs for identifying index 
patients for two reasons: first, it is the cheapest genetic diagnostic test available and, second, 
it detects the lowest number of true-positive index cases. Therefore, it confirms the clinical 
diagnosis in the fewest index cases with FH and for that reason is associated with the lowest 
QALYs of all of the tests included. LDL-C identifies the largest proportion of positives (not 
necessarily true-positives for FH – although all index cases are technically true-positives based 
on their clinical diagnosis) and has the highest QALY gain as it detects the greatest number of 
patients at increased risk of CHD. Of the non-dominated sequences, LIPOchip platform (Spain) 
and CGA are both associated with ICERs between £20,000 and £35,000 per QALY gained.
TABLE 28  Total costs, total QALYs and sequentially presented ICERs for the identification of index cases
Test strategy Total costs (£) Total QALYs Incremental costs (£) Incremental QALYs ICER (£/QALY)
Elucigene FH20 14,192,370 13,005
Elucigene FH20_MLPA 14,462,441 13,016 Ext Dom Ext Dom Ext Dom
LIPOchip 14,991,529 13,037 Ext Dom Ext Dom Ext Dom
Elucigene FH20_LIPOchip 15,063,229 13,037 Dominated Dominated Dominated
LIPOchip platform (Spain) 15,154,374 13,045 962,004 40 24,025
LIPOchip_MLPA 15,254,040 13,048 Ext Dom Ext Dom Ext Dom
Elucigene FH20_LIPOchip_MLPA 15,325,740 13,048 Dominated Dominated Dominated
CGA 15,528,212 13,056 373,838 11 33,402
Elucigene FH20_CGA 15,575,762 13,056 Dominated Dominated Dominated
LIPOchip_CGA 15,699,062 13,056 Dominated Dominated Dominated
Elucigene FH20_LIPOchip_CGA 15,770,762 13,056 Dominated Dominated Dominated
LDL-C 17,678,183 13,079 2,149,970 23 93,518
Ext Dom, extendedly dominated.
Costs and Incremental costs are rounded to the nearest whole pounds sterling. QALYs and incremental QALYs are rounded to the nearest whole 
QALY. ICERs are also rounded to the nearest £/QALY gained from the economic model.64 Assessment design and results: cost-effectiveness
Index cases and relatives
However, where genetic testing has the greatest advantage over LDL-C is in the identification of 
relatives for cascade testing. Cascade testing using LDL-C alone is less likely to be cost-effective 
in this population because of the large number of false-positives (including relatives incorrectly 
identified as having FH) who may be treated using high-intensity statin therapy when low-
intensity therapy would have sufficed to reduce their cholesterol levels. Assumptions regarding 
false-positive relatives are detailed in Table 25 and can be tested in sensitivity analysis within 
the model. Table 29 presents total costs and QALYs for index and relative cases combined (i.e. 
a whole integrated strategy for the identification and management of index cases and relatives 
with FH). Cascade testing of relatives of an index case with an identified mutation is by targeted 
sequencing. This is because targeted sequencing is less costly than both of the other candidate 
tests. Therefore, as all tests would detect the identified mutation they are supposed to in the 
relatives, targeted sequencing is the most cost-effective way to do this in relatives of a mutation-
positive index case.
In the analysis presented in Table 29, LDL-C is the least effective of all tests. Elucigene FH20 is 
the least costly genetic testing strategy and is also the most cost-effective of all non-dominated 
genetic testing strategies relative to LDL-C, being less costly, more effective and thus dominant. 
CGA is the most effective non-dominated strategy in terms of QALYs gained, with an associated 
ICER of £2135 per QALY gained relative to the next most effective non-dominated strategy 
(LIPOchip platform, Spain). Combination genetic tests are dominated by single genetic test 
strategies. For example, Elucigene FH20 followed by LIPOchip is dominated by LIPOchip 
alone-meaning that the extra cost of pretesting with Elucigene FH20 does not add any additional 
QALYs over and above LIPOchip. The reason for this is that LIPOchip will detect the same 
mutations and cost more when added to Elucigene FH20. A similar argument can be made 
for tests used for pre-screening prior to CGA. The case for test strategies including MLPA as 
a component is slightly different in that MLPA detects deletions and duplications of the gene 
and so detects approximately an extra 5% of mutations that would not otherwise be detected 
by Elucigene FH20. MLPA is incorporated and included in the CGA process and has not been 
considered separately here. In relation to LIPOchip, there is some uncertainty in relation to 
TABLE 29  Total cost and QALY implications for index and relative casesa
Test strategy Total costs (£) Total QALYs Incremental costs (£) Incremental QALYs ICER (£/QALY)
Elucigene FH20 43,371,985 36,653      
LDL-C 43,880,789 34,744 Dominated Dominated Dominated
Elucigene FH20_MLPA 44,470,770 37,216 Ext Dom Ext Dom Ext Dom
LIPOchip 46,506,304 38,240 Ext Dom Ext Dom Ext Dom
Elucigene FH20_LIPOchip 46,578,004 38,240 Dominated Dominated Dominated
LIPOchip platform (Spain) 47,298,810 38,668 3,926,825 2015 1949
LIPOchip_MLPA 47,597,529 38,803 Ext Dom Ext Dom Ext Dom
Elucigene FH20_LIPOchip_MLPA 47,669,229 38,803 Dominated Dominated Dominated
CGA 48,501,362 39,231 1,202,552 563 2135
Elucigene FH20_CGA 48,548,912 39,231 Dominated Dominated Dominated
LIPOchip_CGA 48,672,212 39,231 Dominated Dominated Dominated
Elucigene FH20_LIPOchip_CGA 48,743,912 39,231 Dominated Dominated Dominated
Ext Dom, extendedly dominated.
a  Note that cascade testing from negative index cases is undertaken using LDL-C; cascade testing of positive LDL-C index cases is also 
undertaken using LDL-C.
Costs and Incremental costs are rounded to the nearest whole pounds sterling. QALYs and incremental QALYs are rounded to the nearest whole 
QALY. ICERs are also rounded to the nearest £/QALY gained from the economic model.© Queen’s Printer and Controller of HMSO 2012. This work was produced by Sharma et al. under the terms of a commissioning contract issued by the 
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the detection of deletions and duplications of the gene. Therefore, we have taken a pragmatic 
approach and included LIPOchip alone and LIPOchip followed by MLPA. This will allow the 
reader to decide, based on further investigation of LIPOchip, whether or not MLPA would be 
required to obtain a definitive diagnosis among positive test results (i.e. a specificity of 1) as 
assumed in the model.
Incremental analysis for reference case and other scenarios
Index cases
Tables 30 and 31 evaluate the non-dominated sequences compared with the relevant comparators 
for index cases. The scope and protocol for this assessment define two important comparators: (1) 
the comparator recommended as part of the NICE clinical guidelines – full genetic DNA testing 
(or CGA as defined in our protocol) and (2) LDL-C, which is currently the most commonly used 
method as part of the Simon Broome criteria to identify FH in practice in the UK. Currently, 
DNA testing is available only in 15% of UK primary care trusts (UK FH audit project 201018) and 
therefore LDL-C is deemed an appropriate comparator based on current clinical practice in the 
UK (NICE diagnostic advisory group, 2011, personal communication).
Of the non-dominated sequences, LDL-C is the most costly and most effective test overall (see 
Table 30). Elucigene FH20 is the least costly but also the least effective test in terms of QALYs. In 
fact, all of the non-dominated testing strategies are cheaper overall and generate fewer QALYs 
than LDL-C. Although diagnosis costs for LDL-C are lower than the alternatives presented, 
treatment costs are much higher. This is because as all index patients will technically have FH 
based on their clinical diagnosis on the Simon Broome criteria, they will benefit from statin 
therapy. Additionally, even if they were not true FH, they would still be at an increased risk of 
coronary artery disease based on their cholesterol levels and so would benefit from treatment. 
LDL-C is therefore also associated with the greatest number of QALYs gained for index cases. 
This is because, should a negative diagnosis be based on a genetic test, patients who test false-
negative may be inappropriately treated and would thus gain fewer QALYs than if they were 
prescribed high-intensity treatment for their FH based on LDL-C levels.
TABLE 30  Comparison of non-dominated sequences vs LDL-C (index cases only)
Test Total costs (£) Total QALYs Incremental costs (£) Incremental QALYs
Elucigene FH20 14,192,370 13,005 –3,485,812 –74
LIPOchip platform (Spain) 15,154,374 13,045 –2,523,808 –34
CGA 15,528,212 13,056 –2,149,970 –23
LDL-C 17,678,183 13,079
Costs and Incremental costs are rounded to the nearest whole pounds sterling. QALYs and incremental QALYs are rounded to the nearest whole QALY.
TABLE 31  Comparison of non-dominated sequences vs CGA (index cases only)
Test Total costs (£) Total QALYs Incremental costs (£) Incremental QALYs ICER (£/QALY)
Elucigene FH20 14,192,370 13,005 –1,335,842 –51
LIPOchip platform (Spain) 15,154,374 13,045 –373,838 –11
CGA 15,528,212 13,056
LDL-C 17,678,183 13,079 2,149,970 23 93,518
Costs and Incremental costs are rounded to the nearest whole pounds sterling. QALYs and incremental QALYs are rounded to the nearest whole 
QALY. ICERs are also rounded to the nearest £/QALY gained from the economic model.66 Assessment design and results: cost-effectiveness
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FIGURE 10  Cost-effectiveness plane (index cases).
Table 31 presents similar information for index cases alone when the comparator of interest 
is CGA.
When the comparison of interest for index cases alone is CGA, all other non-dominated genetic 
tests are less costly and less effective than CGA. The question for a decision-maker in this 
scenario would thus be whether or not the cost savings are worth the associated QALY loss. 
ICERs are not reported in informing such a question as there is lack of evidence regarding how 
much society is willing to accept in compensation (in the form of cost savings) for a QALY loss.
Figure 10 presents the cost-effectiveness plane comparing all tests for index cases. This confirms 
the results alluded to in the tables of results above.
There are two important things to note from this illustration. First, LDL-C is the most 
costly strategy (driven by high-intensity statin treatment costs). As all patients are at risk of 
cardiovascular disease, however, QALY gain is highest driven by the extra-intensive treatment 
based on false-positive diagnoses of FH by LDL-C. These patients benefit from the increased 
statin therapy as they are at increased risk of cardiovascular disease based on their cholesterol 
levels. Second, the graph illustrates the dominance of single test strategies over similar strategies 
preceded by less-sensitive screening tests such as Elucigene FH20. As all strategies ending 
in CGA generate the same QALY gains, dominance is due to greater costs amongst multiple 
test strategies.
Confirmation of clinical diagnosis in index cases and cascade 
testing of relatives
Tables 32 and 33 evaluate the non-dominated sequences compared with the relevant comparators 
for the full process of index case confirmation of the clinical diagnosis and cascade testing of 
relatives. The comparators are LDL-C and CGA as in the preceding section.© Queen’s Printer and Controller of HMSO 2012. This work was produced by Sharma et al. under the terms of a commissioning contract issued by the 
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Multiple testing strategies are dominated by single testing strategies generating the same 
sensitivity and test-positive rate overall. All non-dominated genetic tests are highly cost-effective 
compared with LDL-C in the identification of index cases with FH and cascade testing of 
relatives (assuming that society’s willingness to pay for a QALY gain is £20,000). The Elucigene 
FH20 single test strategy is the most cost-effective, being less costly and more effective and thus 
dominant over LDL-C (see Table 32). However, should a decision-maker wish to have a DNA 
test with a definitive genetic diagnosis, (i.e. CGA) then this is more expensive but generates the 
most QALYs gained compared with LDL-C. Relative to LDL-C (current practice), CGA could 
be considered a cost-effective testing strategy with an associated ICER of only £1030 per QALY 
gained. This is also well below a willingness-to-pay value of £20,000 per QALY gained.
When cost and QALY pairs are compared with CGA (current NICE recommendations) for the 
whole process of identification of index cases and cascade testing of relatives, all non-dominated 
tests are less costly and less effective than CGA. Table 33 presents this comparison.
Again, as discussed previously, the reporting of ICERs for this scenario does not inform the 
question of what reduction in QALYs a decision-maker is willing to accept in order to achieve a 
predefined cost saving. All non-dominated testing strategies are less costly and also less effective 
than CGA.
Figure 11 presents the cost-effectiveness plane comparing all tests for index cases and cascade 
testing of first-, second- and third-degree biological relatives. This confirms the results alluded to 
in the tables of results above.
In this scenario (including cascade testing of relatives in the analysis), LDL-C used as a method 
of identification of relatives is less costly than all other tests (with the exception of Elucigene 
FH20) but does not generate the same QALY gains as any of the genetics-based tests. LDL-C is 
an inexpensive test to carry out (relative to other more costly genetic options); however, LDL-C 
alone will falsely diagnose many index cases as having FH and hence many relatives will be 
TABLE 32  Comparison of non-dominated sequences vs LDL-C (identification of index cases and cascade testing 
of relatives)
Test Total costs (£) Total QALYs Incremental costs (£) Incremental QALYs ICER (£/QALY)
Elucigene FH20 43,371,985 36,653 –508,805 1909 Dominant
LDL-C 43,880,789 34,744
LIPOchip platform (Spain) 47,298,810 38,668 3,418,020 3924 871
CGA 48,501,362 39,231 4,620,573 4487 1030
Costs and Incremental costs are rounded to the nearest whole pounds sterling. QALYs and incremental QALYs are rounded to the nearest whole 
QALY. ICERs are also rounded to the nearest £/QALY gained from the economic model.
TABLE 33  Comparison of non-dominated sequences vs CGA (identification of index cases and cascade testing 
of relatives)
Test Total costs (£) Total QALYs Incremental costs (£) Incremental QALYs
Elucigene FH20 43,371,985 36,653 –5,129,377 –2578
LIPOchip platform (Spain) 47,298,810 38,668 –1,202,552 –563
CGA 48,501,362 39,231
Costs and Incremental costs are rounded to the nearest whole pounds sterling. QALYs and incremental QALYs are rounded to the nearest whole QALY.68 Assessment design and results: cost-effectiveness
cascade tested unnecessarily for fewer QALYs gained. LDL-C is thus dominated by the lower-cost 
Elucigene FH20 test.
Differential results for subgroups
The impact of varying the age of the index case and associated average age of relatives is 
explored in this section. As with the base-case analysis, results are presented sequentially and 
also incrementally relative to LDL-C and CGA. Analyses for index cases only are presented in 
Appendix 12.
For index cases alone, the results are quite difficult to interpret and there appears to be much 
variability in the ICERs depending on age (see results tables in Appendix 12). As in all other 
analyses, all pre-screen tests are dominated by more effective tests that generate cost savings due 
to treatment effects. For all index case ages, non-dominated test strategies appear to be less costly 
and less effective than LDL-C, with the exception of an 85-year-old index case, for which genetic 
tests are dominant over LDL-C. These results should, however, be interpreted with caution. The 
wide variability in the presented ICERs is due to small or indeed negligible QALY differences 
between strategies. This is because, for index cases alone, most if not all patients will be at risk of 
cardiovascular events and all will have a clinical diagnosis of FH.
Genetic testing has the advantage in the identification and treatment of relatives through the 
cascade testing process for all age subgroups and this is evident from associated tables (for index 
cases and relatives combined) reported in Appendix 13 and discussed in the following paragraph.
The results presented suggest that, as in the base case, all pre-screening strategies are dominated 
by single test strategies detecting the same number of people, regardless of age. The reason for 
this is that costs associated with savings on test-positive cases are offset by submitting a whole 
cohort of negative patients through two or maybe three tests. As only a proportion will have 
a genetic mutation, these additional costs outweigh cost savings from those tested positive on 
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pre-screens such as Elucigene FH20 or LIPOchip. This confirms the base-case results presented 
in Tables 29, 32 and 33. As reported for the base case in Table 29, relative to LDL-C, Elucigene 
FH20 is the most cost-effective option for all age groups analysed, with all ICERs under £1400 
per QALY gained. This probably represents a highly cost-effective use of NHS resources. The 
next most cost-effective testing options after Elucigene FH20 are LIPOchip (platform processed 
in Spain), for which the costs per QALY gained are between £714 and £2513 irrespective of age 
group analysed, and CGA, with ICERs only slightly higher than those of LIPOchip (platform 
processed in Spain). Therefore, as in the base case, there are a number of tests that could be 
deemed cost-effective, all with very low ICERs relative to LDL-C. As discussed, should we wish 
to achieve a definitive diagnosis and generate the greatest QALY gain then CGA is a cost-effective 
means to achieve such an objective.
Summarising these results together, all of the age group analyses are consistent with the 
conclusions of the base-case analysis for an index case aged 50 years. Therefore, one may 
conclude that the conclusions of the model for index and relative cases are not sensitive to the 
age of the index case or associated relatives. CEACs based on probabilistic sensitivity analysis 
of the age subgroup results show some uncertainty at low threshold values of willingness to pay 
but, at threshold values > £5000 per QALY gained, CGA is the most likely cost-effective testing 
strategy, increasing to almost 100% as the threshold value increases towards a threshold ceiling 
ratio of £20,000 per QALY gained. CEACs reporting these results are presented for illustration in 
Appendix 15.
Because of a lack of good-quality data differentiating the sensitivities of the tests for definite and 
possible FH, we have conducted a threshold analysis indicating the prevalence and sensitivity that 
would be required for the candidate tests to be cost-effective as a pre-screen for CGA. Additional 
sensitivity analysis around the maximum and minimum values of all reported studies is 
presented in the following section. At the current estimate of sensitivity of Elucigene FH20, there 
would need to be an underlying prevalence of mutations of 61% at current prices of CGA. Should 
the price of CGA drop in the future as a result of next-generation sequencing, the required 
prevalence of underlying mutations would need to be 93%. This is based on an assumed price 
reduction of 40% in the cost of DNA sequencing in the future. The results for LIPOchip are less 
favourable at current levels of sensitivity as the lower cost of Elucigene FH20 followed by CGA 
would dominate LIPOchip followed by CGA at high prevalence rates, irrespective of whether or 
not we apply a cost reduction of 40% to DNA sequencing as part of CGA.
From an alternative perspective, one may be interested in the sensitivity of Elucigene FH20 and/
or LIPOchip that would be required to generate cost savings as a pre-screen to CGA at current 
levels of mutation prevalence. Elucigene FH20 would be required to have a sensitivity of at least 
73% to be a cost-saving pre-screen to CGA for a mutation prevalence rate of 36.5% as used in the 
base-case economic model. LIPOchip would not be cost-effective as a pre-screen to CGA for any 
plausible sensitivity values at this mutation prevalence level. Plausible values are defined as those 
sensitivities below the sensitivity of CGA. The reason for this is that, because of the relatively 
low prevalence of mutations, even at a sensitivity of 90%, only 33% of cases would be positive, 
with the remaining 67% requiring CGA to confirm the presence or otherwise of a FH-causing 
genetic mutation.
Therefore, if the goal is to gain an unequivocal diagnosis, for low mutation prevalence rates, 
pre-screening with Elucigene FH20 or LIPOchip prior to CGA is not cost-effective. At high 
prevalence rates, > 61%, Elucigene FH20 may offer a cost-effective option; however, this is less 
likely once the costs of next-generation sequencing fall.70 Assessment design and results: cost-effectiveness
Analysis of uncertainty, including probabilistic sensitivity analysis
One-way deterministic sensitivity analyses
A range of one-way deterministic analyses are presented to investigate the sensitivity of the model 
to uncertainty in some of the key parameters and in relation to model structural assumptions as 
outlined in Table 25. All deterministic sensitivity analyses were carried out on the base case of an 
age 50 years index case.
A full range of sensitivity analyses in relation to treatment effect have been carried out previously 
in the NICE clinical guidance CG71.1 The model was found to be insensitive to a range of 
sensitivity analyses including assumptions surrounding nurse and consultant time with patients, 
costs of cholesterol testing, costs of letters to relatives for cascading, cascading from alternative 
numbers of relatives (first and second degree), relative risks of non-cardiovascular disease deaths 
and treatment effect used in the model. As data from the CG711 assessment have been updated 
and used for the purposes of this report, it is highly unlikely that these sensitivity analyses will 
have any impact on the sequences of ICERs for this analysis. We have additionally explored the 
impact of including a cost of £80 (standard A&E tariff) for those patients who die in the model. 
This is to reflect any additional costs that may be involved over the £0 assumed in the base-case 
analysis. The results are not sensitive to this assumed value.
Therefore, the focus of sensitivity analyses for this assessment centres on parameters and 
assumptions that we hypothesise may have an impact on the sequence of ICERs or on the overall 
cost-effectiveness conclusions. Many parameters alter the cost-effectiveness of identifying 
index cases alone; however, as the remit for this report is primarily the detection and treatment 
of relatives with FH, we focus mainly on analyses that affect the overall outcome (i.e. the 
confirmation of index cases and the cascade testing of at-risk relatives). Full analyses for both 
groups are included in Appendix 14 for information. In the appendix, results for the index case 
analysis are presented first, followed by results for index cases and relatives together. The order of 
tables follows the sequence of results presented below.
The following discussion refers to index cases and relatives together.
Prevalence of familial hypercholesterolaemia-causing mutations 
among index cases and relatives
Prevalence of FH-causing mutations among index cases is varied between 28%79 and 52%.41 For 
both low and high estimates of mutation prevalence, the order of the ICERs remains unchanged 
compared with the base case. Elucigene FH20 remains the most cost-effective strategy relative 
to LDL-C (associated ICERs = dominant and £395 per QALY gained for low and high estimates 
respectively). The next most cost-effective options after Elucigene FH20 are LIPOchip (platform 
processed in Spain) and CGA for both low and high mutation prevalence rates with all ICERs 
< £1300 per QALY gained. See Differential results for subgroups for a threshold analysis estimating 
the prevalence required for Elucigene FH20 or LIPOchip to be deemed a cost-effective pre-screen 
to CGA.
Prevalence of FH-causing mutations among relatives of index cases is an uncertain parameter 
that is generally held to be approximately 50%, based on the logic that one out of every two 
offspring will inherit a genetic mutation. Sensitivity analysis varied this assumption by ±20% to 
between 40% and 60% of first-degree relatives inheriting the culprit gene (author assumption). 
A low estimate suggests that Elucigene FH20 is dominant, being less costly and generating more 
QALYs than LDL-C. After that, as in the base-case analysis, LIPOchip platform (processed 
in Spain) and CGA remain the next most cost-effective testing strategies. A higher estimate 
of mutation prevalence among relatives of 60% suggests the same three non-dominated test 
strategies as in the base case, all with ICERs of < £1200 per QALY gained. Therefore, as similar © Queen’s Printer and Controller of HMSO 2012. This work was produced by Sharma et al. under the terms of a commissioning contract issued by the 
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tests are recommended as being cost-effective for all prevalence values considered, the base-case 
conclusions remain insensitive to any assumptions surrounding prevalence rates in either index 
cases or relatives with all ICERs for non-dominated strategies < £1300 per QALY gained relative 
to LDL-C.
Familial hypercholesterolaemia treatment
Analyses reducing the cost of atorvastatin did not change the base-case conclusions, with no 
difference in the sequence of the presented ICERs. Elucigene FH20 remains the most cost-
effective option relative to LDL-C; LIPOchip (platform processed in Spain) is the next most 
cost-effective option followed by CGA, as was reported in the base-case analysis. ICERs for all 
three non-dominated tests are insensitive to changes in the cost of treatment used in the model 
(all reported ICERs are < £1100 per QALY gained relative to LDL-C).
Data in relation to the base-case model sourced treatment proportions for FH from the FH 
audit 201018 and assumed generic simvastatin treatment for those without confirmed FH. 
This assumption was tested using treatment proportions provided by Dr Anthony Wierzbicki 
(personal communication, Guy’s and St Thomas’ Hospitals NHS Trust, 2011). This assumed that 
both genetically confirmed FH and genetically non-confirmed FH patients would receive a range 
of treatments. This included polypharmacy for some patients including treatment with ezetimibe 
as well as statins. The order and magnitude of the ICERs relative to LDL-C remain similar to that 
in the base-case analysis.
The conclusions drawn are therefore not sensitive to changes in treatment pattern or to costs of 
treatment administered to patients.
The impact of the decision to treat negative-testing relatives or 
index cases
The base-case analysis assumes that 10% of negative-testing relatives will require treatment. 
However, it may be that 0% or at least no more than in the general population will require 
treatment. Therefore, sensitivity analysis investigates a scenario in which none of these relatives 
would receive statin therapy. In this scenario, the magnitude and order of the ICERs are very 
similar to those in the base-case analysis, with Elucigene FH20 remaining the most cost-effective 
strategy, dominating LDL-C. LIPOchip (platform processed in Spain) and CGA are the next 
most cost-effective options (ICERs of £902 and £1062 per QALY gained, respectively, relative to 
LDL-C). Hypothetically increasing this proportion to 50% does not lead to any significant change 
in the order or magnitude of the ICERs presented.
In an unlikely situation that negative index cases do not receive treatment or clinical follow-up, 
Elucigene FH20 is the only non-dominated genetic testing strategy and is less costly but less 
effective than LDL-C, the reason being that index cases testing negative for a FH-causing genetic 
mutation are still at significant risk of cardiovascular events and so not treating based on genetic 
mutation alone would lead to large numbers of at-risk individuals being missed, hence the 
reason LDL-C would be the most cost-effective strategy. It is important to note, however, that 
the above-mentioned analysis is for illustration only and is not necessarily a reflection of the true 
care pathway.
Costs of diagnostic strategies
Increasing or decreasing the MOLU costs associated with each test by ±£10 (varying cost per 
MOLU from £20 to £40) does not impact on the overall test order, with only minimal changes in 
the relevant ICERs. This is because the model is determined primarily around lifelong costs and 
health outcomes associated with treatment for FH or otherwise.72 Assessment design and results: cost-effectiveness
Sensitivity of key assumptions (model structure)
The assumption that cascade testing takes place of first-, second- and third-degree biological 
relatives of the index case is tested by assuming that the process stops after the second-degree 
relative regardless of test result. All genetic tests are even more cost-effective in this scenario. 
Elucigene FH20 is less costly and generates greater QALYs than LDL-C and is thus dominant. 
LIPOchip (Spain) and CGA are both associated with ICERs of < £800 per QALY gained.
The base-case analysis assumes that all index patients with a clinical diagnosis will have their 
family pedigree investigated, with cascade testing using targeted sequencing for relatives of 
genetically confirmed index cases. However, those that do not receive a genetic test or are test-
negative will still be cascade tested using LDL-C. This is because, although a genetic mutation 
may not be detected, it is possible that such individuals have mutations or genes that have not 
yet been identified as causing FH. However, as a sensitivity analysis, we have explored the impact 
on the results of not cascade testing from such genetically test-negative index cases. In this 
scenario, all non-dominated genetic tests are actually less costly and less effective than LDL-C 
testing. Although the results are sensitive to this aspect of the model, clinical advice suggests that 
this would be highly unlikely in practice as cascade testing from negative index cases is a very 
important part of the cascade process. The results are not sensitive to assumptions regarding the 
proportion of index and/or relatives agreeing to have their family history investigated or agreeing 
for cascade testing to take place.
We varied the discount rate between 0% and 6% for costs and benefits as is standard practice in 
economic modelling to test our model to assumptions regarding uncertainty surrounding the 
value of future costs and health gains accrued over a lifetime horizon. For a discount of both 0% 
and 6% the order of the ICERs relative to LDL-C remained the same as in the base-case analysis. 
The magnitude of these ICERs showed no significant changes either. The results for the base-case 
analysis present estimates of cost-effectiveness based on current costs of CGA. However, the 
cost of genetic DNA sequencing will fall in the coming months and years with the development 
of next-generation (non-Sanger based) sequencing techniques. Therefore, we have explored the 
impact on the results of reducing the cost of sequencing by an estimated 40% (Dr Gail Norbury, 
Guy’s Hospital, London, 2011, personal communication). In this scenario, LIPOchip (platform 
processed in Spain) becomes extendedly dominated. Elucigene FH20 is dominant and CGA is 
associated with an ICER of £995 per QALY gained relative to LDL-C.
Sensitivity relating to diagnostic test accuracy
For each of the main tests we have investigated the cost-effectiveness based on studies reporting 
the highest and lowest sensitivity values for Elucigene FH20 and for LIPOchip. This gives a 
greater picture of the uncertainty across studies and the impact on associated cost-effectiveness 
results. It also reflects the sensitivity of our analyses to different population groups, some of 
whom may have greater sensitivity on Elucigene FH20, with others doing better with LIPOchip.
In relation to Elucigene FH20, the upper limit of the sensitivity analysis (0.5238) increases the 
ICER associated with Elucigene FH20 relative to LDL-C. This suggests higher proportionate 
increases in costs relative to proportionate increases in QALYs, thereby increasing the ICER 
between the two tests. Lower estimates (0.28636) work in the opposite direction and lead to 
Elucigene FH20 being dominant over LDL-C. Such findings are somewhat counterintuitive, with 
there usually being a positive relationship between higher test sensitivity and improvements in 
cost-effectiveness. The situation here, however, is more complex because of the clinical benefit 
(and QALY gain) of LDL-C at minimal cost as well as the addition of cascade testing. Higher 
sensitivity tests lead to a greater number of positive relatives being given a targeted sequencing 
test (which is more expensive). Although this test detects more true FH cases and generates 
greater QALY gain, this is offset somewhat by the advantages of LDL-C (individuals will gain © Queen’s Printer and Controller of HMSO 2012. This work was produced by Sharma et al. under the terms of a commissioning contract issued by the 
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improvements in QALYs regardless of whether or not they have FH, through statin-based therapy 
for their high cholesterol) that form part of the comparator testing. A similar situation arises 
with LIPOchip strategies relative to LDL-C. However, in all of these analyses, the rank ordering 
of Elucigene FH20, LIPOchip and CGA in terms of effectiveness and cost-effectiveness remains 
the same. As the sensitivity of Elucigene FH20 and LIPOchip increases, their associated ICERs 
approach that of CGA.
The sensitivity and specificity of LDL-C among relatives are taken from Starr and colleagues49 and 
varied according to the upper and lower bounds of the 95% CIs. In both scenarios, Elucigene is 
the most cost-effective option relative to LDL-C. ICERs tend to be slightly lower for genetic tests 
using the higher bound of the CI for sensitivity and slightly higher for the lower bound. These 
differences are, however, small in magnitude and the counterintuitive effect of test sensitivity 
in relation to the ICER can be explained as discussed above. Similar analysis of the specificity 
of LDL-C among relatives does not alter the sequences of the ICERs or the conclusions drawn 
from the relevant comparisons. Again, all non-dominated sequences are highly cost-effective 
relative to LDL-C.
In conclusion, based on the above analyses, the results show some sensitivity to changes in 
some parameters and structure for the confirmation of index cases alone, but are more robust to 
variations in key parameters when index cases and relatives are analysed together. In all scenarios 
presented, Elucigene FH20, LIPOchip (Spain) and CGA are cost-effective uses of NHS resources 
relative to LDL-C. There is some uncertainty surrounding the direction of movement of the ICER 
as a result of changes in the sensitivity of the tests that may seem counterintuitive. The results 
of the one-way sensitivity analyses should therefore be interpreted with caution and, for a more 
accurate measure of overall model uncertainty, probabilistic sensitivity analysis is likely to offer a 
better estimate.
Probabilistic sensitivity analysis
Probabilistic sensitivity analysis is carried out for the base case as described in the methods 
section. Figure 12 illustrates the results in the form of a CEAC.
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FIGURE 12  Cost-effectiveness acceptability curves for the base-case analysis.74 Assessment design and results: cost-effectiveness
This figure shows that, at low threshold values of willingness to pay for a QALY gain relative 
to LDL-C (< £2500), Elucigene FH20 has the highest probability of being cost-effective, but 
this reduces as the willingness to pay for an additional QALY increases. CGA is the most cost-
effective option at threshold values > £2500 and is associated with a > 90% probability of being 
cost-effective at all threshold values > £3500 per QALY gained (Figure 12 is scaled down to aid 
discussion of low threshold values). The other non-dominated strategy, LIPOchip platform 
processed in Spain, is never associated with a probability of cost-effectiveness > 20%. Probabilistic 
analysis also generates similar results and conclusions for each age subgroup in the analysis (see 
Appendix 15). At threshold values of willingness to pay for a QALY gain approaching £20,000, 
CGA is always the most cost-effective option. This is an important point and confirms the 
generalisability of the base-case probabilistic results to other age groups.
In addition to deterministic analysis surrounding the mutation detection rate among clinically 
diagnosed FH patients, we considered some extra analysis based on input from Dr Anthony 
Wierzbicki (Guy’s and St Thomas’ Hospitals NHS Trust, 2011, personal communication), who 
states that, among his patient group, the majority of patients are possible FH and he estimates 
that the proportion likely to be detected by CGA is approximately 20–25% or may even fall to 
5% in some population groups. With this in mind, we have conducted probabilistic sensitivity 
analysis for a range of potential mutation detection rates for CGA. The relevant CEACs are 
presented in Appendix 17 and show that the results are somewhat sensitive to this value in 
the model, especially at low threshold values and for lower rates of prevalence. For the lowest 
prevalence rate considered (5%), there is quite a bit of uncertainty at threshold values < £6000 
per QALY gained. At very low values of willingness to pay (< £3000 per QALY), Elucigene FH20 
is the strategy most likely to be cost-effective. LIPOchip platform processed in Spain is less likely 
to be cost effective except at very specific values of willingness to pay between £3000 and £4000 
per QALY gained and at a low prevalence rate of 5%. However, this test is never associated with 
a probability of cost-effectiveness of > 50% regardless of prevalence rate or willingness-to-pay 
threshold. For higher estimates of prevalence (i.e. 10–50%), the results mirror those of the base-
case analysis. However, of greater importance is that, for all prevalence rates of FH considered, 
CGA is the most cost-effective strategy at threshold values of > £5000 per QALY gained, 
increasing to 70% at the conventional value of willingness to pay of £20,000 per QALY gained 
for a prevalence of 5%. This probability increases to almost 100% for all other prevalence rates 
considered (i.e. 10%, 20% and 50%). Therefore, although there is some uncertainty surrounding 
the results based on varying mutation detection rates in clinically diagnosed index cases, 
probabilistic analysis shows CGA to be the most likely cost-effective use of NHS resources. The 
conclusion of the cost-effectiveness of CGA confirms the results of the previous NICE guidance 
in that the most comprehensive test for FH is cost-effective. NICE CG711 estimated that CGA 
was cost-effective with an associated ICER of £2676 per QALY gained versus LDL-C. Our results 
generate similar conclusions with a lower estimate of the ICER of £1030 per QALY gained relative 
to LDL-C. This is likely to be because of the cost reductions in CGA and in treatment over time.
Summary
Base-case results from deterministic analyses show that Elucigene FH20 is the most cost-
effective diagnostic test, being less costly and more effective and thus dominant over LDL-C. 
However, this test strategy is less effective than recommended alternatives such as CGA (the 
most comprehensive diagnostic test for FH). Other non-dominated test strategies, LIPOchip 
platform processed in Spain and CGA, are also highly cost-effective. The latter strategy generates 
the greatest QALY gain but at additional cost. The sequences of the ICERs remain robust to the 
majority of deterministic sensitivity analyses; however, some plausible variations change the © Queen’s Printer and Controller of HMSO 2012. This work was produced by Sharma et al. under the terms of a commissioning contract issued by the 
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magnitude of these ICERs slightly. It is likely that CGA will become more cost-effective going 
forward because of the emergence of next-generation sequencing techniques, reducing the time 
and cost required to conduct large gene sequencing operations. More important, though, is the 
fact that all three non-dominated test strategies are cost-effective at all conceivable threshold 
values of willingness to pay for a QALY gain. In all cases it is more cost-effective to cascade test 
relatives using targeted sequencing instead of either Elucigene FH20 or LIPOchip. This is because 
of the relative diagnostic cost savings for the same high level of accuracy in a targeted group 
of relatives.
Probabilistic sensitivity analysis more clearly shows the relative cost-effectiveness of the three 
test strategies mentioned above. At usual threshold values of willingness to pay for a QALY gain 
of £20,000, CGA is the most cost-effective test strategy. Although the probabilistic sensitivity 
analysis shows some uncertainties surrounding alternative mutation detection rates among 
clinically diagnosed index cases, CGA still remains the most likely option to be cost-effective. 
The probabilistic results are not sensitive to the age of the index case or associated average age 
of relatives.
Amongst the test strategies identified as being cost-effective, there are other factors that may 
need further consideration before arriving at a judgement on which strategy to recommend. For 
example, there may be practical and resource issues associated with full-scale implementation of 
CGA if this is recommended as a test strategy for all. If so, then judgement is required on whether 
it is ethical to implement cascading based on an index test result that is not as accurate as 
alternative more effective and cost-effective strategies such as CGA. In addition, cost-effectiveness 
will also depend on how clinicians view the outcome of tests such as Elucigene FH20, which 
detect only approximately 44% of cases with a FH-causing mutation; for example, there is the 
potential for missing cases, especially at-risk relatives who may not show high LDL-C levels when 
tested but who may have a FH-causing mutation. These patients may forgo potentially life-saving 
treatment if index cases are managed only on the basis of their clinical diagnosis as opposed 
to their genetic test. This issue does not arise for CGA for which an unequivocal diagnosis is 
reported in so far as this method detects all known FH-causing mutations.© Queen’s Printer and Controller of HMSO 2012. This work was produced by Sharma et al. under the terms of a commissioning contract issued by the 
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Chapter 4 
Assessment of factors relevant to the NHS 
and other parties
Factors relevant to the NHS
Funding of the DNA testing
The current NICE clinical guideline (CG71)1 identifies DNA testing as the recommended method 
for confirming a clinical diagnosis of FH among Simon Broome definite FH and possible FH 
probands and also (and perhaps most importantly) the identification of first-, second- and 
possibly third-degree relatives of the index case for testing using a targeted sequencing test. 
However, findings from the 2010 audit of FH services18 suggest that the current NICE guideline 
is not being widely implemented, primarily because of shortages in funding at a local level. The 
2010 audit found that, although 97% of sites have access to an accredited laboratory for lipid 
measurement, only15% had access to funded DNA testing.
Our results confirm that CGA is the most sensitive testing strategy for identifying at-risk relatives 
and, based on the results from probabilistic sensitivity analysis, is likely to be the most cost-
effective testing strategy. This is in line with recommendations from CG71.1 CGA is, however, 
the most costly diagnostic test (although the cost implications can be partially offset against cost 
savings emanating from reduced cardiovascular events treated and more appropriate targeted 
treatments for these people). With concerns about access to funding for DNA testing being raised 
in the FH audit18 there may be perceived barriers to the widespread adoption of CGA as the 
strategy of choice.
The adoption of less costly approaches than CGA is possible. Other non-dominated strategies 
also appear cost-effective at points below conventional willingness to pay for a QALY values. 
However, strategies such as Elucigene FH20 and LIPOchip are imperfect methods for detecting 
gene deletions and duplications, such that a MLPA test would be required with Elucigene FH20 
and may well be pragmatically required in addition to LIPOchip to confirm the diagnosis for 
these cases. On the plus side, however, such strategies may be simpler and cheaper than CGA.
It is probable, however, that the cost of implementing testing with CGA will reduce in future 
years. It is estimated from previous guidance that the cost of cascade testing of all at-risk 
individuals would be approximately £12.913M per year80 over 5–10 years, after which time costs 
would fall further as more and more of the current 100,000 or so patients with FH would be 
detected. After this 5- to 10-year period, cascade testing would be on a case-by-case basis of those 
who had not previously been tested. With reductions in costs associated with next-generation 
gene sequencing, these cost estimates have fallen over recent years and are likely to fall further 
in coming years. Additionally, atorvastatin therapy is coming off patent in 2011, which will also 
ease the financial burden of implementing the guidance. It may therefore be a more efficient use 
of NHS resources to adopt a comprehensive testing programme now to avoid the additional costs 
of delaying and retesting patients currently cascaded using LDL-C with genetic tests in the future. 
There may therefore be some savings to the NHS that have not as yet been identified. It is difficult 
to quantify such potential savings as this would depend on future NICE guidance and whether or 78 Assessment of factors relevant to the NHS and other parties
not primary care trusts implement the current guidelines as per CG711 to use at least some form 
of DNA testing strategy.
Financial burden to NHS of (as yet) undiagnosed patients
The NHS needs to be aware of the financial burden of the significant number of individuals 
(estimated to be around 100,000) who have FH and are as yet undiagnosed (but who would 
subsequently be diagnosed through cascade testing). The management and treatment of these 
cases, once identified, will generate a significant resource burden to already tight NHS budgets. 
Also, it is unclear whether or not the capacity currently exists in lipid clinics to identify cases, 
trace family history and refer all those requiring testing. Clinical expert opinion suggests that 
capacity is available within the genetics laboratories in the UK to conduct all relevant tests.
Factors relevant to other parties
Benefits to individuals of a definitive diagnosis
Should the widespread implementation of cascade testing be achieved in the UK, there are a 
number of benefits that individuals identified with FH through that process can expect to incur. 
For example, appropriate treatment can be started quickly, cholesterol levels can be monitored 
and managed, the risk of getting CHD and having a heart attack is reduced and close family 
members can be screened and treatment started if necessary. It is also known that, if treatment 
can be started early, before CHD is established, this reduces the risk of dying prematurely.2
Possible adverse sequelae of a definitive diagnosis
Despite the benefits that a definitive diagnosis can bring, it is also well known that psychological 
sequelae can arise for individuals and their family following the formal diagnosis of a clinical 
condition. There are issues of anxiety associated with being diagnosed with a genetic disease; 
however, equally there may be a sense of closure for the patient, who will be able to proceed 
with an action plan to manage his or her FH using appropriate treatment methods. Although 
no evidence exists linking psychological impact to QALY gain for FH patients, as FH is very 
treatable once identified, it is likely that the psychological impact of the genetic testing would 
be positive for the patient. Individuals, especially parents, may also gain positive views from 
the knowledge that a relative, especially their children, will be treated correctly should they be 
diagnosed with FH.
Insurance for those diagnosed with familial hypercholesterolaemia
If you are being treated for a medical condition you usually have to declare it to your insurance 
company, otherwise it could invalidate your insurance. Having a diagnosis of FH may affect how 
a person is treated when they apply for life assurance or travel insurance and could also have 
an impact on mortgage applications. Some insurance companies may decide that a person with 
FH has a higher risk of getting CHD and may charge higher premiums. Also some insurance 
companies may not differentiate between high cholesterol as a result of poor diet and other 
lifestyle factors and high cholesterol caused by an inherited condition such as FH.2
Other issues
The use of strategies involving Elucigene FH20 and/or LIPOchip could provide advantages to 
patients in terms of early detection of disease and provision of an unequivocal diagnosis, allowing 
cascade testing for the early identification and treatment of relatives. Although the benefits of 
such tests in achieving a definitive diagnosis are clearly evident, there are some ethical and equity 
issues arising from the recommendation of a less than fully sensitive and specific genetic test. As 
reported in Chapter 3 (compared with LDL-C), although strategies such as Elucigene FH20 or © Queen’s Printer and Controller of HMSO 2012. This work was produced by Sharma et al. under the terms of a commissioning contract issued by the 
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LIPOchip (platform processed in Spain) appear to offer a cost-effective use of NHS resources at 
less than usual threshold values of willingness to pay, their recommendation as a single test may 
raise ethical concerns. Elucigene FH20 and LIPOchip both detect a limited set of FH-causing 
mutations. Owing to concerns over LIPOchip’s ability to detect copy number changes as 
accurately as MLPA, some relatives of index cases with less commonly occurring mutations may 
go undetected. Such individuals would be disadvantaged owing to the documented inadequacies 
of the use of LDL-C to give a definitive diagnosis of FH.© Queen’s Printer and Controller of HMSO 2012. This work was produced by Sharma et al. under the terms of a commissioning contract issued by the 
Secretary of State for Health.
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Chapter 5 
Discussion
T
he first section of this chapter includes discussion of diagnostic accuracy test performance 
(see Chapter 2); this is followed by discussion of the results of the cost-effectiveness analysis 
(see Chapter 3).
Discussion of test performance results
Statement of principal findings
Fifteen studies were included in this assessment. Three studies (four reports) evaluated Elucigene 
FH20, five studies (six reports) evaluated various versions of LIPOchip, four studies reported 
data on the performance of LDL-C as a part of the Simon Broome criteria or LDL-C cut-offs of 
> 4 mmol/l and three studies reported age-and gender-specific LDL-C cut-offs for cascade testing 
of relatives.
Elucigene FH20 and LIPOchip studies
The included studies on Elucigene FH20 and LIPOchip reported a sequential genotyping test 
in which (1) the participants received a clinical diagnosis of FH followed by the index test (as 
a pre-screen) and then (2) those who tested negative received further genetic investigations 
such as gene sequencing and MLPA. CGA was the reference standard considered in the review. 
Assessment of the methodological quality of the included studies showed that overall the 
participants were representative of those who would receive the tests in practice.
Based on the data from the included studies we were able to deduce true-positive, true-negative 
and false-negative rates for each test. False-positive results could not be derived for any of the 
studies evaluating Elucigene FH20 or LIPOchip as only those who initially tested negative went 
on to receive the reference standard. Therefore, only sensitivity, and not specificity, of Elucigene 
FH20 or LIPOchip could be deduced and reported (sensitivity represented the percentage of 
cases with mutations found by CGA that are also detected by the candidate test).
Because of the sparse data on overall clinical diagnosis and variability in the LIPOchip versions 
used, sensitivity data could not be pooled. Therefore, we have provided a narrative overview and 
graphical presentation of the diagnostic performance of Elucigene FH20 and LIPOchip.
Low-density lipoprotein cholesterol studies
In general, the included studies on LDL-C (as part of the Simon Broome criteria for the 
diagnosis of probands or age-and gender-specific LDL-C cut-offs for the diagnosis of relatives 
as recommended by NICE guideline CG711) provided data on true- and false-positives and 
-negatives, allowing the calculation of both sensitivity and specificity. Again, because of the 
variability in both the clinical diagnosis and the comprehensiveness of the genetic tests used, 
sensitivities and specificities could not be pooled to provide a single estimate.
Diagnostic accuracy
The sensitivity of Elucigene FH20 and LIPOchip in detecting FH varied. Amongst UK 
populations with a clinical diagnosis based on the Simon Broome criteria, Elucigene FH20 
was reported to detect 44% and 52% of those with FH-causing mutations that were detected 82 Discussion
by CGA. The UK has a population with a wide mutational spectrum and, as Elucigene FH20 is 
designed to detect a limited number of mutations, the sensitivity of the kit is largely dependent 
upon the prevalence of these specific FH-causing mutations in the population, hence resulting 
in variations. For example, predicted sensitivities of 32% in Wales48 and approximately 33% in 
Aberdeen, Scotland (prevalence with CGA 28%),79 were reported for Elucigene FH20 (by tallying 
the mutations that are covered in the Elucigene kit against the mutations that were picked up by 
CGA in those setting), which is lower than sensitivities reported by included studies. Moreover, 
it has been suggested that interpretation of the Simon Broome diagnostic criteria is not uniform 
throughout the lipid clinics in the UK and this may also lead to variation in the detection of FH.70
Variation was observed across countries in the sensitivity of Elucigene FH20 in detecting FH 
in those with a clinical diagnosis of definite FH. Elucigene FH20 showed sensitivity of 49% 
in confirming FH in those with a clinical diagnosis of definite FH in a UK population (the 
prevalence of FH in the study was 28%), whereas sensitivity of only 29% was observed in an 
Australian population in which the prevalence of definite FH in the study was very high (78%). 
These differences could possibly be explained at least in part by the following two factors: (1) 
mutations included in the Elucigene FH20 kit were selected based on their frequencies in a 
sample of around 400 patients who were diagnosed as definite FH based on a Simon Broome 
diagnosis26 and (2) differences in the definitions of definite FH used in the two study populations 
(in the Dutch criteria a clinical diagnosis of definite FH does not require the presence of 
xanthomata, unlike the Simon Broome criteria).
The sensitivity of LIPOchip ranged from 33.3% (UK population) to 94.5% (Spanish population) 
using various versions. Using LIPOchip version 8, which contains 251 of the mutations most 
prevalent in a European population, the sensitivity observed in a UK population with a 
clinical diagnosis of FH based on the Simon Broome criteria ranged from 33.3%40 to 56.9%,41 
while specificity was reported as 93.8%.40 It should be noted that LIPOchip version 8 does not 
detect five mutations that are detected by Elucigene FH20 and which are common in the UK 
population; therefore, the sensitivity of the UK version of LIPOchip is likely to be higher. In 
the version of LIPOchip including frequent UK mutations (version 10), sensitivity would be 
improved to 78.5%41 (Progenika, personal communication) in detecting FH in a UK population. 
However, this was based on a very small sample size (n = 120) and only those with a confirmed 
genetic diagnosis were included and therefore the results should be interpreted with caution. 
None of the included LIPOchip studies reported accuracy data separated by definite FH 
or possible FH.
The sensitivity of LDL-C as part of the Simon Broome criteria compared with CGA was high 
(90–93%); however, specificity was low (28–29%) with a large number of false-positives observed. 
Nevertheless, only four of the LDL-C studies (three full text and one abstract) used the most 
complete CGA as defined in the assessment. The implications of this high false-positive rate are 
that potentially unnecessary additional tests or treatments may be given to those who do not have 
(genetically diagnosed) FH.
A risk of 10–20% of either incorrect diagnosis or misdiagnosis of FH has been reported.81,82 In the 
UK, an overlap in LDL-C distributions amongst those with and without FH has been reported. It 
has been suggested that, because of the overlap in LDL-C levels, no cut-offs are 100% accurate.22 
Mabuchi and colleagues46 reported higher accuracy of LDL-C using a cut-off of 4.1 mmol/l 
(sensitivity and specificity of > 98%) among genetically diagnosed FH patients and unaffected 
relatives in Japan. The mean LDL-C levels amongst those with and without FH may differ 
from country to country, with some studies reporting an overlap in LDL-C distributions while 
others do not.49 In the study by Mabuchi and colleagues46 the mean LDL-C level was 6.7 (SD 
1.52) mmol/l in those with FH compared with 2.97 (SD 0.65) mmol/l in those without FH, with © Queen’s Printer and Controller of HMSO 2012. This work was produced by Sharma et al. under the terms of a commissioning contract issued by the 
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almost no overlap in LDL-C distributions. This could partly explain why using a LDL-C cut-off of 
4.1 mmol/l was found to be highly sensitive in this population.
Cascade testing
In a family with FH, 50% of first-degree relatives are likely to have the condition. One of the 
advantages of genetic testing is that, if a mutation is identified in probands, targeted gene 
sequencing can be used in cascade testing of relatives to detect the culprit mutation and provide 
an unequivocal diagnosis of FH. Using targeted gene sequencing, the observed detection rate of 
FH in relatives ranged from 53% to 56% in two studies,37,45 which is broadly consistent with rates 
reported by others (37–56%; see Appendix 18).11,19,67,83–85 A study by Wiegman and colleagues50 
reported that a high detection rate (77%) in children from families in whom a mutation was 
identified in probands was observed through targeted sequencing. However, the authors of the 
study suggested that one possible reason for the high detection rate was that siblings with very 
low LDL-C levels were not taken to the clinic to undergo targeted sequencing. Moreover, children 
are present with monogenic causes of hypercholesterolaemia and are likely to have a higher 
detection rate of FH-causing mutations.
High sensitivity and specificity of age- and gender-specific LDL-C cut-offs compared with CGA 
were reported in cascade testing of relatives, suggesting the clinical utility of this approach in 
the absence of genetic diagnosis. In the study by Lee and colleagues,48 91% sensitivity and 93% 
specificity of cascade testing of relatives were reported using age- and gender-specific LDL-C 
cut-offs, although one explanation for the high values reported is that the included index 
participants were all homozygous for FH. In a subgroup analysis, Wiegman and colleagues50 
reported sensitivity of 96% using LDL-C cut-offs of ≥ 3.5 mmol/l in children of parents with a 
clinical diagnosis of definite FH.48,50 The authors of the study suggested that this sensitivity would 
apply to those children in a family with definite diagnosis of FH only.
Strengths and limitations of the assessment
In terms of strengths of the assessment, screening of articles and quality assessment of full-text 
papers were performed independently by two reviewers. Conference abstracts were included. To 
avoid missing potentially relevant studies reporting Elucigene FH20 or LIPOchip, in addition to 
studies reporting a clinical diagnosis of FH based on the Simon Broome criteria, those reporting 
a clinical diagnosis of FH based on the Dutch or MedPed criteria were also included. We also 
contacted study authors to obtain clarification on aspects of their reports or in an attempt to 
obtain missing data.
In terms of limitations of the assessment, non-English-language studies were excluded. A 
limitation of the literature was that, because the tests evaluated are still new and evolving, a 
limited amount of evidence was identified reporting Elucigene FH20 and LIPOchip in a UK 
population, with sample sizes as low as 22 patients40 and not all published as peer-reviewed 
full reports. One possible mechanism we could have adopted to indirectly infer additional 
information on the tests would have been to back-calculate data from those studies that had 
undertaken CGA (by tallying the mutations that are covered in the Elucigene FH20 kit or 
LIPOchip kit against the mutations that were picked up by CGA) and thence calculate the 
predicted sensitivity of the tests. However, because of time constrains we were unable to do 
so. Also, we would have had to acknowledge the inferred nature of those calculations had they 
been undertaken.
The available evidence varied in terms of the diagnostic criteria used to provide a clinical 
diagnosis of probands, the versions of LIPOchip used, the comprehensiveness of the genetic 
analysis (specifically for studies reporting LDL-C compared with CGA) and the threshold of 84 Discussion
LDL-C cut-offs used to define a positive test result. Because of this heterogeneity it was not 
considered appropriate to calculate pooled estimates.
Methodological quality of the included studies
We did not find any studies that directly compared Elucigene FH20 and/or LIPOchip with 
LDL-C (either as part of the Simon Broome criteria for the diagnosis of probands or age- and 
gender-specific LDL-C for the diagnosis of relatives) against a reference standard of CGA. A 
RCT86 (and its secondary report84) was identified, conducted in the UK, in which all participants 
received a clinical diagnosis based on the Simon Broome criteria and one group received a 
genetic test while the other received a LDL-C test using Simon Broome cut-offs. However, there 
were insufficient data to calculate the sensitivity and specificity of these tests in index cases, and 
also Simon Broome LDL-C cut-offs were used in testing relatives instead of age- and gender-
specific LDL-C cut-offs; hence, this study was excluded from the assessment.
All of the included studies were cross-sectional in nature, with only two studies recruiting 
consecutive patients.37,44 Abstracts were not quality assessed as they were not considered to 
contain sufficient information to allow for an adequate assessment of study methodology. In all 
but one study (LDL-C test46), patients were representative of the spectrum of those who would 
receive the test in practice. These were patients with a clinical diagnosis of FH based on the 
Simon Broome, Dutch or MedPed criteria or, for cascade testing, the relatives of those index 
cases with a confirmed clinical diagnosis of FH. The results from studies in which participants 
are clinically diagnosed based on the Simon Broome criteria would be of specific interest 
to UK practice.
An incomplete genetic testing strategy may result in mutations not being detected because of 
the limitations of the testing strategy. Only one study reporting Elucigene FH20,37 one study 
reporting LIPOchip39 and 50% (three out of six) of the LDL-C studies44,45,49 used genetic analysis 
that comprised DNA sequence analysis of the LDLR and APOB genes in conjunction with MLPA. 
Given that the FH-causing PCSK9 gene is rare and was discovered only fairly recently, those 
studies that otherwise met the definition of CGA but without assessing the PCSK9 gene were 
judged to include an acceptable reference standard in terms of classifying the target condition 
in this assessment. However, only two of the above studies that employed CGA did not perform 
PCSK9 analysis.45,49 With respect to the reference standard used, all six abstracts (two reporting 
Elucigene FH20, three reporting LIPOchip and one reporting LDL-C) used adequately defined 
CGA, which comprised DNA sequence analysis of the LDLR and APOB genes (plus PCSK9 gene) 
in conjunction with MLPA that was likely to classify the target condition.
In the Elucigene FH20 and LIPOchip studies, only those who tested negative went on to receive 
further genetic investigations; thus, none of the test-positives received the reference standard 
(differential verification bias), giving rise to the possibility of overestimation of test performance. 
Because of the sequential nature of the tests used, these studies were also at risk of partial 
verification bias as neither the whole sample nor a random sample received verification with a 
reference standard. All of the LDL-C studies were free of partial verification bias and one was 
free of differential verification bias.44 Test review bias (the results of the index test are interpreted 
with knowledge of the results of the reference standard test) was avoided in the Elucigene FH20 
study, one of the LIPOchip studies and two of the LDL-C studies. It has been suggested that both 
test review bias and diagnostic review bias (in which the results of the reference standard test 
are interpreted with knowledge of the index test) may lead to higher values being reported for 
sensitivity.87 However, these biases are of more importance in tests in which the results are based 
on subjective interpretation rather than automatically generated.© Queen’s Printer and Controller of HMSO 2012. This work was produced by Sharma et al. under the terms of a commissioning contract issued by the 
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Uncertainties
The spectrum of patients considered in this assessment was those with a clinical diagnosis 
of either definite or possible FH (including relatives of confirmed FH cases). Therefore, any 
evidence from this review is not generalisable to the wider, asymptomatic general population. The 
inclusion of population-based screening studies was beyond the scope of this review.
Assessment of a new technique – iPLEX – was also beyond the scope of this review as this was 
not CE marked at the time that the review was conducted. iPLEX is a rapid genetic testing kit 
developed to cover 56 mutations (54 in the LDLR gene, one in the APOB gene and one in the 
PCSK9 gene) most commonly found in the UK population. It has been reported that this kit has 
an average detection rate of 75% (n = 150 patients) with a false-positive rate in a ‘no mutational 
control group’ of 0.015%,88 and that the kit can produce a test result within 1 hour.
Analysis of the sensitivity of Elucigene FH20 and LIPOchip in relation to homozygous 
or compound heterozygous FH was similarly beyond the scope of this assessment. 
People with compound heterozygous FH carry more than one mutation and pre-screening  
with Elucigene FH20 or LIPOchip may miss the second mutation if it is not covered by 
the genetic testing kit and genetic testing stops after the first mutation is identified. In such 
circumstances relatives of the diagnosed proband may carry a different mutation to the one 
identified by the pre-screen and could be misdiagnosed as non-FH if only the mutation 
identified on the pre-screen is checked in cascade testing of relatives. A case study by Taylor 
and colleagues89 reported that compound heterozygous FH gave rise to a severe phenotype 
and suggested that the presence of additional mutations in families should be considered when 
relatives have varying phenotypes. Although such FH cases are very rare in the UK, with a 
prevalence of around 1 in 1 million, recognition of the issue is important.
A wide range of approximately 3027–95%90 of patients with a clinical diagnosis has been reported 
to have a mutation confirmed by genetic diagnosis. In some people with FH the results of 
CGA might still be negative because full sequencing of the APOB and PCSK9 genes is not 
routinely undertaken, and there may be other genes as yet unrecognised that give rise to the 
FH phenotype. Moreover, a number of other high-penetrance genes may harbour quite rare 
mutations (as is emerging in schizophrenia) or alternatively familial clustering of low-penetrance 
alleles may cause a FH phenotype, as reported in familial breast cancer. The recent report found 
that approximately 95% of children meeting the Dutch criteria for FH had a genetic mutation,90 
whereas only approximately 3027–50%37 of patients meeting the Simon Broome criteria had a 
mutation confirmed by genetic diagnosis.
None of the included studies reporting Elucigene FH20 or the LIPOchip UK version provided 
information on clinical effectiveness outcomes. Other studies have shown clinical improvements 
in patients in whom the diagnosis of FH has been confirmed after cascade screening.11,19 In a 
large genetic screening study with 1 year of follow-up, a very high proportion of patients (93%) 
identified with FH started on lipid-lowering medication, showing the effectiveness of the genetic 
testing.19 Significant reductions in TC and LDL-C were observed in those with identified FH 
6 months after genetic screening.11
Other relevant factors
Psychological impact and acceptability of genetic testing
Evidence has suggested that genetic diagnosis of FH has no clinically relevant adverse 
psychological effects.11,91 A RCT conducted in the UK that included probands with FH and their 
relatives found that there was no significant effect of genetic diagnosis on perceptions of control 
over FH, fatalism of FH, control over cholesterol or control over heart disease and adherence to 86 Discussion
risk-reducing behaviour; however, those with a confirmed genetic diagnosis had a strong belief in 
the efficacy of cholesterol-lowering drugs and a less strong belief in the efficacy of diet.86 Another 
prospective comparative study conducted in the Netherlands among participants in a family-
based genetic screening programme, however, found that those with an identified mutation 
perceived that they were at greater risk of heart disease than those with no mutation. The result 
was influenced by age, education, cholesterol level and cardiovascular disease in the family.92
Cascade screening studies have reported high participation rates of 7311–90%.19 In a UK cascade 
screening study in Oxfordshire, 97% of parents asked for their children to be screened.93 In terms 
of approaches used, directly contacting relatives from clinics has reported higher participation 
rates19 than contacting relatives through probands.93 Using both approaches resulted in a higher 
participation rate (73%) than contact through probands but was not higher than directly 
contacting relatives. However, there may also be concerns about the possible consequences of 
receiving a positive genetic test result. In a large genetic screening study in the Netherlands, 10% 
of individuals declined genetic testing because of the fear of negative effects on employment 
or insurance.19
Although genetic diagnosis may be generally acceptable to patients, for clinicians making a 
diagnosis of FH still remains a challenge and dependent upon their judgement in circumstances 
in which patients have raised cholesterol levels but no identified FH-causing mutation.94
Risk associated with different types of mutation
Based on the lipoprotein levels, mutations have been categorised as either ‘severe’ (functional null 
alleles and missense in exon 3/4; or functional null alleles plus splice variants) or ‘mild’ (missense 
outside exons 3/4 and splice; or any missense mutation).84 A null mutation has been identified as 
one of the important risk factors associated with PCVD in FH patients.43,95 A significantly higher 
risk of PCVD, recurrence of cardiovascular events and family history of PCVD was reported 
in patients carrying null mutations compared with patients with defective mutations.95 The 
relative risk of PCVD in patients with a null mutation was 3.1 times higher than that in patients 
with a missense mutation.43 The mean PCVD-free survival time in those with null mutations 
was 51–53 years, in those with missense mutations was 58 years and in those carrying defective 
mutations was 53 years (p < 0.01).43,95
Taylor and colleagues37 reported a similar prevalence of severe mutations across study 
participants with a clinical diagnosis of definite FH, possible FH and also unclassified FH.
Discussion of cost-effectiveness results
Statement of principal findings
Index cases only
The base-case analysis refers to an index case aged 50 years and a mutation detection rate for FH 
equal to 36.5% of cases with a Simon Broome possible or definite FH diagnosis. With regards 
to the identification of index cases alone, Elucigene FH20 was the least costly test but also 
generated the least QALY gain because of the high number of false-negatives associated with 
this test. Accounting for the inclusion of both diagnostic and treatment costs (including clinical 
management), LDL-C was the most costly option for index cases alone but also generated the 
greatest number of QALYs gained. The reason for this is that all patients who meet the Simon 
Broome clinical diagnosis of FH will have elevated cholesterol levels as part of that diagnosis. The 
diagnosis is not definitive but patients with false-positive test results on LDL-C for FH will still 
gain from statin therapy on the basis of them having high cholesterol; the difficulty, however, with 
this strategy arises when cascade testing incorrectly takes place from false-positive index cases.© Queen’s Printer and Controller of HMSO 2012. This work was produced by Sharma et al. under the terms of a commissioning contract issued by the 
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Index cases and relatives
Of greater relevance, however, to the decision problem is the identification of at-risk relatives 
of index cases in whom cascade testing should be carried out. Each 50-year-old index case will 
have on average five first-degree relatives, four second-degree relatives and four third-degree 
relatives still alive and eligible for contact for cascade testing. These numbers refer to the base-
case scenario and will vary depending on the average age of the index case. For example, older 
people may have more second-degree relatives eligible for testing as they are likely to have living 
grandchildren. Similarly, younger people will have more grandparents alive than an index case 
aged 50 years. This variation is incorporated in the model results.
In the analysis of index cases and relatives, LDL-C as a stand-alone test is the least costly testing 
option. CGA dominates pre-screen tests also including CGA as part of the strategy of testing. 
This is because of the assumption that QALY gains for FH are not time sensitive and the extra 
time taken to deliver a tiered-strategy diagnostic test will have no implications for treatment 
or QALY impact. This suggests that, although pre-screen tests such as Elucigene FH20 and 
LIPOchip (Spain) are less costly in their own right, they do not offer overall cost savings as a 
pretest to CGA, suggesting that the extra costs associated with running negative samples through 
all tests in a sequence outweigh the cost savings of those detected as positive on either Elucigene 
FH20 or LIPOchip. Only at very specific prevalence and sensitivity combinations would 
Elucigene FH20 be a cost-effective pre-screen to CGA. As the cost of gene sequencing falls in the 
future, it is less likely that targeted tests (at current prices) will offer a cost-effective pre-screen 
strategy for the majority of the population in whom testing would be carried out.
Of greater interest, however, is the comparison of the non-dominated tests with the relevant 
comparators for this assessment. CG711 recommended that DNA testing in combination with 
LDL-C testing was the most cost-effective strategy to test index cases and identify relatives for 
cascade testing. However, in practice, uptake of DNA testing for FH has been very slow, especially 
in England, where the 2010 FH audit18 suggests that only 12% of trusts have access to a formal 
system of cascade testing, with a further 14% stating that such a system is in development. One 
issue for this may be a lack of funding in the area, and clinical advice suggests that, in reality, 
LDL-C testing in combination with the Simon Broome criteria is a more realistic reference 
standard for this assessment. With this in mind, the main comparison of non-dominated 
sequences is with LDL-C. However, we also report sequential results ordered by cost and a 
comparison of cost and QALY differences against CGA for completeness.
When compared with LDL-C, CGA is a highly cost-effective diagnostic test and is the only 
option that gives an unequivocal diagnosis of FH. This strategy is estimated to cost £1030 per 
QALY gained relative to LDL-C and thus at usual thresholds would appear to be a highly cost-
effective use of NHS resources, and this is further confirmed through probabilistic sensitivity 
analysis. This finding is in agreement with similar findings from NICE clinical guideline CG71,1 
which also found that DNA testing was highly cost-effective in the identification of relatives 
of index cases with FH. As reported in Chapter 2, there is always the potential that there exist 
undiscovered genetic mutations and culprit genes that may lead to FH. For this reason, cascade 
testing would be carried out from mutation-negative index cases using LDL-C testing as they are 
still technically FH positive based on their clinical diagnosis.
The LIPOchip manufacturer, Progenika, offers a service for testing samples in Spain. This 
platform offers LIPOchip as a pre-screen and a follow-up screen of all negative samples using 
sequencing of the LDLR gene. As LIPOchip tests for duplications of and deletions in the 
gene, this may be described by the manufacturer as CGA; however, there is much clinical 
uncertainty in relation to the accuracy of the LIPOchip method of detecting deletions and large 
rearrangements of the gene. Additional evidence suggests that LIPOchip will correctly detect only 88 Discussion
two out of seven exon copy number changes compared with MLPA.69 The authors acknowledge 
that these data are based on small sample numbers; however, they raise further questions with 
regard to the accuracy of LIPOchip compared with MLPA. Therefore, MLPA would also be 
required to obtain a completely unequivocal diagnosis. The LIPOchip platform, processed in 
Spain, does not offer MLPA as part of the process and so it is assumed that the diagnosis obtained 
from this strategy would be inferior to that of CGA as described in this analysis. As this platform 
is slightly less sensitive, it is likely that there will be more uncertainty in the test result in about 
5% of patients in whom the MLPA test would be required for additional confirmation. The 
LIPOchip platform processed in Spain is also found to be a cost-effective strategy, with an ICER 
of £871. Information provided by the manufacturer of LIPOchip suggests that 80.5% of index 
cases would be detected using the LIPOchip test and the remaining 19.5% would need gene 
sequencing to confirm the diagnosis (Progenika, 2011, personal communication to NICE). These 
figures refer to a definite FH sample being tested. However, it is estimated that of all the samples 
presenting for genetic testing, only 30–50% will have an identifiable mutation. Therefore, the 
estimates of cost provided by the manufacturer may have underestimated the number of samples 
testing negative on the LIPOchip test that would also require gene sequencing as the second 
stage of analysis. Equally, it may be that these costs would be reasonable because of manufacturer 
economies of scale. Should this strategy be recommended, it is imperative that the issue of price 
be confirmed before any decision is made.
The results do, however, suggest that if the recommendation to undertake CGA for all was 
considered impractical or too expensive (e.g. sufficiently large increases in CGA testing might 
lead to a requirement for extra laboratory space and associated infrastructure, not captured 
by the existing unit cost assumptions) and an alternative test (Elucigene FH20 or LIPOchip 
platform) is deemed appropriate, then either or both could be recommended. The test chosen for 
a particular population would pragmatically reflect the sensitivity of each of these tests within 
a particular clinic catchment area as it is found that tests may perform differently on groups of 
different ethnic origin. It may also reflect local resource conditions and clinical judgement, as 
there is a trade-off between costs and effects. The difficulty, however, in adopting such a strategy 
is that not all tests detect all individuals. Therefore, should any of these less-than-perfect testing 
strategies be accepted, they may miss out a number of potentially important cases. This may raise 
ethical and equity concerns as only a proportion of people will have the culprit gene identified 
and have their relatives followed up for genetic cascade testing.
The economic model results are more sensitive to changes in parameters for index cases alone 
than for index and relative cases together. As the latter is the main focus of the analysis of this 
project, these results are given the most weight in the discussion and reporting of results.
Relative to the comparator of LDL-C, probabilistic sensitivity analysis reveals that CGA is the 
most cost-effective diagnostic test strategy for the identification and testing of relatives with FH, 
with a probability of cost-effectiveness of > 90% for all age groups at all conventional values of 
willingness to pay for a QALY gain. Some variation is identified in the probabilistic analysis based 
on mutation prevalence rates, which may vary greatly in practice between different geographical 
areas. Although there is some variability in the results at low threshold values and at very low 
mutation prevalence rates, CGA does, however, remain the most likely strategy to be cost-
effective relative to LDL-C (never dropping to < 50% probability at threshold values of societal 
willingness to pay of > £5000 per QALY gained).
Strengths and limitations
The economic analysis has a number of strengths and limitations for the confirmation of FH 
among index cases and the identification of first-, second- and possibly third-degree biological 
relatives for cascade testing. As the modelling processes used to generate this economic model © Queen’s Printer and Controller of HMSO 2012. This work was produced by Sharma et al. under the terms of a commissioning contract issued by the 
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are adapted from a previously developed Markov model for these patient groups, many of the 
relevant strengths and limitations of this economic evaluation have already been reported in 
appendix E to the NICE clinical guideline CG71.1 In addition to those already reported and 
published, the following discussion relates explicitly to additional issues relative to the model that 
may not have been reported elsewhere.
Strengths
This work is important and builds on the health economics evidence generated as part of 
the NICE CG71 development process.1 This economic modelling exercise identifies a range 
of potential diagnostic strategies that were not available for the CG711 assessment (namely 
LIPOchip and Elucigene FH20) and investigates their cost-effectiveness either as stand-alone 
tests or as pre-screens to reduce costs associated with CGA. However, one issue of importance is 
that the cost of CGA, and gene sequencing in particular, has fallen since the CG711 assessment 
and is likely to fall still further with the evolution of next-generation sequencing. This favours 
the CGA approach and means that, in the future, going forward, the costs of gene sequencing 
may well fall further with the evolution of new methods and new technologies. However, even 
at current prices (approximately £480 per test), CGA is still a cost-effective method of cascade 
testing. It is the most cost-effective strategy in terms of attaining an unequivocal genetic diagnosis 
of FH among index cases and for cascade testing those relatives at greatest risk of having the 
disease. The analysis considered all currently available and approved diagnostic tests and linked 
test accuracy with final treatment outcomes measured in terms of QALYs. As additional tests 
become available, it will be possible to incorporate these into the model and re-run the analysis 
incorporating newly available evidence and tests.
The model structure is a key strength of the analysis in that it presents a linked evidence approach 
linking intermediate outcomes (i.e. diagnostic accuracy of each testing strategy) to the associated 
lifelong costs and health outcomes associated with each test result and whether tests were 
true-positive, false-positive, true-negative or false-negative. This was explored for a total of 12 
alternative testing strategies through decision tree and Markov model analysis.
A structured literature search was carried out to identify existing cost-effectiveness evaluations of 
these tests and of the cascade testing of relatives. No studies directly compared the interventions 
under consideration, and only one study detailed the cost-effectiveness of any of the new 
interventions relative with no testing. This referred to the LIPOchip test but was used in relatives. 
As targeted sequencing is a much lower cost method of testing identified relatives, this LIPOchip 
study was not relevant to this analysis. Our results, however, do confirm the findings from a 
number of other studies evaluating the cost-effectiveness of the cascade testing process more 
generally and also the findings of the previous NICE guideline.1
Methods used to identify and obtain parameter estimates for the economic modelling sought 
to identify and utilise published sources and best available information; however, this was not 
possible in all cases. In such scenarios, for example the proportion of patients receiving various 
statin therapies and how treatment changes based on diagnosis, we have relied on clinical expert 
opinion from two or more clinical experts. Estimates of parameters are also sourced from the 
CG711 analysis where available and tested in sensitivity analyses.
Limitations
The model structure focused on the identification and treatment of index cases and relatives 
of index cases with FH as clinically diagnosed using the Simon Broome criteria. The costs and 
benefits of identifying other causes of similar symptoms have not been modelled in detail with 
the exception of the prescription of statin therapy for all index cases with high cholesterol levels. 
The impact of additional therapies such as diet, exercise, smoking cessation, etc. has not been 90 Discussion
included and is beyond the scope of this assessment. The effect of not including such detail in the 
model is uncertain; however, it is generally widely acknowledged that all patients with a clinical 
diagnosis of FH will require some form of active treatment, generally statin therapy.
Another challenge related to the analysis of subgroups of the population, especially in relation to 
FH in children. Relative risks associated with children aged 15 years are assumed to be similar 
to those of adults aged 30 years. There is little evidence linking the efficacy of statins directly to 
cardiovascular events avoided, and for this reason we have assumed risks similar to those of a 
30-year-old in the model. This probably creates some uncertainty in the estimation of quality of 
life in this subgroup of the population. Although data do exist relating to clinical outcomes in 
children (i.e. TC level), these are not linked directly to cases avoided. As Avis and colleagues96 
show, statins are efficacious in reducing cholesterol in children with FH and are not associated 
with significantly different adverse events to placebo; it is therefore assumed that health effects 
are similar to those of the next youngest age group in the model (aged 20–39 years). It is 
unlikely that this assumption greatly impacts on the cost-effectiveness results and associated 
conclusions drawn.
In terms of the estimation of costs for each testing strategy in the economic model, we have used 
the MOLU classification system to assign tests to bands and apply MOLUs to each band. This is 
an agreed costing mechanism devised by the UKGTN and CMGS with some built-in flexibility 
in pricing for each laboratory’s individual circumstances. This is not necessarily an accurate 
reflection of true economic costs or indeed opportunity costs associated with testing for FH. 
However, in the absence of price data for all combinations of tests considered, robust costing 
methods for genetic testing for FH or a NHS tariff for the tests as well as uncertainty surrounding 
variability from laboratory to laboratory, it was impossible to cost all testing strategies fairly 
using any other universally acceptable approach. Using the cost of the test alone would be 
insufficient as it would not account for staff time and consumables required. Therefore, although 
acknowledging its limitations, we have on the basis of expert opinion relied on the MOLU system 
for the estimation of diagnostic testing costs in the economic model. Studies retrieved from the 
cost-effectiveness searches showed great variability in the costs of testing for FH. The reason for 
this is that testing for FH and genetic testing more generally is a rapidly evolving discipline. Many 
studies presented alternative definitions of DNA testing and the costs of completing the tests have 
fallen almost yearly in recent years. Therefore, older estimates would be an overestimate of the 
true costs. This is another reason why the MOLU system was used for this assessment.
A number of other assumptions were made in relation to the clinical management of patients 
with and without disease. Much uncertainty exists among clinicians in the treatment of FH, 
with many advocating a start low approach followed by an increase in treatment intensity if 
a satisfactory response is not achieved. Others believe that, as statin therapy generates very 
few adverse events, it would be appropriate to treat everyone with a high-intensity statin (e.g. 
atorvastatin). The impact of this uncertainty is explored in sensitivity analyses and is found not to 
alter our base-case results and conclusions, with only very small differences in ICERs.
Further, in relation to the utility of diagnostic information, there is no published evidence that 
links the outcome from the results of a genetic test for FH (e.g. increased anxiety) to quality-of-
life outcomes and hence QALYs gained. A number of plausible scenarios are possible, including 
reduction in QALYs emanating from the shock of knowing that one has a genetic disorder. 
Equally, however, people diagnosed with FH could gain some reassurance from the fact that 
they know what is causing their illness and can aim to develop a plan of action in dealing with 
this. Additionally, parents may place a positive value on knowing the source of a child’s illness. 
It is, however, likely that these factors would cancel each other out or favour genetic testing and 
would be much smaller in comparison with the QALY gains associated with being treated for a 
life-threatening condition such as FH.© Queen’s Printer and Controller of HMSO 2012. This work was produced by Sharma et al. under the terms of a commissioning contract issued by the 
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An additional limitation of our analysis is that it is on an average patient level. We are aware 
that some mutations cause greater harm and are associated with greater risk of cardiovascular 
events. For example, mutations of the PCSK9 gene are associated with greater clinical risk. Also, 
there are differences between missense and nonsense genetic mutations. Although these are 
likely to have implications for the prognosis of individual patients, this has not been modelled 
as there is insufficient evidence available to estimate how this would impact on quality of life. 
Further, as cost and QALY differentials are based primarily around treatment decisions and the 
general insensitivity of the model to small changes, it is unlikely that analysing the data on a 
mutation level for the purposes of cost-effectiveness would generate great differences in results or 
conclusions. Further, such data would be available for only few if any mutations and the inclusion 
of these only would generate further ‘noise’ into the analysis.
There are limited data available for the sensitivity of the LIPOchip test, with wide variation in 
all of the reported studies for various versions of the test. This generates a lot of uncertainty 
surrounding the true sensitivity of LIPOchip as used to populate the economic model. As many 
of the tests were analysed at the manufacturer’s own laboratory, there is a lack of academic 
peer-reviewed information on this input for the economic model. To deal with the associated 
uncertainty we have conducted wide variation in the probabilistic sensitivity analysis, which 
should counter any biases that may have arisen as a result of a lack of critique of the estimate of 
sensitivity used for LIPOchip version 10 in the model.
A further limitation of the analysis refers to the accuracy of test sensitivity and specificity 
differentials between those relatives of genetically negative index cases and those relatives 
of genetically confirmed index cases. For the purposes of the economic modelling, we have 
assumed, because of a lack of relevant usable data, that sensitivity and specificity of LDL-C 
testing in both groups are similar. Although this may overestimate the sensitivity and specificity 
of LDL-C as a test for relatives of genetically negative index cases, it is justifiable on the basis 
that all index cases are clinically diagnosed with FH and so may well have genetic mutations 
that as yet may not have been discovered or have not been detected using any of the tests for this 
assessment. In terms of the cost-effectiveness results, this could represent a bias of uncertain 
magnitude in favour of CGA, although in the context of insensitivity to variations in this 
parameter in probabilistic analysis it is unlikely to alter overall results and conclusions.
Uncertainties
Although the cost-effectiveness analysis was performed using the best available data, there was 
nonetheless some uncertainty surrounding some of the parameters used in the model. Current 
NICE guidelines recommend that cascade testing is undertaken for all relatives of index cases 
(using targeted sequencing for those genetically identified and LDL-C for those with no genetic 
test or those with a negative genetic test). As discussed, because of our assumption that similar 
proportions of relatives test positive on LDL-C regardless of the index case’s genetic result, this 
represents some uncertainty. Other issues of uncertainty reflect the parameters and assumptions 
varied in the deterministic and probabilistic analysis. Results, however, indicate that, in general, 
the model is insensitive to a range of plausible changes in structure and parameters.© Queen’s Printer and Controller of HMSO 2012. This work was produced by Sharma et al. under the terms of a commissioning contract issued by the 
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Chapter 6 
Conclusions
Implications for service provision
Based on the available, albeit limited, evidence, Elucigene FH20 and LIPOchip version 10 
(designed to detect 189 UK-specific mutations) will detect approximately 44–52% and 78.5%, 
respectively, of FH-causing mutations that are also detected by CGA amongst people with a 
clinical diagnosis of FH based on Simon Broome criteria. As targeted tests are designed to detect 
a limited number of genetic mutations, Elucigene FH20 and LIPOchip cannot detect all cases 
of FH; therefore, further genetic screening using MLPA and sequencing is still required to give 
an unequivocal diagnosis of FH. This implies that using these targeted tests alone for diagnosis 
of probands would miss up to approximately 50% (using Elucigene FH20) and 20% (using 
LIPOchip version 10) of patients with FH-causing mutations who are at risk of developing CHD. 
As such, these individuals may not receive appropriate treatment and other members of their 
extended families will also be missed (as they will not be identified for cascade testing).
Using the LDL-C test (high sensitivity and low specificity) as part of the Simon Broome criteria 
means that a large number of people will receive a clinical diagnosis of FH who will not have a 
detectable FH-causing mutation. Hence, using LDL-C alone for the diagnosis of FH may lead to 
inappropriate treatment. In a small UK cohort, age- and gender-specific LDL-C was shown to 
perform well in the relatives of homozygous FH probands, suggesting the utility of this test for 
cascade testing (in the absence of genetic tests) among those with a strong phenotype.
As the Elucigene FH20 and LIPOchip kits are designed to detect targeted gene mutations, 
the sensitivities of both of the kits are largely dependent upon the prevalence of these specific 
FH-causing mutations in the population. Sensitivities observed in this assessment may not, 
therefore, be generalisable to other populations or ethnic groups.
At conventional values of willingness to pay for a QALY, CGA is the most cost-effective method 
of confirmation of clinical diagnosis of FH among Simon Broome possible or definite FH index 
cases and for the associated cascade testing of first-, second- and third-degree biological relatives. 
The associated ICER (relative to current practice – LDL-C) is £1030 per QALY gained. The 
LIPOchip platform and Elucigene FH20 have an even lower reported point estimate of the ICER 
but are associated with fewer QALY gains. However, there may be practical and resource issues 
associated with full-scale implementation of CGA if it is recommended as a test strategy for all. 
If so, then a judgement is required on whether or not it is ethical to implement cascade testing 
based on an index test result that is not as accurate as alternative more accurate cost-effective 
options. In addition, a decision-maker needs to be aware that clinicians may or may not base 
treatment decisions on the outcome of tests such as Elucigene FH20, which detect only around 
44% of cases with a FH-causing mutation; for example, there is the potential for missing cases 
(especially at-risk relatives who may not show high LDL-C levels when tested but may have a 
FH-causing mutation). These patients may forgo potentially life-saving treatment if index cases 
are identified only on the basis of their clinical diagnosis as opposed to their genetic test. This 
issue does not arise in CGA, for which an unequivocal diagnosis is reported. Should a decision-
maker deem CGA too expensive given current NHS budgets, Elucigene FH20 and/or LIPOchip 94 Conclusions
platform (processed in Spain) could be recommended as cost-effective strategies. Probabilistic 
sensitivity analysis shows CGA to be associated with a probability of cost-effectiveness that is 
> 90% at threshold values of willingness to pay of > £5000 per QALY gained. Although some 
variation exists depending on mutation prevalence rates among varying populations, CGA 
remains the most likely cost-effective testing strategy when the ultimate goal is the identification 
and treatment of relatives with FH.
It is likely that there would be significant resource use implications associated with implementing 
the findings of this assessment. As there are approximately 100,000 people with FH as yet 
undiagnosed, this will provide a substantial resource burden to already tight NHS budgets; 
however, costs associated with genetic testing are reducing and will continue to do so with the 
emergence of next-generation sequencing techniques. Similarly, costs of treatment are also likely 
to reduce going forward as atorvastatin is due to come off patent in 2011 with an expected retail 
cost similar to that of generic simvastatin.
Currently, CGA is used as the method of cascade testing of choice in only a small number of 
centres in the UK. The use of CGA is observed to be funded less often by primary care trusts 
in England than in other parts of the UK where adoption of the technology as part of current 
practice is much higher. In England, currently 97% of audited sites have access to dedicated lipid 
measurement services; however, only 12% have access to a dedicated genetic testing service for 
FH. As the initial cost of CGA is quite high, less costly tests may appear more attractive; however, 
a judgement call would be required as to what QALY loss would be acceptable to a decision-
maker in order to generate cost savings.
Suggested research priorities
There are a number of potential areas in which further research and data would be useful.
  ■ The test performance results of the UK version of LIPOchip were hypothetical and were 
derived based on a small sample size from one centre where subjects had all been tested 
genetically. There was no evidence on the performance of LIPOchip version 10 across 
different regions of the UK or in different ethnic groups. Limited evidence was identified 
on the sensitivity of Elucigene FH20 across different regions of the UK and in different 
ethnic groups. As the UK has a population with a wide mutational spectrum, the sensitivity 
observed with these tests in different populations may vary. Therefore, a prospective 
multicentre study comparing the performance of Elucigene FH20 and LIPOchip with the 
LDL-C test in patients with a clinical diagnosis of FH based on the Simon Broome criteria, 
in which both test-positives and test-negatives are verified against a reference standard 
of CGA, would be informative. Such a study should also include subgroup analysis of the 
performance of the tests in different ethnic groups, if possible have a period of follow-up to 
allow provision of relevant longer-term clinical effectiveness outcomes and incorporate an 
economic evaluation. The economic evaluation should aim to include a measure of utility of 
diagnostic information, (especially in relation to the impact of false-negative or false-positive 
test results on quality-of-life estimates). Such information could be used to assess the impact 
on QALYs of future modelling exercises.
  ■ There is little evidence linking efficacy of statins in children to the onset of CHD. Although 
systematic reviews show that statins are efficacious in lowering cholesterol, we have assumed 
that this leads to similar reductions in cardiovascular events as in the young adult population 
group. There is a need to assess the relative risks of onset of disease in this group of patients.
  ■ There are many mutations that may have a varying impact in terms of risk of CHD. Evidence 
on the effect of these mutations is lacking and is an ongoing area of research. There is a © Queen’s Printer and Controller of HMSO 2012. This work was produced by Sharma et al. under the terms of a commissioning contract issued by the 
Secretary of State for Health.
95   Health Technology Assessment 2012; Vol. 16: No. 17 DOI: 10.3310/hta16170
need for a systematic review of all of the FH-causing mutations currently detectable in the 
UK population as a whole and in specific ethnic groups and their associated impact on 
risk of CHD.
  ■ There is a requirement for continuing research into finding new, as yet unknown, FH-causing 
genetic mutations. As only approximately 30–50% of patients with a clinical diagnosis have a 
mutation confirmed by genetic diagnosis, it is possible that there are many genetic causes of 
FH as yet undiscovered. This is an area that is progressing and further research is required to 
inform and update the positive detection rate of CGA based on ongoing clinical research.
  ■ It was outwith the scope of the review to consider tests such as iPLEX, which may also be 
used for detecting FH but are not as yet CE marked for this purpose. Therefore, further 
research into the diagnostic accuracy and cost-effectiveness of this test would be informative.© Queen’s Printer and Controller of HMSO 2012. This work was produced by Sharma et al. under the terms of a commissioning contract issued by the 
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Appendix 1 
Age-specific low-density lipoprotein 
cholesterol cut-offs for females
LDL-C cut-off (mmol/l)
Age (years) 
0–14  15–24  25–34  35–44  45–54  55+
5.3  5.3  5.3  5.3  5.3  5.3 
5.2  5.2  5.2  5.2  5.2  5.2 
5.1  5.1  5.1  5.1  5.1  5.1 
5.0  5.0  5.0  5.0  5.0  5.0 
4.9  4.9  4.9  4.9  4.9  4.9 
4.8  4.8  4.8  4.8  4.8  4.8 
4.7  4.7  4.7  4.7  4.7  4.7 
4.6  4.6  4.6  4.6  4.6  4.6 
4.5  4.5  4.5  4.5  4.5  4.5 
4.4  4.4  4.4  4.4  4.4  4.4 
4.3  4.3  4.3  4.3  4.3  4.3 
4.2  4.2  4.2  4.2  4.2  4.2 
4.1  4.1  4.1  4.1  4.1  4.1 
4.0  4.0  4.0  4.0  4.0  4.0 
3.9  3.9  3.9  3.9  3.9  3.9 
3.8  3.8  3.8  3.8  3.8  3.8 
3.7  3.7  3.7  3.7  3.7  3.7 
3.6  3.6  3.6  3.6  3.6  3.6 
3.5  3.5  3.5  3.5  3.5  3.5 
3.4  3.4  3.4  3.4  3.4  3.4 
3.3  3.3  3.3  3.3  3.3  3.3 
3.2  3.2  3.2  3.2  3.2  3.2 
Relatives with LDL-C levels in the unshaded zone are likely to have a clinical diagnosis of FH.
The diagnosis of FH for relatives in the lightly shaded zone is uncertain.
Relatives with LDL-C levels in the darker shaded zone are unlikely to have FH.’
[The NICE guideline used the following colour shading in this table: red zone (likely to have a clinical diagnosis of FH); grey zone (diagnosis 
uncertain; green zone (unlikely to have FH)].
Source: NICE.1© Queen’s Printer and Controller of HMSO 2012. This work was produced by Sharma et al. under the terms of a commissioning contract issued by the 
Secretary of State for Health.
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Appendix 2 
Age-specific low-density lipoprotein 
cholesterol cut-offs for males
LDL-C cut-off (mmol/l)
Age (years) 
0–14  15–24  25–34  35–44  45–54  55+
5.3  5.3  5.3  5.3  5.3  5.3 
5.2  5.2  5.2  5.2  5.2  5.2 
5.1  5.1  5.1  5.1  5.1  5.1 
5.0  5.0  5.0  5.0  5.0  5.0 
4.9  4.9  4.9  4.9  4.9  4.9 
4.8  4.8  4.8  4.8  4.8  4.8 
4.7  4.7  4.7  4.7  4.7  4.7 
4.6  4.6  4.6  4.6  4.6  4.6 
4.5  4.5  4.5  4.5  4.5  4.5 
4.4  4.4  4.4  4.4  4.4  4.4 
4.3  4.3  4.3  4.3  4.3  4.3 
4.2  4.2  4.2  4.2  4.2  4.2 
4.1  4.1  4.1  4.1  4.1  4.1 
4.0  4.0  4.0  4.0  4.0  4.0 
3.9  3.9  3.9  3.9  3.9  3.9 
3.8  3.8  3.8  3.8  3.8  3.8 
3.7  3.7  3.7  3.7  3.7  3.7 
3.6  3.6  3.6  3.6  3.6  3.6 
3.5  3.5  3.5  3.5  3.5  3.5 
3.4  3.4  3.4  3.4  3.4  3.4 
3.3  3.3  3.3  3.3  3.3  3.3 
3.2  3.2  3.2  3.2  3.2  3.2 
3.1  3.1  3.1  3.1  3.1  3.1 
3.0  3.0  3.0  3.0  3.0  3.0 
Relatives with LDL-C levels in the unshaded zone are likely to have a clinical diagnosis of FH.
The diagnosis of FH for relatives in the lightly shaded zone is uncertain.
Relatives with LDL-C levels in the darker shaded zone are unlikely to have FH.’
[The NICE guideline used the following colour shading in this table: red zone (likely to have a clinical diagnosis of FH); grey zone (diagnosis 
uncertain; green zone (unlikely to have FH)].
Source: NICE.1© Queen’s Printer and Controller of HMSO 2012. This work was produced by Sharma et al. under the terms of a commissioning contract issued by the 
Secretary of State for Health.
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Appendix 3 
Search strategy
Diagnostic accuracy and clinical effectiveness
MEDLINE (1948 to Week 1 2011), MEDLINE In-Process & Other Non-
Indexed Citations (10 January 2011), EMBASE (1980 to 2011 Week 1)
Ovid multifile search
URL: http://gateway.ovid.com
1.  Hyperlipoproteinemia Type II/di 
2.  familial hypercholesterolemia/di
3.  lipochip.tw.
4.  elucigene.tw.
5.  or/1-4
6.  Hyperlipoproteinemia Type II/ use prmz
7.  familial hypercholesterolemia/ use emez
8.  (autosomal dominant adj5 hypercholesterol?emia).tw.
9.  familial hypercholesterol?emia.tw.
10.  hyperlipoprotein?emia.tw.
11.  (familial adj5 apolipoprotein$).tw.
12.  or/6-11
13.  exp Genetic Predisposition to Disease/ use prmz
14.  Genetic Testing/
15.  Gene Amplification/ use prmz
16.  exp Gene Amplification/ use emez
17.  exp Nucleic Acid Amplification Techniques/ use prmz
18.  dna microarray/ use emez
19.  sequence analysis/ use emez
20.  exp polymerase chain reaction/
21.  exp sequence analysis/ use prmz
22.  base sequence/ use prmz
23.  (dna adj3 test$).tw.
24.  gene sequencing.tw.
25.  comprehensive genetic analysis.tw.
26.  mutation screen$.tw.
27.  direct sequencing.tw.
28.  fragment analysis.tw.
29.  (sanger adj3 (method or sequenc$)).tw.
30.  (target$ adj3 gene$ sequenc$).tw.
31.  (sequenc$ adj3 analysis).tw.
32.  (cascade adj3 (test$ or screen$)).tw.
33.  (genetic adj3 (test$ or screen$)).tw.
34.  (arms or amplification refractory mutation system).tw.
35.  (PCR or polymerase chain reaction).tw.
36.  Polymorphism, Single-Stranded Conformational/
37.  (sscp or single-stranded conformation polymorphism).tw.112 Appendix 3
38.  (mlpa or Multiplex ligation-dependent probe amplification).tw.
39.  (hrm or high resolution melt analysis).tw.
40.  (DGGE or denaturing gradient gel electrophoresis).tw.
41.  (dhplc or denaturing high performance liquid chromatography).tw.
42.  Cholesterol, LDL/ use prmz
43.  low density lipoprotein cholesterol/ use emez
44.  ldl-c.tw.
45.  simon broome.tw.
46.  or/13-45
47.  12 and 46
48.  “sensitivity and specificity”/
49.  roc curve/
50.  receiver operating characteristic/ use emez
51.  predictive value of tests/
52.  diagnostic errors/ use emez
53.  false positive reactions/ use prmz
54.  false negative reactions/ use prmz
55.  diagnostic accuracy/ use emez
56.  diagnostic value/ use emez
57.  du.fs. use prmz
58.  sensitivity.tw.
59.  distinguish$.tw.
60.  differentiat$.tw.
61.  identif$.tw.
62.  detect$.tw.
63.  diagnos$.tw.
64.  (predictive adj4 value$).tw.
65.  accura$.tw.
66.  comparison.tw.
67.  or/48-66
68.  47 and 67
69.  exp clinical trial/ use emez
70.  randomized controlled trial.pt.
71.  controlled clinical trial.pt.
72.  randomization/ use emez
73.  randomi?ed.ab.
74.  randomly.ab.
75.  trial.ab.
76.  groups.ab.
77.  or/69-76
78.  exp animals/ not humans/
79.  77 not 78
80.  79 and 47
81.  comparative study/ use prmz
82.  major clinical study/ use emez
83.  controlled study/ use emez
84.  clinical trial/ use emez
85.  (compare$ or compara$).tw.
86.  or/81-85
87.  86 and 47
88.  5 or 68 or 80 or 87
89.  remove duplicates from 88© Queen’s Printer and Controller of HMSO 2012. This work was produced by Sharma et al. under the terms of a commissioning contract issued by the 
Secretary of State for Health.
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90.  limit 89 to yr=“2000-current”
91.  limit 90 to english language
Science Citation Index (1970 to 10 January 2011), Conference Proceedings 
Citation Index – Science (1990 to 10 January 2011)
URL: www.isiknowledge.com
#1 TS=hyperlipoprotein*emia
#2  TS=(familial SAME hyperlipid*emia)
#3  TS=familial hypercholesterol*emia
#4  TS=((autosomal dominant) SAME hypercholesterol*emia)
#5  TS=(familial SAME apolipoprotein*)
#6  #5 OR #4 OR #3 OR #2 OR #1
#7  TS=low-density lipoprotein cholesterol
#8 TS=ldl-c
#9  TS=ldl cholesterol
#10  TS=simon broome
#11  TS=gene amplification
#12  TS= (DNA same “sequence analysis”)
#13  TS=(genetic SAME (test* or screen*))
#14  TS=(cascade SAME (test* or screen*))
#15  TS=mutation screen*
#16  TS=(#6 AND genetic analysis)
#17  TS=(#6 AND gene sequenc*)
#18  #17 OR #16 OR #15 OR #14 OR #13 OR #12 OR #11 OR #10 OR #9 OR #8 OR #7
#19  TS=(elucigene or lipochip)
#20  #18 and #6
#21  TS=(#6 SAME (diagnos* or test* or screen* or identif* or detect* or accura* or false 
positive or false negative))
#22  TS=(#6 SAME (trial* or random* or comparison or compare or comparative))
#23  #22 OR #21
#24  #23 AND #20
#25  #24 OR #19
#26  #24 OR #19 Refined by: Languages=(ENGLISH)
#27  #24 OR #19 Refined by: Languages=(ENGLISH) AND [excluding] Publication 
Years=(1999)
BIOSIS (1956 to 10 January 2011)
URL: www.isiknowledge.com
#1 TS=hyperlipoprotein*emia
#2  TS=(familial SAME hyperlipid*emia)
#3  TS=familial hypercholesterol*emia
#4  TS=((autosomal dominant) SAME hypercholesterol*emia)
#5  TS=(familial SAME apolipoprotein*)
#6  #5 OR #4 OR #3 OR #2 OR #1
#7 TS=ldl-c 
#8  TS=ldl cholesterol
#9  TS=simon broome
#10  TS=gene amplification
#11  TS= (DNA same “sequence analysis”)
#12  TS=(genetic SAME (test* or screen*))114 Appendix 3
#13  TS=(cascade SAME (test* or screen*))
#14  TS=(#6 AND genetic analysis)
#15  TS=(#6 AND gene sequenc*)
#16  TS=(#6 AND low-density lipoprotein cholesterol)
#17  TS=(#6 AND mutation screen*)
#18  #17 OR #16 OR #15 OR #14 OR #13 OR #12 OR #11 OR #10 OR #9 OR #8 OR #7
#19  TS=(elucigene or lipochip)
#20  #18 and #6
#21  TS=(#6 SAME (diagnos* or test* or screen* or identif* or detect* or accura* or false 
positive or false negative))
#22  TS=(#6 SAME (trial* or random* or comparison or compare or comparative))
#23  #22 OR #21
#24  #23 AND #20
#25  #24 OR #19
#26  #24 OR #19 Refined by: [excluding] Publication Years=(1999 OR 1998) AND 
Languages=(ENGLISH)
Cochrane Controlled Trials Register, Cochrane Database of Systematic 
Reviews (The Cochrane Library, Issue 1, 2011)
URL: www.thecochranelibrary.com
#1  MeSH descriptor Hyperlipoproteinemia Type II, this term only with qualifier: DI
#2 Lipochip
#3 Elucigene
#4  #1 or #2 or #3
#5  MeSH descriptor Hyperlipoproteinemia Type II, this term only
#6  MeSH descriptor Hyperlipidemia, Familial Combined, this term only
#7  familial hyperlipid*emia
#8  familial hypercholesterol*emia
#9  #5 or #6 or #7 or #8
#10  MeSH descriptor Genetic Predisposition to Disease explode tree 1
#11  MeSH descriptor Genetic Testing, this term only
#12  MeSH descriptor Gene Amplification, this term only
#13  MeSH descriptor Nucleic Acid Amplification Techniques explode all trees
#14  MeSH descriptor Oligonucleotide Array Sequence Analysis explode tree 4 
#15  MeSH descriptor Sequence Analysis, DNA explode all trees
#16  dna near/3 test*
#17  gene sequencing
#18  comprehensive genetic analysis
#19  target* near/3 gene* sequenc*
#20  sequenc* near/3 analysis
#21  cascade near/3 (test* or screen*)
#22  genetic near/3 (test$ or screen*)
#23  arms or “amplification refractory mutation system”
#24  PCR or “polymerase chain reaction”
#25  MeSH descriptor Polymorphism, Single-Stranded Conformational, this term only
#26  sscp or “single-stranded conformation polymorphism”
#27  mlpa or “Multiplex ligation-dependent probe amplification”
#28  MeSH descriptor Cholesterol, LDL, this term only
#29 ldl-c
#30  #10 or #11 or #12 or #13 or #14 or#15 or #16 or #17 or #18 or #19 or #20 or #21 or #22 or 
#23 or #24 or #25 or #26 or #27 or #28 or #29© Queen’s Printer and Controller of HMSO 2012. This work was produced by Sharma et al. under the terms of a commissioning contract issued by the 
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#31  (#9 AND #30)
#32  (#4 OR #31)
#33  (#32), from 2000 to 2010
Database of Abstracts of Reviews of Effects, Health Technology Assessment 
database (January 2011), Centre for Reviews and Dissemination
URL: www.york.ac.uk/inst/crd/ 
#1   MeSH Hyperlipoproteinemia Type II QUALIFIERS DI 
#2  elucigene OR lipochip
#3  #1 or #2
#4  MeSH Hyperlipoproteinemia Type II
#5  familial AND hypercholesterolemia
#6  familial AND hypercholesterolaemia
#7 hyperlipoproteinemia
#8 hyperlipoproteinaemia
#9  familial AND hyperlipidemia
#10  familial AND hyperlipidaemia
#11  #3 or #4 or #5 or #6 or #7 or #8 or #9 or #10
#12  #3 or #11 RESTRICT YR 2000 2011
ClinicalTrials.gov (December 2010)
URL: www.clinicaltrials.gov
familial hypercholesterolemia OR familial hypercholesterolaemia OR hyperlipoproteinemia type 
II OR familial combined hyperlipidemia
CenterWatch (December 2010)
URL: www.centerwatch.com
high cholesterol (hyperlipidemia)
Controlled Trials (December 2010)
URL: www.controlledtrials.com/mrct
familial hypercholesterolaemia OR familial hypercholesterolemia OR hyperlipoproteinemia 
type II OR hyperlipoproteinaemia type II OR familial combined hyperlipidemia OR familial 
combined hyperlipidaemia
International Clinical Trials Registry (December 2010)
URL: http://apps.who.int/trialsearch/
familial hypercholesterolaemia OR familial hypercholesterolemia OR hyperlipoproteinemia type 
II OR familial combined hyperlipidemia
Websites consulted
American Association for Clinical Chemistry (December 2010)
URL: www.aacc.org 
2010 annual meeting
2009 annual meeting116 Appendix 3
American Society of Human Genetics (December 2010)
URL: www.ashg.org 
2010 meeting
2009 meeting
Atherosclerosis Supplements (December 2010)
URL: www.sciencedirect.com/science/journal/15675688
78th European Atherosclerosis Society Congress, Atherosclerosis Supplements 2010;11(2)
XII Brazilian Congress of Atherosclerosis, Brazilian Society of Cardiology, Atherosclerosis 
Supplements 2009;10(3)
XV International Symposium on Atherosclerosis, Atherosclerosis Supplements 2009;10(2) 
European Society of Human Genetics (December 2010)
URL: www.eshg.org 
European Human Genetics Conference 2010, European Journal of Human Genetics 
2010;18(Suppl. 1)
European Human Genetics Conference 2009
https://www.eshg.org/eshg2009/abstracts.htm.
Fonazione Giovanni Lorenzini (December 2010)
URL: www.lorenzinifoundation.org 
4th International Conference of Biomarkers in Chronic Diseases (Diabetes, Obesity and 
Cardiovascular Diseases) 2010
National Genetics Reference Laboratory (December 2010)
URL: www.ngrl.org.uk/Wessex/tech_meeting10.html
New and Developing Technologies for Genetic Diagnostics ‘10
Cost-effectiveness
MEDLINE (1948 to Week 4 2011), MEDLINE In-Process & Other Non-
Indexed Citations (2 February 2011), EMBASE (1980 to 2011 Week 4)
Ovid multifile search
URL: http://gateway.ovid.com 
1.  Hyperlipoproteinemia Type II/di [Diagnosis]
2.  familial hypercholesterolemia/di
3.  lipochip.tw.
4.  elucigene.tw.
5.  or/1-4
6.  Hyperlipoproteinemia Type II/ use prmz
7.  familial hypercholesterolemia/ use emez
8.  (autosomal dominant adj5 hypercholesterol?emia).tw.
9.  familial hypercholesterol?emia.tw.© Queen’s Printer and Controller of HMSO 2012. This work was produced by Sharma et al. under the terms of a commissioning contract issued by the 
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10.  hyperlipoprotein?emia.tw.
11.  (familial adj5 apolipoprotein$).tw.
12.  or/6-11
13.  exp Genetic Predisposition to Disease/ use prmz
14.  Genetic Testing/
15.  Gene Amplification/ use prmz
16.  exp Gene Amplification/ use emez
17.  exp Nucleic Acid Amplification Techniques/ use prmz
18.  dna microarray/ use emez
19.  sequence analysis/ use emez
20.  exp polymerase chain reaction/
21.  exp sequence analysis/ use prmz
22.  base sequence/ use prmz
23.  (dna adj3 test$).tw.
24.  gene sequencing.tw.
25.  comprehensive genetic analysis.tw.
26.  mutation screen$.tw.
27.  direct sequencing.tw.
28.  fragment analysis.tw.
29.  (sanger adj3 (method or sequenc$)).tw.
30.  (target$ adj3 gene$ sequenc$).tw.
31.  (sequenc$ adj3 analysis).tw.
32.  (cascade adj3 (test$ or screen$)).tw.
33.  (genetic adj3 (test$ or screen$)).tw.
34.  (arms or amplification refractory mutation system).tw.
35.  (PCR or polymerase chain reaction).tw.
36.  Polymorphism, Single-Stranded Conformational/
37.  (sscp or single-stranded conformation polymorphism).tw.
38.  (mlpa or Multiplex ligation-dependent probe amplification).tw.
39.  (hrm or high resolution melt analysis).tw.
40.  (DGGE or denaturing gradient gel electrophoresis).tw.
41.  (dhplc or denaturing high performance liquid chromatography).tw.
42.  Cholesterol, LDL/ use prmz
43.  low density lipoprotein cholesterol/ use emez
44.  ldl-c.tw.
45.  simon broome.tw.
46.  or/13-45
47.  12 and 5 and 46
48.  exp “costs and cost analysis”/ use prmz
49.  economics/
50.  exp economic evaluation/ use emez
51.  exp models, economic/
52.  exp decision theory/
53.  ec.fs.
54.  monte carlo method/
55.  markov chains/
56.  exp health status indicators/
57.  cost$.ti.
58.  (cost$ adj2 (effective$ or utilit$ or benefit$ or minimis$)).ab.
59.  economic$ model$.tw.118 Appendix 3
60.  (price$ or pricing).tw.
61.  (financial or finance or finances or financed).tw.
62.  markov$.tw.
63.  monte carlo.tw.
64.  (decision$ adj2 (tree? or analy$ or model$)).tw.
65.  (standard adj1 gamble).tw.
66.  trade off.tw.
67.  or/48-66
68.  47 and 67
69.  limit 68 to yr=“2000 -Current”
70.  limit 69 to english language
71.  remove duplicates from 70
Science Citation Index (1970 to 2 February 2011), Conference Proceedings 
Citation Index – Science (1990 to 2 February 2011)
URL: www.isiknowledge.com
#1 TS=hyperlipoprotein*emia
#2  TS=(familial SAME hyperlipid*emia)
#3  TS=familial hypercholesterol*emia
#4  TS=((autosomal dominant) SAME hypercholesterol*emia)
#5  TS=(familial SAME apolipoprotein*)
#6  #5 OR #4 OR #3 OR #2 OR #1
#7  TS=low-density lipoprotein cholesterol
#8 TS=ldl-c
#9  TS=ldl cholesterol
#10  TS=simon broome
#11  TS=gene amplification
#12  TS= (DNA same “sequence analysis”)
#13  TS=(genetic SAME (test* or screen*))
#14  TS=(cascade SAME (test* or screen*))
#15  TS=mutation screen*
#16  TS=(#6 AND genetic analysis)
#17  TS=(#6 AND gene sequenc*)
#18  #17 OR #16 OR #15 OR #14 OR #13 OR #12 OR #11 OR #10 OR #9 OR #8 OR #7
#19  TS=(elucigene or lipochip)
#20  #18 and #6
#21  TS=(#20 AND economic*)
#22  TS=(#20 AND cost*)
#23  TS=(#20 AND price*)
#24  TS=(#20 AND pricing*)
#25  TS=(#20 AND financ*)
#26  TS=(#20 AND markov*)
#27  TS=(#20 AND monte carlo)
#28  TS=(decision SAME (tree* OR analy* OR model*))
#29  #28 OR #27 OR #26 OR #25 OR #24 OR #23 OR #22 OR #21
#30  #29 AND #20 
#31  #30 OR #19
#32  #30 OR #19 Refined by: Languages=( ENGLISH ) AND [excluding] Publication 
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NHS Economic Evaluation Database (February 2011), Centre for Reviews 
and Dissemination
URL: www.york.ac.uk/inst/crd/
#1  MeSH Hyperlipoproteinemia Type II QUALIFIERS DI 
#2  elucigene OR lipochip
#3  #1 or #2
#4  MeSH Hyperlipoproteinemia Type II
#5  familial AND hypercholesterolemia
#6  familial AND hypercholesterolaemia
#7 hyperlipoproteinemia
#8 hyperlipoproteinaemia
#9  familial AND hyperlipidemia
#10  familial AND hyperlipidaemia
#11  #3 or #4 or #5 or #6 or #7 or #8 or #9 or #10
#12  #3 or #11 RESTRICT YR 2000 2011
Cost-effectiveness Analysis Registry (February 2011)
URL: https://research.tufts-nemc.org/cear4/default.aspx 
Search terms: familial hypercholesterolaemia OR familial hypercholesterolemia
Quality-of-life and cost data for model
MEDLINE (1948 to Week 4 2011), MEDLINE In-Process & Other Non-
Indexed Citations (2 February 2011), EMBASE (1980 to 2011 Week 4)
Ovid multifile search
URL: http://gateway.ovid.com
1.  Hyperlipoproteinemia Type II/di [Diagnosis]
2.  familial hypercholesterolemia/di
3.  lipochip.tw.
4.  elucigene.tw.
5.  or/1-4
6.  Hyperlipoproteinemia Type II/ use prmz
7.  familial hypercholesterolemia/ use emez
8.  (autosomal dominant adj5 hypercholesterol?emia).tw.
9.  familial hypercholesterol?emia.tw.
10.  hyperlipoprotein?emia.tw.
11.  (familial adj5 apolipoprotein$).tw.
12.  or/6-11
13.  exp Genetic Predisposition to Disease/ use prmz
14.  Genetic Testing/
15.  Gene Amplification/ use prmz
16.  exp Gene Amplification/ use emez
17.  exp Nucleic Acid Amplification Techniques/ use prmz
18.  dna microarray/ use emez
19.  sequence analysis/ use emez
20.  exp polymerase chain reaction/
21.  exp sequence analysis/ use prmz120 Appendix 3
22.  base sequence/ use prmz
23.  (dna adj3 test$).tw.
24.  gene sequencing.tw.
25.  comprehensive genetic analysis.tw.
26.  mutation screen$.tw.
27.  direct sequencing.tw.
28.  fragment analysis.tw.
29.  (sanger adj3 (method or sequenc$)).tw.
30.  (target$ adj3 gene$ sequenc$).tw.
31.  (sequenc$ adj3 analysis).tw.
32.  (cascade adj3 (test$ or screen$)).tw.
33.  (genetic adj3 (test$ or screen$)).tw.
34.  (arms or amplification refractory mutation system).tw.
35.  (PCR or polymerase chain reaction).tw.
36.  Polymorphism, Single-Stranded Conformational/
37.  (sscp or single-stranded conformation polymorphism).tw.
38.  (mlpa or Multiplex ligation-dependent probe amplification).tw.
39.  (hrm or high resolution melt analysis).tw.
40.  (DGGE or denaturing gradient gel electrophoresis).tw.
41.  (dhplc or denaturing high performance liquid chromatography).tw.
42.  Cholesterol, LDL/ use prmz
43.  low density lipoprotein cholesterol/ use emez
44.  ldl-c.tw.
45.  simon broome.tw.
46.  or/13-45
47.  5 and 12 and 46
48.  quality of life/
49.  quality adjusted life year/
50.  “Value of Life”/ use prmz
51.  health status indicators/ use prmz
52.  health status/ use emez
53.  sickness impact profile/ use prmz
54.  disability evaluation/ use prmz
55.  disability/ use emez
56.  activities of daily living/ use prmz
57.  exp daily life activity/ use emez
58.  cost utility analysis/ use emez
59.  rating scale/
60.  questionnaires/
61.  (quality adj1 life).tw.
62.  quality adjusted life.tw.
63.  disability adjusted life.tw.
64.  (qaly? or qald? or qale? or qtime? or daly?).tw.
65.  (euroqol or euro qol or eq5d or eq 5d).tw.
66.  (hql or hqol or h qol or hrqol or hr qol).tw.
67.  (hye or hyes).tw.
68.  health$ year$ equivalent$.tw.
69.  (hui or hui1 or hui2 or hui3).tw.
70.  (health adj3 (utilit$ or disutili$)).tw.
71.  (health adj3 (state or status)).tw.
72.  (sf36 or sf 36 or short form 36 or shortform 36).tw.
73.  (sf6 or sf 6 or short form 6 or shortform 6).tw.© Queen’s Printer and Controller of HMSO 2012. This work was produced by Sharma et al. under the terms of a commissioning contract issued by the 
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74.  (sf12 or sf 12 or short form 12 or shortform 12).tw.
75.  (sf16 or sf 16 or short form 16 or shortform 16).tw.
76.  (sf20 or sf 20 or short form 20 or shortform 20).tw.
77.  willingness to pay.tw.
78.  standard gamble.tw.
79.  trade off.tw.
80.  conjoint analys?s.tw.
81.  discrete choice.tw.
82.  or/48-81
83.  47 and 82
84.  limit 83 to yr=“2000-current”
85.  limit 84 to english language
IDEAS (February 2011)
URL: http://ideas.repec.org/
Efficacy of statins
MEDLINE (1948 to Week 9 2011), MEDLINE In-Process & Other Non-
Indexed Citations (9 March 2011), EMBASE (1980 to 2011 Week 9)
Ovid multifile search
URL: http://gateway.ovid.com
1.  Hyperlipoproteinemia Type II/ use prmz
2.  familial hypercholesterolemia/ use emez
3.  (autosomal dominant adj5 hypercholesterol?emia).tw.
4.  familial hypercholesterol?emia.tw.
5.  hyperlipoprotein?emia.tw.
6.  (familial adj5 apolipoprotein$).tw.
7.  or/1-6
8.  exp Hydroxymethylglutaryl-CoA Reductase Inhibitors/ use prmz
9.  hydroxymethylglutaryl coenzyme A reductase inhibitor/ use emez
10.  Simvastatin/
11.  Pravastatin/
12.  rosuvastatin/ use emez
13.  fluindostatin/ use emez
14.  atorvastatin/ use emez
15.  (simvastatin or pravastatin or rosuvastatin or fluvastatin or atorvastatin or statin$).tw.
16.  hmg-coa.tw.
17.  or/8-12
18.  7 and 17
19.  exp animals/ not humans/
20.  18 not 19
21.  limit 20 to yr=“2008-current”
22.  2008$.ed.
23.  2008$.em.
24.  22 or 23
25.  20 and 24
26.  21 or 25
27.  (letter or comment or editorial).pt.
28.  26 not 27122 Appendix 3
29.  remove duplicates from 28
30.  limit 29 to english language
31.  limit 28 to yr=“2000-current”
Database of Abstracts of Reviews of Effects, NHS Economic Evaluation 
Database, Health Technology Assessment database (March 2011),  
Centre for Reviews and Dissemination
URL: www.york.ac.uk/inst/crd/ 
#1  MeSH Hyperlipoproteinemia Type II
#2  familial AND hypercholesterolemia 
#3  familial AND hypercholesterolaemia 
#4 hyperlipoproteinemia 
#5 hyperlipoproteinaemia 
#6  familial AND hyperlipidemia 
#7  familial AND hyperlipidaemia 
#8  #1 or #2 or #3 or #4 or #5 or #6 or #7
#9  MeSH Hydroxymethylglutaryl-CoA Reductase Inhibitors
#10  MeSH Simvastatin
#11  MeSH Pravastatin
#12  simvastatin OR pravastatin OR rosuvastatin OR fluvastatin OR atorvastatin OR statin* 
#13 hmg-coa 
#14  #9 or #10 or #11 or #12 or #13
#15  #8 and #14 RESTRICT YR 2000 2011
Cochrane Database of Systematic Reviews (The Cochrane Library, Issue 3, 2011)
URL: www.thecochranelibrary.com
#1  MeSH descriptor Hyperlipoproteinemia Type II, this term only
#2  MeSH descriptor Hyperlipidemia, Familial Combined, this term only
#3  familial hyperlipid*emia
#4  familial hypercholesterol*emia
#5  (#1 OR #2 OR #3 OR #4)
#6  MeSH descriptor Hydroxymethylglutaryl-CoA Reductase Inhibitors explode tree 1
#7  MeSH descriptor Simvastatin, this term only
#8  MeSH descriptor Pravastatin, this term only
#9  simvastatin OR pravastatin OR rosuvastatin OR fluvastatin OR atorvastatin OR statin*
#10 hmg-coa
#11  (#6 OR #7 OR #8 OR #9 OR #10)
#12  (#5 AND #11), from 2007 to 2011
Effect of mutation type on treatment choice
MEDLINE (1948 to March Week 1 2011), MEDLINE In-Process & Other Non-
Indexed Citations (14 March 2011), EMBASE (1980 to 2011 Week 10)
Ovid multifile search
URL: http://gateway.ovid.com
1.  Hyperlipoproteinemia Type II/ use prmz
2.  familial hypercholesterolemia/ use emez© Queen’s Printer and Controller of HMSO 2012. This work was produced by Sharma et al. under the terms of a commissioning contract issued by the 
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3.  (autosomal dominant adj5 hypercholesterol?emia).tw.
4.  familial hypercholesterol?emia.tw.
5.  hyperlipoprotein?emia.tw.
6.  (familial adj5 apolipoprotein$).tw.
7.  or/1-6
8.  Hyperlipoproteinemia Type II/dt [Drug Therapy]
9.  familial hypercholesterolemia/dt [Drug Therapy]
10.  or/8-9
11.  exp Mutation/
12.  (mutation$ adj2 variation$).tw.
13.  (mutation$ adj2 type$).tw.
14.  or/11-13
15.  Niacin/ use prmz
16.  nicotinic acid/ use emez
17.  (niacin or nicotonic acid).tw.
18.  exp Fibric Acids/ use prmz
19.  exp fibric acid derivative/ use emez
20.  fibrate$.tw.
21.  exp Fish Oils/ use prmz
22.  fish oil/ use emez
23.  omega 3 fatty acid/ use emez
24.  fish oil$.tw.
25.  omega 3.tw.
26.  exp Blood Component Removal/ use prmz
27.  exp apheresis/ use emez
28.  (aphersis or plasmapheresis).tw.
29.  resin/ use emez
30.  resin$.tw.
31.  ezetimibe/ use emez
32.  ezetimibe.tw.
33.  or/15-32
34.  10 and 14
35.  7 and 14 and 33
36.  34 or 35
37.  (comment or letter or editorial).pt.
38.  36 not 37
39.  limit 36 to english language
40.  limit 39 to yr=“2000 -Current”
41.  remove duplicates from 40
Cochrane Database of Systematic Reviews (The Cochrane Library, Issue 3, 2011)
URL: www.thecochranelibrary.com 
#1  MeSH descriptor Hyperlipoproteinemia Type II, this term only
#2  MeSH descriptor Hyperlipidemia, Familial Combined, this term only
#3  familial hyperlipid*emia
#4  familial hypercholesterol*emia
#5  (#1 OR #2 OR #3 OR #4)
#6  MeSH descriptor Hyperlipoproteinemia Type II, this term only with qualifier: DT
#7  MeSH descriptor Mutation explode all trees
#8  mutation* variation*124 Appendix 3
#9  mutation* type*
#10  (#7 OR #8 OR #9)
#11  (#5 AND #10)
#12  (#6 AND #10)
#13  (#11 OR #12)
Database of Abstracts of Reviews of Effects, NHS Economic Evaluation 
Database, Health Technology Assessment database (March 2011),  
Centre for Reviews and Dissemination
URL: www.york.ac.uk/inst/crd/
#1  MeSH Hyperlipoproteinemia Type II
#2  familial AND hypercholesterolemia 
#3  familial AND hypercholesterolaemia 
#4  familial AND hyperlipidemia 
#5  familial AND hyperlipidaemia 
#6  #1 #2 or #3 or #4 or #5 
#7  MeSH Hyperlipoproteinemia Type II QUALIFIERS DT
#8  MeSH Mutation EXPLODE 1
#9  mutation* AND type* 
#10  mutation* AND variation* 
#11  #8 or #9 or #10 
#12  #6 and #11
#13  #7 or #12
Utility of diagnostic information
MEDLINE (1996 to February Week 4 2011)
Ovid multifile search
URL: http://gateway.ovid.com 
1.  *genetic testing/ 
2.  *quality of life/px 
3.  *psychology/ 
4.  *patient satisfaction/ 
5.  *patient acceptance of health care/ 
6.  *attitude to health/ 
7.  *rating scale/ 
8.  *questionnaires/ 
9.  (quality adj1 life).tw
10.  (patient? adj1 (preferenc$ or experienc$ or perception$ or satisfaction$)).ti. 
11.  quality of life/ 
12.  quality adjusted life year/ 
13.  “Value of Life”/
14.  health status indicators/ 
15.  sickness impact profile/ 
16.  quality adjusted life.tw. 
17.  disability adjusted life.tw. 
18.  (qaly? or qald? or qale? or qtime? or daly?).tw. 
19.  (euroqol or euro qol or eq5d or eq 5d).tw
20.  (hql or hqol or h qol or hrqol or hr qol).tw. © Queen’s Printer and Controller of HMSO 2012. This work was produced by Sharma et al. under the terms of a commissioning contract issued by the 
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21.  (hye or hyes).tw
22.  health$ year$ equivalent$.tw
23.  (hui or hui1 or hui2 or hui3).tw. 
24.  (health adj3 (utilit$ or disutili$)).tw. 
25.  (health adj3 (state or status)).tw. 
26.  (sf36 or sf 36 or short form 36 or shortform 36).tw. 
27.  (sf6 or sf 6 or short form 6 or shortform 6).tw. 
28.  (sf12 or sf 12 or short form 12 or shortform 12).tw. 
29.  (sf16 or sf 16 or short form 16 or shortform 16).tw. 
30.  (sf20 or sf 20 or short form 20 or shortform 20).tw. 
31.  willingness to pay.tw. 
32.  standard gamble.tw. 
33.  trade off.tw. 
34.  conjoint analys?s.tw. 
35.  discrete choice.tw. 
36.  or/2-35 
37.  1 and 36 
38.  limit 37 to (english language and yr=“2000 -Current”)
Database of Abstracts of Reviews of Effects, NHS Economic Evaluation 
Database, Health Technology Assessment database (March 2011),  
Centre for Reviews and Dissemination
URL: www.york.ac.uk/inst/crd/ 
#1 MeSH Genetic Screening EXPLODE 1 2 3 4 5 6 7 RESTRICT YR 2000 2011
#2 cost:ty
#3 #1 NOT #2© Queen’s Printer and Controller of HMSO 2012. This work was produced by Sharma et al. under the terms of a commissioning contract issued by the 
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Appendix 4 
Data extraction form128 Appendix 4
Elucigene FH20 and LIPOchip for FH - data extraction form 
Reviewer ID:              Date: 
Administration details 
Study ID:                                                                                     Publication status:  
 
Other papers this study may link with: 
 
 
Aim of the study 
 
 
 
 
 
Test(s) reported 
                                                       Index cases              Cascade testing 
 
Elucigene 
 
LIPOchip 
 
LDL-C                      
 
Targeted gene sequencing 
                                                                                                  
*CGA                                   
                                                               
* includes DNA sequence analysis+ test for deletion/duplication+ analysis of APOB p.Arg3527Gln and 
PCSK9 p.Asp374Tyr using various techniques. 
 
Outcomes reported 
 
Diagnostic accuracy              Mutation detection rate             Clinical effectiveness 
 
Study details 
 
Cross-sectional comparative                           RCT                     Case control study 
 
Cross-sectional single test                                Other, please specify:  
 
 
Multicentre study?     Yes                No                If Yes, number of centres: 
 
Consecutive recruitment?     Yes             No              Not stated 
 
Country:  
 
Study dates:                                           
 
Length of follow up: 
 
Source of funding: 
Inclusion criteria: 
 
 
 
 
	 ﾠ 	 ﾠ
	 ﾠ 	 ﾠ
	 ﾠ 	 ﾠ
	 ﾠ
	 ﾠ 	 ﾠ
	 ﾠ 	 ﾠ 	 ﾠ
	 ﾠ 	 ﾠ 	 ﾠ
	 ﾠ
	 ﾠ
	 ﾠ 	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 ﾠ 	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Exclusion criteria: 
 
 
 
 
 
 
 
 
 
Baseline characteristics of participants 
 
Adults                           Children 
 
 
Criteria used for clinical diagnosis:   
 
Simon Broome              
 
Dutch              
 
Medped               
 
Other                                  specify the LDLC cut offs  used and definition  
 
 
Type of FH:   
 
Possible                                        Unclassified FH           
 
Definite                                           Not stated        
 
 
Heterozygous FH                           Homozygous FH 
                
 
Diagnosis of the Index cases confirmed by:   
 
Clinical test                                     Genetic test  
 
 
Who perform the clinical diagnosis?  
 
 
 
 
 
 
 
Number of participant/sample 
give detail of each type 
of FH if reported 
All  Index cases  Relatives 
Eligible 
 
  
     
	 ﾠ 	 ﾠ
	 ﾠ
	 ﾠ
	 ﾠ
	 ﾠ
	 ﾠ 	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Enrolled  
 
 
     
Analysed 
 
 
     
Received index test(s)  
 
 
     
Received comparator 
test(s) for index cases 
 
 
 
 
 
   
Received cascade test(s) 
1
st degree relatives  
2
nd degree relatives 
3
rd degree relatives 
     
Received comparator 
test(s)  
1
st degree relatives  
2
nd degree relatives 
3
rd degree relatives 
     
Age (mean/ median, SD, 
range) 
 
 
     
Receiving treatment for 
hyper- cholestorelaemia 
(specify treatment) 
     
Ethnicity  
 
 
 
     
Gender  
 
 
 
M: 
 
F: 
M: 
 
F: 
M: 
 
F: 
Tendon xanthomas       
Coronary Heart Disease 
 
 
     
Intervention tests 
Elucigene FH20 (Tepnel molecular diagnostics)                                  
 
If not FH20 which version and how many mutations was it designed to detect? 
 
 
 
Gel-based analysis                    Fluorescent analysis: 
 
 
Who carried out the test? 
 
 
Where was the test undertaken? 
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Time taken to obtain test results: 
 
 
Additional  information on the test: 
 
 
 
 
LIPOchip (Progenika Biopharma) 
 
If not version 10 which version and how many mutations was it designed to detect? 
 
 
Samples processed at: LIPOchip laboratory                       Other                   If other, please give details: 
 
 
Methodology used: 
 
DNA array  
 
Analysis for large gene re-arrangements 
 
Automated sequencing of the LDLR 
 
 
Who carried out the test? 
 
 
Where was the test undertaken? 
 
 
Time taken to obtain test results: 
 
 
Additional  information on the test: 
 
 
 
Comparator tests  
CGA (as defined on page 5 of the protocol) 
 
CGA should include following: 
 
          DNA sequence analysis of the promoter, all exons, the exon/intron boundaries and 
          into 3’ untranslated region of the LDLR gene  
 
Manufacturer and any other technical characteristics of the test: 
 
 
 
 
 
      
          MLPA for each exon and the promoter region  of the LDLR gene to detect deletions 
          and duplications  
          
Manufacturer and any other technical characteristics of the test: 
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          Analysis for the common APOB p.Arg3527Gin and PCSK9 p.Asp374Tyr gene 
          mutations 
 
Manufacturer and any other technical characteristics of the test: 
 
 
 
Who carried out the test? 
 
 
 
Where was the test undertaken? 
 
 
 
Time taken to obtain test results: 
 
 
 
Additional  information on the test: 
 
 
 
 
 
 
 
 
 
LDL-C concentration 
 
Estimated from a fasting blood sample using the Friedwald equation?  Yes             No  
 
If No please specify method used: 
 
 
 
For cascade test please specify age and gender specific LDL-C cut offs:  
 
 
 
No. of times LDL-C was measured?  Once             Twice             Not stated 
 
 
Criteria used to define a positive test result:  
 
 
Who carried out the test? 
 
 
Where was the test undertaken? 
 
 
Time taken to obtain test results: 
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Additional  information on the test: 
 
 
 
 
 
 
If targeted gene sequencing of relatives was undertaken, please give details: 
 
 
 
 
 
 
 
 
 
Reference standard test 
 
Was there a reference standard test that consisted of either of the followings? 
 
CGA in combination with Simon Broome criteria   
 
CGA only  
 
Simon Broome only  
 
Results for Index cases 
 
1.  Genetic test …………………….. 
  LDLR  APOB  PCSK9  MLPA  sequencing  Total  
Number of 
participants 
 
 
 
 
         
Number of 
samples analysed 
 
 
 
 
         
n/N (%)  with 
mutation detected 
 
 
 
 
         
n/N (%) with no 
mutation detected 
  
 
 
 
         
 
2.   Genetic test …………………….. 
Number of 
participants 
 
 
           
Number of 
samples analysed 
 
 
           
n/N (%)  with 
mutation detected 
           
n/N (%) with no 
mutation detected 
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3.  LDL-C as a clinical test  
Number of 
participants 
 
 
           
Number of 
samples analysed 
 
           
Number of FH 
diagnosed  
 
 
           
Number of FH not 
diagnosed 
 
 
           
Results for Cascade test 
 
Specify the genetic test…………………….. 
Number of 
participants 
(Index cases) 
           
Number of 
samples analysed 
 
 
 
 
         
Number of 
families tested 
 
           
n/N (%) with 
mutation detected 
 
           
n/N (%) with no 
mutation detected 
  
 
 
 
         
 
LDL-C age and sex specific test 
Number of 
participants 
(Index cases) 
           
Number of 
samples analysed 
 
           
Number of 
families tested 
 
           
Number of FH 
diagnosed 
 
           
Number of FH not 
diagnosed 
 
 
           
Record data on each level of analysis containing 2x2 tables of  true and false positives and negatives 
for  
Test accuracy of genetic test (Elucigene/Lipochip) vs genetic test (CGA) 
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Subgroup analysis reported (e.g. ethnicity)?  Yes                 No     
 
If Yes please give details: 
 
 
 
 
 
 
 
Give details of any clinical effectiveness outcomes reported, e.g. cholesterol levels following 
treatment, CHD events etc or probability of true FH:   
 
 
 
 
 
 
 
 
 
 
 
Give details of any information reported on acceptability and/or interpretability of the tests 
 
 
 
 
 
 
 
 
 
 
 
Additional information: 
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Appendix 5 
Modified QUADAS checklist
Item Yes No Unclear
1 Was the spectrum of patients representative of the patients who will receive the test in 
practice?
2 Is the reference standard likely to correctly classify the target condition?a
3 Did the whole sample or a random selection of the sample receive verification using a 
reference standard of diagnosis?
4 Did patients receive the same reference standard regardless of the index test result?
5 Was the reference standard independent of the index test (i.e. the index test did not form part 
of the reference standard)? 
6 Were the index test results interpreted without knowledge of the results of the reference 
standard? 
7 Were the reference standard results interpreted without knowledge of the results of the index 
test?
8 Were the same clinical data available when test results were interpreted as would be available 
when the test is used in practice?b
9 Were uninterpretable/intermediate/test results reported? 
10 Were withdrawals from the study explained? 
11 Were cut-off values established before the study was started?
12 Is the technology of the index test unchanged since the study was carried out?
13 Did the study provide a clear definition of what was considered to be a ‘positive’ result?c
a  ‘Yes’ if studies reported the following: (1) DNA sequence analysis of the promoter, all exons, the exon/intron boundaries and into the 3′ 
untranslated region of the LDLR gene; (2) MLPA for each exon and the promoter region of the LDLR gene to detect deletions and duplications; 
and (3) APOB analysis.
b  ‘Yes’ if studies reporting on clinical diagnosis also include personal and family history of cardiovascular diseases and hyperlipidaemia.
c  For FH diagnosed clinically only.
Please also note if the paper reported details of any of the following issues:
  ■ MLPA: the location of probes in the intron; single nucleotide polymorphism (SNP) at probe 
binding site
  ■ Elucigene FH20: inadequate electrophoretic separation and misidentification of the 
FH20 mutations
  ■ LIPOchip: assessment of batch capacity; assessment of training requirements; assessment of 
instrumentation required, maintenance, etc.© Queen’s Printer and Controller of HMSO 2012. This work was produced by Sharma et al. under the terms of a commissioning contract issued by the 
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Appendix 6 
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Appendix 7 
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t
y
p
e
:
 
a
b
s
t
r
a
c
t
O
t
h
e
r
 
r
e
l
a
t
e
d
 
r
e
p
o
r
t
s
:
 
S
t
e
f
 
2
0
1
0
5
2
 
(
p
r
e
s
e
n
t
a
t
i
o
n
 
f
r
o
m
 
P
r
o
g
e
n
i
k
a
 
B
i
o
p
h
a
r
m
a
)
,
 
p
l
u
s
 
s
o
m
e
 
a
d
d
i
t
i
o
n
a
l
 
d
a
t
a
 
f
r
o
m
 
P
r
o
g
e
n
i
k
a
 
B
i
o
p
h
a
r
m
a
N
u
m
b
e
r
 
o
f
 
s
t
u
d
y
 
c
e
n
t
r
e
s
:
 
2
S
e
t
t
i
n
g
:
 
N
R
C
o
u
n
t
r
y
:
 
U
K
 
R
e
c
r
u
i
t
m
e
n
t
 
d
a
t
e
:
P
a
t
i
e
n
t
s
 
r
e
c
r
u
i
t
e
d
 
c
o
n
s
e
c
u
t
i
v
e
l
y
,
 
Y
/
N
:
S
o
u
r
c
e
 
o
f
 
f
u
n
d
i
n
g
:
 
P
r
o
g
e
n
i
k
a
 
B
i
o
p
h
a
r
m
a
S
t
e
f
 
2
0
1
0
:
5
2
 
s
a
m
p
l
e
s
 
f
r
o
m
 
t
w
o
 
c
e
n
t
r
e
s
 
w
e
r
e
 
i
n
c
l
u
d
e
d
 
(
N
e
w
c
a
s
t
l
e
 
a
n
d
 
W
a
l
e
s
)
;
 
h
o
w
e
v
e
r
,
 
t
h
e
 
W
e
l
s
h
 
s
a
m
p
l
e
s
 
d
o
 
n
o
t
 
h
a
v
e
 
i
n
f
o
r
m
a
t
i
o
n
 
o
n
 
c
l
i
n
i
c
a
l
 
d
i
a
g
n
o
s
i
s
 
a
n
d
 
a
l
s
o
 
d
o
 
n
o
t
 
h
a
v
e
 
p
r
e
v
i
o
u
s
 
g
e
n
e
t
i
c
 
d
i
a
g
n
o
s
i
s
 
(
a
c
c
o
r
d
i
n
g
 
t
o
 
r
e
s
p
o
n
s
e
 
t
o
 
q
u
e
r
i
e
s
 
f
r
o
m
 
t
h
e
 
m
a
n
u
f
a
c
t
u
r
e
r
)
,
 
h
e
n
c
e
 
s
t
u
d
y
 
w
a
s
 
n
o
t
 
i
n
c
l
u
d
e
d
 
f
o
r
 
t
h
e
 
r
e
v
i
e
w
 
p
u
r
p
o
s
e
I
n
c
l
u
s
i
o
n
 
c
r
i
t
e
r
i
a
:
 
D
N
A
 
s
a
m
p
l
e
s
 
f
r
o
m
 
p
a
t
i
e
n
t
s
 
w
i
t
h
 
c
l
i
n
i
c
a
l
 
d
i
a
g
n
o
s
i
s
 
b
a
s
e
d
 
o
n
 
S
i
m
o
n
 
B
r
o
o
m
e
 
c
r
i
t
e
r
i
a
 
a
n
d
 
p
r
e
v
i
o
u
s
l
y
 
t
e
s
t
e
d
 
w
i
t
h
 
g
e
n
e
t
i
c
 
t
e
s
t
 
(
A
R
M
S
 
+
 
S
S
C
P
/
d
H
P
L
C
/
d
i
r
e
c
t
 
s
e
q
u
e
n
c
i
n
g
 
+
 
M
L
P
A
)
E
x
c
l
u
s
i
o
n
 
c
r
i
t
e
r
i
a
:
 
N
R
C
l
i
n
i
c
a
l
 
d
i
a
g
n
o
s
i
s
:
 
S
i
m
o
n
 
B
r
o
o
m
e
 
c
r
i
t
e
r
i
a
F
H
 
d
i
a
g
n
o
s
i
s
:
 
N
R
I
n
d
e
x
 
c
a
s
e
s
E
n
r
o
l
l
e
d
,
 
n
1
2
6
A
n
a
l
y
s
e
d
,
 
n
1
2
0
T
e
s
t
 
1
:
 
L
I
P
O
c
h
i
p
 
p
l
a
t
f
o
r
m
 
c
o
n
s
i
s
t
i
n
g
 
o
f
 
t
w
o
 
s
t
a
g
e
s
:
S
t
a
g
e
 
1
 
(
i
n
d
e
x
 
t
e
s
t
)
:
 
L
I
P
O
c
h
i
p
 
v
e
r
s
i
o
n
 
8
 
d
e
t
e
c
t
s
 
p
o
i
n
t
 
m
u
t
a
t
i
o
n
s
 
i
n
 
t
h
e
 
L
D
L
R
,
 
A
P
O
B
 
a
n
d
 
P
C
S
K
9
 
g
e
n
e
s
 
a
n
d
 
c
o
p
y
 
n
u
m
b
e
r
 
c
h
a
n
g
e
s
 
i
n
 
t
h
e
 
L
D
L
R
 
g
e
n
e
.
 
I
n
c
l
u
d
e
s
 
2
5
1
 
m
u
t
a
t
i
o
n
s
 
m
o
s
t
 
p
r
e
v
a
l
e
n
t
 
i
n
 
S
p
a
i
n
,
 
t
h
e
 
N
e
t
h
e
r
l
a
n
d
s
,
 
N
o
r
w
a
y
,
 
I
t
a
l
y
 
a
n
d
 
t
h
e
 
U
K
S
t
a
g
e
 
2
 
(
c
o
m
p
o
n
e
n
t
 
o
f
 
C
G
A
)
:
 
s
e
q
u
e
n
c
i
n
g
 
o
f
 
L
D
L
R
 
i
f
 
n
o
 
m
u
t
a
t
i
o
n
 
w
a
s
 
d
e
t
e
c
t
e
d
 
b
y
 
L
I
P
O
c
h
i
p
T
e
s
t
 
2
:
 
g
e
n
e
t
i
c
 
s
c
r
e
e
n
i
n
g
 
i
n
 
t
h
r
e
e
 
s
t
a
g
e
s
 
(
C
G
A
)
:
S
t
a
g
e
 
1
:
 
E
l
u
c
i
g
e
n
e
 
(
A
P
O
B
,
 
P
C
S
K
9
 
i
n
c
l
u
d
e
d
)
 
S
t
a
g
e
 
2
:
 
S
S
C
P
/
d
H
P
L
C
/
d
i
r
e
c
t
 
s
e
q
u
e
n
c
i
n
g
 
o
f
 
a
l
l
 
e
x
o
n
s
 
i
f
 
n
o
 
m
u
t
a
t
i
o
n
 
w
a
s
 
d
e
t
e
c
t
e
d
S
t
a
g
e
 
3
:
 
M
L
P
A
 
i
f
 
n
o
 
m
u
t
a
t
i
o
n
 
w
a
s
 
d
e
t
e
c
t
e
d
T
e
s
t
 
1
T
e
s
t
 
2
S
t
a
g
e
 
1
S
t
a
g
e
 
2
E
n
r
o
l
l
e
d
,
 
n
1
2
6
1
2
6
 
m
u
t
a
t
i
o
n
 
p
o
s
i
t
i
v
e
R
e
c
e
i
v
e
d
 
t
e
s
t
,
 
n
1
2
0
8
9
 
P
a
t
i
e
n
t
s
 
w
i
t
h
 
m
u
t
a
t
i
o
n
 
d
e
t
e
c
t
e
d
 
b
y
 
e
a
c
h
 
t
e
s
t
D
i
a
g
n
o
s
t
i
c
 
a
c
c
u
r
a
c
y
T
i
m
e
 
t
a
k
e
n
 
t
o
 
o
b
t
a
i
n
 
p
o
s
i
t
i
v
e
 
r
e
s
u
l
t
s
 
w
i
t
h
 
L
I
P
O
c
h
i
p
 
p
l
a
t
f
o
r
m
 
(
t
e
s
t
 
w
a
s
 
p
e
r
f
o
r
m
e
d
 
b
y
 
P
r
o
g
e
n
i
k
a
 
i
n
 
S
p
a
i
n
)
L
I
P
O
c
h
i
p
 
U
K
 
v
e
r
s
i
o
n
 
1
0
 
w
a
s
 
d
e
v
e
l
o
p
e
d
 
b
y
 
a
n
a
l
y
s
i
n
g
 
1
0
0
0
 
p
a
t
i
e
n
t
s
 
f
r
o
m
 
s
e
v
e
r
a
l
 
c
o
h
o
r
t
s
.
 
T
h
e
 
c
h
i
p
 
c
o
n
t
a
i
n
s
 
t
h
e
 
m
o
s
t
 
f
r
e
q
u
e
n
t
 
m
u
t
a
t
i
o
n
s
 
f
o
u
n
d
 
i
n
 
t
h
e
 
U
K
 
a
s
 
w
e
l
l
 
a
s
 
h
a
v
i
n
g
 
t
h
e
 
a
b
i
l
i
t
y
 
t
o
 
d
e
t
e
c
t
 
c
o
p
y
 
n
u
m
b
e
r
 
c
h
a
n
g
e
s
 
i
n
 
t
h
e
 
L
D
L
R
 
g
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n
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S
t
u
d
y
 
d
e
t
a
i
l
s
P
a
r
t
i
c
i
p
a
n
t
s
 
T
e
s
t
 
c
h
a
r
a
c
t
e
r
i
s
t
i
c
s
O
u
t
c
o
m
e
s
 
r
e
p
o
r
t
e
d
C
o
m
m
e
n
t
s
S
t
a
r
r
 
2
0
0
8
4
9
S
t
u
d
y
 
d
e
s
i
g
n
:
 
c
r
o
s
s
-
s
e
c
t
i
o
n
a
l
 
c
o
m
p
a
r
a
t
i
v
e
,
 
r
e
t
r
o
s
p
e
c
t
i
v
e
P
u
b
l
i
c
a
t
i
o
n
 
t
y
p
e
:
 
f
u
l
l
 
t
e
x
t
O
t
h
e
r
 
r
e
p
o
r
t
s
 
t
h
i
s
 
p
a
p
e
r
 
m
a
y
 
l
i
n
k
 
w
i
t
h
:
 
L
e
r
e
n
 
2
0
0
4
5
3
 
(
N
o
r
w
a
y
)
,
 
U
m
a
n
s
-
E
c
k
e
n
h
a
u
s
e
n
 
2
0
0
1
1
9
 
 
(
t
h
e
 
N
e
t
h
e
r
l
a
n
d
s
)
,
 
D
a
m
g
a
a
r
d
 
2
0
0
5
4
5
 
(
D
e
n
m
a
r
k
)
;
 
s
a
m
p
l
e
s
 
c
o
m
e
 
f
r
o
m
 
t
h
e
s
e
 
s
t
u
d
i
e
s
.
N
u
m
b
e
r
 
o
f
 
s
t
u
d
y
 
c
e
n
t
r
e
s
:
 
3
S
e
t
t
i
n
g
:
 
l
i
p
i
d
 
c
l
i
n
i
c
s
C
o
u
n
t
r
y
:
 
U
K
R
e
c
r
u
i
t
m
e
n
t
 
d
a
t
e
:
 
N
R
P
a
t
i
e
n
t
s
 
r
e
c
r
u
i
t
e
d
 
c
o
n
s
e
c
u
t
i
v
e
l
y
,
 
Y
/
N
:
 
N
R
S
o
u
r
c
e
s
 
o
f
 
f
u
n
d
i
n
g
:
 
D
e
p
a
r
t
m
e
n
t
 
o
f
 
H
e
a
l
t
h
,
 
B
r
i
t
i
s
h
 
H
e
a
r
t
 
F
o
u
n
d
a
t
i
o
n
.
 
O
n
e
 
a
u
t
h
o
r
 
s
u
p
p
o
r
t
e
d
 
b
y
 
t
h
e
 
D
e
p
a
r
t
m
e
n
t
 
o
f
 
T
r
a
d
e
 
a
n
d
 
I
n
d
u
s
t
r
y
 
f
o
r
 
t
h
e
 
I
D
E
A
S
 
G
e
n
e
t
i
c
s
 
K
n
o
w
l
e
d
g
e
 
P
a
r
k
I
n
c
l
u
s
i
o
n
 
c
r
i
t
e
r
i
a
:
 
a
 
d
a
t
a
 
s
e
t
 
o
f
 
a
 
c
o
h
o
r
t
 
o
f
 
r
e
l
a
t
i
v
e
s
 
o
f
 
k
n
o
w
n
 
m
u
t
a
t
i
o
n
 
s
t
a
t
u
s
 
(
p
r
e
v
i
o
u
s
l
y
 
g
e
n
e
t
i
c
a
l
l
y
 
t
e
s
t
e
d
)
 
f
r
o
m
 
a
 
E
u
r
o
p
e
a
n
 
c
o
u
n
t
r
y
 
(
t
h
e
 
N
e
t
h
e
r
l
a
n
d
s
,
 
N
o
r
w
a
y
,
 
D
e
n
m
a
r
k
)
E
x
c
l
u
s
i
o
n
 
c
r
i
t
e
r
i
a
:
 
t
h
o
s
e
 
o
n
 
l
i
p
i
d
-
l
o
w
e
r
i
n
g
 
t
h
e
r
a
p
y
,
 
n
o
n
-
f
a
s
t
i
n
g
 
s
a
m
p
l
e
s
 
a
n
d
 
t
h
o
s
e
 
w
i
t
h
 
t
r
i
g
l
y
c
e
r
i
d
e
 
l
e
v
e
l
s
 
o
f
 
>
 
2
 
m
m
o
l
/
l
P
a
r
t
i
c
i
p
a
n
t
s
:
 
fi
r
s
t
-
d
e
g
r
e
e
 
r
e
l
a
t
i
v
e
s
 
w
i
t
h
 
k
n
o
w
n
 
m
u
t
a
t
i
o
n
a
l
 
s
t
a
t
u
s
 
o
f
 
F
H
 
i
n
d
e
x
 
c
a
s
e
s
 
i
n
 
w
h
o
m
 
a
 
m
u
t
a
t
i
o
n
 
h
a
d
 
b
e
e
n
 
f
o
u
n
d
C
l
i
n
i
c
a
l
 
d
i
a
g
n
o
s
i
s
:
 
b
a
s
e
d
 
o
n
 
D
u
t
c
h
 
c
r
i
t
e
r
i
a
 
(
t
h
e
 
N
e
t
h
e
r
l
a
n
d
s
)
;
 
a
 
c
o
m
b
i
n
a
t
i
o
n
 
o
f
 
l
i
p
i
d
 
l
e
v
e
l
s
,
 
c
l
i
n
i
c
a
l
 
c
h
a
r
a
c
t
e
r
i
s
t
i
c
s
 
a
n
d
 
f
a
m
i
l
y
 
h
i
s
t
o
r
y
 
(
N
o
r
w
a
y
 
a
n
d
 
D
e
n
m
a
r
k
)
F
H
 
d
i
a
g
n
o
s
i
s
:
 
d
e
fi
n
i
t
e
 
F
H
 
o
r
 
p
o
s
s
i
b
l
e
 
F
H
T
h
e
 
N
e
t
h
e
r
l
a
n
d
s
 
M
u
t
+
M
u
t
–
E
n
r
o
l
l
e
d
,
 
n
8
2
5
2
4
6
9
A
n
a
l
y
s
e
d
,
 
n
8
2
5
2
4
6
9
A
g
e
,
 
y
e
a
r
s
,
 
 
m
e
a
n
 
(
S
D
)
3
0
.
7
 
(
1
8
.
1
)
4
2
.
8
 
(
1
9
.
3
)
S
e
x
,
 
M
 
%
5
0
4
4
L
D
L
-
C
,
 
m
m
o
l
/
l
,
 
 
m
e
a
n
 
(
S
D
)
 
4
.
3
6
 
(
1
.
3
9
)
3
.
0
2
 
(
0
.
9
4
)
T
C
,
 
m
m
o
l
/
l
,
 
 
m
e
a
n
 
(
S
D
)
 
6
.
2
3
 
(
1
.
4
3
)
4
.
9
9
 
(
1
.
0
5
)
D
e
n
m
a
r
k
M
u
t
+
M
u
t
–
A
n
a
l
y
s
e
d
,
 
n
1
6
0
1
6
1
A
g
e
,
 
y
e
a
r
s
,
 
m
e
a
n
 
(
S
D
)
3
5
.
5
 
(
1
5
.
0
)
4
1
.
2
 
(
1
6
.
9
)
S
e
x
,
 
M
 
%
4
4
4
3
L
D
L
-
C
,
 
m
m
o
l
/
l
,
 
 
m
e
a
n
 
(
S
D
)
 
5
.
7
2
 
(
1
.
8
6
)
3
.
5
6
 
(
1
.
1
4
)
T
C
,
 
m
m
o
l
/
l
,
 
 
m
e
a
n
 
(
S
D
)
 
7
.
7
4
 
(
1
.
8
8
)
5
.
6
4
 
(
1
.
2
8
)
T
e
s
t
 
1
:
 
C
G
A
 
(
D
G
G
E
/
d
i
r
e
c
t
 
s
e
q
u
e
n
c
i
n
g
/
P
C
R
 
o
r
 
s
c
r
e
e
n
i
n
g
 
o
f
 
t
h
r
e
e
 
c
o
m
m
o
n
 
m
u
t
a
t
i
o
n
s
 
i
n
 
D
a
n
i
s
h
 
p
o
p
u
l
a
t
i
o
n
/
S
S
C
P
/
s
e
q
u
e
n
c
i
n
g
/
M
L
P
A
 
o
r
 
s
e
q
u
e
n
c
i
n
g
/
M
L
P
A
)
T
e
s
t
 
2
:
 
l
i
p
i
d
 
t
e
s
t
s
T
h
e
 
N
e
t
h
e
r
l
a
n
d
s
:
 
b
l
o
o
d
 
s
a
m
p
l
e
 
m
e
a
s
u
r
e
d
 
u
s
i
n
g
 
c
h
o
l
e
s
t
e
r
o
l
 
a
n
a
l
y
s
i
s
 
e
q
u
i
p
m
e
n
t
 
(
c
a
l
i
b
r
a
t
e
d
)
.
 
S
u
b
j
e
c
t
s
 
r
e
f
r
a
i
n
e
d
 
f
r
o
m
 
e
a
t
i
n
g
 
f
o
r
 
2
 
h
o
u
r
s
 
b
e
f
o
r
e
 
t
e
s
t
N
o
r
w
a
y
:
 
c
h
o
l
e
s
t
e
r
o
l
 
w
a
s
 
m
e
a
s
u
r
e
d
 
u
s
i
n
g
 
R
o
c
h
e
 
m
o
d
u
l
a
r
 
P
i
n
s
t
r
u
m
e
n
t
 
(
m
e
t
h
o
d
 
s
t
a
n
d
a
r
d
i
s
e
d
)
.
 
R
e
s
u
l
t
s
 
f
r
o
m
 
n
o
n
-
f
a
s
t
i
n
g
 
s
a
m
p
l
e
s
 
e
x
c
l
u
d
e
d
D
e
n
m
a
r
k
:
 
v
a
l
i
d
a
t
e
d
 
w
i
t
h
 
r
e
f
e
r
e
n
c
e
 
s
t
a
n
d
a
r
d
L
D
L
-
C
 
w
a
s
 
c
a
l
c
u
l
a
t
e
d
 
a
c
c
o
r
d
i
n
g
 
t
o
 
t
h
e
 
F
r
i
e
d
w
a
l
d
 
f
o
r
m
u
l
a
A
g
e
-
 
a
n
d
 
g
e
n
d
e
r
-
s
p
e
c
i
fi
c
 
L
D
L
-
C
 
c
u
t
-
o
f
f
s
 
a
c
c
o
r
d
i
n
g
 
t
o
 
N
I
C
E
 
g
u
i
d
e
l
i
n
e
 
u
s
e
d
T
e
s
t
 
3
:
 
M
e
d
P
e
d
 
a
g
e
-
s
p
e
c
i
fi
c
 
L
D
L
-
C
 
c
u
t
-
o
f
f
s
 
f
o
r
 
r
e
l
a
t
i
v
e
s
F
o
r
 
a
l
l
 
t
e
s
t
s
:
R
e
c
e
i
v
e
d
 
t
e
s
t
,
 
n
M
u
t
+
M
u
t
–
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Appendix 9 
Quality assessment results for the individual 
studies (full text)
Q1 Q2 Q3 Q4 Q5 Q6 Q7 Q8a Q9 Q10 Q11a Q12 Q13a
Taylor 201037 + + – – + + ? N/A – – N/A + N/A
Alonso 200939 + + – – + + ? N/A – – N/A – N/A
Tejedor 200543 + – – – + ? ? N/A – – N/A – N/A
Civeira 200844 + + + – + + ? + – – + + +
Damgaard 
200545
+ + + + + ? ? + + – + + +
Mabuchi 200546 ? – + + + ? ? + – – – + –
bStarr 200849 + + + + + – + + – – – + –
Widhalm 200747 + – + + + + ? + – – + + +
Wiegman 200350 + – + + + ? ? + – – – + –
+ ,yes; –, no; ?, unclear; N/A, not applicable.
a  Questions 8, 11 and 13 were considered to be not applicable to studies reporting Elucigene FH20 or LIPOchip because the Elucigene and 
LIPOchip test results do not require subjective interpretation (Q8), the tests either detect a mutation or do not detect a mutation, there are no 
cut-off levels (Q11), and because a result is either positive or negative there is no need to provide a definition of a positive result (Q13).
b  Of the three cohorts included in the study, two had the complete reference standard (Denmark, Norway) but one did not receive the MLPA test. 
With consensus this was judged as ‘yes’ by two reviewers.
The questions were: Q1, Spectrum representative?; Q2, Reference standard correctly classifies condition?; Q3, Partial verification bias avoided?; 
Q4, Differential verification bias avoided?; Q5, Incorporation bias avoided?; Q6, Test review bias avoided?; Q7, Diagnostic review bias avoided?; 
Q8, Clinical review bias avoided?; Q9, Uninterpretable results reported?; Q10, Withdrawals explained?; Q11, Cut-offs established before study 
started?; Q12, Index test technology unchanged since study?; Q13, Clear definition of ‘positive’ result?.© Queen’s Printer and Controller of HMSO 2012. This work was produced by Sharma et al. under the terms of a commissioning contract issued by the 
Secretary of State for Health.
175   Health Technology Assessment 2012; Vol. 16: No. 17 DOI: 10.3310/hta16170
Appendix 10 
Individual study results for Elucigene 
FH20/LIPOchip176 Appendix 10
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TABLE 35a  Mutational-level analysis: analytical accuracy of LIPOchip as reported in the paper
Study Criteria Total, n Mutation samples  TP FP TN FN
Sensitivity 
(%)
Specificity 
(%)
Alonso 200939 Dutch criteria 
– DFH or 
probable FH
808 phenotyped 
cases
178 real positive calls; 
442 real negative calls
177 1 441 1 99.8 99.5
Tejedor 200543 Dutch–MedPed 
criteria
1180 genotyped; 
407 blind 
phenotyped 
samples
118 of the LDLR 
mutations tested 
with 1180 previously 
sequenced DNA 
samples and 10 
control DNA samples
NR NR NR NR 99.9 99.7
Manufacturer 
data for version 
10 LIPOchip
Against the mutation 
already present in 
LIPOchip version 9
NR NR NR NR 100 100
DFH, definite FH; FN, false-negative; FP, false-positive; NR, not reported; TN, true-negative; TP, true-positive.© Queen’s Printer and Controller of HMSO 2012. This work was produced by Sharma et al. under the terms of a commissioning contract issued by the 
Secretary of State for Health.
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TABLE 35b  Mutational-level analysis: analytical accuracy of LIPOchip as reported in the paper
Study 
LIPOchip 
version Samples used Total samples
Test used to 
verify
Number 
correctly 
detected  Comments
Alonso 200939 Validation of 
LIPOchip (194 
mutations)
Dutch samples 
(positive LDLR point 
mutations)
53 DNA array 51 One false-positive and 
one false-negative result 
(false-negative identified 
by sequencing) – based 
on mutational-level 
analysis 
Spanish samples 
(positive deletions in 
LDLR by QMFSP)
43 MLPA 42 One sample – detected 
deletions between exons 
varied
Spanish random 
sample (positive on 
DNA array) 
125 Re-sequencing  125
Tejedor 200543 To identify 
unidentified 
mutation 
that could be 
introduced into 
DNA array
Samples with 
negative mutations 
on DNA array 
123  Sequencing  43  28 new mutations 
identified not detected 
previously in Spanish 
population
Manufacturer of 
LIPOchip
LIPOchip 
version 10 – a 
technical 
validation to 
evaluate its 
reproducibility
NR NR NR For point mutations and 
CNV, the reproducibility 
obtained was 99.49% 
and 98.33% respectively
Internal 
validation 
of LIPOchip 
version 9 
Samples negative 
on LIPOchip
130 Sequencing  All the mutations revealed 
by sequencing were 
not present on the chip 
(12 new mutations 
on sequencing, two 
discrepancies with MLPA)
Samples positive 
for point mutation/
negative for CNV on 
LIPOchip
30  MLPA 29 One discrepancy
Point mutation and 
CNV positives on 
LIPOchip 
5 Sequencing 4
Point mutation and 
CNV positives on 
LIPOchip
5 MLPA 4
Samples positive for 
CNV/ negative for 
point mutation on 
LIPOchip
30 Sequencing 30
Samples positive for 
CNV/ negative for 
point mutation on 
LIPOchip
30 MLPA 29 One discrepancy
CNV, copy number variation; NR, not reported.182 Appendix 10
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Appendix 11 
MOLU classification of genetic tests
C
linical Molecular Genetics Society, MOLU workload units guide version 2.2, March 
2010. Available from http://www.cmgs.org /GeneralDownloads/MOLUsystemv2.2.pdf 
(accessed March 2011).
Band
MOLU
score General examples Specific examples
A 1   ■ All DNA extractions to include: extract > test locally; 
extract > DNA banking
  ■ DNA/sample export
B 2   ■ Single amplicon (genotyping or sequencing)   ■ FraX PCR
  ■ Haemochromatosis
  ■ Factor V
  ■ Jak2
  ■ HD (diagnostic and predictive tests)
  ■ Other triplet disorders in which a single PCR is required 
(e.g. SBMA)
  ■ Y deletions
C 4   ■ Genotyping 2–4 amplicons
  ■ Sequencing: very small gene with 2–4 exons/amplicons
  ■ Sequencing: predictive tests, confirmations and carrier 
tests
  ■ MS-PCR
  ■ MLPA with no other test (including DMD)
  ■ Prenatal tests to include the MCC
  ■ One lane on Southern
  ■ Triplet disorders that require two PCRs (allele specific 
and TP-PCR)
  ■ Aneuploidy (to include 13, 18, 21 and X/Y)
  ■ Identity/paternity tests
  ■ CF-ARMS, CF-OLA, CF-HT
  ■ AS/PWS
  ■ FraX if Southern blotted
  ■ DM, Friedreich’s ataxia
D 10   ■ 5–19 amplicons (MLPA to count as two amplicons when 
part of full screen)
  ■ All linkage tests including UPD
  ■ Sequencing MECP2
  ■ DMD linkage
  ■ AS/PWS if linked markers used
E 15   ■ 20–49 amplicons (MLPA to count as two amplicons 
when part of full screen)
  ■ Sequencing factor 8
F 25   ■ 50–100 amplicons (MLPA to count as two amplicons 
when part of full screen)
  ■ Sequencing FBN1
  ■ Sequencing BRCA1 + BRCA2
G 40   ■ > 100 amplicons   ■ Sequencing a group of genes in parallel that contribute 
to a single report
AS/PWS, Angelman syndrome/Prader–Willi syndrome; BRCA1, breast cancer gene 1; BRCA2, breast cancer gene 2; CF-ARMS, cystic fibrosis – 
amplification refractory mutation system; CF-HT, cystic fibrosis – high throughput; CF-OLA, cystic fibrosis – oliogonucleotide ligation assay; DM, 
diabetes mellitus ; DMD, Duchenne muscular dystrophy; DNA, deoxyribonucleic acid ; FBN1, fibrillan 1; FraX PCR, Fragile X syndrome polymerase 
chain reaction; HD, Huntington’s disease; MCC, maternal cell contamination; MECP2, methyl CpG binding protein 2; MLPA, multiplex ligation-
dependant probe amplification; MS-PCR, mutagenically separated polymerase chain reaction; PCR, polymerase chain reaction; SBMA, spinal and 
bulbar muscular atrophy; TP-PCR, triplet repeat primed – polymerase chain reaction; UPD, uniparental disomy.© Queen’s Printer and Controller of HMSO 2012. This work was produced by Sharma et al. under the terms of a commissioning contract issued by the 
Secretary of State for Health.
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Appendix 12 
Age-specific analysis for index cases only
In each of the following analyses, costs and incremental costs are rounded to the nearest whole 
pounds sterling. QALYs and incremental QALYs are rounded to the nearest whole QALY. ICERs 
are also rounded to the nearest £/QALY gained from the economic model. Therefore, the ratio 
of reported costs divided by reported QALYs may not always reflect an exact recalculation of 
the numbers from the tables. This is caused due to rounding; however, the ICERs reported are 
the true and exact ICERs as generated by the economic model and so minimise the impact of 
rounding errors on our results.
TABLE 37a  Aged 15 years, index case (sequential ICERs)
Test strategy Total costs (£) Total QALYs Incremental costs (£) Incremental QALYs ICER (£/QALY)
Elucigene FH20 21,356,696 17,842
Elucigene FH20_MLPA 21,615,298 17,844 Ext Dom Ext Dom Ext Dom
LIPOchip 22,123,539 17,847 Ext Dom Ext Dom Ext Dom
Elucigene FH20_LIPOchip 22,195,239 17,847 Dominated Dominated Dominated
LIPOchip platform – Spain 22,277,670 17,848 920,975 7 137,963
LIPOchip_MLPA 22,374,581 17,849 Ext Dom Ext Dom Ext Dom
Elucigene FH20_LIPOchip_MLPA 22,446,281 17,849 Dominated Dominated Dominated
CGA 22,640,040 17,850 Ext Dom Ext Dom Ext Dom
Elucigene FH20_CGA 22,687,590 17,850 Dominated Dominated Dominated
LIPOchip_CGA 22,810,890 17,850 Dominated Dominated Dominated
Elucigene FH20_LIPOchip_CGA 22,882,590 17,850 Dominated Dominated Dominated
LDL-C 25,788,322 17,873 3,510,651 25 142,303
Ext Dom, extendedly dominated.
TABLE 37b  Age 15 years, index case (relevant comparison LDL-C)
Test Total costs (£) Total QALYs Incremental costs (£) Incremental QALYs
Elucigene FH20 21,356,696 17,842 –4,431,626 –31
LIPOchip platform – Spain 22,277,670 17,848 –3,510,651 –25
LDL-C 25,788,322 17,873
TABLE 37c  Age 15 years, index case (relevant comparison CGA)
Test Total costs (£) Total QALYs Incremental costs (£) Incremental QALYs ICER (£/QALY)
Elucigene FH20 21,356,696 17,842 –1,283,344 –9
LIPOchip platform – Spain 22,277,670 17,848 –362,370 –2
CGA 22,640,040 17,850
LDL-C 25,788,322 17,873 3,148,282 23 138,056188 Appendix 12
TABLE 38a  Aged 30 years, index case (sequential ICERs)
Test strategy Total costs (£) Total QALYs Incremental costs (£) Incremental QALYs ICER (£/QALY)
Elucigene FH20 19,797,956 15,873      
Elucigene FH20_MLPA 20,047,551 15,875 Ext Dom Ext Dom Ext Dom
LIPOchip 20,539,419 15,877 Ext Dom Ext Dom Ext Dom
Elucigene FH20_LIPOchip 20,611,119 15,877 Dominated Dominated Dominated
LIPOchip platform – Spain 20,686,707 15,878 Ext Dom Ext Dom Ext Dom
LIPOchip_MLPA 20,781,455 15,878 Ext Dom Ext Dom Ext Dom
Elucigene FH20_LIPOchip_MLPA 20,853,155 15,878 Dominated Dominated Dominated
CGA 21,040,070 15,879 Ext Dom Ext Dom Ext Dom
Elucigene FH20_CGA 21,087,620 15,879 Dominated Dominated Dominated
LIPOchip_CGA 21,210,920 15,879 Dominated Dominated Dominated
Elucigene FH20_LIPOchip_CGA 21,282,620 15,879 Dominated Dominated Dominated
LDL-C 23,864,524 15,925 4,066,569 51 79,053
Ext Dom, extendedly dominated.
TABLE 38b  Age 30 years, index case (relevant comparison LDL-C)
Test Total costs (£) Total QALYs Incremental costs (£) Incremental QALYs
Elucigene FH20 19,797,956 15,873 –4,066,569 –51
LDL-C 23,864,524 15,925
TABLE 38c  Age 30 years, index case (relevant comparison CGA)
Test Total costs (£) Total QALYs Incremental costs (£) Incremental QALYs ICER (£/QALY)
Elucigene FH20 19,797,956 15,873 –1,242,114 –5
CGA 21,040,070 15,879
LDL-C 23,864,524 15,925 2,824,455 46 61,363
TABLE 39a  Aged 65 years, index case (sequential ICERs)
Test strategy Total costs (£) Total QALYs Incremental costs (£) Incremental QALYs ICER (£/QALY)
Elucigene FH20 10,501,988 9395      
Elucigene FH20_MLPA 10,737,632 9401 Ext Dom Ext Dom Ext Dom
LIPOchip 11,204,139 9411 Ext Dom Ext Dom Ext Dom
Elucigene FH20_LIPOchip 11,275,839 9411 Dominated Dominated Dominated
LIPOchip platform – Spain 11,340,826 9415 838,838 21 40,607
LIPOchip_MLPA 11,432,222 9417 Ext Dom Ext Dom Ext Dom
Elucigene FH20_LIPOchip_MLPA 11,503,922 9417 Dominated Dominated Dominated
CGA 11,680,237 9421 339,411 6 58,782
Elucigene FH20_CGA 11,727,787 9421 Dominated Dominated Dominated
LIPOchip_CGA 11,851,087 9421 Dominated Dominated Dominated
Elucigene FH20_LIPOchip_CGA 11,922,787 9421 Dominated Dominated Dominated
LDL-C 13,140,258 9434 1,460,021 13 109,771
Ext Dom, extendedly dominated.© Queen’s Printer and Controller of HMSO 2012. This work was produced by Sharma et al. under the terms of a commissioning contract issued by the 
Secretary of State for Health.
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TABLE 39b  Aged 65 years, index case (relevant comparison LDL-C)
Test Total costs (£) Total QALYs Incremental costs (£) Incremental QALYs
Elucigene FH20 10,501,988 9395 –2,638,270 –40
LIPOchip platform – Spain 11,340,826 9415 –1,799,432 –19
CGA 11,680,237 9421 –1,460,021 –13
LDL-C 13,140,258 9434
TABLE 39c  Aged 65 years, index case (relevant comparison CGA)
Test Total costs (£) Total QALYs Incremental costs (£) Incremental QALYs ICER (£/QALY)
Elucigene FH20 10,501,988 9395 –1,178,249 –26
LIPOchip platform – Spain 11,340,826 9415 –339,411 –6
CGA 11,680,237 9421
LDL-C 13,140,258 9434 1,460,021 13 109,771
TABLE 40a  Aged 75 years, index case (sequential ICERs)
Test strategy Total costs (£) Total QALYs Incremental costs (£) Incremental QALYs ICER (£/QALY)
Elucigene FH20 7,645,809 6624      
Elucigene FH20_MLPA 7,832,406 6628 Ext Dom Ext Dom Ext Dom
LIPOchip 8,209,757 6634 Ext Dom Ext Dom Ext Dom
Elucigene FH20_LIPOchip 8,281,457 6634 Dominated Dominated Dominated
LIPOchip platform – Spain 8,309,178 6637 663,369 12 53,738
LIPOchip_MLPA 8,388,794 6637 Ext Dom Ext Dom Ext Dom
Elucigene FH20_LIPOchip_MLPA  8,460,494 6637 Dominated Dominated Dominated
CGA 8,599,543 6640 290,365 3 84,152
Elucigene FH20_CGA 8,647,093 6640 Dominated Dominated Dominated
LIPOchip_CGA 8,770,393 6640 Dominated Dominated Dominated
Elucigene FH20_LIPOchip_CGA 8,842,093 6640 Dominated Dominated Dominated
LDL-C 9,545,838 6641 946,294 1 1,183,172
Ext Dom, extendedly dominated.
TABLE 40b  Aged 75 years, index case (relevant comparison LDL-C)
Test Total costs (£) Total QALYs Incremental costs (£) Incremental QALY
Elucigene FH20 7,645,809 6624 –1,900,029 –17
LIPOchip platform – Spain 8,309,178 6637 –1,236,659 –4
CGA 8,599,543 6640 –946,294 –1
LDL-C 9,545,838 6641190 Appendix 12
TABLE 40c  Aged 75 years, index case (relevant comparison CGA)
Test Total costs (£) Total QALYs Incremental costs (£) Incremental QALY ICER (£/QALY)
Elucigene FH20 7,645,809 6624 –953,734 –16
LIPOchip platform – Spain 8,309,178 6637 –290,365 –3
CGA 8,599,543 6640
LDL-C 9,545,838 6641 946,294 1 1,183,172
TABLE 41a  Aged 85 years, index case (sequential ICERs)
Test strategy Total costs (£) Total QALYs Incremental costs (£) Incremental QALYs ICER (£/QALY)
Elucigene FH20 5,006,181 4036      
Elucigene FH20_MLPA 5,139,959 4038 Ext Dom Ext Dom Ext Dom
LIPOchip 5,421,293 4041 Ext Dom Ext Dom Ext Dom
LIPOchip platform – Spain 5,480,582 4042 474,401 6 78,151
Elucigene FH20_LIPOchip 5,492,993 4041 Dominated Dominated Dominated
LIPOchip_MLPA 5,547,511 4043 Ext Dom Ext Dom Ext Dom
Elucigene FH20_LIPOchip_MLPA 5,619,211 4043 Dominated Dominated Dominated
CGA 5,718,127 4044 237,545 2 139,999
Elucigene FH20_CGA 5,765,677 4044 Dominated Dominated Dominated
LIPOchip_CGA 5,888,977 4044 Dominated Dominated Dominated
Elucigene FH20_LIPOchip_CGA 5,960,677 4044 Dominated Dominated Dominated
LDL-C 6,159,018 4032 Dominated Dominated Dominated
Ext Dom, extendedly dominated.
TABLE 41b  Aged 85 years, index case (relevant comparison LDL-C)
Test Total costs (£) Total QALYs Incremental costs (£) Incremental QALYs ICER (£/QALY)
Elucigene FH20 5,006,181 4036 –1,152,837 4 Dominant
LIPOchip platform – Spain 5,480,582 4042 –678,436 10 Dominant
CGA 5,718,127 4044 –440,891 12 Dominant
LDL-C 6,159,018 4032
TABLE 41c  Aged 85 years, index case (relevant comparison CGA)
Test Total costs (£) Total QALYs Incremental costs (£) Incremental QALYs
Elucigene FH20 5,006,181 4036 –711,946 –8
LIPOchip platform – Spain 5,480,582 4042 –237,545 –2
CGA 5,718,127 4044© Queen’s Printer and Controller of HMSO 2012. This work was produced by Sharma et al. under the terms of a commissioning contract issued by the 
Secretary of State for Health.
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Appendix 13 
Age-specific analysis for index cases 
and relatives
In each of the following analyses, costs and incremental costs are rounded to the nearest whole 
pounds sterling. QALYs and incremental QALYs are rounded to the nearest whole QALY. ICERs 
are also rounded to the nearest £/QALY gained from the economic model. Therefore, the ratio 
of reported costs divided by reported QALYs may not always reflect an exact recalculation of 
the numbers from the tables. This is caused due to rounding; however, the ICERs reported are 
the true and exact ICERs as generated by the economic model and so minimise the impact of 
rounding errors on our results.
TABLE 42a  Analysis of index cases and relatives cascaded from index case aged 15 years
Test strategy Total costs (£) Total QALYs Incremental costs (£) Incremental QALYs ICER (£/QALY)
Elucigene FH20 48,382,902 39,682
LDL-C 49,384,423 37,360 Dominated Dominated Dominated
Elucigene FH20_MLPA 49,596,348 40,338 Ext Ext Dom Ext Dom
LIPOchip 51,840,314 41,532 Ext Dom Ext Dom Ext Dom
Elucigene FH20_LIPOchip 51,912,014 41,532 Dominated Dominated Dominated
LIPOchip platform – Spain 52,719,939 42,031 4,337,038 2350 1846
LIPOchip_MLPA 53,046,200 42,189 Ext Dom Ext Dom Ext Dom
Elucigene FH20_LIPOchip_MLPA 53,117,900 42,189 Dominated Dominated Dominated
CGA 54,037,153 42,688 1,317,213 657 2005
Elucigene FH20_CGA 54,084,703 42,688 Dominated Dominated Dominated
LIPOchip_CGA 54,208,003 42,688 Dominated Dominated Dominated
Elucigene FH20_LIPOchip_CGA 54,279,703 42,688 Dominated Dominated Dominated
Ext Dom, extendedly dominated.
TABLE 42b  Analysis of index cases and relatives cascaded from index case aged 15 years (relevant comparison 
LDL-C)
Test Total costs (£) Total QALYs Incremental costs (£) Incremental QALYs ICER (£/QALY)
Elucigene FH20 48,382,902 39,682 –1,001,521 2321 Dominant
LDL-C 49,384,423 37,360
LIPOchip platform – Spain 52,719,939 42,031 3,335,516 4671 714
CGA 54,037,153 42,688 4,652,730 5328 873192 Appendix 13
TABLE 43a  Analysis of index cases and relatives cascaded from index case aged 30 years
Test strategy Total costs (£) Total QALYs Incremental costs (£) Incremental QALYs ICER (£/QALY)
Elucigene FH20 72,338,134 44,143    
LDL-C 72,671,492 43,013 Dominated Dominated Dominated
Elucigene FH20_MLPA 73,626,950 44,473 Ext Dom Ext Dom Ext Dom
LIPOchip 76,007,923 45,073 Ext Dom Ext Dom Ext Dom
Elucigene FH20_LIPOchip 76,079,623 45,073 Dominated Dominated Dominated
LIPOchip platform – Spain 76,944,814 45,324 4,606,680 1181 3901
LIPOchip_MLPA 77,289,179 45,403 Ext Dom Ext Dom Ext Dom
Elucigene FH20_LIPOchip_MLPA 77,360,879 45,403 Dominated Dominated Dominated
CGA 78,337,397 45,654 1,392,583 330 4219
Elucigene FH20_CGA 78,384,947 45,654 Dominated Dominated Dominated
LIPOchip_CGA 78,508,247 45,654 Dominated Dominated Dominated
Elucigene FH20_LIPOchip_CGA 78,579,947 45,654 Dominated Dominated Dominated
Ext Dom, extendedly dominated.
TABLE 43b  Analysis of index cases and relatives cascaded from index case aged 30 years (relevant comparison 
LDL-C)
Test Total costs (£) Total QALYs Incremental costs (£) Incremental QALYs ICER (£/QALY)
Elucigene FH20 72,338,134 44,143 –333,358  1130 Dominant
LDL-C 72,671,492 43,013
LIPOchip platform – Spain 76,944,814 45,324 4,273,322 2311 1849
CGA 78,337,397 45,654 5,665,905 2641 2145
TABLE 44a  Analysis of index cases and relatives cascaded from index case aged 65 years
Test strategy Total costs (£) Total QALYs Incremental costs (£) Incremental QALYs ICER (£/QALY)
LDL-C 58,704,114 34,704
Elucigene FH20 60,370,422 36,158 1,666,308 1454 1146
Elucigene FH20_MLPA 61,804,338 36,580 Ext Dom Ext Dom Ext Dom
LIPOchip 64,449,077 37,346 Ext Dom Ext Dom Ext Dom
Elucigene FH20_LIPOchip 64,520,777 37,346 Dominated Dominated Dominated
LIPOchip platform – Spain 65,496,216 37,667 5,125,794 1508 3398
LIPOchip_MLPA 65,875,433 37,768 Ext Dom Ext Dom Ext Dom
Elucigene FH20_LIPOchip_MLPA 65,947,133 37,768 Dominated Dominated Dominated
CGA 67,033,899 38,088 1,537,683 422 3647
Elucigene FH20_CGA 67,081,449 38,088 Dominated Dominated Dominated
LIPOchip_CGA 67,204,749 38,088 Dominated Dominated Dominated
Elucigene FH20_LIPOchip_CGA 67,276,449 38,088 Dominated Dominated Dominated
Ext Dom, extendedly dominated.© Queen’s Printer and Controller of HMSO 2012. This work was produced by Sharma et al. under the terms of a commissioning contract issued by the 
Secretary of State for Health.
193   Health Technology Assessment 2012; Vol. 16: No. 17 DOI: 10.3310/hta16170
TABLE 44b  Analysis of index cases and relatives cascaded from index case aged 65 years (relevant comparison 
LDL-C)
Test Total costs (£) Total QALYs Incremental costs (£) Incremental QALYs ICER (£/QALY)
LDL-C 58,704,114 34,704      
Elucigene FH20 60,370,422 36,158 1,666,308 1454 1146
LIPOchip platform – Spain 65,496,216 37,667 6,792,102 2962 2293
CGA 67,033,899 38,088 8,329,786 3384 2462
TABLE 45a  Analysis of index cases and relatives cascaded from index case aged 75 years
Test strategy Total costs (£) Total QALYs Incremental costs (£) Incremental QALYs ICER (£/QALY)
LDL-C 33,141,939 26,128
Elucigene FH20 34,672,015 28,464 1,530,076 2336 655
Elucigene FH20_MLPA 35,813,456 29,123 Ext Dom Ext Dom Ext Dom
LIPOchip 37,926,532 30,319 Ext Dom Ext Dom Ext Dom
Elucigene FH20_LIPOchip 37,998,232 30,319 Dominated Dominated Dominated
LIPOchip platform – Spain 38,751,448 30,820 4,079,432 2355 1732
LIPOchip_MLPA 39,060,413 30,978 Ext Dom Ext Dom Ext Dom
Elucigene FH20_LIPOchip_MLPA 39,132,113 30,978 Dominated Dominated Dominated
CGA 39,996,656 31,478 1,245,209 658 1891
Elucigene FH20_CGA 40,044,206 31,478 Dominated Dominated Dominated
LIPOchip_CGA 40,167,506 31,478 Dominated Dominated Dominated
Elucigene FH20_LIPOchip_CGA 40,239,206 31,478 Dominated Dominated Dominated
Ext Dom, extendedly dominated.
TABLE 45b  Analysis of index cases and relatives cascaded from index case aged 75 years (relevant comparison 
LDL-C)
Test Total costs (£) Total QALYs Incremental costs (£) Incremental QALYs ICER (£/QALY)
LDL-C 33,141,939 26,128      
Elucigene FH20 34,672,015 28,464 1,530,076 2336 655
LIPOchip platform – Spain 38,751,448 30,820 5,609,509 4692 1196
CGA 39,996,656 31,478 6,854,717 5350 1281194 Appendix 13
TABLE 46a  Analysis of index cases and relatives cascaded from index case aged 85 years
Test strategy Total costs (£) Total QALYs Incremental costs (£) Incremental QALYs ICER (£/QALY)
LDL-C 30,692,288 17,638      
Elucigene FH20 31,577,622 18,313 885,334 675 1312
Elucigene FH20_MLPA 32,278,769 18,501 Ext Dom Ext Dom Ext Dom
LIPOchip 33,591,472 18,844 Ext Dom Ext Dom Ext Dom
Elucigene FH20_LIPOchip 33,663,172 18,844 Dominated Dominated Dominated
LIPOchip platform – Spain 34,081,850 18,987 2,504,228 674 3715
LIPOchip_MLPA 34,285,059 19,032 Ext Dom Ext Dom Ext Dom
Elucigene FH20_LIPOchip_MLPA 34,356,759 19,032 Dominated Dominated Dominated
CGA 34,886,764 19,175 804,914 188 4272
Elucigene FH20_CGA 34,934,314 19,175 Dominated Dominated Dominated
LIPOchip_CGA 35,057,614 19,175 Dominated Dominated Dominated
Elucigene FH20_LIPOchip_CGA 35,129,314 19,175 Dominated Dominated Dominated
Ext Dom, extendedly dominated.
TABLE 46b  Analysis of index cases and relatives cascaded from index case aged 85 years (relevant comparison 
LDL-C)
Test Total costs (£) Total QALYs Incremental costs (£) Incremental QALYs ICER (£/QALY)
LDL-C 30,692,288 17,638  
Elucigene FH20 31,577,622 18,313 885,334 675 1312
LIPOchip platform – Spain 34,081,850 18,987 3,389,562 1349 2513
CGA 34,886,764 19,175 4,194,476 1537 2728© Queen’s Printer and Controller of HMSO 2012. This work was produced by Sharma et al. under the terms of a commissioning contract issued by the 
Secretary of State for Health.
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Appendix 14 
One-way sensitivity analyses carried 
out on the base-case model
In each of the following analyses, costs and incremental costs are rounded to the nearest whole 
pounds sterling. QALYs and incremental QALYs are rounded to the nearest whole QALY. ICERs 
are also rounded to the nearest £/QALY gained from the economic model. Therefore, the ratio 
of reported costs divided by reported QALYs may not always reflect an exact recalculation of 
the numbers from the tables. This is caused due to rounding; however, the ICERs reported are 
the true and exact ICERs as generated by the economic model and so minimise the impact of 
rounding errors on our results.
The analysis presented in Tables 47 and 48 refers to the variation in prevalence of FH in the 
UK. Base-case analysis uses data from Taylor and colleagues,37 supported by the expert clinical 
opinion of Dr Zosia Miedzybrodzka (University of Aberdeen). The following analysis uses values 
ranging from 28%79 to 52%.41
TABLE 47.1a  Low estimate of FH prevalence in the UK (mutation positive on Simon Broome) = 28%, index cases only 
(sequentially presented results)
Test strategy Total costs (£) Total QALYs Incremental costs (£) Incremental QALYs ICER (£/QALY)
Elucigene FH20 13,834,026 13,126
Elucigene FH20_MLPA 14,055,008 13,135 Ext Dom Ext Dom Ext Dom
LIPOchip 14,488,607 13,150 Ext Dom Ext Dom Ext Dom
Elucigene FH20_LIPOchip 14,571,407 13,150 Dominated Dominated Dominated
LIPOchip platform – Spain 14,618,431 13,157 784,405 31 25,558
LIPOchip_MLPA 14,703,829 13,159 Ext Dom Ext Dom Ext Dom
Elucigene FH20_LIPOchip_MLPA 14,786,569 13,159 Dominated Dominated Dominated
CGA 14,934,997 13,166 316,566 9 36,901
Elucigene FH20_CGA 14,999,197 13,166 Dominated Dominated Dominated
LIPOchip_CGA 15,135,997 13,166 Dominated Dominated Dominated
Elucigene FH20_LIPOchip_CGA 15,218,347 13,166 Dominated Dominated Dominated
LDL-C 17,501,754 13,195 2,566,757 29 87,175
Ext Dom, extendedly dominated.
TABLE 47.1b  Low estimate of FH prevalence in the UK (mutation positive on Simon Broome) = 28%, index cases only 
(relevant comparison LDL-C)
Test Total costs (£) Total QALYs Incremental costs (£) Incremental QALYs
Elucigene FH20 13,834,026 13,126 –3,667,728 –69
LIPOchip platform – Spain 14,618,431 13,157 –2,883,323 –38
CGA 14,934,997 13,166 –2,566,757 –29
LDL-C 17,501,754 13,195 – –196 Appendix 14
TABLE 47.1c  Low estimate of FH prevalence in the UK (mutation positive on Simon Broome) = 28%, index cases only 
(relevant comparison CGA)
Test Total costs (£) Total QALYs Incremental costs (£) Incremental QALYs ICER (£/QALY)
Elucigene FH20 13,834,026 13,126 –1,100,971 –39
LIPOchip platform – Spain 14,618,431 13,157 –316,566 –9
CGA 14,934,997 13,166 – –
LDL-C 17,501,754 13,195 2,566,757 29 87,175
TABLE 47.2a  Low estimate of FH prevalence in the UK (mutation positive on Simon Broome) = 28%, index cases and 
relatives (sequentially presented results)
Test strategy Total costs (£) Total QALYs Incremental costs (£) Incremental QALYs ICER (£/QALY)
Elucigene FH20 42,318,489 36,311
Elucigene FH20_MLPA 43,174,675 36,743 Ext Dom Ext Dom Ext Dom
LDL-C 43,704,361 34,860 Dominated Dominated Dominated
LIPOchip 44,762,955 37,527 Ext Dom Ext Dom Ext Dom
Elucigene FH20_LIPOchip 44,845,755 37,527 Dominated Dominated Dominated
LIPOchip platform – Spain 45,375,409 37,855 3,056,920 1544 1979
LIPOchip_MLPA 45,613,381 37,959 Ext Dom Ext Dom Ext Dom
Elucigene FH20_LIPOchip_MLPA 45,696,121 37,959 Dominated Dominated Dominated
CGA 46,327,179 38,287 951,770 432 2205
Elucigene FH20_CGA 46,391,379 38,287 Dominated Dominated Dominated
LIPOchip_CGA 46,528,179 38,287 Dominated Dominated Dominated
Elucigene FH20_LIPOchip_CGA 46,610,529 38,287 Dominated Dominated Dominated
Ext Dom, extendedly dominated.
TABLE 47.2b  Low estimate of FH prevalence in the UK (mutation positive on Simon Broome) = 28%, index cases and 
relatives (relevant comparison LDL-C)
Test Total costs (£) Total QALYs Incremental costs (£) Incremental QALYs ICER (£/QALY)
Elucigene FH20 42,318,489 36,311 –1,385,872 1451 Dominant
LDL-C 43,704,361 34,860
LIPOchip platform – Spain 45,375,409 37,855 1,671,048 2996 558
CGA 46,327,179 38,287 2,622,819 3427 765
TABLE 47.2c  Low estimate of FH prevalence in the UK (mutation positive on Simon Broome) = 28%, index cases and 
relatives (relevant comparison CGA)
Test Total costs (£) Total QALYs Incremental costs (£) Incremental QALYs
Elucigene FH20 42,318,489 36,311 –4,008,691 –1976
LIPOchip platform – Spain 45,375,409 37,855 –951,770 –432
CGA 46,327,179 38,287 – –© Queen’s Printer and Controller of HMSO 2012. This work was produced by Sharma et al. under the terms of a commissioning contract issued by the 
Secretary of State for Health.
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TABLE 48.1a  High estimate of FH prevalence in the UK (mutation positive on Simon Broome) = 52%, index cases 
(sequentially presented results)
Test strategy Total costs (£) Total QALYs Incremental costs (£) Incremental QALYs ICER (£/QALY)
Elucigene FH20 14,842,263 12,786
Elucigene FH20_MLPA 15,201,307 12,802 Ext Dom Ext Dom Ext Dom
LIPOchip 15,903,629 12,830 Ext Dom Ext Dom Ext Dom
Elucigene FH20_LIPOchip 15,954,929 12,830 Dominated Dominated Dominated
LIPOchip platform – Spain 16,126,407 12,843 1,284,143 57 22,530
LIPOchip_MLPA 16,251,932 12,846 Ext Dom Ext Dom Ext Dom
Elucigene FH20_LIPOchip_MLPA 16,303,172 12,846 Dominated Dominated Dominated
CGA 16,604,067 12,859 477,660 16 29,981
Elucigene FH20_CGA 16,621,017 12,859 Dominated Dominated Dominated
LIPOchip_CGA 16,720,467 12,859 Dominated Dominated Dominated
Elucigene FH20_LIPOchip_CGA 16,771,317 12,859 Dominated Dominated Dominated
LDL-C 17,998,153 12,870 1,394,087 11 123,530
Ext Dom, extendedly dominated.
TABLE 48.1b  High estimate of FH prevalence in the UK (mutation positive on Simon Broome) = 52%, index cases 
(relevant comparison LDL-C)
Test Total costs (£) Total QALYs Incremental costs (£) Incremental QALYs
Elucigene FH20 14,842,263 12,786 –3,155,890 –84
LIPOchip platform – Spain 16,126,407 12,843 –1,871,747 –27
CGA 16,604,067 12,859 –1,394,087 –11
LDL-C 17,998,153 12,870 – –
TABLE 48.1c  High estimate of FH prevalence in the UK (mutation positive on Simon Broome) = 52%, index cases 
(relevant comparison CGA)
Test  Total costs (£) Total QALYs Incremental costs (£) Incremental QALYs ICER (£/QALY)
Elucigene FH20 14,842,263 12,786 –1,761,804 –73
LIPOchip platform – Spain 16,126,407 12,843 –477,660 –16
CGA 16,604,067 12,859
LDL-C 17,998,153 12,870 1,394,087 11 123,530198 Appendix 14
TABLE 48.2a  High estimate of FH prevalence in the UK (mutation positive on Simon Broome) = 52%, index cases and 
relatives (sequentially presented results)
Test strategy Total costs (£) Total QALYs Incremental costs (£) Incremental QALYs ICER (£/QALY)
LDL-C 44,200,760 34,535
Elucigene FH20 45,282,603 37,273 1,081,843 2739 395
Elucigene FH20_MLPA 46,821,312 38,075 Ext Dom Ext Dom Ext Dom
LIPOchip 49,668,040 39,532 Ext Dom Ext Dom Ext Dom
Elucigene FH20_LIPOchip 49,719,340 39,532 Dominated Dominated Dominated
LIPOchip platform – Spain 50,787,132 40,141 5,504,529 2868 1919
LIPOchip_MLPA 51,196,009 40,334 Ext Dom Ext Dom Ext Dom
Elucigene FH20_LIPOchip_MLPA 51,247,249 40,334 Dominated Dominated Dominated
CGA 52,444,457 40,943 1,657,325 802 2067
Elucigene FH20_CGA 52,461,407 40,943 Dominated Dominated Dominated
LIPOchip_CGA 52,560,857 40,943 Dominated Dominated Dominated
Elucigene FH20_LIPOchip_CGA 52,611,707 40,943 Dominated Dominated Dominated
Ext Dom, extendedly dominated.
TABLE 48.2b  High estimate of FH prevalence in the UK (mutation positive on Simon Broome) = 52%, index cases and 
relatives (relevant comparison LDL-C)
Test Total costs (£) Total QALYs Incremental costs (£) Incremental QALYs ICER (£/QALY)
LDL-C 44,200,760 34,535      
Elucigene FH20 45,282,603 37,273 1,081,843 2739 395
LIPOchip platform – Spain 50,787,132 40,141 6,586,372 5607 1175
CGA 52,444,457 40,943 8,243,697 6409 1286
TABLE 48.2c  High estimate of FH prevalence in the UK (mutation positive on Simon Broome) = 52%, index cases and 
relatives (relevant comparison CGA)
Test Total costs (£) Total QALYs Incremental costs (£) Incremental QALYs
LDL-C 44,200,760 34,535 –8,243,697 –6409
Elucigene FH20 45,282,603 37,273 –7,161,854 –3670
LIPOchip platform – Spain 50,787,132 40,141 –1,657,325 –802
CGA 52,444,457 40,943 – –© Queen’s Printer and Controller of HMSO 2012. This work was produced by Sharma et al. under the terms of a commissioning contract issued by the 
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The base-case assumption in our model is that, on average, 50% of first-degree relatives of a 
diagnosed index case will possess the culprit genetic mutation causing FH. This, however, is an 
assumption based on expert opinion; therefore, in our model we need to assume some variance 
around this estimate. In Tables 49 and 50 the prevalence of FH among relatives is varied by 
±20%, that is, between 40% and 60%. As these results refer only to relatives, there is no impact on 
index cases.
TABLE 49a  Low estimate of FH prevalence among relatives = 40%, index cases and relatives (sequentially 
presented results)
Test strategy Total costs (£) Total QALYs Incremental costs (£) Incremental QALYs ICER (£/QALY)
Elucigene FH20 37,215,919 32,419      
Elucigene FH20_MLPA 37,891,155 32,677 Ext Dom Ext Dom Ext Dom
LIPOchip 39,156,757 33,146 Ext Dom Ext Dom Ext Dom
Elucigene FH20_LIPOchip 39,228,457 33,146 Dominated Dominated Dominated
LDL-C 39,246,248 31,607 Dominated Dominated Dominated
LIPOchip platform – Spain 39,627,448 33,342 2,411,529 923 2613
LIPOchip_MLPA 39,824,433 33,404 Ext Dom Ext Dom Ext Dom
Elucigene FH20_LIPOchip_MLPA 39,896,133 33,404 Dominated Dominated Dominated
CGA 40,406,451 33,600 779,003 258 3020
Elucigene FH20_CGA 40,454,001 33,600 Dominated Dominated Dominated
LIPOchip_CGA 40,577,301 33,600 Dominated Dominated Dominated
Elucigene FH20_LIPOchip_CGA 40,649,001 33,600 Dominated Dominated Dominated
Ext Dom, extendedly dominated.
TABLE 49b  Low estimate of FH prevalence among relatives = 40%, index cases and relatives (relevant comparison 
LDL-C)
Test Total costs (£) Total QALYs Incremental costs (£) Incremental QALYs ICER (£/QALY)
Elucigene FH20 37,215,919 32,419 –2,030,329 812 Dominant
LDL-C 39,246,248 31,607
LIPOchip platform – Spain 39,627,448 33,342 381,200 1735 220
CGA 40,406,451 33,600 1,160,203 1993 582
TABLE 49c  Low estimate of FH prevalence among relatives = 40%, index cases and relatives (relevant 
comparison CGA)
Test Total costs (£) Total QALYs Incremental costs (£) Incremental QALYs
Elucigene FH20 37,215,919 32,419 –3,190,532 –1181
LIPOchip platform – Spain 39,627,448 33,342 –779,003 –258
CGA 40,406,451 33,600200 Appendix 14
TABLE 50a  High estimate of FH prevalence among relatives = 60%, index cases and relatives (sequentially 
presented results)
Test strategy Total costs (£) Total QALYs Incremental costs (£) Incremental QALYs ICER (£/QALY)
LDL-C 49,065,143 38,227
Elucigene FH20 50,587,294 41,583 1,522,151 3356 454
Elucigene FH20_MLPA 52,251,440 42,549 Ext Dom Ext Dom Ext Dom
LIPOchip 55,314,692 44,305 Ext Dom Ext Dom Ext Dom
Elucigene FH20_LIPOchip 55,386,392 44,305 Dominant Dominant Dominant
LIPOchip platform – Spain 56,536,761 45,039 5,949,467 3456 1721
LIPOchip_MLPA 56,971,278 45,271 Ext Dom Ext Dom Ext Dom
Elucigene FH20_LIPOchip_MLPA 57,042,978 45,271 Dominant Dominant Dominant
CGA 58,304,674 46,006 1,767,913 966 1830
Elucigene FH20_CGA 58,352,224 46,006 Dominant Dominant Dominant
LIPOchip_CGA 58,475,524 46,006 Dominant Dominant Dominant
Elucigene FH20_LIPOchip_CGA 58,547,224 46,006 Dominant Dominant Dominant
Ext Dom, extendedly dominated.
TABLE 50b  High estimate of FH prevalence among relatives = 60%, index cases and relatives (relevant comparison 
LDL-C)
Test Total costs (£) Total QALYs Incremental costs (£) Incremental QALYs ICER (£/QALY)
LDL-C 49,065,143 38,227
Elucigene FH20 50,587,294 41,583 1,522,151 3356 454
LIPOchip platform – Spain 56,536,761 45,039 7,471,618 6812 1097
CGA 58,304,674 46,006 9,239,531 7778 1188
TABLE 50c  High estimate of FH prevalence among relatives = 60%, index cases and relatives (relevant 
comparison CGA)
Test Total costs (£) Total QALYs Incremental costs (£) Incremental QALYs
LDL-C 49,065,143 38,227 –9,239,531 –7778
Elucigene FH20 50,587,294 41,583 –7,717,380 –4422
LIPOchip platform – Spain 56,536,761 45,039 –1,767,913 –966
CGA 58,304,674 46,006 – –© Queen’s Printer and Controller of HMSO 2012. This work was produced by Sharma et al. under the terms of a commissioning contract issued by the 
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TABLE 51.1a  Reducing the cost of atorvastatin to that of generic simvastatin 80 mg, index cases (sequentially 
presented results)
Test strategy Total costs (£) Total QALYs Incremental costs (£) Incremental QALYs ICER (£/QALY)
Elucigene FH20 13,878,892 13,005
Elucigene FH20_MLPA 14,061,700 13,016 Ext Dom Ext Dom Ext Dom
LIPOchip 14,432,160 13,037 Ext Dom Ext Dom Ext Dom
Elucigene FH20_LIPOchip 14,503,860 13,037 Dominated Dominated Dominated
LIPOchip platform – Spain 14,528,702 13,045 649,809 40 16,229
LIPOchip_MLPA 14,607,407 13,048 Ext Dom Ext Dom Ext Dom
Elucigene FH20_LIPOchip_MLPA 14,697,107 13,048 Dominated Dominated Dominated
CGA 14,815,276 13,056 286,575 11 25,605
Elucigene FH20_CGA 14,862,826 13,056 Dominated Dominated Dominated
LIPOchip_CGA 14,986,126 13,056 Dominated Dominated Dominated
Elucigene FH20_LIPOchip_CGA 15,057,826 13,056 Dominated Dominated Dominated
LDL-C 16,109,186 13,079 1,293,910 23 56,282
Ext Dom, extendedly dominated.
TABLE 51.1b  Reducing the cost of atorvastatin to that of generic simvastatin 80 mg, index cases (relevant comparison 
LDL-C)
Test Total costs (£) Total QALYs Incremental costs (£) Incremental QALYs
Elucigene FH20 13,878,892 13,005 –2,230,294 –74
LIPOchip platform – Spain 14,528,702 13,045 –1,580,485 –34
CGA 14,815,276 13,056 –1,293,910 –23
LDL-C 16,109,186 13,079 – –
TABLE 51.1c  Reducing the cost of atorvastatin to that of generic simvastatin 80 mg, index cases (relevant 
comparison CGA)
Test Total costs (£) Total QALYs Incremental costs (£) Incremental QALYs ICER (£/QALY)
Elucigene FH20 13,878,892 13,005 –936,384 –51
LIPOchip platform – Spain 14,528,702 13,045 –286,575 –11
CGA 14,815,276 13,056 – –
LDL-C 16,109,186 13,079 1,293,910 23 56,282202 Appendix 14
TABLE 51.2a  Reducing the cost of atorvastatin to that of generic simvastatin 80 mg, index cases and relatives 
(sequentially presented results)
Test strategy Total costs (£) Total QALYs Incremental costs (£) Incremental QALYs ICER (£/QALY)
LDL-C 39,531,598 34,744
Elucigene FH20 39,976,768 36,653 445,170 1909 233
Elucigene FH20_MLPA 40,904,348 37,216 Ext Dom Ext Dom Ext Dom
LIPOchip 42,628,666 38,240 Ext Dom Ext Dom Ext Dom
Elucigene FH20_LIPOchip 42,700,366 38,240 Dominated Dominated Dominated
LIPOchip platform – Spain 43,291,089 38,668 3,314,321 2015 1645
LIPOchip_MLPA 43,548,686 38,803 Ext Dom Ext Dom Ext Dom
Elucigene FH20_LIPOchip_MLPA 43,620,386 38,803 Dominated Dominated Dominated
CGA 44,322,437 39,231 1,031,348 563 1831
Elucigene FH20_CGA 44,369,987 39,231 Dominated Dominated Dominated
LIPOchip_CGA 44,493,287 39,231 Dominated Dominated Dominated
Elucigene FH20_LIPOchip_CGA 44,564,987 39,231 Dominated Dominated Dominated
Ext Dom, extendedly dominated.
TABLE 51.2b  Reducing the cost of atorvastatin to that of generic simvastatin 80 mg, index cases and relatives (relevant 
comparison LDL-C)
Test Total costs (£) Total QALYs Incremental costs (£) Incremental QALYs ICER (£/QALY)
LDL-C 39,531,598 34,744
Elucigene FH20 39,976,768 36,653 445,170 1909 233
LIPOchip platform – Spain 43,291,089 38,668 3,759,492 3924 958
CGA 44,322,437 39,231 4,790,839 4487 1068
TABLE 51.2c  Reducing the cost of atorvastatin to that of generic simvastatin 80 mg, index cases and relatives (relevant 
comparison CGA)
Test Total costs (£) Total QALYs Incremental costs (£) Incremental QALYs
LDL-C 39,531,598 34,744 –4,790,839 –4487
Elucigene FH20 39,976,768 36,653 –4,345,669 –2578
LIPOchip platform – Spain 43,291,089 38,668 –1,031,348 –563
CGA 44,322,437 39,231 – –© Queen’s Printer and Controller of HMSO 2012. This work was produced by Sharma et al. under the terms of a commissioning contract issued by the 
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TABLE 52.1a  Alternative high- and low-intensity treatment scenarios (Dr Anthony Wierzbicki), index cases (sequentially 
reported results)
Test strategy Total costs (£) Total QALYs Incremental costs (£) Incremental QALYs ICER (£/QALY)
Elucigene FH20 19,077,991 13,005
Elucigene FH20_MLPA 19,123,772 13,016 Ext Dom Ext Dom Ext Dom
LIPOchip platform – Spain 19,237,573 13,045 Ext Dom Ext Dom Ext Dom
LIPOchip 19,245,144 13,037 Dominated Dominated Dominated
LIPOchip_MLPA 19,283,365 13,048 Ext Dom Ext Dom Ext Dom
LDL-C 19,311,875 13,079 233,884 74 3161
Elucigene FH20_LIPOchip 19,316,844 13,037 Dominated Dominated Dominated
Elucigene FH20_LIPOchip_MLPA 19,355,065 13,048 Dominated Dominated Dominated
CGA 19,387,121 13,056 Dominated Dominated Dominated
Elucigene FH20_CGA 19,434,671 13,056 Dominated Dominated Dominated
LIPOchip_CGA 19,557,971 13,056 Dominated Dominated Dominated
Elucigene FH20_LIPOchip_CGA 19,629,671 13,056 Dominated Dominated Dominated
Ext Dom, extendedly dominated.
TABLE 52.1b  Alternative high- and low-intensity treatment scenarios (Dr Anthony Wierzbicki), index cases (relevant 
comparison LDL-C)
Test Total costs (£) Total QALYs Incremental costs (£) Incremental QALYs
Elucigene FH20 19,077,991 13,005 –233,884 –74
LDL–C 19,311,875 13,079 – –
TABLE 52.1c  Alternative high- and low-intensity treatment scenarios (Dr Anthony Wierzbicki), index cases (relevant 
comparison CGA)
Test Total costs (£) Total QALYs Incremental costs (£) Incremental QALYs ICER (£/QALY)
Elucigene FH20 19,077,991 13,005 –309,130 –51
LDL-C 19,311,875 13,079 –75,246 23 Dominant
CGA 19,387,121 13,056204 Appendix 14
TABLE 52.2a  Alternative high- and low-intensity treatment scenarios (Dr Anthony Wierzbicki), index cases and relatives 
(sequentially reported results)
Test strategy Total costs (£) Total QALYs Incremental costs (£) Incremental QALYs ICER (£/QALY)
LDL-C 47,524,644 34,744
Elucigene FH20 50,339,916 36,653 2,815,272 1909 1475
Elucigene FH20_MLPA 51,234,495 37,216 Ext Dom Ext Dom Ext Dom
LIPOchip 52,898,822 38,240 Ext Dom Ext Dom Ext Dom
Elucigene FH20_LIPOchip 52,970,522 38,240 Dominated Dominated Dominated
LIPOchip platform – Spain 53,536,172 38,668 3,196,256 2015 1586
LIPOchip_MLPA 53,785,842 38,803 Ext Dom Ext Dom Ext Dom
Elucigene FH20_LIPOchip_MLPA 53,857,542 38,803 Dominated Dominated Dominated
CGA 54,534,518 39,231 998,347 563 1773
Elucigene FH20_CGA 54,582,068 39,231 Dominated Dominated Dominated
LIPOchip_CGA 54,705,368 39,231 Dominated Dominated Dominated
Elucigene FH20_LIPOchip_CGA 54,777,068 39,231 Dominated Dominated Dominated
Ext Dom, extendedly dominated.
TABLE 52.2b  Alternative high- and low-intensity treatment scenarios (Dr Anthony Wierzbicki), index cases and relatives 
(relevant comparison LDL-C)
Test Total costs (£) Total QALYs Incremental costs (£) Incremental QALYs ICER (£/QALY)
LDL-C 47,524,644 34,744
Elucigene FH20 50,339,916 36,653 2,815,272 1909 1475
LIPOchip platform – Spain 53,536,172 38,668 6,011,528 3924 1532
CGA 54,534,518 39,231 7,009,875 4487 1562
TABLE 52.2c  Alternative high- and low-intensity treatment scenarios (Dr Anthony Wierzbicki), index cases and relatives 
(relevant comparison CGA)
Test Total costs (£) Total QALYs Incremental costs (£) Incremental QALYs
LDL-C 47,524,644 34,744 –7,009,875 –4487
Elucigene FH20 50,339,916 36,653 –4,194,603 –2578
LIPOchip platform – Spain 53,536,172 38,668 –998,347 –563
CGA 54,534,518 39,231 – –© Queen’s Printer and Controller of HMSO 2012. This work was produced by Sharma et al. under the terms of a commissioning contract issued by the 
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The analyses presented in Table 53 relate to the potential treatment of negative-testing relatives. 
This value is assumed to be 10% in the model. As this is purely an assumption based on author 
opinion, this value is varied between 0% and 50% in sensitivity analysis. As this has no effect 
on the results for index cases alone, results are presented only for index cases and relatives 
combined. It is assumed that if negative relatives are treated then their treatment of choice will be 
low-intensity statin therapy as defined for the base-case model.
TABLE 53.1a  Impact of reducing proportion of negative-testing relatives receiving treatment to 0%, index cases and 
relatives (sequentially presented results)
Test strategy Total costs (£) Total QALYs Incremental costs (£) Incremental QALYs ICER (£/QALY)
Elucigene FH20 42,251,638 33,421
LDL-C 42,709,251 31,523 Dominated Dominated Dominated
Elucigene FH20_MLPA 43,364,673 33,981 Ext Dom Ext Dom Ext Dom
LIPOchip 45,426,111 34,999 Ext Dom Ext Dom Ext Dom
Elucigene FH20_LIPOchip 45,497,811 34,999 Dominated Dominated Dominated
LIPOchip platform – Spain 46,229,444 35,425 3,977,806 2004 1985
LIPOchip_MLPA 46,531,587 35,559 Ext Dom Ext Dom Ext Dom
Elucigene FH20_LIPOchip_MLPA 46,603,287 35,559 Dominated Dominated Dominated
CGA 47,446,247 35,985 1,216,803 560 2172
Elucigene FH20_CGA 47,493,797 35,985 Dominated Dominated Dominated
LIPOchip_CGA 47,617,097 35,985 Dominated Dominated Dominated
Elucigene FH20_LIPOchip_CGA 47,688,797 35,985 Dominated Dominated Dominated
Ext Dom, extendedly dominated.
TABLE 53.1b  Impact of reducing proportion of negative-testing relatives receiving treatment to 0%, index cases and 
relatives (relevant comparison LDL-C)
Test Total costs (£) Total QALYs Incremental costs (£) Incremental effects ICER (£/QALY)
Elucigene FH20 42,251,638 33,421 –457,614 1898 Dominant
LDL-C 42,709,251 31,523
LIPOchip platform – Spain 46,229,444 35,425 3,520,193 3902 902
CGA 47,446,247 35,985 4,736,995 4462 1062
TABLE 53.1c  Impact of reducing proportion of negative-testing relatives receiving treatment to 0%, index cases and 
relatives (relevant comparison CGA)
Test Total costs (£) Total QALYs Incremental costs (£) Incremental QALYs
Elucigene FH20 42,251,638 33,421 –5,194,609 –2564
LIPOchip platform – Spain 46,229,444 35,425 –1,216,803 –560
CGA 47,446,247 35,985 – –206 Appendix 14
TABLE 53.2a  Impact of increasing proportion of negative-testing relatives receiving treatment to 50%, index cases and 
relatives (sequentially presented results)
Test strategy Total costs (£) Total QALYs Incremental costs (£) Incremental QALYs ICER (£/QALY)
Elucigene FH20 47,853,372 49,583
LDL-C 48,566,941 47,630 Dominated Dominated Dominated
Elucigene FH20_MLPA 48,895,157 50,158 Ext Dom Ext Dom Ext Dom
LIPOchip 50,827,075 51,204 Ext Dom Ext Dom Ext Dom
Elucigene FH20_LIPOchip 50,898,775 51,204 Dominated Dominated Dominated
LIPOchip platform – Spain 51,576,271 51,641 3,722,899 2059 1808
LIPOchip_MLPA 51,861,300 51,780 Ext Dom Ext Dom Ext Dom
Elucigene FH20_LIPOchip_MLPA 51,933,000 51,780 Dominated Dominated Dominated
CGA 52,721,823 52,217 1,145,552 575 1991
Elucigene FH20_CGA 52,769,373 52,217 Dominated Dominated Dominated
LIPOchip_CGA 52,892,673 52,217 Dominated Dominated Dominated
Elucigene FH20_LIPOchip_CGA 52,964,373 52,217 Dominated Dominated Dominated
Ext Dom, extendedly dominated.
TABLE 53.2b  Impact of increasing proportion of negative-testing relatives receiving treatment to 50%, index cases and 
relatives (relevant comparison LDL-C)
Test Total costs (£) Total QALYs Incremental costs (£) Incremental QALYs ICER (£/QALY)
Elucigene FH20 47,853,372 49,583 –713,569 1953 Dominant
LDL-C 48,566,941 47,630
LIPOchip platform – Spain 51,576,271 51,641 3,009,331 4011 750
CGA 52,721,823 52,217 4,154,883 4587 906
TABLE 53.2c  Impact of increasing proportion of negative-testing relatives receiving treatment to 50%, index cases and 
relatives (relevant comparison CGA)
Test Total costs (£) Total QALYs Incremental costs (£) Incremental QALYs
Elucigene FH20 47,853,372 49,583 –4,868,451 –2634
LIPOchip in Spain  51,576,271 51,641 –1,145,552 –575
CGA 52,721,823 52,217
Base-case analysis assumes that all test-negative index cases will require some treatment. The 
justification for this assumption is that all these patients will have elevated lipids and will thus be 
at increased risk of CHD. However, it is possible that these patients could be managed effectively 
using diet and exercise interventions, the evaluation of which is beyond the scope of this report. 
Therefore, to assess the impact of this assumption on our results, Table 54 presents the analysis 
assuming an extreme case scenario in which none of the test-negative index cases will receive 
treatment. Index cases are therefore not followed up clinically in this scenario.© Queen’s Printer and Controller of HMSO 2012. This work was produced by Sharma et al. under the terms of a commissioning contract issued by the 
Secretary of State for Health.
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TABLE 54.1a  Test-negative index cases do not receive treatment, index cases (sequentially presented results)
Test strategy Total costs (£) Total QALYs Incremental costs (£) Incremental QALYs ICER (£/QALY)
Elucigene FH20 8,205,446 1967
Elucigene FH20_MLPA 8,863,412 2514 Ext Dom Ext Dom Ext Dom
LIPOchip 10,097,620 3509 Ext Dom Ext Dom Ext Dom
Elucigene FH20_LIPOchip 10,169,320 3509 Dominated Dominated Dominated
LIPOchip platform – Spain 10,555,189 3925 Ext Dom Ext Dom Ext Dom
LIPOchip_MLPA 10,748,025 4057 Ext Dom Ext Dom Ext Dom
Elucigene FH20_LIPOchip_MLPA 10,819,725 4057 Dominated Dominated Dominated
CGA 11,316,921 4473 Ext Dom Ext Dom Ext Dom
Elucigene FH20_CGA 11,364,471 4473 Dominated Dominated Dominated
LIPOchip_CGA 11,487,771 4473 Dominated Dominated Dominated
Elucigene FH20_LIPOchip_CGA 11,559,471 4473 Dominated Dominated Dominated
LDL-C 16,140,001 10,152 7,934,555 8185 969
Ext Dom, extendedly dominated.
TABLE 54.1b  Test-negative index cases do not receive treatment, index cases (relevant comparison LDL-C)
Test Total costs (£) Total QALYs Incremental costs (£) Incremental QALYs
Elucigene FH20 8,205,446 1967 –7,934,555 –8185
LDL-C 16,140,001 10,152 – –
TABLE 54.1c  Test-negative index cases do not receive treatment, index cases (relevant comparison CGA)
Test Total costs (£) Total QALYs Incremental costs (£) Incremental QALYs ICER (£/QALY)
Elucigene FH20 8,205,446 1967 –3,111,475 –2506
CGA 11,316,921 4473 – –
LDL-C 16,140,001 10,152 4,823,079 5679 849
TABLE 54.2a  Test-negative index cases do not receive treatment, index cases and relatives (sequentially 
presented results)
Test strategy Total costs (£) Total QALYs Incremental costs (£) Incremental QALYs ICER (£/QALY)
Elucigene FH20 37,385,060 25,614
Elucigene FH20_MLPA 38,871,740 26,714 Ext Dom Ext Dom Ext Dom
LIPOchip 41,612,394 28,713 Dominated Dominated Dominated
Elucigene FH20_LIPOchip 41,684,094 28,713 Dominated Dominated Dominated
LDL-C 42,342,607 31,817 4,957,547 6202 799
LIPOchip platform – Spain 42,699,624 29,548 Dominated Dominated Dominated
LIPOchip_MLPA 43,091,514 29,812 Dominated Dominated Dominated
Elucigene FH20_LIPOchip_MLPA 43,163,214 29,812 Dominated Dominated Dominated
CGA 44,290,071 30,648 Dominated Dominated Dominated
Elucigene FH20_CGA 44,337,621 30,648 Dominated Dominated Dominated
LIPOchip_CGA 44,460,921 30,648 Dominated Dominated Dominated
Elucigene FH20_LIPOchip_CGA 44,532,621 30,648 Dominated Dominated Dominated
Ext Dom, extendedly dominated.208 Appendix 14
TABLE 54.2b  Test-negative index cases do not receive treatment, index cases and relatives (relevant comparison 
LDL-C)
Test Total costs (£) Total QALYs Incremental costs (£) Incremental QALYs ICER (£/QALY)
Elucigene FH20 37,385,060 25,614 –4,957,547 –6202
LDL-C 42,342,607 31,817 – – –
TABLE 54.2c  Test-negative index cases do not receive treatment, index cases and relatives (relevant comparison CGA)
Test Total costs (£) Total QALYs Incremental costs (£) Incremental QALYs ICER (£/QALY)
Elucigene FH20 37,385,060 25,614 –6,905,011 –5033
LDL-C 42,342,607 31,817 –1,947,464 1169 Dominant
CGA 44,290,071 30,648 – –
TABLE 55.1a  Cost of MOLU (high value) = £40, index cases (sequentially presented results)
Test strategy Total costs (£) Total QALYs Incremental costs (£) Incremental QALYs ICER (£/QALY)
Elucigene FH20 14,242,370 13,005
Elucigene FH20_MLPA 14,529,221 13,016 Ext Dom Ext Dom Ext Dom
LIPOchip 15,101,529 13,037 Ext Dom Ext Dom Ext Dom
LIPOchip platform – Spain 15,154,374 13,045 912,004 40 22,777
Elucigene FH20_LIPOchip 15,197,129 13,037 Dominated Dominated Dominated
LIPOchip_MLPA 15,378,300 13,048 Ext Dom Ext Dom Ext Dom
Elucigene FH20_LIPOchip_MLPA 15,473,900 13,048 Dominated Dominated Dominated
CGA 15,688,212 13,056 533,838 11 47,698
Elucigene FH20_CGA 15,751,612 13,056 Dominated Dominated Dominated
LIPOchip_CGA 15,916,012 13,056 Dominated Dominated Dominated
Elucigene FH20_LIPOchip_CGA 16,011,612 13,056 Dominated Dominated Dominated
LDL-C 17,678,183 13,079 1,989,970 23 86,558
Ext Dom, extendedly dominated.
TABLE 55.1b  Cost of MOLU (high value) = £40, index cases (relevant comparison LDL-C)
Test Total costs (£) Total QALYs Incremental costs (£) Incremental QALYs
Elucigene FH20 14,242,370 13,005 –3,435,812 –74
LIPOchip platform – Spain 15,154,374 13,045 –2,523,808 –34
CGA 15,688,212 13,056 –1,989,970 –23
LDL–C 17,678,183 13,079 – –
TABLE 55.1c  Cost of MOLU (high value) = £40, index cases (relevant comparison CGA)
Test Total costs (£) Total QALYs Incremental costs (£) Incremental QALYs ICER (£/QALY)
Elucigene FH20 14,242,370 13,005 –1,445,842 –51
LIPOchip platform – Spain 15,154,374 13,045 –533,838 –11
CGA 15,688,212 13,056
LDL-C 17,678,183 13,079 1,989,970 23 86,558© Queen’s Printer and Controller of HMSO 2012. This work was produced by Sharma et al. under the terms of a commissioning contract issued by the 
Secretary of State for Health.
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TABLE 55.2a  Cost of MOLU (high value) = £40, index cases and relatives (sequentially presented results)
Test strategy Total costs (£) Total QALYs Incremental costs (£) Incremental QALYs ICER (£/QALY)
Elucigene FH20 43,444,427 36,653
LDL-C 43,880,789 34,744 Dominated Dominated Dominated
Elucigene FH20_MLPA 44,566,239 37,216 Ext Dom Ext Dom Ext Dom
LIPOchip 46,656,350 38,240 Ext Dom Ext Dom Ext Dom
Elucigene FH20_LIPOchip 46,751,950 38,240 Dominated Dominated Dominated
LIPOchip platform – Spain 47,343,602 38,668 3,899,175 2015 1935
LIPOchip_MLPA 47,768,083 38,803 Ext Dom Ext Dom Ext Dom
Elucigene FH20_LIPOchip_MLPA 47,863,683 38,803 Dominated Dominated Dominated
CGA 48,712,402 39,231 1,368,800 563 2430
Elucigene FH20_CGA 48,775,802 39,231 Dominated Dominated Dominated
LIPOchip_CGA 48,940,202 39,231 Dominated Dominated Dominated
Elucigene FH20_LIPOchip_CGA 49,035,802 39,231 Dominated Dominated Dominated
Ext Dom, extendedly dominated.
TABLE 55.2b  Cost of MOLU (high value) = £40, index cases and relatives (relevant comparison LDL-C)
Test Total costs (£) Total QALYs Incremental costs (£) Incremental QALYs ICER (£/QALY)
Elucigene FH20 43,444,427 36,653 –436,362 1909 Dominant
LDL-C 43,880,789 34,744
LIPOchip platform – Spain 47,343,602 38,668 3,462,813 3924 883
CGA 48,712,402 39,231 4,831,613 4487 1077
TABLE 55.2c  Cost of MOLU (high value) = £40, index cases and relatives (relevant comparison CGA)
Test Total costs (£) Total QALYs Incremental costs (£) Incremental QALYs
Elucigene FH20 43,444,427 36,653 –5,267,975 –2578
LIPOchip platform – Spain 47,343,602 38,668 –1,368,800 –563
CGA 48,712,402 39,231
TABLE 56.1a  Cost of MOLU (low value) = £20, index cases (sequentially presented results)
Test strategy Total costs (£) Total QALYs Incremental costs (£) Incremental QALYs ICER (£/QALY)
Elucigene FH20 14,142,370 13,005
Elucigene FH20_MLPA 14,395,661 13,016 Ext Dom Ext Dom Ext Dom
LIPOchip 14,881,529 13,037 Ext Dom Ext Dom Ext Dom
Elucigene FH20_LIPOchip 14,929,329 13,037 Dominated Dominated Dominated
LIPOchip_MLPA 15,129,780 13,048 987,410 43 23,108
LIPOchip platform – Spain 15,154,374 13,045 Dominated Dominated Dominated
Elucigene FH20_LIPOchip_MLPA 15,177,580 13,048 Dominated Dominated Dominated
CGA 15,368,212 13,056 238,432 9 28,038
Elucigene FH20_CGA 15,399,912 13,056 Dominated Dominated Dominated
LIPOchip_CGA 15,482,112 13,056 Dominated Dominated Dominated
Elucigene FH20_LIPOchip_CGA 15,529,912 13,056 Dominated Dominated Dominated
LDL-C 17,678,183 13,079 2,309,970 23 100,474
Ext Dom, extendedly dominated.210 Appendix 14
TABLE 56.1b  Cost of MOLU (low value) = £20, index cases (relevant comparison LDL-C)
Test Total costs (£) Total QALYs Incremental costs (£) Incremental QALYs
Elucigene FH20 14,142,370 13,005 –3,535,812 –74
LIPOchip_MLPA 15,129,780 13,048 –2,548,403 –31
CGA 15,368,212 13,056 –2,309,970 –23
LDL-C 17,678,183 13,079 – –
TABLE 56.1c  Cost of MOLU (low value) = £20, index cases (relevant comparison CGA)
Test Total costs (£) Total QALYs Incremental costs (£) Incremental QALYs ICER (£/QALY)
Elucigene FH20 14,142,370 13,005 –1,225,842 –51
LIPOchip_MLPA 15,129,780 13,048 –238,432 –9
CGA 15,368,212 13,056 –
LDL-C 17,678,183 13,079 2,309,970 23 100,477
TABLE 56.2a  Cost of MOLU (low value) = £20, index cases and relatives (sequentially presented results)
Test strategy Total costs (£) Total QALYs Incremental costs (£) Incremental QALYs ICER (£/QALY)
Elucigene FH20 43,299,542 36,653
LDL-C 43,880,789 34,744 Dominated Dominated Dominated
Elucigene FH20_MLPA 44,375,300 37,216 Ext Dom Ext Dom Ext Dom
LIPOchip 46,356,258 38,240 Ext Dom Ext Dom Ext Dom
Elucigene FH20_LIPOchip 46,404,058 38,240 Dominated Dominated Dominated
LIPOchip platform – Spain 47,254,017 38,668 Ext Dom Ext Dom Ext Dom
LIPOchip_MLPA 47,426,976 38,803 4,127,434 2150 1920
Elucigene FH20_LIPOchip_MLPA 47,474,776 38,803 Dominated Dominated Dominated
CGA 48,290,322 39,231 863,346 428 2017
Elucigene FH20_CGA 48,322,022 39,231 Dominated Dominated Dominated
LIPOchip_CGA 48,404,222 39,231 Dominated Dominated Dominated
Elucigene FH20_LIPOchip_CGA 48,452,022 39,231 Dominated Dominated Dominated
Ext Dom, extendedly dominated.
TABLE 56.2b  Cost of MOLU (low value) = £20, index cases and relatives (relevant comparison LDL-C)
Test Total costs (£) Total QALYs Incremental costs (£) Incremental QALYs ICER (£/QALY)
Elucigene FH20 43,299,542 36,653 –581,247 1909 Dominant
LDL-C 43,880,789 34,744
LIPOchip_MLPA 47,426,976 38,803 3,546,187 4059 874
CGA 48,290,322 39,231 4,409,532 4487 983© Queen’s Printer and Controller of HMSO 2012. This work was produced by Sharma et al. under the terms of a commissioning contract issued by the 
Secretary of State for Health.
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TABLE 56.2c  Cost of MOLU (low value) = £20, index cases and relatives (relevant comparison CGA)
Test Total costs (£) Total QALYs Incremental costs (£) Incremental QALYs
Elucigene FH20 43,299,542 36,653 –4,990,780 –2578
LIPOchip_MLPA 47,426,976 38,803 –863,346 –428
CGA 48,290,322 39,231
TABLE 57a  Cascade testing of first- and second-degree relatives only (sequentially presented results)
Test strategy Total costs (£) Total QALYs Incremental costs (£) Incremental QALYs ICER (£/QALY)
Elucigene FH20 37,712,894 32,096
Elucigene FH20_MLPA 38,506,088 32,440 Ext Dom Ext Dom Ext Dom
LDL-C 39,319,481 30,973 Dominated Dominated Dominated
LIPOchip 39,986,115 33,066 Ext Dom Ext Dom Ext Dom
Elucigene FH20_LIPOchip 40,057,815 33,066 Dominated Dominated Dominated
LIPOchip platform – Spain 40,546,431 33,328 2,833,537 1232 2299
LIPOchip_MLPA 40,771,748 33,411 Ext Dom Ext Dom Ext Dom
Elucigene FH20_LIPOchip_MLPA 40,843,448 33,411 Dominated Dominated Dominated
CGA 41,443,392 33,673 896,961 344 2604
Elucigene FH20_CGA 41,490,942 33,673 Dominated Dominated Dominated
LIPOchip_CGA 41,614,242 33,673 Dominated Dominated Dominated
Elucigene FH20_LIPOchip_CGA 41,685,942 33,673 Dominated Dominated Dominated
Ext Dom, extendedly dominated.
TABLE 57b  Cascade testing of first- and second-degree relatives only (relevant comparison LDL-C)
Test Total costs (£) Total QALYs Incremental costs (£) Incremental QALYs ICER (£/QALY)
Elucigene FH20 37,712,894 32,096 –1,606,587 1123 Dominant
LDL-C 39,319,481 30,973
LIPOchip platform – Spain 40,546,431 33,328 1,226,950 2355 521
CGA 41,443,392 33,673 2,123,911 2700 787
TABLE 57c  Cascade testing of first- and second-degree relatives only (relevant comparison CGA)
Test Total costs (£) Total QALYs Incremental costs (£) Incremental QALYs
Elucigene FH20 37,712,894 32,096 –3,730,498 –1577
LIPOchip platform – Spain 40,546,431 33,328 –896,961 –344
CGA 41,443,392 33,673212 Appendix 14
The sensitivity analyses in Table 58 refers to not cascade testing from index cases in whom a 
genetic mutation has not been identified.
TABLE 58.1a  No cascade testing of relatives of index test-negative cases, index cases (sequentially presented results)
Test strategy Total costs (£) Total QALYs Incremental costs (£) Incremental QALYs ICER (£/QALY)
Elucigene FH20 14,192,370 13,005
Elucigene FH20_MLPA 14,462,441 13,016 Ext Dom Ext Dom Ext Dom
LIPOchip 14,991,529 13,037 Ext Dom Ext Dom Ext Dom
Elucigene FH20_LIPOchip 15,063,229 13,037 Dominated Dominated Dominated
LIPOchip platform – Spain 15,154,374 13,045 962,004 40 24,025
LIPOchip_MLPA 15,254,040 13,048 Ext Dom Ext Dom Ext Dom
Elucigene FH20_LIPOchip_MLPA 15,325,740 13,048 Dominated Dominated Dominated
CGA 15,528,212 13,056 373,838 11 33,402
Elucigene FH20_CGA 15,575,762 13,056 Dominated Dominated Dominated
LIPOchip_CGA 15,699,062 13,056 Dominated Dominated Dominated
Elucigene FH20_LIPOchip_CGA 15,770,762 13,056 Dominated Dominated Dominated
LDL-C 17,678,183 13,079 2,149,970 23 93,518
Ext Dom, extendedly dominated.
TABLE 58.1b  No cascade testing of relatives of index test-negative cases, index cases (relevant comparison LDL-C)
Test Total costs (£) Total QALYs Incremental costs (£) Incremental QALYs
Elucigene FH20 14,192,370 13,005 –3,485,812 –74
LIPOchip platform – Spain 15,154,374 13,045 –2,523,808 –34
CGA 15,528,212 13,056 –2,149,970 –23
LDL-C 17,678,183 13,079 – –
TABLE 58.1c  No cascade testing of relatives of index test-negative cases, index cases (relevant comparison CGA)
Test Total costs (£) Total QALYs Incremental costs (£) Incremental QALYs ICER (£/QALY)
Elucigene FH20 14,192,370 13,005 –1,335,842 –51
LIPOchip platform – Spain 15,154,374 13,045 –373,838 –11
CGA 15,528,212 13,056
LDL-C 17,678,183 13,079 2,149,970 23 93,518© Queen’s Printer and Controller of HMSO 2012. This work was produced by Sharma et al. under the terms of a commissioning contract issued by the 
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TABLE 58.2a  No cascade testing of relatives of index test-negative cases, index cases and relatives (sequentially 
presented results)
Test strategy Total costs (£) Total QALYs Incremental costs (£) Incremental QALYs ICER (£/QALY)
Elucigene FH20 21,378,104 18,468
Elucigene FH20_MLPA 23,648,479 20,000 Ext Dom Ext Dom Ext Dom
LIPOchip 27,813,741 22,785 Ext Dom Ext Dom Ext Dom
Elucigene FH20_LIPOchip 27,885,441 22,785 Dominated Dominated Dominated
LIPOchip platform – Spain 29,496,425 23,949 Ext Dom Ext Dom Ext Dom
LIPOchip_MLPA 30,076,556 24,317 Ext Dom Ext Dom Ext Dom
Elucigene FH20_LIPOchip_MLPA 30,148,256 24,317 Dominated Dominated Dominated
CGA 31,870,568 25,481 Ext Dom Ext Dom Ext Dom
Elucigene FH20_CGA 31,918,118 25,481 Dominated Dominated Dominated
LIPOchip_CGA 32,041,418 25,481 Dominated Dominated Dominated
Elucigene FH20_LIPOchip_CGA 32,113,118 25,481 Dominated Dominated Dominated
LDL-C 38,100,678 29,965 16,722,574 11,497 1455
Ext Dom, extendedly dominated.
TABLE 58.2b  No cascade testing of relatives of index test-negative cases, index cases and relatives (relevant 
comparison LDL-C)
Test Total costs (£) Total QALYs Incremental costs (£) Incremental QALYs
Elucigene FH20 21,378,104 18,468 –16,722,574 –11,497
LDL-C 38,100,678 29,965
TABLE 58.2c  No cascade testing of relatives of index test-negative cases, index cases and relatives (relevant 
comparison CGA)
Test Total costs (£) Total QALYs Incremental costs (£) Incremental QALYs ICER (£/QALY)
Elucigene FH20 21,378,104 18,468 –10,492,464 –7012
CGA 31,870,568 25,481
LDL-C 38,100,678 29,965 6,230,110 4484 1389214 Appendix 14
Hadfeld and colleagues66 estimate that 69% of index cases and also 69% of qualifiable relatives 
will agree to genetic testing being carried out. There will not be any implications here for index 
cases alone and therefore the results in Table 59 are for index and relative cases combined only.
TABLE 59a  Adjusting proportions of index cases and relatives agreeing to be tested to 69% (sequentially 
presented results)
Test strategy Total costs (£) Total QALYs Incremental costs (£) Incremental QALYs ICER (£/QALY)
LDL-C 54,528,198 43,548
Elucigene FH20 55,623,568 46,562 1,095,370 3015 363
Elucigene FH20_MLPA 57,168,909 47,433 Ext Dom Ext Dom Ext Dom
LIPOchip 60,016,199 49,016 Ext Dom Ext Dom Ext Dom
Elucigene FH20_LIPOchip 60,087,899 49,016 Dominated Dominated Dominated
LIPOchip platform – Spain 61,148,000 49,678 5,524,433 3116 1773
LIPOchip_MLPA 61,553,981 49,887 Ext Dom Ext Dom Ext Dom
Elucigene FH20_LIPOchip_MLPA 61,625,681 49,887 Dominated Dominated Dominated
CGA 62,797,109 50,549 1,649,109 871 1893
Elucigene FH20_CGA 62,844,659 50,549 Dominated Dominated Dominated
LIPOchip_CGA 62,967,959 50,549 Dominated Dominated Dominated
Elucigene FH20_LIPOchip_CGA 63,039,659 50,549 Dominated Dominated Dominated
Ext Dom, extendedly dominated.
TABLE 59b  Adjusting proportions of index cases and relatives agreeing to be tested to 69% (relevant comparison 
LDL-C)
Test Total costs (£) Total QALYs Incremental costs (£) Incremental QALYs ICER (£/QALY)
LDL-C 54,528,198 43,548      
Elucigene FH20 55,623,568 46,562 1,095,370 3015 363
LIPOchip platform – Spain 61,148,000 49,678 6,619,802 6131 1080
CGA 62,797,109 50,549 8,268,912 7002 1181
TABLE 59c  Adjusting proportions of index cases and relatives agreeing to be tested to 69% (relevant comparison CGA)
Test Total costs (£) Total QALYs Incremental costs (£) Incremental QALYs
LDL-C 54,528,198 43,548 –8,268,912 –7002
Elucigene FH20 55,623,568 46,562 –7,173,542 –3987
LIPOchip platform – Spain 61,148,000 49,678 –1,649,109 –871
CGA 62,797,109 50,549© Queen’s Printer and Controller of HMSO 2012. This work was produced by Sharma et al. under the terms of a commissioning contract issued by the 
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TABLE 60.1a  Assume discount rate for costs and benefits = 0%, index cases (sequentially produced results)
Test strategy Total costs (£) Total QALYs Incremental costs (£) Incremental QALYs ICER (£/QALY)
Elucigene FH20 27,204,825 20,571
Elucigene FH20_MLPA 27,611,712 20,594 Ext Dom Ext Dom Ext Dom
LIPOchip 28,389,507 20,636 Ext Dom Ext Dom Ext Dom
Elucigene FH20_LIPOchip 28,461,207 20,636 Dominated Dominated Dominated
LIPOchip platform – Spain 28,656,305 20,654 1,451,480 84 17,377
LIPOchip_MLPA 28,788,833 20,660 Ext Dom Ext Dom Ext Dom
Elucigene FH20_LIPOchip_MLPA 28,860,533 20,660 Dominated Dominated Dominated
CGA 29,166,959 20,678 510,654 23 21,872
Elucigene FH20_CGA 29,214,509 20,678 Dominated Dominated Dominated
LIPOchip_CGA 29,337,809 20,678 Dominated Dominated Dominated
Elucigene FH20_LIPOchip_CGA 29,409,509 20,678 Dominated Dominated Dominated
LDL_C 32,978,473 20,728 3,811,514 50 75,678
Ext Dom, extendedly dominated.
TABLE 60.1b  Assume discount rate for costs and benefits = 0%, index cases (relevant comparison LDL-C)
Test Total costs (£) Total QALYs Incremental costs (£) Incremental QALYs
Elucigene FH20 27,204,825 20,571 –5,773,648 –157
LIPOchip platform – Spain 28,656,305 20,654 –4,322,169 –74
CGA 29,166,959 20,678 –3,811,514 –50
LDL-C 32,978,473 20,728 – –
TABLE 60.1c  Assume discount rate for costs and benefits = 0%, index cases (relevant comparison CGA)
Test Total costs (£) Total QALYs Incremental costs (£) Incremental QALYs ICER (£/QALY)
Elucigene FH20 27,204,825 20,571 –1,962,134 –107
LIPOchip platform – Spain 28,656,305 20,654 –510,654 –23
CGA 29,166,959 20,678 – –
LDL-C 32,978,473 20,728 3,811,514 50 75,678
TABLE 60.2a  Assume discount rate for costs and benefits = 0%, index cases and relatives (sequentially 
produced results)
Test strategy Total costs (£) Total QALYs Incremental costs (£) Incremental QALYs ICER (£/QALY)
Elucigene FH20 80,370,221 58,348
LDL-C 80,740,629 55,359 Dominated Dominated Dominated
Elucigene FH20_MLPA 82,281,317 59,248 Ext Dom Ext Dom Ext Dom
LIPOchip 85,793,478 60,883 Ext Dom Ext Dom Ext Dom
Elucigene FH20_LIPOchip 85,865,178 60,883 Dominated Dominated Dominated
LIPOchip platform – Spain 87,203,180 61,566 6,832,959 3218 2123
LIPOchip_MLPA 87,697,014 61,782 Ext Dom Ext Dom Ext Dom
Elucigene FH20_LIPOchip_MLPA 87,768,714 61,782 Dominated Dominated Dominated
CGA 89,218,043 62,466 2,014,863 899 2240
Elucigene FH20_CGA 89,265,593 62,466 Dominated Dominated Dominated
LIPOchip_CGA 89,388,893 62,466 Dominated Dominated Dominated
Elucigene FH20_LIPOchip_CGA 89,460,593 62,466 Dominated Dominated Dominated
Ext Dom, extendedly dominated.216 Appendix 14
TABLE 60.2b  Assume discount rate for costs and benefits = 0%, index cases and relatives (relevant comparison LDL-C)
Test Total costs (£) Total QALYs Incremental costs (£) Incremental QALYs ICER (£/QALY)
Elucigene FH20 80,370,221 58,348 –370,048 2990 Dominant
LDL-C 80,740,629 55,359
LIPOchip platform – Spain 87,203,180 61,566 6,462,911 6208 1041
CGA 89,218,043 62,466 8,477,774 7107 1193
TABLE 60.2c  Assume discount rate for costs and benefits = 0%, index cases and relatives (relevant comparison CGA)
Test Total costs (£) Total QALYs Incremental costs (£) Incremental QALYs
Elucigene FH20 80,370,221 58,348 –8,814,822 –4117
LIPOchip platform – Spain 87,203,180 61,566 –2,014,863 –899
CGA 89,218,043 62,466
TABLE 61.1a  Assume discount rate for costs and benefits = 6%, index cases (sequentially produced results)
Test strategy Total costs (£) Total QALYs Incremental costs (£) Incremental QALYs ICER (£/QALY)
Elucigene FH20 10,029,010 10,117
Elucigene FH20_MLPA 10,248,696 10,125 Ext Dom Ext Dom Ext Dom
LIPOchip 10,686,196 10,138 Ext Dom Ext Dom Ext Dom
Elucigene FH20_LIPOchip 10,757,896 10,138 Dominated Dominated Dominated
LIPOchip platform – Spain 10,810,758 10,143 781,748 26 30,023
LIPOchip_MLPA 10,898,322 10,145 Ext Dom Ext Dom Ext Dom
Elucigene FH20_LIPOchip_MLPA 10,970,022 10,145 Dominated Dominated Dominated
CGA 11,134,212 10,151 323,454 7 44,442
Elucigene FH20_CGA 11,181,762 10,151 Dominated Dominated Dominated
LIPOchip_CGA 11,305,062 10,151 Dominated Dominated Dominated
Elucigene FH20_LIPOchip_CGA 11,376,762 10,151 Dominated Dominated Dominated
LDL-C 12,668,695 10,165 1,534,483 14 109,720
Ext Dom, extendedly dominated.
TABLE 61.1b  Assume discount rate for costs and benefits = 6%, index cases (relevant comparison LDL-C)
Test Total costs (£) Total QALYs Incremental costs (£) Incremental QALYs
Elucigene FH20 10,029,010 10,117 –2,639,685 –47
LIPOchip platform – Spain 10,810,758 10,143 –1,857,937 –21
CGA 11,134,212 10,151 –1,534,483 –14
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TABLE 61.1c  Assume discount rate for costs and benefits = 6%, index cases (relevant comparison CGA)
Test Total costs (£) Total QALYs Incremental costs (£) Incremental QALYs ICER (£/QALY)
Elucigene FH20 10,029,010 10,117 –1,105,202 –33
LIPOchip platform – Spain 10,810,758 10,143 –323,454 –7
CGA 11,134,212 10,151 – –
LDL-C 12,668,695 10,165 1,534,483 14 109,720
TABLE 61.2a  Assume discount rate for costs and benefits = 6%, index cases and relatives (sequentially 
produced results)
Test strategy Total costs (£) Total QALYs Incremental costs (£) Incremental QALYs ICER (£/QALY)
Elucigene FH20 31,278,303 28,428
LDL-C 31,745,080 26,934 Dominated Dominated Dominated
Elucigene FH20_MLPA 32,102,865 28,865 Ext Dom Ext Dom Ext Dom
LIPOchip 33,639,915 29,658 Ext Dom Ext Dom Ext Dom
Elucigene FH20_LIPOchip 33,711,615 29,658 Dominated Dominated Dominated
LIPOchip platform – Spain 34,224,064 29,989 2,945,761 1561 1887
LIPOchip_MLPA 34,456,917 30,094 Ext Dom Ext Dom Ext Dom
Elucigene FH20_LIPOchip_MLPA 34,528,617 30,094 Dominated Dominated Dominated
CGA 35,152,394 30,426 928,329 436 2127
Elucigene FH20_CGA 35,199,944 30,426 Dominated Dominated Dominated
LIPOchip_CGA 35,323,244 30,426 Dominated Dominated Dominated
Elucigene FH20_LIPOchip_CGA 35,394,944 30,426 Dominated Dominated Dominated
Ext Dom, extendedly dominated.
TABLE 61.2b  Assume discount rate for costs and benefits = 6%, index cases and relatives (relevant comparison LDL-C)
Test Total costs (£) Total QALYs Incremental costs (£) Incremental QALYs ICER (£/QALY)
Elucigene FH20 31,278,303 28,428 –466,777 1494 Dominant
LDL-C 31,745,080 26,934
LIPOchip platform – Spain 34,224,064 29,989 2,478,984 3055 811
CGA 35,152,394 30,426 3,407,313 3492 976
TABLE 61.2c  Assume discount rate for costs and benefits = 6%, index cases and relatives (relevant comparison CGA)
Test Total costs (£) Total QALYs Incremental costs (£) Incremental QALYs
Elucigene FH20 31,278,303 28,428 –3,874,090 –1998
LIPOchip platform – Spain 34,224,064 29,989 –928,329 –436
CGA 35,152,394 30,426218 Appendix 14
The base-case analysis assumes that there will be no reduction in the cost of next-generation 
sequencing. Clinical advice is that there will be a reduction in cost; however, we are unsure as 
to how much that reduction will be in practice. Table 62 presents the results of the sensitivity 
analysis assuming that next-generation sequencing costs will reduce by 40% into the future.
TABLE 62.1a  Forty per cent reduction in costs of next-generation sequencing, index cases (sequentially 
presented results)
Test strategy Total costs (£) Total QALYs Incremental costs (£) Incremental QALYs ICER (£/QALY)
Elucigene FH20 14,192,370 13,005
Elucigene FH20_MLPA 14,462,441 13,016 Ext Dom Ext Dom Ext Dom
LIPOchip 14,991,529 13,037 Ext Dom Ext Dom Ext Dom
Elucigene FH20_LIPOchip 15,063,229 13,037 Dominated Dominated Dominated
LIPOchip platform – Spain 15,154,374 13,045 Ext Dom Ext Dom Ext Dom
LIPOchip_MLPA 15,254,040 13,048 Ext Dom Ext Dom Ext Dom
Elucigene FH20_LIPOchip_MLPA 15,325,740 13,048 Dominated Dominated Dominated
CGA 15,372,212 13,056 1,179,842 51 23,029
Elucigene FH20_CGA 15,444,878 13,056 Dominated Dominated Dominated
LIPOchip_CGA 15,587,834 13,056 Dominated Dominated Dominated
Elucigene FH20_LIPOchip_CGA 15,659,534 13,056 Dominated Dominated Dominated
LDL-C 17,678,183 13,079 2,305,970 23 100,303
Ext Dom, extendedly dominated.
TABLE 62.1b  Forty per cent reduction in costs of next-generation sequencing, index cases (relevant comparison 
LDL-C)
Test Total costs (£) Total QALYs Incremental costs (£) Incremental QALYs
Elucigene FH20 14,192,370 13,005 –3,485,812 –74
CGA 15,372,212 13,056 –2,305,970 –23
LDL-C 17,678,183 13,079
TABLE 62.1c  Forty per cent reduction in costs of next-generation sequencing, index cases (relevant comparison CGA)
Test Total costs (£) Total QALYs Incremental costs (£) Incremental QALYs ICER (£/QALY)
Elucigene FH20 14,192,370 13,005 –1,179,842 –51
CGA 15,372,212 13,056
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TABLE 62.2a  Forty per cent reduction in costs of next-generation sequencing, index cases and relatives (sequentially 
presented results)
Test strategy Total costs (£) Total QALYs Incremental costs (£) Incremental QALYs ICER (£/QALY)
Elucigene FH20 43,371,985 36,653
LDL-C 43,880,789 34,744 Dominated Dominated Dominated
Elucigene FH20_MLPA 44,470,770 37,216 Ext Dom Ext Dom Ext Dom
LIPOchip 46,506,304 38,240 Ext Dom Ext Dom Ext Dom
Elucigene FH20_LIPOchip 46,578,004 38,240 Dominated Dominated Dominated
LIPOchip platform – Spain 47,298,810 38,668 Ext Dom Ext Dom Ext Dom
LIPOchip_MLPA 47,597,529 38,803 Ext Dom Ext Dom Ext Dom
Elucigene FH20_LIPOchip_MLPA 47,669,229 38,803 Dominated Dominated Dominated
CGA 48,345,362 39,231 4,973,377 2578 1929
Elucigene FH20_CGA 48,418,028 39,231 Dominated Dominated Dominated
LIPOchip_CGA 48,560,984 39,231 Dominated Dominated Dominated
Elucigene FH20_LIPOchip_CGA 48,632,684 39,231 Dominated Dominated Dominated
Ext Dom, extendedly dominated.
TABLE 62.2b  Forty per cent reduction in costs of next-generation sequencing, index cases and relatives (relevant 
comparison LDL-C)
Test Total costs (£) Total QALYs Incremental costs (£) Incremental QALYs ICER (£/QALY)
Elucigene FH20 43,371,985 36,653 –508,805 1909 Dominant
LDL-C 43,880,789 34,744
CGA 48,345,362 39,231 4,464,573 4487 995
TABLE 62.2c  Forty per cent reduction in costs of next-generation sequencing, index cases and relatives (relevant 
comparison CGA)
Test Total costs (£) Total QALYs Incremental costs (£) Incremental QALYs
Elucigene FH20 43,371,985 36,653 –4,973,377 –2578
CGA 48,345,362 39,231220 Appendix 14
Table 63 details the effect of a high value for the sensitivity of Elucigene FH20. This is the highest 
estimate from the clinical effectiveness review and is 52%.38
TABLE 63.1a  High estimate for sensitivity of Elucigene FH20 = 0.52, index cases (sequentially presented results)
Test strategy Total costs (£) Total QALYs Incremental costs (£) Incremental QALYs ICER (£/QALY)
Elucigene FH20 14,336,524 13,013
Elucigene FH20_MLPA 14,604,854 13,024 Ext Dom Ext Dom Ext Dom
LIPOchip 14,991,529 13,037 Ext Dom Ext Dom Ext Dom
Elucigene FH20_LIPOchip 15,054,529 13,037 Dominated Dominated Dominated
LIPOchip platform – Spain 15,154,374 13,045 817,851 33 25,012
LIPOchip_MLPA 15,254,040 13,048 Ext Dom Ext Dom Ext Dom
Elucigene FH20_LIPOchip_MLPA 15,317,040 13,048 Dominated Dominated Dominated
CGA 15,528,212 13,056 373,838 11 33,402
Elucigene FH20_CGA 15,562,712 13,056 Dominated Dominated Dominated
LIPOchip_CGA 15,699,062 13,056 Dominated Dominated Dominated
Elucigene FH20_LIPOchip_CGA 15,762,062 13,056 Dominated Dominated Dominated
LDL-C 17,678,183 13,079 2,149,970 23 93,518
Ext Dom, extendedly dominated.
TABLE 63.1b  High estimate for sensitivity of Elucigene FH20 = 0.52, index cases (relevant comparison LDL-C)
Test Total costs (£) Total QALYs Incremental costs (£) Incremental QALYs
Elucigene FH20 14,336,524 13,013 –3,341,659 –67
LIPOchip platform – Spain 15,154,374 13,045 –2,523,808 –34
CGA 15,528,212 13,056 –2,149,970 –23
LDL-C 17,678,183 13,079
TABLE 63.1c  High estimate for sensitivity of Elucigene FH20 = 0.52, index cases (relevant comparison CGA) 
Test Total costs (£) Total QALYs Incremental costs (£) Incremental QALYs ICER (£/QALY)
Elucigene FH20 14,336,524 13,013 –1,191,689 –44
LIPOchip platform – Spain 15,154,374 13,045 –373,838 –11
CGA 15,528,212 13,056
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TABLE 63.2a  High estimate for sensitivity of Elucigene FH20 = 0.52, index cases and relatives (sequentially 
presented results)
Test strategy Total costs (£) Total QALYs Incremental costs (£) Incremental QALYs ICER (£/QALY)
LDL-C 43,880,789 34,744
Elucigene FH20 44,059,813 37,022 179,023 2278 79
Elucigene FH20_MLPA 45,156,858 37,586 Ext Dom Ext Dom Ext Dom
LIPOchip 46,506,304 38,240 Ext Dom Ext Dom Ext Dom
Elucigene FH20_LIPOchip 46,569,304 38,240 Dominated Dominated Dominated
LIPOchip platform – Spain 47,298,810 38,668 3,238,997 1645 1968
LIPOchip_MLPA 47,597,529 38,803 Ext Dom Ext Dom Ext Dom
Elucigene FH20_LIPOchip_MLPA 47,660,529 38,803 Dominated Dominated Dominated
CGA 48,501,362 39,231 1,202,552 563 2135
Elucigene FH20_CGA 48,535,862 39,231 Dominated Dominated Dominated
LIPOchip_CGA 48,672,212 39,231 Dominated Dominated Dominated
Elucigene FH20_LIPOchip_CGA 48,735,212 39,231 Dominated Dominated Dominated
Ext Dom, extendedly dominated.
TABLE 63.2b  High estimate for sensitivity of Elucigene FH20 = 0.52, index cases and relatives (relevant comparison 
LDL-C)
Test Total costs (£) Total QALYs Incremental costs (£) Incremental QALYs ICER (£/QALY)
LDL-C 43,880,789 34,744
Elucigene FH20 44,059,813 37,022 179,023 2278 79
LIPOchip platform – Spain 47,298,810 38,668 3,418,020 3924 871
CGA 48,501,362 39,231 4,620,573 4487 1030
TABLE 63.2c  High estimate for sensitivity of Elucigene FH20 = 0.52, index cases and relatives (relevant 
comparison CGA)
Test Total costs (£) Total QALYs Incremental costs (£) Incremental QALYs
LDL-C 43,880,789 34,744 –4,620,573 –4487
Elucigene FH20 44,059,813 37,022 –4,441,549 –2209
LIPOchip platform – Spain 47,298,810 38,668 –1,202,552 –563
CGA 48,501,362 39,231222 Appendix 14
Table 64 presents the results of sensitivity analysis in which the lower limit of the sensitivity of 
Elucigene FH20 is used (i.e. a sensitivity of 0.286, taken from Hooper and colleagues36).
TABLE 64.1a  Low estimate for sensitivity of Elucigene FH20 = 0.286, index cases (sequentially presented results) 
Test strategy Total costs (£) Total QALYs Incremental costs (£) Incremental QALYs ICER (£/QALY)
Elucigene FH20 13,916,450 12,991
Elucigene FH20_MLPA 14,189,881 13,002 Ext Dom Ext Dom Ext Dom
LIPOchip 14,991,529 13,037 Ext Dom Ext Dom Ext Dom
Elucigene FH20_LIPOchip 15,080,029 13,037 Dominated Dominated Dominated
LIPOchip platform – Spain 15,154,374 13,045 1,237,924 54 22,884
LIPOchip_MLPA 15,254,040 13,048 Ext Dom Ext Dom Ext Dom
Elucigene FH20_LIPOchip_MLPA 15,342,480 13,048 Dominated Dominated Dominated
CGA 15,528,212 13,056 373,838 11 33,402
Elucigene FH20_CGA 15,600,962 13,056 Dominated Dominated Dominated
LIPOchip_CGA 15,699,062 13,056 Dominated Dominated Dominated
Elucigene FH20_LIPOchip_CGA 15,787,112 13,056 Dominated Dominated Dominated
LDL-C 17,678,183 13,079 2,149,970 23 93,518
Ext Dom, extendedly dominated.
TABLE 64.1b  Low estimate for sensitivity of Elucigene FH20 = 0.286, index cases (relevant comparison LDL-C) 
Test Total costs (£) Total QALYs Incremental costs (£) Incremental QALYs
Elucigene FH20 13,916,450 12,991 –3,761,732 –88
LIPOchip platform – Spain 15,154,374 13,045 –2,523,808 –34
CGA 15,528,212 13,056 –2,149,970 –23
LDL-C 17,678,183 13,079
TABLE 64.1c  Low estimate for sensitivity of Elucigene FH20 = 0.286, index cases (relevant comparison CGA) 
Test Total costs (£) Total QALYs Incremental costs (£) Incremental QALYs ICER (£/QALY)
Elucigene FH20 13,916,450 12,991 –1,611,762 –65
LIPOchip platform – Spain 15,154,374 13,045 –373,838 –11
CGA 15,528,212 13,056
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TABLE 64.2a  Low estimate for sensitivity of Elucigene FH20 = 0.286, index cases and relatives (sequentially 
presented results) 
Test strategy Total costs (£) Total QALYs Incremental costs (£) Incremental QALYs ICER (£/QALY)
Elucigene FH20 42,055,432 35,946
Elucigene FH20_MLPA 43,157,577 36,509 Ext Dom Ext Dom Ext Dom
LDL-C 43,880,789 34,744 Dominated Dominated Dominated
LIPOchip 46,506,304 38,240 Ext Dom Ext Dom Ext Dom
Elucigene FH20_LIPOchip 46,594,804 38,240 Dominated Dominated Dominated
LIPOchip platform – Spain 47,298,810 38,668 5,243,377 2722 1926
LIPOchip_MLPA 47,597,529 38,803 Ext Dom Ext Dom Ext Dom
Elucigene FH20_LIPOchip_MLPA 47,685,969 38,803 Dominated Dominated Dominated
CGA 48,501,362 39,231 1,202,552 563 2135
Elucigene FH20_CGA 48,574,112 39,231 Dominated Dominated Dominated
LIPOchip_CGA 48,672,212 39,231 Dominated Dominated Dominated
Elucigene FH20_LIPOchip_CGA 48,760,262 39,231 Dominated Dominated Dominated
Ext Dom, extendedly dominated.
TABLE 64.2b  Low estimate for sensitivity of Elucigene FH20 = 0.286, index cases and relatives (relevant comparison 
LDL-C) 
Test Total costs (£) Total QALYs Incremental costs (£) Incremental QALYs ICER (£/QALY)
Elucigene FH20 42,055,432 35,946 –1,825,357 1202 Dominant
LDL-C 43,880,789 34,744
LIPOchip platform – Spain 47,298,810 38,668 3,418,020 3924 871
CGA 48,501,362 39,231 4,620,573 4487 1030
TABLE 64.2c  Low estimate for sensitivity of Elucigene FH20 = 0.286, index cases and relatives (relevant 
comparison CGA) 
Test  Total costs (£) Total QALYs Incremental costs (£) Incremental QALYs
Elucigene FH20 42,055,432 35,946 –6,445,390 –3285
LIPOchip platform – Spain 47,298,810 38,668 –1,202,552 –563
CGA 48,501,362 39,231224 Appendix 14
Tables 65 and 66 report deterministic sensitivity analyses for LIPOchip sensitivity. The high value 
is taken from Stef and colleagues42 and the low value is taken from Callaway and colleagues.40
TABLE 65.1a  High estimate for sensitivity of LIPOchip = 0.945, index cases (sequentially presented results)
Test strategy Total costs (£) Total QALYs Incremental costs (£) Incremental QALYs ICER (£/QALY)
Elucigene FH20 14,192,370 13,005
Elucigene FH20_MLPA 14,462,411 13,016 Ext Dom Ext Dom Ext Dom
LIPOchip platform – Spain 15,149,123 13,045 Ext Dom Ext Dom Ext Dom
LIPOchip 15,279,477 13,051 Ext Dom Ext Dom Ext Dom
Elucigene FH20_LIPOchip 15,351,177 13,051 Dominated Dominated Dominated
CGA 15,528,212 13,056 Ext Dom Ext Dom Ext Dom
LIPOchip_MLPAa 15,538,448 13,063 1,346,078 57 23,452
Elucigene FH20_CGA 15,575,762 13,056 Dominated Dominated Dominated
Elucigene FH20_LIPOchip_MLPA 15,610,148 13,063 Dominated Dominated Dominated
LIPOchip_CGA 15,672,512 13,056 Dominated Dominated Dominated
Elucigene FH20_LIPOchip_CGA 15,744,212 13,056 Dominated Dominated Dominated
LDL-C 17,678,183 13,079 2,139,735 17 127,161
Ext Dom, extendedly dominated.
a  Results for this extreme scenario are not reliable as they would lead to a sensitivity of LIPOchip_MLPA of > 1.
TABLE 65.1b  High estimate for sensitivity of LIPOchip = 0.945, index cases (relevant comparison LDL-C) 
Test Total costs (£) Total QALYs Incremental costs (£) Incremental QALYs
Elucigene FH20 14,192,370 13,005 –3,485,812 –74
LIPOchip_MLPAa 15,538,448 13,063 –2,139,735 –17
LDL-C 17,678,183 13,079
a  Results for this extreme scenario are not reliable as they would lead to a sensitivity of LIPOchip_MLPA of > 1.
TABLE 65.1c  High estimate for sensitivity of LIPOchip = 0.945, index cases (relevant comparison CGA) 
Test  Total costs (£) Total QALYs Incremental costs (£) Incremental QALYs ICER (£/QALY)
Elucigene FH20 14,192,370 13,005 –1,335,842 –51
CGA 15,528,212 13,056
LIPOchip_MLPAa 15,538,448 13,063 10,235 6 1661
LDL-C 17,678,183 13,079 2,149,970 23 93,518
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TABLE 65.2a  High estimate for sensitivity of LIPOchip = 0.945, index cases and relatives (sequentially presented results) 
Test strategy Total costs (£) Total QALYs Incremental costs (£) Incremental QALYs ICER (£/QALY)
Elucigene FH20 43,371,985 36,653
LDL-C 43,880,789 34,744 Dominated Dominated Dominated
Elucigene FH20_MLPA 44,470,770 37,216 Ext Dom Ext Dom Ext Dom
LIPOchip platform – Spain 47,293,559 38,668 Ext Dom Ext Dom Ext Dom
LIPOchip 47,880,247 38,978 Ext Dom Ext Dom Ext Dom
Elucigene FH20_LIPOchip 47,951,947 38,978 Dominated Dominated Dominated
CGA 48,501,362 39,231 Ext Dom Ext Dom Ext Dom
Elucigene FH20_CGA 48,548,912 39,231 Dominated Dominated Dominated
LIPOchip_CGA 48,645,662 39,231 Dominated Dominated Dominated
Elucigene FH20_LIPOchip_CGA 48,717,362 39,231 Dominated Dominated Dominated
LIPOchip_MLPAa 48,967,932 39,541 5,595,947 2888 1937
Elucigene FH20_LIPOchip_MLPA 49,039,632 39,541 Dominated Dominated Dominated
Ext Dom, extendedly dominated.
a  Results for this extreme scenario are not reliable as they would lead to a sensitivity of LIPOchip_MLPA of > 1.
TABLE 65.2b  High estimate for sensitivity of LIPOchip = 0.945, index cases and relatives (relevant comparison LDL-C) 
Test Total costs (£) Total QALYs Incremental costs (£) Incremental QALYs ICER (£/QALY)
Elucigene FH20 43,371,985 36,653 –508,805 1909 Dominant
LDL-C 43,880,789 34,744
LIPOchip_MLPAa 48,967,932 39,541 5,087,143 4797 1060
a  Results for this extreme scenario are not reliable as they would lead to a sensitivity of LIPOchip_MLPA of > 1.
TABLE 65.2c  High estimate for sensitivity of LIPOchip = 0.945, index cases and relatives (relevant comparison CGA)
Test  Total costs (£) Total QALYs Incremental costs (£) Incremental QALYs ICER (£/QALY)
Elucigene FH20 43,371,985 36,653 –5,129,377 –2578
CGA 48,501,362 39,231 – –
LIPOchip_MLPAa 48,967,932 39,541 466,570 310 1504
a  Results for this extreme scenario are not reliable as they would lead to a sensitivity of LIPOchip_MLPA of > 1.226 Appendix 14
TABLE 66.1a  Low estimate for sensitivity of LIPOchip = 0.33, index cases (sequentially presented results)
Test strategy Total costs (£) Total QALYs Incremental costs (£) Incremental QALYs ICER (£/QALY)
LIPOchip 14,175,438 12,995
Elucigene FH20 14,192,370 13,005 Ext Dom Ext Dom Ext Dom
Elucigene FH20_LIPOchip 14,247,138 12,995 Dominated Dominated Dominated
LIPOchip_MLPA 14,447,909 13,006 Ext Dom Ext Dom Ext Dom
Elucigene FH20_MLPA 14,462,441 13,016 287,002 21 13,523
Elucigene FH20_LIPOchip_MLPA 14,519,669 13,006 Dominated Dominated Dominated
LIPOchip platform – Spain 15,169,148 13,045 706,707 29 24,497
CGA 15,528,212 13,056 359,064 11 32,082
Elucigene FH20_CGA 15,575,762 13,056 Dominated Dominated Dominated
LIPOchip_CGA 15,773,762 13,056 Dominated Dominated Dominated
Elucigene FH20_LIPOchip_CGA 15,845,912 13,056 Dominated Dominated Dominated
LDL-C 17,678,183 13,079 2,149,970 23 93,518
Ext Dom, extendedly dominated.
TABLE 66.1b  Low estimate for sensitivity of LIPOchip = 0.33, index cases (relevant comparison LDL-C) 
Test Total costs (£) Total QALYs Incremental costs (£) Incremental QALYs
LIPOchip 14,175,438 12,995 –3,502,744 –84
Elucigene FH20_MLPA 14,462,441 13,016 –3,215,742 –63
LIPOchip platform – Spain 15,169,148 13,045 –2,509,034 –34
CGA 15,528,212 13,056 –2,149,970 –23
LDL-C 17,678,183 13,079
TABLE 66.1c  Low estimate for sensitivity of LIPOchip = 0.33, index cases (relevant comparison CGA) 
Test Total costs (£) Total QALYs Incremental costs (£) Incremental QALYs ICER (£/QALY)
LIPOchip 14,175,438 12,995 –1,352,774 –61
Elucigene FH20_MLPA 14,462,441 13,016 –1,065,771 –40
LIPOchip platform – Spain 15,169,148 13,045 –359,064 –11
CGA 15,528,212 13,056
LDL-C 17,678,183 13,079 2,149,970 23 93,518© Queen’s Printer and Controller of HMSO 2012. This work was produced by Sharma et al. under the terms of a commissioning contract issued by the 
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TABLE 66.2a  Low estimate for sensitivity of LIPOchip = 0.33, index cases and relatives (sequentially presented results) 
Test strategy Total costs (£) Total QALYs Incremental costs (£) Incremental QALYs ICER (£/QALY)
LIPOchip 42,612,324 36,148
Elucigene FH20_LIPOchip 42,684,024 36,148 Dominated Dominated Dominated
Elucigene FH20 43,371,985 36,653 Ext Dom Ext Dom Ext Dom
LIPOchip_MLPA 43,713,509 36,711 Ext Dom Ext Dom Ext Dom
Elucigene FH20_LIPOchip_MLPA 43,785,269 36,711 Dominated Dominated Dominated
LDL-C 43,880,789 34,744 Dominated Dominated Dominated
Elucigene FH20_MLPA 44,470,770 37,216 1,858,445 1068 1740
LIPOchip platform – Spain 47,313,584 38,668 2,842,814 1452 1958
CGA 48,501,362 39,231 1,187,778 563 2109
Elucigene FH20_CGA 48,548,912 39,231 Dominated Dominated Dominated
LIPOchip_CGA 48,746,912 39,231 Dominated Dominated Dominated
Elucigene FH20_LIPOchip_CGA 48,819,062 39,231 Dominated Dominated Dominated
Ext Dom, extendedly dominated.
TABLE 66.2b  Low estimate for sensitivity of LIPOchip = 0.33, index cases and relatives (relevant comparison LDL-C) 
Test Total costs (£) Total QALYs Incremental costs (£) Incremental QALYs ICER (£/QALY)
LIPOchip 42,612,324 36,148 –1,268,465 1404 Dominant
LDL-C 43,880,789 34,744
Elucigene FH20_MLPA 44,470,770 37,216 589,980 2472 239
LIPOchip platform – Spain 47,313,584 38,668 3,432,794 3924 875
CGA 48,501,362 39,231 4,620,573 4487 1030
TABLE 66.2c  Low estimate for sensitivity of LIPOchip = 0.33, index cases (relevant comparison CGA) 
Test Total costs (£) Total QALYs Incremental costs (£) Incremental QALYs
LIPOchip 42,612,324 36,148 –5,889,038 –3083
Elucigene FH20_MLPA 44,470,770 37,216 –4,030,592 –2015
LIPOchip platform – Spain 47,313,584 38,668 –1,187,778 –563
CGA 48,501,362 39,231228 Appendix 14
Table 67 details the results of sensitivity analysis using the upper bound of the CI for the 
sensitivity of LDL-C among relatives from Starr and colleagues.49 This applies only to relatives 
and therefore results for index cases alone will not change in this analysis.
TABLE 67a  High estimate for sensitivity of LDL-C in relatives = 0.679 (aged 50 years), index cases and relatives 
(sequentially presented results) 
Test strategy Total costs (£) Total QALYs Incremental costs (£) Incremental QALYs ICER (£/QALY)
Elucigene FH20 48,545,084 40,457
Elucigene FH20_MLPA 49,368,304 40,817 Ext Dom Ext Dom Ext Dom
LDL-C 50,043,807 39,276 Dominated Dominated Dominated
LIPOchip 50,902,913 41,473 Ext Dom Ext Dom Ext Dom
Elucigene FH20_LIPOchip 50,974,613 41,473 Dominated Dominated Dominated
LIPOchip platform – Spain 51,486,042 41,747 2,940,959 1290 2280
LIPOchip_MLPA 51,718,572 41,833 Ext Dom Ext Dom Ext Dom
Elucigene FH20_LIPOchip_MLPA 51,790,272 41,833 Dominated Dominated Dominated
CGA 52,413,029 42,107 926,987 361 2571
Elucigene FH20_CGA 52,460,579 42,107 Dominated Dominated Dominated
LIPOchip_CGA 52,583,879 42,107 Dominated Dominated Dominated
Elucigene FH20_LIPOchip_CGA 52,655,579 42,107 Dominated Dominated Dominated
Ext Dom, extendedly dominated.
TABLE 67b  High estimate for sensitivity of LDL-C in relatives = 0.679 (aged 50 years), index cases and relatives (relevant 
comparison LDL-C) 
Test Total costs (£) Total QALYs Incremental costs (£) Incremental QALYs ICER (£/QALY)
Elucigene FH20 48,545,084 40,457 –1,498,723 1181 Dominant
LDL-C 50,043,807 39,276
LIPOchip platform – Spain 51,486,042 41,747 1,442,235 2471 584
CGA 52,413,029 42,107 2,369,222 2832 837
TABLE 67c  High estimate for sensitivity of LDL-C in relatives = 0.679 (aged 50 years), index cases and relatives (relevant 
comparison CGA) 
Test Total costs (£) Total QALYs Incremental costs (£) Incremental QALYs
Elucigene FH20 48,545,084 40,457 –3,867,946 –1651
LIPOchip platform – Spain 51,486,042 41,747 –926,987 –361
CGA 52,413,029 42,107© Queen’s Printer and Controller of HMSO 2012. This work was produced by Sharma et al. under the terms of a commissioning contract issued by the 
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Table 68 details the results of sensitivity analysis using the lower bound of the CI for the 
sensitivity of LDL-C among relatives from Starr and colleagues.49 This applies only to relatives 
and therefore results for index cases alone will not change in this analysis.
TABLE 68a  Low estimate for sensitivity of LDL-C in relatives = 0.469 (aged 50 years), index cases and relatives 
(sequentially presented results) 
Test strategy Total costs (£) Total QALYs Incremental costs (£) Incremental QALYs ICER (£/QALY)
LDL-C 38,314,283 30,629      
Elucigene FH20 38,699,584 33,199 385,301 2570 150
Elucigene FH20_MLPA 40,047,263 33,946 Ext Dom Ext Dom Ext Dom
LIPOchip 42,535,238 35,304 Ext Dom Ext Dom Ext Dom
Elucigene FH20_LIPOchip 42,606,938 35,304 Dominated Dominated Dominated
LIPOchip platform – Spain 43,516,854 35,872 4,817,270 2673 1802
LIPOchip_MLPA 43,875,357 36,051 Ext Dom Ext Dom Ext Dom
Elucigene FH20_LIPOchip_MLPA 43,947,057 36,051 Dominated Dominated Dominated
CGA 44,968,300 36,619 1,451,446 747 1942
Elucigene FH20_CGA 45,015,850 36,619 Dominated Dominated Dominated
LIPOchip_CGA 45,139,150 36,619 Dominated Dominated Dominated
Elucigene FH20_LIPOchip_CGA 45,210,850 36,619 Dominated Dominated Dominated
Ext Dom, extendedly dominated.
TABLE 68b  Low estimate for sensitivity of LDL-C in relatives = 0.469 (aged 50 years), index cases and relatives (relevant 
comparison LDL-C) 
Test Total costs (£) Total QALYs Incremental costs (£) Incremental QALYs ICER (£/QALY)
LDL-C 38,314,283 30,629
Elucigene FH20 38,699,584 33,199 385,301 2570 150
LIPOchip platform – Spain 43,516,854 35,872 5,202,571 5243 992
CGA 44,968,300 36,619 6,654,018 5990 1111
TABLE 68c  Low estimate for sensitivity of LDL-C in relatives = 0.469 (aged 50 years), index cases and relatives (relevant 
comparison CGA) 
Test Total costs (£) Total QALYs Incremental costs (£) Incremental QALYs
LDL-C 38,314,283 30,629 –6,654,018 –5990
Elucigene FH20 38,699,584 33,199 –6,268,716 –3420
LIPOchip platform – Spain 43,516,854 35,872 –1,451,446 –747
CGA 44,968,300 36,619230 Appendix 14
Table 69 presents analysis for the high estimate of the sensitivity of LDL-C in index cases (high 
value = 1), assuming that if the LDL-C test result is negative then the index case is a true negative; 
however, this is not always the case in reality.
TABLE 69.1a  High estimate for sensitivity of LDL-C among index patients = 1, index cases (sequentially 
presented results) 
Test strategy Total costs (£) Total QALYs Incremental costs (£) Incremental QALYs ICER (£/QALY)
Elucigene FH20 14,192,370 13,005
Elucigene FH20_MLPA 14,462,441 13,016 Ext Dom Ext Dom Ext Dom
LIPOchip 14,991,529 13,037 Ext Dom Ext Dom Ext Dom
Elucigene FH20_LIPOchip 15,063,229 13,037 Dominated Dominated Dominated
LIPOchip platform – Spain 15,154,374 13,045 962,004 40 24,025
LIPOchip_MLPA 15,254,040 13,048 Ext Dom Ext Dom Ext Dom
Elucigene FH20_LIPOchip_MLPA 15,325,740 13,048 Dominated Dominated Dominated
CGA 15,528,212 13,056 373,838 11 33,402
Elucigene FH20_CGA 15,575,762 13,056 Dominated Dominated Dominated
LIPOchip_CGA 15,699,062 13,056 Dominated Dominated Dominated
Elucigene FH20_LIPOchip_CGA 15,770,762 13,056 Dominated Dominated Dominated
LDL-C 17,857,701 13,089 2,329,489 32 72,493
Ext Dom, extendedly dominated.
TABLE 69.1b  High estimate for sensitivity of LDL-C among index patients = 1, index cases (relevant comparison LDL-C)
Test Total costs (£) Total QALYs Incremental costs (£) Incremental QALYs
Elucigene FH20 14,192,370 13,005 –3,665,331 –83
LIPOchip platform – Spain 15,154,374 13,045 –2,703,327 –43
CGA 15,528,212 13,056 –2,329,489 –32
LDL-C 17,857,701 13,089
TABLE 69.1c  High estimate for sensitivity of LDL-C among index patients = 1, index cases (relevant comparison CGA) 
Test Total costs (£) Total QALYs Incremental costs (£) Incremental QALYs
Elucigene FH20 14,192,370 13,005 –1,335,842 –51
LIPOchip platform – Spain 15,154,374 13,045 –373,838 –11
CGA 15,528,212 13,056© Queen’s Printer and Controller of HMSO 2012. This work was produced by Sharma et al. under the terms of a commissioning contract issued by the 
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TABLE 69.2a  High estimate for sensitivity of LDL-C among index patients = 1, index cases and relatives (sequentially 
presented results) 
Test strategy Total costs (£) Total QALYs Incremental costs (£) Incremental QALYs ICER (£/QALY)
Elucigene FH20 43,371,985 36,653
LDL-C 44,060,308 34,753 Dominated Dominated Dominated
Elucigene FH20_MLPA 44,470,770 37,216 Ext Dom Ext Dom Ext Dom
LIPOchip 46,506,304 38,240 Ext Dom Ext Dom Ext Dom
Elucigene FH20_LIPOchip 46,578,004 38,240 Dominated Dominated Dominated
LIPOchip platform – Spain 47,298,810 38,668 3,926,825 2015 1949
LIPOchip_MLPA 47,597,529 38,803 Ext Dom Ext Dom Ext Dom
Elucigene FH20_LIPOchip_MLPA 47,669,229 38,803 Dominated Dominated Dominated
CGA 48,501,362 39,231 1,202,552 563 2135
Elucigene FH20_CGA 48,548,912 39,231 Dominated Dominated Dominated
LIPOchip_CGA 48,672,212 39,231 Dominated Dominated Dominated
Elucigene FH20_LIPOchip_CGA 48,743,912 39,231 Dominated Dominated Dominated
Ext Dom, extendedly dominated.
TABLE 69.2b  High estimate for sensitivity of LDL-C among index patients = 1, index cases (relevant comparison LDL-C) 
Test Total costs (£) Total QALYs Incremental costs (£) Incremental QALYs ICER (£/QALY)
Elucigene FH20 43,371,985 36,653 –688,323 1900 Dominant
LDL-C 44,060,308 34,753
LIPOchip platform – Spain 47,298,810 38,668 3,238,502 3915 827
CGA 48,501,362 39,231 4,441,054 4478 992
TABLE 69.2c  High estimate for sensitivity of LDL-C among index patients = 1, index cases (relevant comparison CGA) 
Test Total costs (£) Total QALYs Incremental costs (£) Incremental QALYs
Elucigene FH20 43,371,985 36,653 –5,129,377 –2578
LIPOchip platform – Spain 47,298,810 38,668 –1,202,552 –563
CGA 48,501,362 39,231232 Appendix 14
Table 70 presents analysis for the low estimate of sensitivity of LDL-C among index cases (low 
value = 0.54,45 MedPed criteria).
TABLE 70.1a  Low estimate for sensitivity of LDL-C among index patients = 0.54, index cases (sequentially 
presented results) 
Test strategy Total costs (£) Total QALYs Incremental costs (£) Incremental QALYs ICER (£/QALY)
Elucigene FH20 14,192,370 13,005      
Elucigene FH20_MLPA 14,462,441 13,016 Ext Dom Ext Dom Ext Dom
LIPOchip 14,991,529 13,037 Ext Dom Ext Dom Ext Dom
Elucigene FH20_LIPOchip 15,063,229 13,037 Dominated Dominated Dominated
LIPOchip platform – Spain 15,154,374 13,045 962,004 40 24,025
LIPOchip_MLPA 15,254,040 13,048 Ext Dom Ext Dom Ext Dom
Elucigene FH20_LIPOchip_MLPA 15,325,740 13,048 Dominated Dominated Dominated
CGA 15,528,212 13,056 373,838 11 33,402
Elucigene FH20_CGA 15,575,762 13,056 Dominated Dominated Dominated
LIPOchip_CGA 15,699,062 13,056 Dominated Dominated Dominated
Elucigene FH20_LIPOchip_CGA 15,770,762 13,056 Dominated Dominated Dominated
LDL-C 17,031,916 13,047 Dominated Dominated Dominated
Ext Dom, extendedly dominated.
TABLE 70.1b  Low estimate for sensitivity of LDL-C among index patients = 0.54, index cases (relevant comparison 
LDL-C) 
Test Total costs (£) Total QALYs Incremental costs (£) Incremental QALYs ICER (£/QALY)
Elucigene FH20 14,192,370 13,005 –2,839,546 –41
LIPOchip platform – Spain 15,154,374 13,045 –1,877,542 –1
CGA 15,528,212 13,056 –1,503,704 10 Dominant
LDL-C 17,031,916 13,047
TABLE 70.1c  Low estimate for sensitivity of LDL-C among index patients = 0.54, index cases (relevant 
comparison CGA) 
Test Total costs (£) Total QALYs Incremental costs (£) Incremental QALYs
Elucigene FH20 14,192,370 13,005 –1,335,842 –51
LIPOchip platform – Spain 15,154,374 13,045 –373,838 –11
CGA 15,528,212 13,056© Queen’s Printer and Controller of HMSO 2012. This work was produced by Sharma et al. under the terms of a commissioning contract issued by the 
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TABLE 70.2a  Low estimate for sensitivity of LDL-C among index patients = 0.54, index cases and relatives (sequentially 
presented results) 
Test strategy Total costs (£) Total QALYs Incremental costs (£) Incremental QALYs ICER (£/QALY)
LDL-C 43,234,523 34,711      
Elucigene FH20 43,371,985 36,653 137,462 1942 71
Elucigene FH20_MLPA 44,470,770 37,216 Ext Dom Ext Dom Ext Dom
LIPOchip 46,506,304 38,240 Ext Dom Ext Dom Ext Dom
Elucigene FH20_LIPOchip 46,578,004 38,240 Dominated Dominated Dominated
LIPOchip platform – Spain 47,298,810 38,668 3,926,825 2015 1949
LIPOchip_MLPA 47,597,529 38,803 Ext Dom Ext Dom Ext Dom
Elucigene FH20_LIPOchip_MLPA 47,669,229 38,803 Dominated Dominated Dominated
CGA 48,501,362 39,231 1,202,552 563 2135
Elucigene FH20_CGA 48,548,912 39,231 Dominated Dominated Dominated
LIPOchip_CGA 48,672,212 39,231 Dominated Dominated Dominated
Elucigene FH20_LIPOchip_CGA 48,743,912 39,231 Dominated Dominated Dominated
Ext Dom, extendedly dominated.
TABLE 70.2b  Low estimate for sensitivity of LDL-C among index patients = 0.54, index cases (relevant comparison 
LDL-C) 
Test Total costs (£) Total QALYs Incremental costs (£) Incremental QALYs ICER (£/QALY)
LDL-C 43,234,523 34,711
Elucigene FH20 43,371,985 36,653 137,462 1942 71
LIPOchip platform – Spain 47,298,810 38,668 4,064,287 3957 1027
CGA 48,501,362 39,231 5,266,839 4520 1165
TABLE 70.2c  Low estimate for sensitivity of LDL-C among index patients = 0.54, index cases (relevant 
comparison CGA) 
Test  Total costs (£) Total QALYs Incremental costs (£) Incremental QALYs
LDL-C 43,234,523 34,711 –5,266,839 –4520
Elucigene FH20 43,371,985 36,653 –5,129,377 –2578
LIPOchip platform – Spain 47,298,810 38,668 –1,202,552 –563
CGA 48,501,362 39,231234 Appendix 14
Table 71 details the results of sensitivity analysis using the upper bound of the CI for the 
specificity of LDL-C among relatives (values are taken from Starr and colleagues49 and apply only 
to index cases and relatives together). Results refer to relatives of a 50-year-old index case as in 
the base-case model.
TABLE 71a  High estimate for specificity of LDL-C among relatives = 0.87, index cases and relatives (sequentially 
presented results) 
Test strategy Total costs (£) Total QALYs Incremental costs (£) Incremental QALYs ICER (£/QALY)
Elucigene FH20 41,972,619 35,492
LDL-C 42,213,642 33,361 Dominated Dominated Dominated
Elucigene FH20_MLPA 43,145,947 36,117 Ext Dom Ext Dom Ext Dom
LIPOchip 45,316,985 37,253 Ext Dom Ext Dom Ext Dom
Elucigene FH20_LIPOchip 45,388,685 37,253 Dominated Dominated Dominated
LIPOchip platform – Spain 46,166,129 37,728 4,193,510 2236 1875
LIPOchip_MLPA 46,482,753 37,878 Ext Dom Ext Dom Ext Dom
Elucigene FH20_LIPOchip_MLPA 46,554,453 37,878 Dominated Dominated Dominated
CGA 47,443,224 38,353 1,277,095 625 2043
Elucigene FH20_CGA 47,490,774 38,353 Dominated Dominated Dominated
LIPOchip_CGA 47,614,074 38,353 Dominated Dominated Dominated
Elucigene FH20_LIPOchip_CGA 47,685,774 38,353 Dominated Dominated Dominated
Ext Dom, extendedly dominated.
TABLE 71b  High estimate for specificity of LDL-C among relatives = 0.87, index cases and relatives (relevant 
comparison LDL-C) 
Test Total costs (£) Total QALYs Incremental costs (£) Incremental QALYs ICER (£/QALY)
Elucigene FH20 41,972,619 35,492 –241,023 2131 Dominant
LDL-C 42,213,642 33,361
LIPOchip platform – Spain 46,166,129 37,728 3,952,486 4367 905
CGA 47,443,224 38,353 5,229,581 4992 1048
TABLE 71C  High estimate for specificity of LDL-C among relatives = 0.87, index case and relatives (relevant 
comparison CGA) 
Test Total costs (£) Total QALYs Incremental costs (£) Incremental QALYs
Elucigene FH20 41,972,619 35,492 –5,470,605 –2861
LIPOchip platform – Spain 46,166,129 37,728 –1,277,095 –625
CGA 47,443,224 38,353© Queen’s Printer and Controller of HMSO 2012. This work was produced by Sharma et al. under the terms of a commissioning contract issued by the 
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Table 72 details the results of sensitivity analysis using the lower bound of the CI for the 
specificity of LDL-C among relatives (values are taken from Starr and colleagues49 and apply only 
to index cases and relatives together). Results refer to relatives of a 50-year-old index case as in 
the base-case model.
TABLE 72a  Low estimate for specificity of LDL-C among relatives = 0.80, index cases and relatives (sequentially 
presented results) 
Test strategy Total costs (£) Total QALYs Incremental costs (£) Incremental QALYs ICER (£/QALY)
Elucigene FH20 45,013,836 38,015
LDL-C 45,836,823 36,367 Dominated Dominated Dominated
Elucigene FH20_MLPA 46,025,161 38,506 Ext Dom Ext Dom Ext Dom
LIPOchip 47,901,711 39,398 Ext Dom Ext Dom Ext Dom
Elucigene FH20_LIPOchip 48,973,411 39,398 Dominated Dominated Dominated
LIPOchip platform – Spain 48,627,764 39,771 3,613,928 1755 2059
LIPOchip_MLPA 48,905,476 39,888 Ext Dom Ext Dom Ext Dom
Elucigene FH20_LIPOchip_MLPA 48,977,176 39,888 Dominated Dominated Dominated
CGA 49,742,857 40,261 1,115,093 491 2273
Elucigene FH20_CGA 49,790,407 40,261 Dominated Dominated Dominated
LIPOchip_CGA 49,913,707 40,261 Dominated Dominated Dominated
Elucigene FH20_LIPOchip_CGA 49,985,407 40,261 Dominated Dominated Dominated
Ext Dom, extendedly dominated.
TABLE 72b  Low estimate for specificity of LDL-C among relatives = 0.80, index cases and relatives (relevant 
comparison LDL-C) 
Test Total costs (£) Total QALYs Incremental costs (£) Incremental QALYs ICER (£/QALY)
Elucigene FH20 45,013,836 38,015 –822,988 1,648 Dominant
LDL-C 45,836,823 36,367
LIPOchip platform – Spain 48,627,764 39,771 2,790,941 3403 820
CGA 49,742,857 40,261 3,906,033 3894 1003
TABLE 72c  Low estimate for specificity of LDL-C among relatives = 0.80, index cases and relatives (relevant 
comparison CGA)
Test Total costs (£) Total QALYs Incremental costs (£) Incremental QALYs
Elucigene FH20 45,013,836 38,015 –4,729,021 –2246
LIPOchip platform – Spain 48,627,764 39,771 –1,115,093 –491
CGA 49,742,857 40,261© Queen’s Printer and Controller of HMSO 2012. This work was produced by Sharma et al. under the terms of a commissioning contract issued by the 
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Appendix 15 
Cost-effectiveness acceptability curves for 
each age subgroup
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FIGURE 13  Cost-effectiveness acceptability curve: age 15 years, index case.
FIGURE 14  Cost-effectiveness acceptability curve: age 30 years, index case.238 Appendix 15
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FIGURE 15  Cost-effectiveness acceptability curve: age 65 years, index case.
FIGURE 16  Cost-effectiveness acceptability curve: age 75 years, index case.
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Appendix 16 
Parameters for estimation of the 
distributions for the probabilistic model 
(base case)
TABLE 73  Cost parameters
Parameter Value Low High Source Distribution Alpha Beta
Costs of cardiovascular events (£)
No event 74 NICE 20081  Gamma 25 2.96
MI (first year) 3780 NICE 20081 Gamma 25 151.1952
MI (subsequent) 500 NICE 20081  Gamma 25 20
Stroke (first year) 4335 NICE 20081  Gamma 25 173.4137
Stroke (subsequent) 2336 NICE 20081  Gamma 25 93.44554
PAD (first year) 2212 NICE 20081  Gamma 25 88.4974
PAD (subsequent) 285 NICE 20081  Gamma 25 11.4053
Heart failure (first year) 4379 NICE 20081  Gamma 25 175.1699
Heart failure (subsequent) 500 NICE 20081  Gamma 25 20
Revascularisation (first year) 8610 NICE 20081  Gamma 25 344.3940
Revascularisation (subsequent) 500 NICE 20081 Gamma 25 20
Unstable angina (first year) 2074 NICE 20081  Gamma 25 82.9677
Unstable angina (subsequent) 500 NICE 20081  Gamma 25 20
Additional cost parameters
Cost per MOLU 30 20 40 Personal communication Beta 1 1
Cost LDL-C 19.97 15.97 23.96 Assumed high and low Beta 1 1
Cost low-intensity statins 17.21 13.77 20.65 Assumed high and low  Beta 1 1
Cost high-intensity statins 377 302 453 Assumed standard error Gamma 25 15.0993
Test sensitivity and specificity
Elucigene sensitivity 0.4397 0.286a 0.52a Taylor 201037 Beta 102 130
LIPOchip sensitivity 0.7846 0.33a 0.945a Palacios 201041 Beta 57 8
LIPOchip platform – Spain, 
sensitivity
0.8776 0.805 1 Assumption Beta 57 8
LDL-C index cases, sensitivity 0.9 0.72 1 Damgaard, 200545 Beta 1 1
LDL-C (relatives) sensitivity 0.576 0.469 0.679 Starr, 200849 Beta 50.36 37.07
LDL-C (relatives) specificity 0.837 0.8 0.87 Starr, 200849 Beta 401.99 78.29
Health-state multipliers
MI 0.76 0.56 0.96 NICE 20081 Beta 427.09 134.8711
Post MI 0.88 0.78 1.00 NICE 20081 Beta 285.93 38.9911
Stroke 0.629 0.43 0.83 NICE 20081 Beta 91.1103 53.7391
Post stroke 0.629 0.43 0.83 NICE 20081 Beta 91.1103 53.7391
PAD 0.9 0.86 0.98 NICE 20081 Beta 201.6 22.4
continued240 Appendix 16
Parameter Value Low High Source Distribution Alpha Beta
Post PAD 0.9 0.86 0.98 NICE 20081 Beta 201.6 22.4
Heart failure 0.683 0.48 0.88 NICE 20081 Beta 369.0095 171.268
Post heart failure 0.683 0.48 0.88 NICE 20081 Beta 369.0095 171.268
Revascularisation 0.93 0.74 1.00 NICE 20081 Beta 31.3118 2.3568
Post revascularisation 0.93 0.74 1.00 NICE 20081 Beta 40.9973 3.0858
Unstable angina 0.77 0.57 0.97 NICE 20081 Beta 420.1158 125.4891
Post unstable angina 0.88 0.78 1.00 NICE 20081 Beta 285.9348 38.9911
General population quality of life
< 25 years 0.94 0.705 1 NICE 20081 Beta 1 1
25–34 years 0.93 0.636 1 NICE 20081 Beta 1 1
35–44 years 0.91 0.596 1 NICE 20081 Beta 1 1
45–54 years 0.85 0.36 1 NICE 20081 Beta 1 1
55–64 years 0.8 0.29 1 NICE 20081 Beta 1 1
65–74 years 0.78 0.27 1 NICE 20081 Beta 1 1
75+ years 0.73 0.20 1 NICE 20081 Beta 1 1
Treatment effect for each health state in the model
MI 0.81 0.72 0.91 Assumed standard error  Beta 47.079 11.0432
Stroke 0.82 0.70 0.96 Assumed standard error  Beta 22.902 5.0273
TIA 0.79 0.65 0.94 Assumed standard error  Beta 21.587 5.7383
PAD 0.87 0.69 1.00 Assumed standard error  Beta 21.497 3.2122
Heart failure 0.77 0.65 0.92 Assumed standard error  Beta 22.513 6.7247
Revascularisation 0.78 0.69 1.00 Assumed standard error  Beta 9.8438 2.7764
Unstable angina 0.84 0.71 0.86 Assumed standard error  Beta 1083.4132 206.3644
CVD death 0.92 0.72 1.00 Assumed standard error  Beta 39.7241 3.4543
Death other 1.00 0.80 1.00 Assumed standard error  Beta 1 1
CVD, cardiovascular disease; PAD, peripheral arterial disease; TIA, transient ischaemic attack.
a  Bounded between high and low values of all reported studies for that test.
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Appendix 17 
Cost-effectiveness acceptability curves for 
alternative mutation test-positive rates on 
comprehensive genetic analysis
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FIGURE 18  Cost-effectiveness acceptability curve: incidence of genetic mutation = 5%.
FIGURE 19  Cost-effectiveness acceptability curve: incidence of genetic mutation = 10%.242 Appendix 17
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FIGURE 20  Cost-effectiveness acceptability curve: incidence of genetic mutation = 20%.
FIGURE 21  Cost-effectiveness acceptability curve: incidence of genetic mutation = 50%.© Queen’s Printer and Controller of HMSO 2012. This work was produced by Sharma et al. under the terms of a commissioning contract issued by the 
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Appendix 18 
Proportion identified by cascade testing 
using comprehensive genetic analysis 
(targeted sequencing) or age- and 
gender- specific low-density lipoprotein 
cholesterol cut-offs244 Appendix 18
Study  Country
Clinical diagnosis 
of index cases
Study 
participants 
Number of 
participants
Test for 
cascading 
Proportion 
identified from 
cascade testing 
Bourbon 200885 Portugal Simon Broome 
criteria 
Relatives of 
index cases 
Index cases = 88; 
relatives = 206
Families = 165; 
relatives = 226
Targeted 
sequencing 
(LDLR/APOB/
PCSK9). Index 
cases tested 
with dHPLC/
sequencing/MLPA 
56% (116/206) 
(as of 2008); 51% 
(226/443) (as of 
2010)
Hadfield 200966 UK Definite or possible 
Simon Broome 
criteria
First-degree 
relatives of 
index cases
Index cases = 931; 
relatives = 591
LDL-C age- and 
gender-specific 
cut-offs according 
to NICE guideline. 
Living in 
catchment area 
Likely plus 
uncertain = 42% 
(250/591); 
likely = 28% 
(168/591); 
uncertain = 14% 
(82/591)
Relatives = 178 LDL-C age- and 
gender-specific 
cut-offs according 
to NICE guideline. 
Living in non-
catchment area 
Likely plus 
uncertain = 40% 
(72/178); 
likely = 29% 
(51/178); 
uncertain = 12% 
(21/178)
Humphries 200684 UK  Definite or possible 
Simon Broome 
criteria
First-degree 
relatives of 
index cases
Index cases = 69; 
relatives = 54
Targeted 
sequencing 
(LDLR/APOB). 
Index cases 
tested with SSCP/
sequencing/
UPQFM-PCR
50% (27/54)
Leren 200811 Norway Not reported  First-degree 
relatives of 
index cases 
Index cases = 440; 
relatives = 1805
Targeted 
sequencing 
(LDLR/APOB). 
Index cases 
tested with 
sequencing/
MLPA/PCR for 
APOB
45% (808/1805)
Umans-
Eckenhausen 
200119
The 
Netherlands
Dutch criteria  First- and 
second-degree 
relatives of 
index cases 
237 families; 
relatives = 2039
Targeted 
sequencing 
(LDLR/APOB). 
Index cases 
tested with DGGE/
sequencing/
restriction digest 
analysis
37% (2039/5442)
Vergotine 200183 South Africa Families of 
index cases 
Index cases = 379; 
relatives = 790
Targeted 
sequencing 
(LDLR)
43% (338/790)
UPQFM-PCR, universal primer quantitative fluorescent multiplex PCR.© Queen’s Printer and Controller of HMSO 2012. This work was produced by Sharma et al. under the terms of a commissioning contract issued by the 
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Appendix 19 
Protocol
Final protocol, 16th December 2010
1. Title of the project
The clinical and cost-effectiveness of Elucigene FH20 and LIPOchip for the diagnosis of familial 
hypercholesterolaemia: systematic review and economic evaluation.
2. Name of External Assessment Group (EAG) and project lead
Aberdeen Technology Assessment Group
Pawana Sharma
Research Fellow
Health Services Research Unit
3rd Floor
University of Aberdeen
Health Sciences Building
Foresterhill
Aberdeen
AB25 2ZD
Tel: 01224 559055
Email: p.sharma@abdn.ac.uk
Reserve contact:
Graham Mowatt
Senior Research Fellow
Health Services Research Unit
3rd Floor
University of Aberdeen
Health Sciences Building
Foresterhill
Aberdeen
AB25 2ZD
Tel: 01224 552494
Email: g.mowatt@abdn.ac.uk
3. Plain English Summary
Familial hypercholesterolaemia (FH) is an inherited (genetic) condition resulting in raised 
levels of cholesterol in the blood. A person can either inherit the genetic defect from one parent 
(heterozygous FH) or from both parents (homozygous FH). In the UK heterozygous FH has 
a frequency of 1 in 500, affecting around 100,000 people in England, while homozygous FH is 246 Appendix 19
much rarer, with a frequency of 1 in one million.1 The condition is transmitted from generation 
to generation, so that the siblings or children of a person with FH have a 50% risk of inheriting 
the genetic defect.
The raised levels of cholesterol in the blood that characterise heterozygous FH lead to a greater 
than 50% risk of coronary heart disease (CHD) by the age of 50 in men and at least 30% risk in 
women by the age of 60.2 If untreated, around 50% of men will die before the age of 60.3 People 
with homozygous FH have a significantly poorer prognosis than those with heterozygous FH.
FH is generally characterised by the presence of increased levels of cholesterol concentration and 
clinical symptoms such as tendon xanthomata (yellowish skin lesions on the tendons of the hands 
and feet) and a family history of CHD. However there are variations in the time at which clinical 
signs and CHD appear.4 Tendon xanthomata, which are frequent but not always present, may be 
seen in the second decade of life, while CHD is usually present by the fourth decade. Diagnosis 
of FH by cholesterol concentration is not entirely reliable3 with a 10% risk of misdiagnosis.5 FH 
is an underdiagnosed condition, with at least 75% of people in the UK with heterozygous FH 
remaining undiagnosed.6
The NICE clinical guideline on identification and management of familial hypercholesterolaemia 
recommends that a diagnosis of FH should be made using the Simon Broome criteria, which 
include a combination of family history, clinical signs, cholesterol concentration and DNA 
testing, to improve diagnosis and early identification of FH.7 Cascade testing (a mechanism 
for identifying people at risk of FH by a process of family tracing) using a combination of 
DNA testing and low density lipoprotein cholesterol (LDL-C) concentration measurement is 
recommended to identify affected relatives of those individuals with a clinical diagnosis of FH.7 
The aim of early identification is to reduce the risk of vascular diseases by starting treatment 
with cholesterol-lowering drugs such as statins and by allowing management by lifestyle changes 
and diet modification.8 The use of statins, even in lower doses than recommended, can reduce 
the risk of CHD in patients with FH.9 The standard method of DNA testing is comprehensive 
genetic analysis, which is the most complete genetic analysis generally available for FH within 
a diagnostic setting; however the process is slow and expensive (estimated at around £500 to 
£1000 per patient in the UK setting).10,11 Elucigene FH2012 and LIPOchip13 are recently developed 
rapid genetic testing kits that are designed to detect a more limited number of genetic mutations 
associated with FH that are commonly found in the UK population.
This systematic review will assess the clinical and cost-effectiveness of the Elucigene FH20 kit, 
LIPOchip, and comparators, for the diagnosis and cascade testing of FH.
4. Decision problem
4.1 Purpose of the decision to be made
The purpose of this appraisal is to address the following questions:
1.  What are the most effective and cost-effective strategies for confirming a diagnosis of FH in 
index individuals and for cascade testing of relatives?
2.  In cascade testing of relatives for mutations identified in index individuals by Elucigene 
FH20 or LIPOchip, would it be more cost-effective to use those tests rather than targeted 
gene sequencing?© Queen’s Printer and Controller of HMSO 2012. This work was produced by Sharma et al. under the terms of a commissioning contract issued by the 
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4.2 Clear definition of the intervention
Elucigene FH20
The Elucigene FH20 kit (Gen-Probe Life Sciences, UK), using the principle of an amplification 
refractory mutation system (ARMS), is designed to detect 20 genetic mutations associated 
with FH that are commonly found in the UK population (see Table 1).14 These mutations, with 
a frequency ranging from 1.3% to 11.4%, were identified from a cohort study involving 400 
patients in the UK with FH.15 Of the 20 mutations, 18 are found in the Low-density lipoprotein 
receptor (LDLR) gene, one in the Apolipoprotein B (APOB) gene and one in the Protein 
convertase subtilisin/kexin 9 (PCSK) gene (Table 1).14
By using ARMS, the Elucigene FH20 kit combines the amplification step and diagnostic steps,16 
making the process faster. A limitation of the kit is that it only tests for 20 FH mutations. 
Worldwide approximately 1200 FH-causing mutations have been identified,17 of which over 200 
have been reported in the UK population.
LIPOchip
LIPOchip (Progenika Biopharma, Spain) is an alternative genetic test designed to diagnose 
FH.13 LIPOchip is a tiered system that uses DNA array technology. The chip can detect point 
mutations, copy number changes and variation of number of copies of the LDLR gene. The 
current version (version 10) tests for 189 mutations in the LDLR, APOB and PCSK genes that are 
known to occur in the UK population. 
The LIPOchip platform involves the following steps: 
(a)  Firstly, samples are analysed using the DNA array which is designed to detect 189 mutations 
in the LDLR and APOB genes. 
(b)  If the samples fail to detect these mutations they are analysed for large gene re-arrangements. 
(c)  If the first two steps fail to detect mutations then samples are analysed by automated 
sequencing of the LDLR. 
(d)  If all three of the above steps fail to detect mutations then the sample is confirmed as 
FH negative. 
(e)  Finally, the LIPOchip software generates a report containing information on the 
pathogenicity of detected mutations.
The manufacturer also offers a LIPOchip test processing service from its laboratory in Spain.
4.3 Populations and relevant subgroups
The populations considered are adults and children with a clinical diagnosis of FH (the index 
individuals/probands) based on the Simon Broome criteria, and, for cascade testing, first-, 
second- and third-degree biological relatives.
TABLE 1  FH genetic mutations detected by Elucigene FH20
Gene Mutation
Low-density lipoprotein receptor (LDLR) P664L, L458P, R329X, E207X, D200G, E80K, IVS3+1G>A, D461H, ∆G197, fs206, Q363X, 
W66G, V408M, D206E, C656R, K290RfsX20, C163Y and D461N
Apolipoprotein B (APOB) R3500Q
Protein convertase subtilisin/kexin 9 (PCSK9) D374Y248 Appendix 19
4.4 Place of the interventions in the treatment pathway(s)
The care pathway for this assessment is based on the NICE clinical guideline on the identification 
and management of FH.7 
Index individuals 
The assessment will investigate the effect of diagnostic strategies including Elucigene FH20 and/
or LIPOchip for providing an unequivocal diagnosis of FH for those with a clinical diagnosis 
based on the Simon Broome criteria. 
Cascade testing of relatives
The assessment will investigate the effect of diagnostic strategies including Elucigene FH20 for 
cascade testing to identify FH in the relatives of index individuals. The use of Elucigene FH20 
for cascade testing will depend on the mutation detected in the index individual and the cost of 
targeted gene sequencing. (In index individuals with an identified genetic mutation, depending 
on the test used to detect the mutation, targeted gene sequencing will also be considered for 
cascade testing of relatives. In index individuals without an identified genetic mutation, cascade 
testing using LDL-C concentration measurement will be considered.)
A scenario encompassing a single test strategy (Elucigene FH20 or LIPOchip) that does not 
end in comprehensive genetic analysis for test negatives may not detect all cases of FH. In such 
a scenario there may be implications for test negative patients in terms of how their condition 
is managed.
4.5 Relevant comparators
Comprehensive genetic analysis
Comprehensive genetic analysis is defined as the most complete genetic analysis generally 
available for FH within a diagnostic setting and is expected to detect almost all known FH 
causing mutations. This analysis will include DNA sequence analysis of the promoter, all exons, 
the exon/intron boundaries and into 3ʹ untranslated region of the LDLR gene that will detect the 
majority (~88%) of detectable FH mutations, multiplex ligation-dependent probe amplification 
(MLPA)18 for each exon and the promoter region of the LDLR gene to detect deletions and 
duplications (~5% detectable FH mutations) plus analysis for the common APOB p.Arg3527Gin 
gene mutation (~5% FH mutations) and the PCSK9 p.Asp374Tyr gene mutation (~2% 
FH mutations). 
Multiplex ligation-dependent probe amplification (MLPA) (MRC-Holland) is a commercial 
kit that enhances the molecular diagnosis of FH with an ability to detect large deletions and or 
duplications for each of the LDLR 18 exons.18 Comprehensive genetic analysis including DNA 
sequencing with MLPA is considered to be the ‘gold standard’ of genetic testing. 
Targeted gene sequencing
Targeted gene sequencing (the genetic test for sequencing a specific part of the gene where a 
family mutation is found) may be used for cascade testing to identify FH in the relatives of index 
individuals. The use of targeted sequencing for cascade testing will depend on the test used to 
detect a genetic mutation in the index individual.
LDL-C concentration as part of the Simon Broome criteria
In UK a clinical diagnosis of FH should be made based on the Simon Broome criteria,7 which 
include a combination of family history of CHD, clinical signs such as tendon xanthomata, 
cholesterol concentration and DNA testing11,19 (Table 2). This approach categorises FH as ‘definite’ 
or ‘possible’. DNA based evidence was subsequently introduced into the criteria for provision of © Queen’s Printer and Controller of HMSO 2012. This work was produced by Sharma et al. under the terms of a commissioning contract issued by the 
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an unequivocal diagnosis of FH. However, around 10% of people with FH do not meet the Simon 
Broome criteria. 
LDL-C concentration is usually estimated from a fasting blood sample using the Friedwald 
equation. Due to NHS commissioning arrangements of genetic tests, LDL-C concentration 
measurement is the main test currently used to diagnosis FH in index cases and for cascade 
testing of relatives.20 However, it has some limitations in terms of diagnostic accuracy, including: 
1.  There is an overlap in LDL-C levels between affected and unaffected individuals, and the 
cut-offs used can result in diagnostic ambiguity in an estimated 15% of children (aged 
5–15 years) and in nearly 50% of adults (aged 45–55 years).21,22
2.  In children who are at risk of FH, cholesterol levels may appear normal initially with the 
levels rising only later in life.23 
3.  Girls generally have lower cholesterol concentration than boys at an early age but may go on 
to develop CHD in later years.22 
Age adjusted LDL-C measurement has been found to give better clinical diagnosis of FH, with 
a sensitivity of 72% and specificity of 71%.24 The gender- and age-specific LDL-C criteria rather 
than the Simon Broome LDL-C criteria are the recommended criteria for cascade testing of 
relatives of index individuals.7
4.6 Key factors to be addressed
This systematic review will aim to: 
1.  Assess the diagnostic accuracy and clinical effectiveness of Elucigene FH20, LIPOchip and 
comparators in confirming a diagnosis of FH in patients with a clinical diagnosis of FH.
2.  Assess the diagnostic accuracy and clinical effectiveness of Elucigene FH20 and comparators 
in cascade testing of relatives of index individuals with a confirmed diagnosis of FH.
3.  Estimate the costs of different diagnostic strategies for detecting FH in index individuals and 
for cascade testing of relatives of index individuals with a confirmed diagnosis of FH.
TABLE 2  Simon Broome diagnostic criteria11,19
Criteria required for clinical diagnosis of FH  Definite FH Possible FH
Cholesterol concentration:
Child/young person: Total cholesterol (TC) > 6.7 mmol/L, Low density lipoprotein cholesterol 
(LDL-C) > 4 mmol/L; Adult: TC > 7.5 mmol/L, LDL-C: > 4.9 mmol/L
Yes Yes
Clinical symptoms:
Tendon xanthomata, or evidence of these signs in first- or second-degree relative
Yes No
Family history of:
  ■ myocardial infarction in second degree relative (aged < 50 years) or in first degree relative (aged 
< 60 years), or
  ■ raised TC (> 7.5 mmol/L in adult first, second degree relative, or > 6.7 mmol/L in child and sibling 
< 16 years)
No  Yes (at least one of 
these criteria)
Or DNA based evidence of mutation in LDL-R, APOB or PCSK9 genes gives an unequivocal diagnosis of FH. 250 Appendix 19
5. Report methods for assessing the outcomes arising from the 
use of the interventions 
A systematic review of the evidence on Elucigene FH20 and LIPOchip for the diagnosis of 
familial hypercholesterolaemia will be undertaken following the general principles of the Centre 
for Reviews and Dissemination (CRD) guidance for conducting reviews in health care25 and 
NICE Diagnostics Assessment Programme interim methods statement.26
5.1 Inclusion and Exclusion criteria
Population
The populations considered are adults and children with a clinical diagnosis of FH (the index 
cases/probands) based on the Simon Broome criteria, and, for cascade testing, first-, second- and 
third-degree biological relatives of the index individual.
If the evidence allows, subgroup analysis will be undertaken on the performance of Elucigene 
FH20 and LIPOchip in ethnic populations.
Setting 
The setting considered is secondary or tertiary care.
Interventions
The interventions considered are Elucigene FH20 and LIPOchip for index cases and Elucigene 
FH20 for cascade testing. 
Comparators
The comparators for testing in index individuals are (i) comprehensive genetic analysis and 
(ii) LDL-C concentration measurement (Simon Broome criteria). The comparators for cascade 
testing of relatives are (i) targeted gene sequencing and (ii) LDL-C concentration measurement 
(gender- and age-specific criteria as recommended in NICE CG71).
Reference standard
The reference standard is comprehensive genetic analysis in combination with the Simon 
Broome Criteria. 
Outcomes
The following outcomes will be considered:
(a)  Test accuracy; 
(b)  Mutation detection rate – proportion of cases with an unequivocal diagnosis identified by 
Elucigene and LIPOchip;
(c)  Proportion requiring comprehensive genetic analysis after Elucigene and LIPOchip; and 
(d)  Proportion of FH identified from cascade testing;
In any studies reporting the above outcomes the following outcomes will also be considered 
if reported: 
(a)  Acceptability of the tests; and
(b)  Interpretability of the tests.
Studies reporting test accuracy must report the absolute numbers of true positives, false positives, 
false negatives and true negatives, or provide information allowing their calculation.© Queen’s Printer and Controller of HMSO 2012. This work was produced by Sharma et al. under the terms of a commissioning contract issued by the 
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Study design 
The following types of studies will be included:
(a)  Direct (head-to-head) studies in which the index test, comparator test and reference standard 
test are done independently in the same group of people. 
(b)  Randomised controlled trials (RCTs) in which people are randomised to the index and 
comparator test(s) and all receive the reference standard test. 
In case of insufficient evidence from direct and randomised studies, we will consider indirect 
(between-study) comparisons of the following types of study: 
(a)  Diagnostic cross-sectional studies comparing the index test or comparator test against a 
reference standard test.
(b)  Case–control studies in which two groups are created, one known to have the target disease 
and one known not to have the target disease, where it is reasonable for all included to go 
through the tests. 
Exclusion criteria
We will exclude the following types of report:
  ■ Preclinical and biological studies
  ■ Reviews, editorials and opinions
  ■ Case reports
  ■ Reports investigating technical aspects of a test
Non-English language reports may be excluded if the evidence base containing English-language 
reports is sufficiently large. 
5.2 Search strategy
Extensive electronic searches will be conducted to identify reports of published and ongoing 
studies on Elucigene FH20 and LIPOchip for the detection and cascade testing of FH. The search 
strategies will be designed to retrieve all studies that assess the diagnostic accuracy and clinical 
effectiveness of the index, comparator and reference standard tests. Searches will be restricted 
to publications from 2000 onwards. Both full-text papers and recent conference abstracts will 
be sought. Potentially relevant non-English-language studies will be excluded and listed in an 
appendix to the review, unless the English-language evidence base is deemed to be insufficient 
in which case they will be included. Databases to be searched will include: MEDLINE, 
EMBASE, Science Citation Index, Biosis and the Cochrane Controlled Trials Register. A 
preliminary MEDLINE search strategy is shown in Appendix A and will be adapted for use in 
other databases.
A search for systematic reviews and other background publications will also be undertaken. 
Sources will include the Cochrane Database of Systematic Reviews, HTA Database and DARE.
Current research registers, including Current Controlled Trials, Clinical Trials and WHO 
International Clinical Trials Registry will be searched. Recent conference proceedings of key 
organisations will also be screened and will include the European Society of Human Genetics, 
American Association for Clinical Chemistry, International Atherosclerosis Society and 
Heart UK.
In addition, an internet search using Copernic Agent will be undertaken and will also include key 
professional organisations.252 Appendix 19
5.3 Data extraction strategy
Two reviewers will independently screen the titles (and abstracts if available) of all reports 
identified by the search strategy. Full-text copies of all studies deemed to be potentially 
relevant will be obtained, and two reviewers will independently assess them for inclusion. Any 
disagreements will be resolved by consensus or arbitration by a third party.
A data extraction form will be developed and piloted. One reviewer will extract details of study 
design, participants, index, comparator, reference standard tests and outcome data. A second 
reviewer will check the data extraction. Any disagreements will be resolved by consensus or 
arbitration by a third party.
Study data requested and received from the manufacturers that meet the inclusion criteria, and 
are received in time to be incorporated into the review, will be extracted and quality assessed in 
accordance with the procedures outlined in this protocol.
5.4 Quality assessment strategy
Two reviewers will independently assess the methodological quality of the included diagnostic 
studies. Any disagreements will be resolved by consensus or arbitration by a third party. Studies 
will not be included or excluded on the basis of methodological quality.
Various quality assessment tools will be used depending upon the type of studies included. 
For instance, included diagnostic studies will be quality assessed using QUADAS, a quality 
assessment tool developed for use in systematic reviews of diagnostic studies.27 The quality 
assessment tool will be adapted to make it more applicable to assess the quality of studies of tests 
for detecting FH. 
5.5 Methods of analysis/synthesis
Analysis will focus on the ability of Elucigene FH20, LIPOchip and relevant comparators to 
detect FH. Where appropriate two by two tables will be extracted from each included study where 
information is provided on the numbers of true and false-positives and negatives for the index 
and/or comparator test compared with the reference standard for detecting those mutations 
that the index and/or comparator test are designed to identify. For each study we will attempt to 
calculate sensitivity, specificity, positive and negative likelihood ratios and diagnostic odds ratios 
and their confidence intervals. 
Where appropriate and given sufficient information, we will use summary receiver operating 
characteristic (SROC) curves for the meta-analysis of data from studies reporting estimates of 
true and false-positives and negatives. This approach characterises the relationship between 
sensitivity and 1–specificity across studies and takes into account variation in the threshold for 
test positivity between studies. ROC curves will be generated, where possible, for each testing 
procedure. Where data are available, potential sources of heterogeneity will be investigated by 
extending the SROC regression models to include study level covariates. These potential sources 
of heterogeneity include characteristics of the population such as age, race, family history and 
whether the test is cascade testing.
Where appropriate, models will be fitted using the hierarchical summary receiver operating 
characteristic (HSROC) framework, which takes proper account of the diseased and non-
diseased sample sizes in each study, and allows estimation of random effects for the threshold 
and accuracy effects, and testing of the impact of potential sources of heterogeneity. Estimates 
and their CI’s for the average operating points, expressed as sensitivity, specificity and likelihood 
ratios will be obtained by combining these estimates.28 © Queen’s Printer and Controller of HMSO 2012. This work was produced by Sharma et al. under the terms of a commissioning contract issued by the 
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Average and ranges of feasible operating points will be identified on the fitted ROC points to 
convert ROC curve values into estimates of true positive and false positive rates which will serve 
as parameters within the economic model.
5.6 Methods for estimating quality of life – relevance to the decision analysis
Quality of life estimates used in the economic model will be informed by the current NICE 
guideline on the identification and management of familial hypercholesterolaemia7 and relevant 
literature searches together with clinical expert opinion as appropriate. As FH is a chronic disease 
requiring long-term care, we will extrapolate cost and QALY values over a life-time horizon 
and discount both cost and QALYs at a rate of 3.5% as recommended by NICE. This will use a 
linked evidence approach linking diagnostic accuracy of the various strategies with any potential 
changes in clinical management and thus life-time final health outcomes. The economic model 
informing current NICE guideline CG71 for treatment of FH will be validated and used to 
estimate the final treatment outcomes.
6. Report methods for synthesising evidence of cost-
effectiveness
A systematic search for existing cost-effectiveness literature will be undertaken 
for diagnostic assessment strategies for the detection of genetic mutations causing 
familial hypercholesterolaemia.
6.1 Identifying and systematically searching published cost-effectiveness studies.
Studies will be sought, reporting both costs and outcomes for diagnostic assessment strategies, 
from a systematic review of the literature. No language restrictions or limitations to searches will 
be imposed.
Databases to be searched will include MEDLINE, EMBASE, Science Citation Index, NHS 
EED, HTA Database, Health Management Information Consortium and the CEA Registry. In 
addition, reference lists of all included studies will be scanned to identify additional potentially 
relevant studies. A draft MEDLINE search strategy is appended and will be adapted for use in the 
other databases.
6.2 Evaluation of costs and cost-effectiveness
The evidence on costs and cost-effectiveness will be evaluated using the NICE Diagnostics 
Assessment Programme interim methods.26 An economic model will be developed to estimate 
the cost-effectiveness of each care pathway and link this to final treatment outcomes. Current 
NICE guideline CG71 will be used to inform the development of this approach.
6.3 Development of a health economic model
An economic evaluation of the cost-effectiveness of Elucigene, LIPOchip and identified 
comparators will be conducted. An economic model will be developed to determine which 
diagnostic and treatment strategy is the most cost-effective use of scarce NHS resources for 
genetic testing for FH among proband cases (identified using the Simon Broome criteria) and 
cascade testing of relatives.
The primary economic model output will be incremental cost per quality adjusted life year 
(QALY) gained associated with the use of a variety of genetic testing strategies for the detection 
of FH. A life-time horizon will be used in the model and costs and benefits will be discounted at 
a rate of 3.5% as recommended by NICE.29 The development of this economic model will be an 
iterative approach and it will be developed in a way that is adaptable to the analysis of new and 254 Appendix 19
emerging technologies. A possible scenario for the modelling is presented in Appendix B for 
the index cases and Appendix C for the cascade testing of their relatives (Appendix B, Appendix 
C). A range of diagnostic strategies will be explored initially for index patients with a clinical 
diagnosis based on the Simon Broome criteria. The model will further estimate the most cost-
effective method of cascade testing for FH in first-, second-, and possibly third-degree relatives 
of the index patient. This too will be presented as incremental cost per QALY gained. We note 
that the diagnostic test used to detect the family mutation may not be the same as that used to 
detect the mutation in the index individual. This is due to the potential for cost savings among 
alternative cheaper tests for cascade testing (e.g. Elucigene) once the FH-causing family mutation 
has been identified. Our analysis will be from the perspective of the NHS as well as a personal 
social services perspective as appropriate. Any assumptions made in the modelling approach and 
parameter development will be taken primarily from the literature and supplemented by clinical 
expert opinion as appropriate/required. 
Health related quality of life and QALY data for lifelong health outcomes have already been 
modelled in terms of management of FH in cascade testing and treatment strategy. These data 
will be validated, updated as necessary and used to help populate the economic model being 
developed. Any evidence on detection rates and diagnostic accuracy of the comparators will be 
sourced from the literature. As it is unlikely that a large evidence base exists in the literature, 
data will be supplemented by clinical expert opinion as required. A key challenge in terms of 
diagnostic accuracy of the genetic testing kits will be to generalise detection rates to the general 
UK population. It is likely that detection rates will vary depending on ethnicity and so this will 
need to be fully understood and uncertainties explored through sensitivity analyses. Data from 
the genetic bank held in London, together with manufacturer and clinical expert supplied input 
will be used to estimate detection rates of the different strategies. 
Resource use and costs for detection are likely to be the major driver of the cost-effectiveness 
results. It will be important to fully incorporate all economic costs associated with testing and 
processing diagnostic samples for each treatment strategy and the range of scenarios required 
by the model. A combination of national resources such as NHS reference costs, the Personal 
Social Services Research Unit (PSSRU) and the British National Formulary (BNF) will be used 
as appropriate together with any other relevant sources of data identified. Costs of diagnostic 
kits will be sourced from the manufacturers and costs of processing samples sourced from 
a combination of manufacturer and clinical expert data. As obtaining test results is not time 
sensitive due to the clinical nature of FH, the base case analysis will assume genetic laboratories 
will batch test to gain maximum efficiency (i.e. minimum cost). The impact of operating testing 
procedures below maximum efficiency will be considered in model sensitivity analyses. A 
key challenge will be to generalise the cost of comprehensive genetic analysis across the UK, 
where various laboratories report different unit workload costs. The effect of alternative costing 
strategies will be explored through model sensitivity analyses.
The development of this economic model will be an iterative approach. As the evidence base 
changes and new evidence arises, the economic model structure and parameters will evolve 
to reflect this. We further suspect that the evidence base will be lacking for some of the model 
parameters. With this in mind, uncertainty in model parameters will be explored in terms of 
their outputs through a range of one-way and multi-way sensitivity analyses deemed appropriate 
as the modelling progresses. As we anticipate a lack of evidence to inform the model, we will 
explore parameter uncertainty through probabilistic sensitivity analyses, with the generation of 
cost-effectiveness acceptability curves illustrating this uncertainty graphically.© Queen’s Printer and Controller of HMSO 2012. This work was produced by Sharma et al. under the terms of a commissioning contract issued by the 
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7. Handling information from the companies
Following a request for information, any ‘commercial in confidence’ data provided by a 
manufacturer and specified as such will be highlighted in blue and underlined in the assessment 
report (followed by an indication of the relevant company name e.g. in brackets).
8. Competing interests of authors
None
9. Timetable/milestones
Milestones Date to be completed
Draft protocol  24/11/10
Final protocol  14/12/10
Progress report  w/c 18/02/11
Draft version of report  01/04/11
Final version of report  28/04/11
10. References
1.  Austin MA, Hutter CM, Zimmern RL, Humphries SE. Genetic causes of monogenic 
heterozygous familial hypercholesterolemia: A HuGE prevalence review. Am J Epidemiol 
2004;160:407–20.
2.  Model of care: familial hypercholesterolaemia [document on the Internet]. Perth: Office of 
Population Health Genomics, Department of Health, Government of Western Australia; 
2008 [accessed December 2010]. http://www.genomics.health.wa.gov.au/fh/docs/FH_Model_
of_care.pdf.
3.  Connor M, Ferguson-Smith M. Essential medical genetics. 5th ed. Oxford: Blackwell; 2010.
4.  Heath KE, Humphries SE, Middleton-Price H, Boxer M. A molecular genetic service for 
diagnosing individuals with familial hypercholesterolaemia (FH) in the United Kingdom. 
Eur J Hum Genet 2001;9:244–52.
5.  Koivisto PVI, Koivisto UM, Miettinen TA, Kontula K. Diagnosis of heterozygous familial 
hypercholesterolemia: DNA analysis complements clinical examination and analysis of 
serum lipid levels. Arterioscler Thromb 1992;12:584–92.
6.  Marks D, Thorogood M, Farrer JM, Humphries SE. Census of clinics providing specialist 
lipid services in the United Kingdom. J Public Health 2004;26:353–4.
7.  CG71 Identification and management of familiar hypercholesterolaemia [document on the 
Internet]. London: National Institute for Health and Clinical Excellence; 2008 [accessed 
October 2010]. http://www.nice.org.uk/nicemedia/live/12048/41700/41700.pdf.
8.  Shafiq N, Singh M, Kaur S, Khosla P, Malhotra S. Dietary treatment for familial 
hypercholesterolaemia. Cochrane Database of System Rev 2010;Issue 1:DOI.: 10.1002./14.256 Appendix 19
9.  Versmissen J, Oosterveer DM, Yazdanpanah M, Defesche JC, Basart DCG, Liem AH et 
al. Efficacy of statins in familial hypercholesterolaemia: A long term cohort study. BMJ 
2009;338:223–6.
10.  Centre for Evidence-based Purchasing. CEP 10034 Evidence review: rapid genetic testing for 
familial hypercholesteraemia. London: NHS Purchasing and Supply Agency; 2010.
11.  Marks D, Thorogood M, Neil HAW, Humphries SE. A review on the diagnosis, natural 
history, and treatment of familial hypercholesterolaemia. Atherosclerosis 2003;168:1–14.
12.  Taylor A, Patel K, Tsedeke J, Humphries SE, Norbury G. Mutation screening in patients for 
familial hypercholesterolaemia (ADH). Clin Genet 2010;77:97–9.
13.  Alonso R, Defesche JC, Tejedor D, Castillo S, Stef M, Mata N et al. Genetic diagnosis 
of familial hypercholesterolemia using a DNA-array based platform. Clin Biochem 
2009;42:899–903.
14.  Taylor A, Martin B, Wang D, Patel K, Humphries SE, Norbury G. Multiplex ligation-
dependent probe amplification analysis to screen for deletions and duplications of the LDLR 
gene in patients with familial hypercholesterolaemia. Clin Genet 2009;76:69–75.
15.  Humphries SE, Whittall RA, Hubbart CS, Maplebeck S, Cooper JA, Soutar AK et al. Genetic 
causes of familial hypercholesterolaemia in patients in the UK: Relation to plasma lipid levels 
and coronary heart disease risk. J Med Genet 2006;43:943–9.
16.  Lo YMD. The amplification refractory mutation system. In: Lo YMD, editor. Clinical 
applications of PCR. Totawa, NJ: Humana; 1998. pp. 61–70.
17.  Leigh SEA, Foster AH, Whittall RA, Hubbart CS, Humphries SE. Update and analysis of the 
university college London low density lipoprotein receptor familial hypercholesterolemia 
database. Ann Hum Genet 2008;72:485–98.
18.  Wang J, Ban MR, Hegele RA. Multiplex ligation-dependent probe amplification of LDLR 
enhances molecular diagnosis of familial hypercholesterolemia. J Lipid Res 2005;46:366–72.
19.  Betteridge DJ, Broome K, Durrington PN, Mann JI, Miller JP, Neil HAW et al. Risk of fatal 
coronary heart disease in familial hypercholesterolaemia. Br Med J 1991;303:893–6.
20.  National Clinical Audit of the Management of Familial Hypercholesterolaemia 2009: Pilot 
[document on the Internet]. London: Royal College of Physicians; 2009 [accessed December 
2010]. http://www.rcplondon.ac.uk/clinical-standards/ceeu/Current-work/Documents/
FH%20Pilot%20Audit%20Report%20v8%20Full%20Report.pdf.
21.  Kwiterovich Jr PO, Fredrickson DS, Levy RI. Familial hypercholesterolemia (one form 
of familial type II hyperlipoproteinemia). A study of its biochemical, genetic and clinical 
presentation in childhood. J Clin Invest 1974;53:1237–49.
22.  Leonard JV, Whitelaw AGL, Wolff OH. Diagnosing familial hypercholesterolaemia in 
childhood by measuring serum cholesterol. Br Med J 1977;1:1566–8.
23.  Kessling AM, Seed M, Taylor R, Wynn V, Humphries SE. Rising cholesterol levels in children 
with familial hypercholesterolaemia. Biomed Pharmacother 1990;44:373–9.
24.  Civeira F, Ros E, Jarauta E, Plana N, Zambon D, Puzo J et al. Comparison of Genetic Versus 
Clinical Diagnosis in Familial Hypercholesterolemia. Am J Cardiol 2008;102:1187–93.
25.  Centre of Reviews and Dissemination. Systematic reviews: CRD’s guidance for undertaking 
reviews in health care [Internet]. York: University of York; 2009 [accessed November 2010]. 
http://www.york.ac.uk/inst/crd/systematic_reviews_book.htm.© Queen’s Printer and Controller of HMSO 2012. This work was produced by Sharma et al. under the terms of a commissioning contract issued by the 
Secretary of State for Health.
257   Health Technology Assessment 2012; Vol. 16: No. 17 DOI: 10.3310/hta16170
26.  Diagnostics Assessment programme – interim methods statement (programme) 
[document on the Internet]. London: National Institute for Health and Clinical 
Excellence; 2010 [accessed December 2010]. http://www.nice.org.uk/media/164/3C/
DAPInterimMethodsStatementProgramme.pdf.
27.  Whiting P, Rutjes AW, Reitsma JB, Bossuyt PM, Kleijnen J. The development of QUADAS: 
a tool for the quality assessment of studies of diagnostic accuracy included in systematic 
reviews. BMC Med Res Methodol 2003;3:Nov 10.
28.  Rutter CM, Gatsonis CA. A hierarchical regression approach to meta-analysis of diagnostic 
test accuracy evaluations. Stat Med 2001;20:2865–84.
29.  Updated guide to the methods of technology appraisal [document on the Internet]. London: 
National Institute for Health and Clinical Excellence; 2008 [accessed November 2010]. http://
www.nice.org.uk/media/B52/A7/TAMethodsGuideUpdatedJune2008.pdf.
11. Appendices
Appendix A
Preliminary MEDLINE strategy
Diagnostic Accuracy and Clinical Effectiveness of Elucigene FH20, LIPOchip and Comparators
1.  Hyperlipoproteinemia Type II/di [Diagnosis]
2.  lipochip.tw.
3.  elucigene.tw.
4.  Hyperlipoproteinemia Type II/
5.  hyperlipidemia, familial combined/
6.  familial hypercholesterol?emia.tw.
7.  hyperlipoprotein?emia.tw.
8.  familial hyperlipid?emia.tw.
9.  or/4-8
10.  exp Genetic Predisposition to Disease/
11.  Genetic Testing/
12.  Gene Amplification/
13.  exp Nucleic Acid Amplification Techniques/
14.  exp oligonucleotide array sequence analysis/ or exp sequence analysis, dna/
15.  (dna adj3 test$).tw.
16.  gene sequencing.tw.
17.  (sequenc$ adj3 analysis).tw.
18.  (cascade adj3 (test$ or screen$)).tw.
19.  (genetic adj3 (test$ or screen$)).tw.
20.  (arms or amplification refractory mutation system).tw.
21.  (PCR or polymerase chain reaction).tw.
22.  Polymorphism, Single-Stranded Conformational/
23.  (sscp or single-stranded conformation polymorphism).tw.
24.  (mlpa or Multiplex ligation-dependent probe amplification).tw.
25.  Cholesterol, LDL/
26.  ldl-c.tw.
27.  or/10-26
28.  9 and 27
29.  “sensitivity and specificity”/
30.  roc curve/
31.  predictive value of tests/258 Appendix 19
32.  false positive reactions/ 
33.  false negative reactions/ 
34.  du.fs. 
35.  sensitivity.tw.
36.  distinguish$.tw.
37.  differentiat$.tw.
38.  identif$.tw.
39.  detect$.tw.
40.  diagnos$.tw.
41.  (predictive adj4 value$).tw.
42.  accura$.tw.
43.  comparison.tw.
44.  or/29-43
45.  28 and 44
46.  1 or 2 or 3 or 45
47.  limit 46 to yr=”2000 -Current»
48.  randomized controlled trial.pt.
49.  controlled clinical trial.pt.
50.  randomi?ed.ab.
51.  placebo.ab.
52.  drug therapy.fs.
53.  randomly.ab.
54.  trial.ab.
55.  groups.ab.
56.  or/48-55
57.  exp animals/ not humans/
58.  56 not 57
59.  28 and 58
60.  limit 59 to yr=”2000 -Current»
61.  46 or 60
Preliminary MEDLINE strategy
Economic evaluations of Elucigene FH20, LIPOchip and Comparators
1.  Hyperlipoproteinemia Type II/di 
2.  elucigene.tw
3.  lipochip.tw
4.  Hyperlipoproteinemia Type II/ 
5.  hyperlipidemia, familial combined/ 
6.  familial hypercholesterol?emia.tw. 
7.  hyperlipoprotein?emia.tw. 
8.  familial hyperlipid?emia.tw. 
9.  or/4-8
10.  genetic predisposition to disease/ 
11.  genetic testing/ 
12.  (genetic adj3 (test$ or screen$)).tw. 
13.  (cascade adj3 (test$ or screen$)).tw. 
14.  (dna adj3 test$).tw
15.  gene amplification/ 
16.  exp Nucleic Acid Amplification Techniques/ 
17.  exp sequence analysis,dna/ 
18.  exp oligonucleotide array sequence analysis/ © Queen’s Printer and Controller of HMSO 2012. This work was produced by Sharma et al. under the terms of a commissioning contract issued by the 
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19.  (arms or amplification refractory mutation system).tw. 
20.  (PCR or polymerase chain reaction).tw
21.  (sscp or single-stranded conformation polymorphism).tw
22.  (mlpa or Multiplex ligation-dependent probe amplification).tw. 
23.  gene sequencing.tw. 
24.  sequence analys?s.tw.
25.  ldl-c.tw. 
26.  or/10-25 
27.  9 and 26 
28.  or/1-3,27
29.  exp “costs and cost analysis»/ 
30.  economics/ 
31.  exp economics,medical/
32.  economics,pharmaceutical/ 
33.  exp budgets/
34.  exp models, economic/ 
35.  exp decision theory/ 
36.  monte carlo method/
37.  markov chains/ 
38.  exp technology assessment, biomedical/
39.  cost$.ti. 
40.  (cost$ adj2 (effective$ or utilit$ or benefit$ or minimis$)).ab. 
41.  economics model$.tw. 
42.  economic$ .tw. 
43.  (price or prices or pricing).tw. 
44.  (value adj1 money).tw. 
45.  markov$.tw. 
46.  monte carlo.tw. 
47.  (decision$ adj2 (tree? or analy$ or model$)).tw. 
48.  or/29-47
49.  28 and 48
Appendix B
Patient care pathways (Index cases with a clinical diagnosis of FH 
using the Simon Broome criteria – including a LDL-c test)*
*The above is a guideline to the main strategies, there may be exceptions to these strategies which 
will be explored as the analysis progresses.
1. Elucigene Treatment decision
2. Elucigene Lipochip for negatives Treatment decision
3. Elucigene MLPA for negatives Treatment decision
4. Elucigene CGA for negatives Treatment decision
5. Elucigene Lipochip for negatives GA for negatives Treatment decision
6. Elucigene Lipochip for negatives MLPA for negatives Treatment decision
7. Lipochip Treatment decision
8. Lipochip CGA for negatives Treatment decision
9. Lipochip MLPA for negatives Treatment decision
10. CGA Treatment decision
11. LDL-c Treatment decision (current practice)260 Appendix 19
Appendix C
Patient care pathways (Cascade testing of relatives of FH identified 
index patients)**
**Once a relative is found to be negative for the mutation being tested for, cascade testing stops 
and further cascade testing is not conducted
Index case identified by Cascade testing of relatives Clinical management
Elucigene Elucigene Treatment decision
Elucigene Targeted Sequencing Treatment decision
Lipochip Elucigene Treatment decision
Lipochip Targeted Sequencing Treatment decision
CGA Elucigene Treatment decision
CGA Targeted Sequencing Treatment decision© Queen’s Printer and Controller of HMSO 2012. This work was produced by Sharma et al. under the terms of a commissioning contract issued by the 
Secretary of State for Health.
261   Health Technology Assessment 2012; Vol. 16: No. 17 DOI: 10.3310/hta16170
Health Technology Assessment programme
Director,
Professor Tom Walley, CBE,
Director, NIHR HTA programme,  
Professor of Clinical Pharmacology,  
University of Liverpool
Deputy Director,
Professor Hywel Williams,
Professor of Dermato-Epidemiology, 
Centre of Evidence-Based Dermatology, 
University of Nottingham
Prioritisation Group
Members
Chair,
Professor Tom Walley, CBE,
Director, NIHR HTA 
programme, Professor of Clinical 
Pharmacology, University of 
Liverpool
Professor Imti Choonara, 
Professor in Child Health, 
Academic Division of Child 
Health, University of Nottingham
Chair – Pharmaceuticals Panel
Dr Bob Coates,
Consultant Advisor – Disease 
Prevention Panel
Dr Andrew Cook,
Consultant Advisor – Intervention 
Procedures Panel
Dr Peter Davidson,
Director of NETSCC, Health 
Technology Assessment
Dr Nick Hicks,
Consultant Adviser – Diagnostic 
Technologies and Screening Panel, 
Consultant Advisor–Psychological 
and Community Therapies Panel
Ms Susan Hird,
Consultant Advisor, External 
Devices and Physical Therapies 
Panel
Professor Sallie Lamb,
Director, Warwick Clinical Trials 
Unit, Warwick Medical School, 
University of Warwick
Chair – HTA Clinical Evaluation 
and Trials Board
Professor Jonathan Michaels,
Professor of Vascular Surgery, 
Sheffield Vascular Institute, 
University of Sheffield
Chair – Interventional Procedures 
Panel
Professor Ruairidh Milne,
Director – External Relations
Dr John Pounsford,
Consultant Physician, Directorate 
of Medical Services, North Bristol 
NHS Trust
Chair – External Devices and 
Physical Therapies Panel
Dr Vaughan Thomas,
Consultant Advisor – 
Pharmaceuticals Panel, Clinical 
Lead – Clinical Evaluation Trials  
Prioritisation Group
Professor Margaret Thorogood,
Professor of Epidemiology, Health 
Sciences Research Institute, 
University of Warwick
Chair – Disease Prevention Panel
Professor Lindsay Turnbull,
Professor of Radiology, Centre for 
the MR Investigations, University 
of Hull
Chair – Diagnostic Technologies 
and Screening Panel
Professor Scott Weich,
Professor of Psychiatry, Health 
Sciences Research Institute, 
University of Warwick
Chair – Psychological and 
Community Therapies Panel
Professor Hywel Williams,
Director of Nottingham Clinical 
Trials Unit, Centre of Evidence-
Based Dermatology, University of 
Nottingham
Chair – HTA Commissioning 
Board
Deputy HTA Programme Director
HTA Commissioning Board
Chair,
Professor Hywel Williams,
Professor of Dermato-Epidemiology,  
Centre of Evidence-Based Dermatology, 
University of Nottingham
Deputy Chair,
Professor Jon Deeks,
Department of Public Health and 
Epidemiology,  
University of Birmingham
Professor Tom Walley, CBE,
Professor of Clinical Pharmacology,  
Director, NIHR HTA programme,  
University of Liverpool
Members
Professor Ann Ashburn,
Professor of Rehabilitation and 
Head of Research, Southampton 
General Hospital
Professor Judith Bliss,
Director of ICR-Clinical Trials 
and Statistics Unit, The Institute of 
Cancer Research
Professor Peter Brocklehurst,
Professor of Women's Health, 
Institute for Women's Health, 
University College London
Professor David Fitzmaurice,
Professor of Primary Care 
Research, Department of Primary 
Care Clinical Sciences, University 
of Birmingham
Professor John W Gregory,
Professor in Paediatric 
Endocrinology, Department of 
Child Health, Wales School of 
Medicine, Cardiff University
Professor Steve Halligan,
Professor of Gastrointestinal 
Radiology, University College 
Hospital, London
Professor Angela Harden,
Professor of Community and 
Family Health, Institute for 
Health and Human Development, 
University of East London
Dr Martin J Landray,
Reader in Epidemiology, Honorary 
Consultant Physician, Clinical 
Trial Service Unit, University of 
Oxford 
Dr Joanne Lord,
Reader, Health Economics 
Research Group, Brunel University 
Professor Stephen Morris,
Professor of Health Economics, 
University College London, 
Research Department of 
Epidemiology and Public Health, 
University College London
Professor Dion Morton,
Professor of Surgery, Academic 
Department of Surgery, University 
of Birmingham
Professor Gail Mountain,
Professor of Health Services 
Research, Rehabilitation and 
Assistive Technologies Group, 
University of Sheffield
Professor Irwin Nazareth,
Professor of Primary Care and 
Head of Department, Department 
of Primary Care and Population 
Sciences, University College 
London
Professor E Andrea Nelson,
Professor of Wound Healing and 
Director of Research, School of 
Healthcare, University of Leeds
Professor John David Norrie,
Chair in Clinical Trials and 
Biostatistics, Robertson Centre for 
Biostatistics, University of Glasgow
Dr Rafael Perera,
Lecturer in Medical Statisitics, 
Department of Primary Health 
Care, University of OxfordCurrent and past membership details of all HTA programme ‘committees’ are available from the HTA website (www.hta.ac.uk)
262 Health Technology Assessment programme
Professor Barney Reeves,
Professorial Research Fellow 
in Health Services Research, 
Department of Clinical Science, 
University of Bristol
Professor Peter Tyrer,
Professor of Community 
Psychiatry, Centre for Mental 
Health, Imperial College London
Professor Martin Underwood,
Professor of Primary Care 
Research, Warwick Medical 
School, University of Warwick
Professor Caroline Watkins,
Professor of Stroke and Older 
People’s Care, Chair of UK 
Forum for Stroke Training, Stroke 
Practice Research Unit, University 
of Central Lancashire
Dr Duncan Young,
Senior Clinical Lecturer and 
Consultant, Nuffield Department 
of Anaesthetics, University of 
Oxford
Observers
Dr Tom Foulks,
Medical Research Council
Dr Kay Pattison,
Senior NIHR Programme 
Manager, Department of Health
HTA Commissioning Board (continued)
HTA Clinical Evaluation and Trials Board
Chair,
Professor Sallie Lamb, 
Director,  
Warwick Clinical Trials Unit, 
Warwick Medical School, 
University of Warwick and Professor of 
Rehabilitation, 
Nuffield Department of Orthopaedic, 
Rheumatology and Musculoskeletal Sciences, 
University of Oxford
Deputy Chair,
Professor Jenny Hewison,
Professor of the Psychology of Health Care, 
Leeds Institute of Health Sciences, 
University of Leeds
Programme Director, 
Professor Tom Walley, CBE, 
Director, NIHR HTA programme,  
Professor of Clinical Pharmacology,  
University of Liverpool
Members
Professor Keith Abrams,
Professor of Medical Statistics, 
Department of Health Sciences, 
University of Leicester
Professor Martin Bland,
Professor of Health Statistics, 
Department of Health Sciences, 
University of York
Professor Jane Blazeby,
Professor of Surgery and 
Consultant Upper GI Surgeon, 
Department of Social Medicine, 
University of Bristol
Professor Julia M Brown,
Director, Clinical Trials Research 
Unit, University of Leeds
Professor Alistair Burns,
Professor of Old Age Psychiatry, 
Psychiatry Research Group, School 
of Community-Based Medicine, 
The University of Manchester & 
National Clinical Director for 
Dementia, Department of Health
Dr Jennifer Burr,
Director, Centre for Healthcare 
Randomised trials (CHART), 
University of Aberdeen
Professor Linda Davies,
Professor of Health Economics, 
Health Sciences Research Group, 
University of Manchester
Professor Simon Gilbody,
Prof of Psych Medicine and Health 
Services Research, Department of 
Health Sciences, University of York 
Professor Steven Goodacre,
Professor and Consultant in 
Emergency Medicine, School of 
Health and Related Research, 
University of Sheffield
Professor Dyfrig Hughes,
Professor of Pharmacoeconomics, 
Centre for Economics and Policy 
in Health, Institute of Medical 
and Social Care Research, Bangor 
University
Professor Paul Jones,
Professor of Respiratory Medicine, 
Department of Cardiac and 
Vascular Science, St George‘s 
Hospital Medical School, 
University of London
Professor Khalid Khan,
Professor of Women’s Health and 
Clinical Epidemiology, Barts and 
the London School of Medicine, 
Queen Mary, University of London
Professor Richard J McManus,
Professor of Primary Care 
Cardiovascular Research, Primary 
Care Clinical Sciences Building, 
University of Birmingham
Professor Helen Rodgers,
Professor of Stroke Care, Institute 
for Ageing and Health, Newcastle 
University
Professor Ken Stein,
Professor of Public Health, 
Peninsula Technology Assessment 
Group, Peninsula College 
of Medicine and Dentistry, 
Universities of Exeter and 
Plymouth
Professor Jonathan Sterne,
Professor of Medical Statistics 
and Epidemiology, Department 
of Social Medicine, University of 
Bristol
Mr Andy Vail, 
Senior Lecturer, Health Sciences 
Research Group, University of 
Manchester
Professor Clare Wilkinson,
Professor of General Practice and 
Director of Research North Wales 
Clinical School, Department of 
Primary Care and Public Health, 
Cardiff University
Dr Ian B Wilkinson,
Senior Lecturer and Honorary 
Consultant, Clinical Pharmacology 
Unit, Department of Medicine, 
University of Cambridge
Observers
Ms Kate Law,
Director of Clinical Trials, 
Cancer Research UK
Dr Morven Roberts,
Clinical Trials Manager, Health 
Services and Public Health 
Services Board, Medical Research 
Council© Queen’s Printer and Controller of HMSO 2012. This work was produced by Sharma et al. under the terms of a commissioning contract issued by the 
Secretary of State for Health.
263   Health Technology Assessment 2012; Vol. 16: No. 17 DOI: 10.3310/hta16170
Diagnostic Technologies and Screening Panel
Members
Chair,
Professor Lindsay Wilson 
Turnbull,
Scientific Director of the 
Centre for Magnetic Resonance 
Investigations and YCR Professor 
of Radiology, Hull Royal Infirmary
Professor Judith E Adams,
Consultant Radiologist, 
Manchester Royal Infirmary, 
Central Manchester & Manchester 
Children’s University Hospitals 
NHS Trust, and Professor of 
Diagnostic Radiology, University 
of Manchester
Mr Angus S Arunkalaivanan,
Honorary Senior Lecturer, 
University of Birmingham and 
Consultant Urogynaecologist 
and Obstetrician, City Hospital, 
Birmingham
Dr Diana Baralle,
Consultant and Senior Lecturer 
in Clinical Genetics, University of 
Southampton
Dr Stephanie Dancer,
Consultant Microbiologist, 
Hairmyres Hospital, East Kilbride
Dr Diane Eccles,
Professor of Cancer Genetics, 
Wessex Clinical Genetics Service, 
Princess Anne Hospital
Dr Trevor Friedman,
Consultant Liason Psychiatrist, 
Brandon Unit, Leicester General 
Hospital
Dr Ron Gray,
Consultant, National Perinatal 
Epidemiology Unit, Institute of 
Health Sciences, University of 
Oxford
Professor Paul D Griffiths,
Professor of Radiology, Academic 
Unit of Radiology, University of 
Sheffield
Mr Martin Hooper,
Public contributor
Professor Anthony Robert 
Kendrick,
Associate Dean for Clinical 
Research and Professor of Primary 
Medical Care, University of 
Southampton
Dr Nicola Lennard,
Senior Medical Officer, MHRA
Dr Anne Mackie,
Director of Programmes, UK 
National Screening Committee, 
London
Mr David Mathew,
Public contributor
Dr Michael Millar,
Consultant Senior Lecturer in 
Microbiology, Department of 
Pathology & Microbiology, Barts 
and The London NHS Trust, Royal 
London Hospital
Mrs Una Rennard,
Public contributor
Dr Stuart Smellie,
Consultant in Clinical Pathology, 
Bishop Auckland General Hospital
Ms Jane Smith,
Consultant Ultrasound 
Practitioner, Leeds Teaching 
Hospital NHS Trust, Leeds
Dr Allison Streetly,
Programme Director, NHS Sickle 
Cell and Thalassaemia Screening 
Programme, King’s College School 
of Medicine
Dr Matthew Thompson,
Senior Clinical Scientist and GP, 
Department of Primary Health 
Care, University of Oxford
Dr Alan J Williams,
Consultant Physician, General and 
Respiratory Medicine, The Royal 
Bournemouth Hospital
Observers
Dr Tim Elliott,
Team Leader, Cancer Screening, 
Department of Health
Dr Joanna Jenkinson,
Board Secretary, Neurosciences 
and Mental Health Board 
(NMHB), Medical Research 
Council
Professor Julietta Patnick,
Director, NHS Cancer Screening 
Programme, Sheffield
Dr Kay Pattison,
Senior NIHR Programme 
Manager, Department of Health
Professor Tom Walley, CBE,
Director, NIHR HTA 
programme, Professor of Clinical 
Pharmacology, University of 
Liverpool
Dr Ursula Wells,
Principal Research Officer, Policy 
Research Programme, Department 
of Health
Disease Prevention Panel
Members
Chair,
Professor Margaret Thorogood,
Professor of Epidemiology, 
University of Warwick Medical 
School, Coventry
Dr Robert Cook,
Clinical Programmes Director, 
Bazian Ltd, London
Dr Colin Greaves,
Senior Research Fellow, Peninsula 
Medical School (Primary Care)
Mr Michael Head, 
Public contributor
Professor Cathy Jackson,
Professor of Primary Care 
Medicine, Bute Medical School, 
University of St Andrews
Dr Russell Jago,
Senior Lecturer in Exercise, 
Nutrition and Health, Centre 
for Sport, Exercise and Health, 
University of Bristol
Dr Julie Mytton,
Consultant in Child Public Health, 
NHS Bristol
Professor Irwin Nazareth,
Professor of Primary Care and 
Director, Department of Primary 
Care and Population Sciences, 
University College London
Dr Richard Richards, 
Assistant Director of Public 
Health, Derbyshire County 
Primary Care Trust
Professor Ian Roberts,
Professor of Epidemiology and 
Public Health, London School of 
Hygiene & Tropical Medicine
Dr Kenneth Robertson,
Consultant Paediatrician, Royal 
Hospital for Sick Children, 
Glasgow
Dr Catherine Swann,
Associate Director, Centre for 
Public Health Excellence, NICE
Mrs Jean Thurston,
Public contributor
Professor David Weller,
Head, School of Clinical Science 
and Community Health, 
University of Edinburgh
Observers
Ms Christine McGuire,
Research & Development, 
Department of Health
Dr Kay Pattison,
Senior NIHR Programme 
Manager, Department of Health
Professor Tom Walley, CBE,
Director, NIHR HTA 
programme, Professor of Clinical 
Pharmacology, University of 
LiverpoolCurrent and past membership details of all HTA programme ‘committees’ are available from the HTA website (www.hta.ac.uk)
264 Health Technology Assessment programme
External Devices and Physical Therapies Panel
Members
Chair,
Dr John Pounsford,
Consultant Physician North Bristol 
NHS Trust
Deputy Chair,
Professor E Andrea Nelson,
Reader in Wound Healing and 
Director of Research, University 
of Leeds
Professor Bipin Bhakta,
Charterhouse Professor in 
Rehabilitation Medicine, 
University of Leeds
Mrs Penny Calder,
Public contributor
Dr Dawn Carnes,
Senior Research Fellow, Barts and 
the London School of Medicine 
and Dentistry
Dr Emma Clark,
Clinician Scientist Fellow & Cons. 
Rheumatologist, University of 
Bristol
Mrs Anthea De Barton-Watson,
Public contributor
Professor Nadine Foster,
Professor of Musculoskeletal 
Health in Primary Care Arthritis 
Research, Keele University
Dr Shaheen Hamdy,
Clinical Senior Lecturer and 
Consultant Physician, University 
of Manchester
Professor Christine Norton,
Professor of Clinical Nursing 
Innovation, Bucks New University 
and Imperial College Healthcare 
NHS Trust
Dr Lorraine Pinnigton,
Associate Professor in 
Rehabilitation, University of 
Nottingham
Dr Kate Radford,
Senior Lecturer (Research), 
University of Central Lancashire
Mr Jim Reece,
Public contributor
Professor Maria Stokes,
Professor of Neuromusculoskeletal 
Rehabilitation, University of 
Southampton
Dr Pippa Tyrrell,
Senior Lecturer/Consultant, 
Salford Royal Foundation 
Hospitals’ Trust and University of 
Manchester
Dr Nefyn Williams,
Clinical Senior Lecturer, Cardiff 
University
Observers
Dr Kay Pattison,
Senior NIHR Programme 
Manager, Department of Health
Dr Morven Roberts,
Clinical Trials Manager, Health 
Services and Public Health 
Services Board, Medical Research 
Council
Professor Tom Walley, CBE,
Director, NIHR HTA 
programme, Professor of Clinical 
Pharmacology, University of 
Liverpool
Dr Ursula Wells,
Principal Research Officer, Policy 
Research Programme, Department 
of Health
Interventional Procedures Panel
Members
Chair,
Professor Jonathan Michaels,
Professor of Vascular Surgery, 
University of Sheffield
Deputy Chair,
Mr Michael Thomas, 
Consultant Colorectal Surgeon, 
Bristol Royal Infirmary
Mrs Isabel Boyer,
Public contributor
Mr Sankaran Chandra Sekharan, 
Consultant Surgeon, Breast 
Surgery, Colchester Hospital 
University NHS Foundation Trust 
Professor Nicholas Clarke, 
Consultant Orthopaedic Surgeon, 
Southampton University Hospitals 
NHS Trust
Ms Leonie Cooke,
Public contributor
Mr Seumas Eckford, 
Consultant in Obstetrics & 
Gynaecology, North Devon 
District Hospital
Professor Sam Eljamel,
Consultant Neurosurgeon, 
Ninewells Hospital and Medical 
School, Dundee
Dr Adele Fielding,
Senior Lecturer and Honorary 
Consultant in Haematology, 
University College London 
Medical School
Dr Matthew Hatton, 
Consultant in Clinical Oncology, 
Sheffield Teaching Hospital 
Foundation Trust
Dr John Holden, 
General Practitioner, Garswood 
Surgery, Wigan
Dr Fiona Lecky,
Senior Lecturer/Honorary 
Consultant in Emergency 
Medicine, University of 
Manchester/Salford Royal 
Hospitals NHS Foundation Trust
Dr Nadim Malik, 
Consultant Cardiologist/Honorary 
Lecturer, University of Manchester
Mr Hisham Mehanna, 
Consultant & Honorary Associate 
Professor, University Hospitals 
Coventry & Warwickshire NHS 
Trust
Dr Jane Montgomery, 
Consultant in Anaesthetics and 
Critical Care, South Devon 
Healthcare NHS Foundation Trust
Professor Jon Moss,
Consultant Interventional 
Radiologist, North Glasgow 
Hospitals University NHS Trust
Dr Simon Padley, 
Consultant Radiologist, Chelsea & 
Westminster Hospital
Dr Ashish Paul, 
Medical Director, Bedfordshire 
PCT
Dr Sarah Purdy, 
Consultant Senior Lecturer, 
University of Bristol
Dr Matthew Wilson,
Consultant Anaesthetist, 
Sheffield Teaching Hospitals NHS 
Foundation Trust
Professor Yit Chiun Yang, 
Consultant Ophthalmologist, 
Royal Wolverhampton Hospitals 
NHS Trust
Observers
Dr Kay Pattison,
Senior NIHR Programme 
Manager, Department of Health
Dr Morven Roberts,
Clinical Trials Manager, Health 
Services and Public Health 
Services Board, Medical Research 
Council
Professor Tom Walley, CBE,
Director, NIHR HTA 
programme, Professor of Clinical 
Pharmacology, University of 
Liverpool
Dr Ursula Wells,
Principal Research Officer, Policy 
Research Programme, Department 
of Health© Queen’s Printer and Controller of HMSO 2012. This work was produced by Sharma et al. under the terms of a commissioning contract issued by the 
Secretary of State for Health.
265   Health Technology Assessment 2012; Vol. 16: No. 17 DOI: 10.3310/hta16170
Pharmaceuticals Panel
Members
Chair,
Professor Imti Choonara,
Professor in Child Health, 
University of Nottingham
Deputy Chair,
Dr Yoon K Loke,
Senior Lecturer in Clinical 
Pharmacology, University of East 
Anglia
Dr Martin Ashton-Key,
Medical Advisor, National 
Commissioning Group, NHS 
London
Dr Peter Elton,
Director of Public Health, Bury 
Primary Care Trust
Dr Ben Goldacre,
Research Fellow, Epidemiology 
London School of Hygiene and 
Tropical Medicine
Dr James Gray,
Consultant Microbiologist, 
Department of Microbiology, 
Birmingham Children’s Hospital 
NHS Foundation Trust
Dr Jurjees Hasan,
Consultant in Medical Oncology, 
The Christie, Manchester
Dr Carl Heneghan,
Deputy Director Centre for 
Evidence-Based Medicine and 
Clinical Lecturer, Department of 
Primary Health Care, University 
of Oxford
Dr Dyfrig Hughes,
Reader in Pharmacoeconomics 
and Deputy Director, Centre for 
Economics and Policy in Health, 
IMSCaR, Bangor University
Dr Maria Kouimtzi,
Pharmacy and Informatics 
Director, Global Clinical Solutions, 
Wiley-Blackwell
Professor Femi Oyebode,
Consultant Psychiatrist and Head 
of Department, University of 
Birmingham
Dr Andrew Prentice,
Senior Lecturer and Consultant 
Obstetrician and Gynaecologist, 
The Rosie Hospital, University of 
Cambridge
Ms Amanda Roberts,
Public contributor
Dr Gillian Shepherd,
Director, Health and Clinical 
Excellence, Merck Serono Ltd
Mrs Katrina Simister,
Assistant Director New Medicines, 
National Prescribing Centre, 
Liverpool
Professor Donald Singer,
Professor of Clinical 
Pharmacology and Therapeutics, 
Clinical Sciences Research 
Institute, CSB, University of 
Warwick Medical School
Mr David Symes,
Public contributor
Dr Arnold Zermansky,
General Practitioner, Senior 
Research Fellow, Pharmacy 
Practice and Medicines 
Management Group, Leeds 
University
Observers
Dr Kay Pattison,
Senior NIHR Programme 
Manager, Department of Health
Mr Simon Reeve,
Head of Clinical and Cost-
Effectiveness, Medicines, 
Pharmacy and Industry Group, 
Department of Health
Dr Heike Weber,
Programme Manager, Medical 
Research Council
Professor Tom Walley, CBE,
Director, NIHR HTA 
programme, Professor of Clinical 
Pharmacology, University of 
Liverpool
Dr Ursula Wells,
Principal Research Officer, Policy 
Research Programme, Department 
of Health
Psychological and Community Therapies Panel
Members
Chair,
Professor Scott Weich,
Professor of Psychiatry, University 
of Warwick, Coventry
Deputy Chair,
Dr Howard Ring, 
Consultant & University Lecturer 
in Psychiatry, University of 
Cambridge 
Professor Jane Barlow,
Professor of Public Health in 
the Early Years, Health Sciences 
Research Institute, Warwick 
Medical School
Dr Sabyasachi Bhaumik,
Consultant Psychiatrist, 
Leicestershire Partnership NHS 
Trust 
Mrs Val Carlill,
Public contributor
Dr Steve Cunningham, 
Consultant Respiratory 
Paediatrician, Lothian Health 
Board 
Dr Anne Hesketh, 
Senior Clinical Lecturer in Speech 
and Language Therapy, University 
of Manchester 
Dr Peter Langdon,
Senior Clinical Lecturer, School 
of Medicine, Health Policy and 
Practice, University of East Anglia
Dr Yann Lefeuvre, 
GP Partner, Burrage Road Surgery, 
London 
Dr Jeremy J Murphy, 
Consultant Physician and 
Cardiologist, County Durham and 
Darlington Foundation Trust 
Dr Richard Neal,
Clinical Senior Lecturer in General 
Practice, Cardiff University
Mr John Needham, 
Public contributor
Ms Mary Nettle, 
Mental Health User Consultant
Professor John Potter, 
Professor of Ageing and Stroke 
Medicine, University of East 
Anglia 
Dr Greta Rait, 
Senior Clinical Lecturer and 
General Practitioner, University 
College London 
Dr Paul Ramchandani, 
Senior Research Fellow/Cons. 
Child Psychiatrist, University of 
Oxford 
Dr Karen Roberts, 
Nurse/Consultant, Dunston Hill 
Hospital, Tyne and Wear 
Dr Karim Saad, 
Consultant in Old Age Psychiatry, 
Coventry and Warwickshire 
Partnership Trust 
Dr Lesley Stockton,
Lecturer, School of Health 
Sciences, University of Liverpool
Dr Simon Wright, 
GP Partner, Walkden Medical 
Centre, Manchester 
Observers
Dr Kay Pattison,
Senior NIHR Programme 
Manager, Department of Health
Dr Morven Roberts,
Clinical Trials Manager, Health 
Services and Public Health 
Services Board, Medical Research 
Council
Professor Tom Walley, CBE,
Director, NIHR HTA 
programme, Professor of Clinical 
Pharmacology, University of 
Liverpool
Dr Ursula Wells,
Principal Research Officer, Policy 
Research Programme, Department 
of HealthNETSCC, Health Technology Assessment 
Alpha House
University of Southampton Science Park 
Southampton SO16 7NS, UK
Email: hta@hta.ac.uk
www.hta.ac.uk  ISSN 1366-5278
Feedback
The HTA programme and the authors would like to know 
your views about this report.
The Correspondence Page on the HTA website 
(www.hta.ac.uk) is a convenient way to publish your 
comments. If you prefer, you can send your comments 
to the address below, telling us whether you would like 
us to transfer them to the website.
We look forward to hearing from you.